NZ790347A - Ectonucleotidase inhibitors and methods of use thereof - Google Patents
Ectonucleotidase inhibitors and methods of use thereof Download PDFInfo
- Publication number
- NZ790347A NZ790347A NZ790347A NZ79034719A NZ790347A NZ 790347 A NZ790347 A NZ 790347A NZ 790347 A NZ790347 A NZ 790347A NZ 79034719 A NZ79034719 A NZ 79034719A NZ 790347 A NZ790347 A NZ 790347A
- Authority
- NZ
- New Zealand
- Prior art keywords
- mmol
- methoxy
- mixture
- etoac
- compound
- Prior art date
Links
- 101710039712 NT5E Proteins 0.000 title description 44
- 230000002401 inhibitory effect Effects 0.000 title description 29
- 239000003112 inhibitor Substances 0.000 title description 19
- 201000011510 cancer Diseases 0.000 abstract description 42
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 4
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 370
- 150000001875 compounds Chemical class 0.000 description 216
- 239000000203 mixture Substances 0.000 description 207
- 235000019439 ethyl acetate Nutrition 0.000 description 170
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 170
- -1 cyano, azido, amino Chemical group 0.000 description 168
- 229910001868 water Inorganic materials 0.000 description 139
- 239000000243 solution Substances 0.000 description 130
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 124
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 111
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 109
- 125000000217 alkyl group Chemical group 0.000 description 99
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 92
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 92
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 80
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 80
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 78
- 239000012267 brine Substances 0.000 description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 71
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 66
- 239000012044 organic layer Substances 0.000 description 64
- 239000007787 solid Substances 0.000 description 63
- 125000000623 heterocyclic group Chemical group 0.000 description 62
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 56
- 239000003208 petroleum Substances 0.000 description 56
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 53
- 125000003118 aryl group Chemical group 0.000 description 50
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 46
- 229960004679 Doxorubicin Drugs 0.000 description 46
- 239000011541 reaction mixture Substances 0.000 description 45
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 44
- 102100017063 NT5E Human genes 0.000 description 42
- 229910003204 NH2 Inorganic materials 0.000 description 41
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 40
- 229960004397 Cyclophosphamide Drugs 0.000 description 40
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 40
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 37
- 201000010099 disease Diseases 0.000 description 37
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 36
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- 230000015572 biosynthetic process Effects 0.000 description 35
- 125000001072 heteroaryl group Chemical group 0.000 description 35
- 230000035492 administration Effects 0.000 description 34
- 230000002194 synthesizing Effects 0.000 description 34
- 238000005160 1H NMR spectroscopy Methods 0.000 description 33
- 125000003710 aryl alkyl group Chemical group 0.000 description 33
- 239000002904 solvent Substances 0.000 description 33
- 238000003786 synthesis reaction Methods 0.000 description 33
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 32
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 32
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 30
- 125000000753 cycloalkyl group Chemical group 0.000 description 30
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 29
- 239000007832 Na2SO4 Substances 0.000 description 29
- 229910000027 potassium carbonate Inorganic materials 0.000 description 29
- 230000002829 reduced Effects 0.000 description 29
- 229910052938 sodium sulfate Inorganic materials 0.000 description 29
- 235000011152 sodium sulphate Nutrition 0.000 description 29
- FTVLMFQEYACZNP-UHFFFAOYSA-N Trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 28
- 229960004528 Vincristine Drugs 0.000 description 28
- 239000002585 base Substances 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 28
- 229960004618 prednisone Drugs 0.000 description 28
- 125000001424 substituent group Chemical group 0.000 description 28
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 28
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 27
- 210000004027 cells Anatomy 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 27
- 229960004316 cisplatin Drugs 0.000 description 26
- 238000010898 silica gel chromatography Methods 0.000 description 26
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 26
- 125000004429 atoms Chemical group 0.000 description 25
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 25
- 239000000460 chlorine Substances 0.000 description 25
- 239000003814 drug Substances 0.000 description 25
- 125000005843 halogen group Chemical group 0.000 description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 25
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 25
- 235000017557 sodium bicarbonate Nutrition 0.000 description 25
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 24
- 229960005420 Etoposide Drugs 0.000 description 24
- 240000000437 Eucalyptus leucoxylon Species 0.000 description 24
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 238000007792 addition Methods 0.000 description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000012043 crude product Substances 0.000 description 23
- 239000000543 intermediate Substances 0.000 description 22
- 235000015320 potassium carbonate Nutrition 0.000 description 22
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 21
- 206010028980 Neoplasm Diseases 0.000 description 21
- 229960000485 methotrexate Drugs 0.000 description 21
- 239000000741 silica gel Substances 0.000 description 21
- 229910002027 silica gel Inorganic materials 0.000 description 21
- 239000008346 aqueous phase Substances 0.000 description 20
- 125000004475 heteroaralkyl group Chemical group 0.000 description 20
- 239000011780 sodium chloride Substances 0.000 description 20
- 239000006260 foam Substances 0.000 description 19
- 125000001183 hydrocarbyl group Chemical group 0.000 description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 19
- 239000012299 nitrogen atmosphere Substances 0.000 description 19
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 18
- 229960002949 Fluorouracil Drugs 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000003153 chemical reaction reagent Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 239000003921 oil Substances 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- 229940079593 drugs Drugs 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- 230000001225 therapeutic Effects 0.000 description 16
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 15
- 229960003048 Vinblastine Drugs 0.000 description 15
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 15
- 125000003342 alkenyl group Chemical group 0.000 description 15
- 239000002246 antineoplastic agent Substances 0.000 description 15
- 238000002648 combination therapy Methods 0.000 description 15
- 125000004122 cyclic group Chemical group 0.000 description 15
- 238000010511 deprotection reaction Methods 0.000 description 15
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 15
- 235000008191 folinic acid Nutrition 0.000 description 15
- 239000011672 folinic acid Substances 0.000 description 15
- 229910052739 hydrogen Inorganic materials 0.000 description 15
- 229960001691 leucovorin Drugs 0.000 description 15
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 15
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 description 14
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 description 14
- AGEZXYOZHKGVCM-UHFFFAOYSA-N Benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 14
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 14
- 229960000684 Cytarabine Drugs 0.000 description 14
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 14
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 229960005305 adenosine Drugs 0.000 description 14
- 125000000304 alkynyl group Chemical group 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 230000003899 glycosylation Effects 0.000 description 14
- 238000006206 glycosylation reaction Methods 0.000 description 14
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 14
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 13
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 13
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 229960001561 Bleomycin Drugs 0.000 description 12
- 108010006654 Bleomycin Proteins 0.000 description 12
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 12
- 125000003545 alkoxy group Chemical group 0.000 description 12
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 12
- 239000002775 capsule Substances 0.000 description 12
- 239000002777 nucleoside Substances 0.000 description 12
- 229960000624 procarbazine Drugs 0.000 description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 11
- 206010006187 Breast cancer Diseases 0.000 description 11
- DRGVLUZIGUIMLB-UHFFFAOYSA-N acetic acid;rhodium Chemical compound [Rh].[Rh].CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O DRGVLUZIGUIMLB-UHFFFAOYSA-N 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 150000001412 amines Chemical class 0.000 description 11
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 11
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 11
- 125000005842 heteroatoms Chemical group 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 11
- 150000003833 nucleoside derivatives Chemical class 0.000 description 11
- 239000006188 syrup Substances 0.000 description 11
- 235000020357 syrup Nutrition 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- MBTURJZVEXPUPL-UHFFFAOYSA-N 2,6-dichloropurin-6-amine Chemical compound NC1(Cl)N=C(Cl)N=C2N=CN=C12 MBTURJZVEXPUPL-UHFFFAOYSA-N 0.000 description 10
- HBJGQJWNMZDFKL-UHFFFAOYSA-N 2-chloro-7H-purin-6-amine Chemical compound NC1=NC(Cl)=NC2=C1NC=N2 HBJGQJWNMZDFKL-UHFFFAOYSA-N 0.000 description 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 10
- 229960000975 Daunorubicin Drugs 0.000 description 10
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 10
- 229960001156 Mitoxantrone Drugs 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- 108090001123 antibodies Proteins 0.000 description 10
- 102000004965 antibodies Human genes 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 102100009509 ENTPD1 Human genes 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 125000003368 amide group Chemical group 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- 238000004108 freeze drying Methods 0.000 description 9
- 230000001965 increased Effects 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 9
- OMJKFYKNWZZKTK-UXBLZVDNSA-N (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1\N=CN=C1C(N)=O OMJKFYKNWZZKTK-UXBLZVDNSA-N 0.000 description 8
- WWYDYZMNFQIYPT-UHFFFAOYSA-L 2-phenylpropanedioate Chemical compound [O-]C(=O)C(C([O-])=O)C1=CC=CC=C1 WWYDYZMNFQIYPT-UHFFFAOYSA-L 0.000 description 8
- 101710011427 ENTPD1 Proteins 0.000 description 8
- 229960001101 Ifosfamide Drugs 0.000 description 8
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 8
- YNESATAKKCNGOF-UHFFFAOYSA-N Lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 8
- 206010033128 Ovarian cancer Diseases 0.000 description 8
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 125000002252 acyl group Chemical group 0.000 description 8
- 125000004432 carbon atoms Chemical group C* 0.000 description 8
- 230000000875 corresponding Effects 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 230000001404 mediated Effects 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000002953 preparative HPLC Methods 0.000 description 8
- 230000001603 reducing Effects 0.000 description 8
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 7
- 229960004961 Mechlorethamine Drugs 0.000 description 7
- 229960004635 Mesna Drugs 0.000 description 7
- HJUGFYREWKUQJT-UHFFFAOYSA-N Tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 7
- 229940035893 Uracil Drugs 0.000 description 7
- 125000004414 alkyl thio group Chemical group 0.000 description 7
- 238000005804 alkylation reaction Methods 0.000 description 7
- 125000002619 bicyclic group Chemical group 0.000 description 7
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 7
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 7
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 229960003901 dacarbazine Drugs 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 239000007903 gelatin capsule Substances 0.000 description 7
- 239000008079 hexane Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 150000002829 nitrogen Chemical group 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrugs Drugs 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 238000004007 reversed phase HPLC Methods 0.000 description 7
- PSINDLUNOGABJV-UHFFFAOYSA-N (Z)-2-diazonio-1,3-diethoxy-3-oxoprop-1-en-1-olate Chemical compound CCO\C([O-])=C(/[N+]#N)C(=O)OCC PSINDLUNOGABJV-UHFFFAOYSA-N 0.000 description 6
- HPXNTHKXCYMIJL-UHFFFAOYSA-N 1,1'-bis(diphenylphosphanyl)ferrocene Chemical compound C12C3C4C5[Fe]4322346(C7(C2C6C4C37)P(C=2C=CC=CC=2)C=2C=CC=CC=2)C15P(C=1C=CC=CC=1)C1=CC=CC=C1 HPXNTHKXCYMIJL-UHFFFAOYSA-N 0.000 description 6
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 6
- WETWJCDKMRHUPV-UHFFFAOYSA-N Acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- ITMCEJHCFYSIIV-UHFFFAOYSA-N Trifluoromethanesulfonic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 6
- 239000000370 acceptor Substances 0.000 description 6
- 239000012346 acetyl chloride Substances 0.000 description 6
- 238000005917 acylation reaction Methods 0.000 description 6
- 230000000111 anti-oxidant Effects 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 125000005418 aryl aryl group Chemical group 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 230000003197 catalytic Effects 0.000 description 6
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 229920000591 gum Polymers 0.000 description 6
- 125000001188 haloalkyl group Chemical group 0.000 description 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 6
- 125000004928 piperidonyl group Chemical group 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 125000005494 pyridonyl group Chemical group 0.000 description 6
- 125000004076 pyridyl group Chemical group 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 6
- 210000001519 tissues Anatomy 0.000 description 6
- SIOVKLKJSOKLIF-CMDGGOBGSA-N trimethylsilyl (1E)-N-trimethylsilylethanimidate Chemical compound C[Si](C)(C)OC(/C)=N/[Si](C)(C)C SIOVKLKJSOKLIF-CMDGGOBGSA-N 0.000 description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 5
- YIEVSJJAWVBFTE-UHFFFAOYSA-N 2-methoxy-5-morpholin-4-ylsulfonylaniline Chemical compound C1=C(N)C(OC)=CC=C1S(=O)(=O)N1CCOCC1 YIEVSJJAWVBFTE-UHFFFAOYSA-N 0.000 description 5
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 5
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 5
- 229960003190 Adenosine Monophosphate Drugs 0.000 description 5
- UDMBCSSLTHHNCD-KQYNXXCUSA-N Adenosine monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 5
- 229950006790 Adenosine phosphate Drugs 0.000 description 5
- BHELZAPQIKSEDF-UHFFFAOYSA-N Allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 5
- 229960004562 Carboplatin Drugs 0.000 description 5
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 229960003957 Dexamethasone Drugs 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 240000006600 Humulus lupulus Species 0.000 description 5
- 235000008694 Humulus lupulus Nutrition 0.000 description 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 5
- 206010025650 Malignant melanoma Diseases 0.000 description 5
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 5
- 229960004857 Mitomycin Drugs 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 5
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 5
- 101710027499 Os03g0268000 Proteins 0.000 description 5
- 206010038389 Renal cancer Diseases 0.000 description 5
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 125000004423 acyloxy group Chemical group 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 229960005243 carmustine Drugs 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 5
- 150000002009 diols Chemical class 0.000 description 5
- 239000012039 electrophile Substances 0.000 description 5
- 230000002708 enhancing Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 201000010982 kidney cancer Diseases 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 229960001924 melphalan Drugs 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 5
- 239000006072 paste Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 235000012239 silicon dioxide Nutrition 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 229910052718 tin Inorganic materials 0.000 description 5
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 5
- 230000001131 transforming Effects 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 4
- QEYCKQXGWOPCQS-UHFFFAOYSA-N 2-chloropurine-6,6-diamine Chemical compound NC1(N)N=C(Cl)N=C2N=CN=C12 QEYCKQXGWOPCQS-UHFFFAOYSA-N 0.000 description 4
- IKJFWUNKUZVHGU-UHFFFAOYSA-N 5,7-dichloro-1H-imidazo[4,5-b]pyridine Chemical compound ClC1=CC(Cl)=C2NC=NC2=N1 IKJFWUNKUZVHGU-UHFFFAOYSA-N 0.000 description 4
- UWUBPQVLQOHMKF-UHFFFAOYSA-N 5-chloro-1H-imidazo[4,5-b]pyridine Chemical compound ClC1=CC=C2NC=NC2=N1 UWUBPQVLQOHMKF-UHFFFAOYSA-N 0.000 description 4
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 4
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical group CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 4
- 229940104302 Cytosine Drugs 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 229960000640 Dactinomycin Drugs 0.000 description 4
- 108010092160 Dactinomycin Proteins 0.000 description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
- 210000002966 Serum Anatomy 0.000 description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 4
- 229960005454 Thioguanine Drugs 0.000 description 4
- 229940113082 Thymine Drugs 0.000 description 4
- 229940116362 Tragacanth Drugs 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 4
- 230000001058 adult Effects 0.000 description 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 4
- 238000002619 cancer immunotherapy Methods 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 229910052681 coesite Inorganic materials 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 229910052906 cristobalite Inorganic materials 0.000 description 4
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 4
- 230000002354 daily Effects 0.000 description 4
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical class O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 229960003668 docetaxel Drugs 0.000 description 4
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 201000004101 esophageal cancer Diseases 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 4
- 230000001506 immunosuppresive Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000000302 ischemic Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 229960002247 lomustine Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 229960001756 oxaliplatin Drugs 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 230000002335 preservative Effects 0.000 description 4
- 125000006513 pyridinyl methyl group Chemical group 0.000 description 4
- 229910052904 quartz Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 229910052682 stishovite Inorganic materials 0.000 description 4
- 230000004083 survival Effects 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 230000000699 topical Effects 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 229910052905 tridymite Inorganic materials 0.000 description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- RQAVSDINDRNIKL-UHFFFAOYSA-N 1-chloro-3-isocyanatopropane Chemical compound ClCCCN=C=O RQAVSDINDRNIKL-UHFFFAOYSA-N 0.000 description 3
- RMFWVOLULURGJI-UHFFFAOYSA-N 2,6-dichloro-7H-purine Chemical compound ClC1=NC(Cl)=C2NC=NC2=N1 RMFWVOLULURGJI-UHFFFAOYSA-N 0.000 description 3
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 3
- ZWTVVWUOTJRXKM-UHFFFAOYSA-N 3-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-bicyclo[2.2.2]octanyl]propanoic acid Chemical compound C1CC(CCC(O)=O)(CC2)CCC12C1=NC(N(C(N(CCC)C2=O)=O)CCC)=C2N1 ZWTVVWUOTJRXKM-UHFFFAOYSA-N 0.000 description 3
- 229960003272 ASPARAGINASE Drugs 0.000 description 3
- LIKZXCROQGHXTI-UHFFFAOYSA-M Acid Blue 25 Chemical compound [Na+].C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S([O-])(=O)=O)C=C1NC1=CC=CC=C1 LIKZXCROQGHXTI-UHFFFAOYSA-M 0.000 description 3
- 108050000203 Adenosine receptors Proteins 0.000 description 3
- 102000009346 Adenosine receptors Human genes 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 102000015790 Asparaginase Human genes 0.000 description 3
- 108010024976 Asparaginase Proteins 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 3
- 229960004117 Capecitabine Drugs 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229940088598 Enzyme Drugs 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 3
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 210000003128 Head Anatomy 0.000 description 3
- 210000000987 Immune System Anatomy 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- PNFZSRRRZNXSMF-WUKNDPDISA-N PPADS Chemical compound O=CC1=C(O)C(C)=NC(\N=N\C=2C(=CC(=CC=2)S(O)(=O)=O)S(O)(=O)=O)=C1COP(O)(O)=O PNFZSRRRZNXSMF-WUKNDPDISA-N 0.000 description 3
- 229940056457 PROMACE Drugs 0.000 description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 3
- 210000002381 Plasma Anatomy 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- PJBFVWGQFLYWCB-UHFFFAOYSA-N Rolofylline Chemical compound C1C(CC(C2)C3)CC3C12C1=NC(N(C(N(CCC)C2=O)=O)CCC)=C2N1 PJBFVWGQFLYWCB-UHFFFAOYSA-N 0.000 description 3
- 229950008067 Rolofylline Drugs 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 210000003491 Skin Anatomy 0.000 description 3
- 206010040984 Sleep disease Diseases 0.000 description 3
- 229940083542 Sodium Drugs 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229940015849 Thiophene Drugs 0.000 description 3
- 229950009502 Tonapofylline Drugs 0.000 description 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 3
- LXNAVEXFUKBNMK-UHFFFAOYSA-N acetic acid;palladium Chemical compound [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000000996 additive Effects 0.000 description 3
- OLCWZBFDIYXLAA-IOSLPCCCSA-N adenosine 5'-methylenediphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)CP(O)(O)=O)[C@@H](O)[C@H]1O OLCWZBFDIYXLAA-IOSLPCCCSA-N 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 125000004103 aminoalkyl group Chemical group 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 238000006065 biodegradation reaction Methods 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000002490 cerebral Effects 0.000 description 3
- 230000000973 chemotherapeutic Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000005712 crystallization Effects 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 125000004185 ester group Chemical group 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 229960000390 fludarabine Drugs 0.000 description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 3
- 229960002074 flutamide Drugs 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 229960005277 gemcitabine Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000002334 glycols Chemical class 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 200000000018 inflammatory disease Diseases 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 229960001428 mercaptopurine Drugs 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 108010045030 monoclonal antibodies Proteins 0.000 description 3
- 102000005614 monoclonal antibodies Human genes 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 230000000269 nucleophilic Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 3
- NJRWNWYFPOFDFN-UHFFFAOYSA-L phosphonate(2-) Chemical compound [O-][P]([O-])=O NJRWNWYFPOFDFN-UHFFFAOYSA-L 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 150000003138 primary alcohols Chemical class 0.000 description 3
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 3
- 231100000486 side effect Toxicity 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000002195 synergetic Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 150000007970 thio esters Chemical class 0.000 description 3
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 3
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 3
- 229960002066 vinorelbine Drugs 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- UTLGQZBGMVTJJZ-UHFFFAOYSA-N (4-acetyloxyoxolan-3-yl) acetate Chemical compound CC(=O)OC1COCC1OC(C)=O UTLGQZBGMVTJJZ-UHFFFAOYSA-N 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- XOSSHQAJIWXWOC-UHFFFAOYSA-N 2,2-dimethyl-N-[(4-sulfamoylphenyl)carbamothioyl]propanamide Chemical compound CC(C)(C)C(=O)NC(=S)NC1=CC=C(S(N)(=O)=O)C=C1 XOSSHQAJIWXWOC-UHFFFAOYSA-N 0.000 description 2
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 2
- JAEJSNFTJMYIEF-UHFFFAOYSA-N 2-benzylpropanedioic acid Chemical compound OC(=O)C(C(O)=O)CC1=CC=CC=C1 JAEJSNFTJMYIEF-UHFFFAOYSA-N 0.000 description 2
- HOEQXFUBJFGJKA-UHFFFAOYSA-N 3-(bromomethyl)furan Chemical compound BrCC=1C=COC=1 HOEQXFUBJFGJKA-UHFFFAOYSA-N 0.000 description 2
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N 3-aminopropanol Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 2
- 125000006483 4-iodobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1I)C([H])([H])* 0.000 description 2
- 102000004008 5'-Nucleotidase Human genes 0.000 description 2
- 108010057533 5'-Nucleotidase Proteins 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- 101710039842 ADORA2A Proteins 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- OZAIFHULBGXAKX-VAWYXSNFSA-N Azobisisobutyronitrile Chemical compound N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- MKTCRJXWGWNJEB-UHFFFAOYSA-N BrCC1=CC=C(C=C1)C=1C(N(C=CC=1)COC)=O Chemical compound BrCC1=CC=C(C=C1)C=1C(N(C=CC=1)COC)=O MKTCRJXWGWNJEB-UHFFFAOYSA-N 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N Bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- JQZNZZVYZFDCHA-SLJHHMTISA-N C(C1=CC=CC=C1)C(C(=O)OCC)(C(=O)OCC)OC[C@H]1OC([C@@H]([C@]1(C#C)OC(C)=O)OC(C)=O)OC(C)=O Chemical compound C(C1=CC=CC=C1)C(C(=O)OCC)(C(=O)OCC)OC[C@H]1OC([C@@H]([C@]1(C#C)OC(C)=O)OC(C)=O)OC(C)=O JQZNZZVYZFDCHA-SLJHHMTISA-N 0.000 description 2
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 description 2
- 208000008787 Cardiovascular Disease Diseases 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Substances CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- 229960001904 EPIRUBICIN Drugs 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 210000002744 Extracellular Matrix Anatomy 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010017758 Gastric cancer Diseases 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229960000908 Idarubicin Drugs 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- 206010027665 Immune disorder Diseases 0.000 description 2
- 206010021425 Immune system disease Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229940067606 Lecithin Drugs 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 229940008250 Leuprolide Drugs 0.000 description 2
- 229960004338 Leuprorelin Drugs 0.000 description 2
- 210000004698 Lymphocytes Anatomy 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 210000004379 Membranes Anatomy 0.000 description 2
- 206010027476 Metastasis Diseases 0.000 description 2
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N N-Propyl bromide Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 2
- JLYAXFNOILIKPP-KXQOOQHDSA-N Navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 2
- 206010053643 Neurodegenerative disease Diseases 0.000 description 2
- 206010061536 Parkinson's disease Diseases 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 229960001285 Quercetin Drugs 0.000 description 2
- JQYMGXZJTCOARG-UHFFFAOYSA-N Reactive blue 2 Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC(S(O)(=O)=O)=C1 JQYMGXZJTCOARG-UHFFFAOYSA-N 0.000 description 2
- 210000000664 Rectum Anatomy 0.000 description 2
- 108010001645 Rituximab Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229960001603 Tamoxifen Drugs 0.000 description 2
- 229960001278 Teniposide Drugs 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 229960001196 Thiotepa Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N Trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Trimethylglycine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229960000237 Vorinostat Drugs 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 229960004217 benzyl alcohol Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 description 2
- 201000005216 brain cancer Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 125000004452 carbocyclyl group Chemical group 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 230000001808 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 210000003162 effector T lymphocyte Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000010931 ester hydrolysis Methods 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 229940027318 hydroxyurea Drugs 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- BVVCBYHYIPYXFG-UHFFFAOYSA-M lithium;oxolane;hydroxide Chemical compound [Li+].[OH-].C1CCOC1 BVVCBYHYIPYXFG-UHFFFAOYSA-M 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- LROBJRRFCPYLIT-UHFFFAOYSA-M magnesium;ethyne;bromide Chemical compound [Mg+2].[Br-].[C-]#C LROBJRRFCPYLIT-UHFFFAOYSA-M 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- AWIJRPNMLHPLNC-UHFFFAOYSA-M methanethioate Chemical compound [O-]C=S AWIJRPNMLHPLNC-UHFFFAOYSA-M 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229960000060 monoclonal antibodies Drugs 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 230000000626 neurodegenerative Effects 0.000 description 2
- 230000000926 neurological Effects 0.000 description 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 150000002895 organic esters Chemical class 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N oxophosphanyl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000000135 prohibitive Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000002633 protecting Effects 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229930002344 quercetin Natural products 0.000 description 2
- 239000010948 rhodium Substances 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 229960003452 romidepsin Drugs 0.000 description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 2
- 108010091666 romidepsin Proteins 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- GSBYVRKLPCSLNV-UHFFFAOYSA-M sodium 2,4-dinitrobenzenesulfonate Chemical compound [Na+].[O-][N+](=O)C1=CC=C(S([O-])(=O)=O)C([N+]([O-])=O)=C1 GSBYVRKLPCSLNV-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- KAGVQRIRFSJQHD-UHFFFAOYSA-N sodium;hydride;oxolane Chemical compound [H-].[Na+].C1CCOC1 KAGVQRIRFSJQHD-UHFFFAOYSA-N 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 2
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 229960004066 trametinib Drugs 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 2
- 150000004072 triols Chemical class 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- MXZROAOUCUVNHX-GSVOUGTGSA-N (1R)-1-aminopropan-1-ol Chemical compound CC[C@H](N)O MXZROAOUCUVNHX-GSVOUGTGSA-N 0.000 description 1
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hy Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 1
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3E)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical compound C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- VYXHVRARDIDEHS-UHFFFAOYSA-N 1,5-Cyclooctadiene Chemical compound C1CC=CCCC=C1 VYXHVRARDIDEHS-UHFFFAOYSA-N 0.000 description 1
- 239000004912 1,5-cyclooctadiene Substances 0.000 description 1
- AYBIPDOLVGEZLF-UHFFFAOYSA-N 1-(3-bromopropyl)pyridin-2-one Chemical compound BrCCCN1C=CC=CC1=O AYBIPDOLVGEZLF-UHFFFAOYSA-N 0.000 description 1
- GQFITODJWOIYPF-UHFFFAOYSA-N 1-(bromomethyl)-2-iodobenzene Chemical compound BrCC1=CC=CC=C1I GQFITODJWOIYPF-UHFFFAOYSA-N 0.000 description 1
- HXBMIQJOSHZCFX-UHFFFAOYSA-N 1-(bromomethyl)-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1CBr HXBMIQJOSHZCFX-UHFFFAOYSA-N 0.000 description 1
- JDNPUJCKXLOHOW-UHFFFAOYSA-N 1-(bromomethyl)-4-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=C(CBr)C=C1 JDNPUJCKXLOHOW-UHFFFAOYSA-N 0.000 description 1
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-Octene Chemical compound CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 1
- PNFHTBDRPOJJTQ-UHFFFAOYSA-N 1-[ethoxy(iodomethyl)phosphoryl]oxyethane Chemical compound CCOP(=O)(CI)OCC PNFHTBDRPOJJTQ-UHFFFAOYSA-N 0.000 description 1
- OPBOOIFXQHPAPJ-UHFFFAOYSA-M 1-amino-4-anilino-9,10-dioxoanthracene-2-sulfonate Chemical compound C1=C(S([O-])(=O)=O)C(N)=C2C(=O)C3=CC=CC=C3C(=O)C2=C1NC1=CC=CC=C1 OPBOOIFXQHPAPJ-UHFFFAOYSA-M 0.000 description 1
- KSTCOLUUDLJNDS-UHFFFAOYSA-N 1-chloroimidazo[4,5-b]pyridine Chemical compound C1=CC=C2N(Cl)C=NC2=N1 KSTCOLUUDLJNDS-UHFFFAOYSA-N 0.000 description 1
- YZNQITSGDRCUKE-UHFFFAOYSA-N 1-chloropropane Chemical group [CH2]CCCl YZNQITSGDRCUKE-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical class O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- YJQPCOGQQFUKPV-UHFFFAOYSA-N 2-chloro-6-phenyl-7H-purine Chemical compound C=12NC=NC2=NC(Cl)=NC=1C1=CC=CC=C1 YJQPCOGQQFUKPV-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- KBWHYRUAHXHHFO-UHFFFAOYSA-N 3-(bromomethyl)thiophene Chemical compound BrCC=1C=CSC=1 KBWHYRUAHXHHFO-UHFFFAOYSA-N 0.000 description 1
- HQSBCDPYXDGTCL-UHFFFAOYSA-N 3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)triazolo[4,5-d]pyrimidin-5-amine Chemical compound C1=C(N)C(C)=CC(CN2C3=NC(N)=NC(=C3N=N2)C=2OC=CC=2)=C1 HQSBCDPYXDGTCL-UHFFFAOYSA-N 0.000 description 1
- ZBMZOFSLQIPSPW-UHFFFAOYSA-K 3-bis(3-sulfonatophenyl)phosphanylbenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC(P(C=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=C(C=CC=2)S([O-])(=O)=O)=C1 ZBMZOFSLQIPSPW-UHFFFAOYSA-K 0.000 description 1
- OTIHOQRZEZNRMZ-UHFFFAOYSA-N 3-bromo-1-(2-hydroxyethyl)pyridin-2-one Chemical compound OCCN1C=CC=C(Br)C1=O OTIHOQRZEZNRMZ-UHFFFAOYSA-N 0.000 description 1
- FFZHICFAHSDFKZ-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-thiophen-2-yl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CS1 FFZHICFAHSDFKZ-UHFFFAOYSA-N 0.000 description 1
- QSVDFJNXDKTKTJ-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1H-indene Chemical compound C1CCCC2=C1CC=C2 QSVDFJNXDKTKTJ-UHFFFAOYSA-N 0.000 description 1
- GICMHQJTKXNMGB-UHFFFAOYSA-N 4-(5-methoxy-1-benzofuran-2-yl)aniline Chemical compound C=1C2=CC(OC)=CC=C2OC=1C1=CC=C(N)C=C1 GICMHQJTKXNMGB-UHFFFAOYSA-N 0.000 description 1
- WYUUHAORVPRPFB-UHFFFAOYSA-N 4-[[tert-butyl(dimethyl)silyl]oxymethyl]aniline Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC=C(N)C=C1 WYUUHAORVPRPFB-UHFFFAOYSA-N 0.000 description 1
- JDUBGYFRJFOXQC-KRWDZBQOSA-N 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)N)=CC=C(Cl)C=C1 JDUBGYFRJFOXQC-KRWDZBQOSA-N 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
- SVNNWKWHLOJLOK-UHFFFAOYSA-N 5-chloropentanoyl chloride Chemical compound ClCCCCC(Cl)=O SVNNWKWHLOJLOK-UHFFFAOYSA-N 0.000 description 1
- RUKDVLFJSMVBLV-UHFFFAOYSA-N 5-iodo-1H-pyrazole Chemical compound IC1=CC=NN1 RUKDVLFJSMVBLV-UHFFFAOYSA-N 0.000 description 1
- ULDXWLCXEDXJGE-UHFFFAOYSA-N 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one Chemical compound C=1C=C(C=2C(=CC=3C=4N(C(NN=4)=O)C=CC=3N=2)C=2C=CC=CC=2)C=CC=1C1(N)CCC1 ULDXWLCXEDXJGE-UHFFFAOYSA-N 0.000 description 1
- AQGAPDRYTMVBHY-YAQKJFNRSA-O ABVD protocol Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)C(O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C AQGAPDRYTMVBHY-YAQKJFNRSA-O 0.000 description 1
- 101710034857 ATIC Proteins 0.000 description 1
- VEJLEEFUXFQSHP-SJKOYZFVSA-N ATL-444 Chemical compound C1[C@H](C)CCC[C@@]1(O)C#CC1=NC(N)=C(N=CN2CC#C)C2=N1 VEJLEEFUXFQSHP-SJKOYZFVSA-N 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 229950009084 Adecatumumab Drugs 0.000 description 1
- 108010090838 Alemtuzumab Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229960003437 Aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N Aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960001220 Amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229950006061 Anatumomab mafenatox Drugs 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 229950003145 Apolizumab Drugs 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- 210000001742 Aqueous Humor Anatomy 0.000 description 1
- 240000005781 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- IUEWAGVJRJORLA-HZPDHXFCSA-N BMN-673 Chemical compound CN1N=CN=C1[C@H]1C(NNC(=O)C2=CC(F)=C3)=C2C3=N[C@@H]1C1=CC=C(F)C=C1 IUEWAGVJRJORLA-HZPDHXFCSA-N 0.000 description 1
- 229960000190 Bacillus Calmette–Guérin vaccine Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N Benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N Benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N Benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L Bis(triphenylphosphine)palladium(II) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FAGYZXSJZUZJFX-UHFFFAOYSA-N BrC=1C(N(C=CC=1)CCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=O Chemical compound BrC=1C(N(C=CC=1)CCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=O FAGYZXSJZUZJFX-UHFFFAOYSA-N 0.000 description 1
- KWGZUNWEQJFJRW-UHFFFAOYSA-N BrCC1=CC=C(C=C1)C=1C(N(C=CC=1)CCC)=O Chemical compound BrCC1=CC=C(C=C1)C=1C(N(C=CC=1)CCC)=O KWGZUNWEQJFJRW-UHFFFAOYSA-N 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N Bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- VVHKZPAENKQEED-UHFFFAOYSA-N C(C)(=O)OC1OC=CO1 Chemical compound C(C)(=O)OC1OC=CO1 VVHKZPAENKQEED-UHFFFAOYSA-N 0.000 description 1
- ZNLCBRSPDNXNFM-KWYVSSJISA-N C(C)(=O)O[C@@]1([C@H](O[C@@H]2OC(O[C@@H]21)(C)C)CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C#CC1CC1 Chemical compound C(C)(=O)O[C@@]1([C@H](O[C@@H]2OC(O[C@@H]21)(C)C)CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C#CC1CC1 ZNLCBRSPDNXNFM-KWYVSSJISA-N 0.000 description 1
- SMFNJDQGCZQPMP-YUBNGQEKSA-N C(C1=CC=CC=C1)C(C(=O)OCC)(C(=O)OCC)OC[C@H]1OC([C@@H]([C@@]1(O)C#C)O)O Chemical compound C(C1=CC=CC=C1)C(C(=O)OCC)(C(=O)OCC)OC[C@H]1OC([C@@H]([C@@]1(O)C#C)O)O SMFNJDQGCZQPMP-YUBNGQEKSA-N 0.000 description 1
- VGDDSRZVVAUTHR-PGGWPXBNSA-N C(C1=CC=CC=C1)C(C(=O)OCC)(C(=O)OCC)OC[C@H]1OC([C@@H]([C@]1(C#CC)O)O)O Chemical compound C(C1=CC=CC=C1)C(C(=O)OCC)(C(=O)OCC)OC[C@H]1OC([C@@H]([C@]1(C#CC)O)O)O VGDDSRZVVAUTHR-PGGWPXBNSA-N 0.000 description 1
- NSNKWKMIXASNOI-SCTDMFTHSA-N C(C1=CC=CC=C1)C(C(=O)OCC)(C(=O)OCC)OC[C@H]1OC([C@@H]([C@]1(C#CC)OC(C)=O)OC(C)=O)OC(C)=O Chemical compound C(C1=CC=CC=C1)C(C(=O)OCC)(C(=O)OCC)OC[C@H]1OC([C@@H]([C@]1(C#CC)OC(C)=O)OC(C)=O)OC(C)=O NSNKWKMIXASNOI-SCTDMFTHSA-N 0.000 description 1
- 108010080422 CD39 antigen Proteins 0.000 description 1
- GZBCQHINVNJZDO-UHFFFAOYSA-L COC1=NC=CC=C1C1=CC=C(CC(C(=O)[O-])C(=O)[O-])C=C1 Chemical compound COC1=NC=CC=C1C1=CC=C(CC(C(=O)[O-])C(=O)[O-])C=C1 GZBCQHINVNJZDO-UHFFFAOYSA-L 0.000 description 1
- OMFHQUCUWSMFOJ-FMONCPFKSA-N COMP protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 OMFHQUCUWSMFOJ-FMONCPFKSA-N 0.000 description 1
- XMJCOTSQMHGIPF-SNSGICDFSA-N COPP protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.CNNCC1=CC=C(C(=O)NC(C)C)C=C1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 XMJCOTSQMHGIPF-SNSGICDFSA-N 0.000 description 1
- 102100006435 CSF3 Human genes 0.000 description 1
- 102100005310 CTLA4 Human genes 0.000 description 1
- 101700054183 CTLA4 Proteins 0.000 description 1
- 101710024147 CYP716A53v2 Proteins 0.000 description 1
- DVBUNONAEWNNSA-ALOLQEJTSA-N CYVADIC protocol Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O.ClCCN(CCCl)P1(=O)NCCCO1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 DVBUNONAEWNNSA-ALOLQEJTSA-N 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L Calcium hydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N Carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 241001603164 Carp edema virus Species 0.000 description 1
- 229920002301 Cellulose acetate Polymers 0.000 description 1
- JCYRRZITSZDHKN-WODMUGMNSA-N ChlVPP protocol Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1.OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1.O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JCYRRZITSZDHKN-WODMUGMNSA-N 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- 229960003677 Chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N Chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- GWVWVPHYHIDFGS-UHFFFAOYSA-N ClC1=C(C=CC=C1)C1=NC=C2N=CNC2=N1 Chemical compound ClC1=C(C=CC=C1)C1=NC=C2N=CNC2=N1 GWVWVPHYHIDFGS-UHFFFAOYSA-N 0.000 description 1
- HIRRYELEAGFLOP-UUTQCIBDSA-N ClC1=NC(=C2N=CN(C2=N1)[C@H]1[C@@H]([C@@]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=CSC=C1)(O)C#C)O)NC(C)C Chemical compound ClC1=NC(=C2N=CN(C2=N1)[C@H]1[C@@H]([C@@]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=CSC=C1)(O)C#C)O)NC(C)C HIRRYELEAGFLOP-UUTQCIBDSA-N 0.000 description 1
- 229960002286 Clodronic Acid Drugs 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N Clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- BSMCAPRUBJMWDF-KRWDZBQOSA-N Cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 1
- 229960002271 Cobimetinib Drugs 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L Copper(II) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N Crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229940097362 Cyclodextrins Drugs 0.000 description 1
- HGCIXCUEYOPUTN-UHFFFAOYSA-N Cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 1
- DUSHUSLJJMDGTE-ZJPMUUANSA-N Cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
- 229960001305 Cysteine Hydrochloride Drugs 0.000 description 1
- 229960002887 Deanol Drugs 0.000 description 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N Decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
- SWJBYJJNDIXFSA-KUHUBIRLSA-N Demethoxyviridin Chemical compound O=C1C2=C3CCC(=O)C3=CC=C2[C@]2(C)C3=C1OC=C3C(=O)C[C@H]2O SWJBYJJNDIXFSA-KUHUBIRLSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 229940120124 Dichloroacetate Drugs 0.000 description 1
- 229960003839 Dienestrol Drugs 0.000 description 1
- NFDFQCUYFHCNBW-SCGPFSFSSA-N Dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N Diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229950009791 Durvalumab Drugs 0.000 description 1
- 108030007212 EC 3.4.21.79 Proteins 0.000 description 1
- 102100009513 ENTPD2 Human genes 0.000 description 1
- 210000002889 Endothelial Cells Anatomy 0.000 description 1
- 210000003038 Endothelium Anatomy 0.000 description 1
- 229950006370 Epacadostat Drugs 0.000 description 1
- 229950009760 Epratuzumab Drugs 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 Erlotinib Drugs 0.000 description 1
- 229960005309 Estradiol Drugs 0.000 description 1
- 229960001842 Estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N Ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 229940012356 Eye Drops Drugs 0.000 description 1
- 229960004177 Filgrastim Drugs 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N Fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
- 229960002011 Fludrocortisone Drugs 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N Fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 Fluoxymesterone Drugs 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- XPFVYQJUAUNWIW-UHFFFAOYSA-N Furfuryl alcohol Chemical compound OCC1=CC=CO1 XPFVYQJUAUNWIW-UHFFFAOYSA-N 0.000 description 1
- 108090000045 G-protein coupled receptors Proteins 0.000 description 1
- 102000003688 G-protein coupled receptors Human genes 0.000 description 1
- 102100004391 GZMB Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229940045109 Genistein Drugs 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N Genistin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 208000005017 Glioblastoma Diseases 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229960002913 Goserelin Drugs 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 229960003690 Goserelin Acetate Drugs 0.000 description 1
- 108009000344 Head and Neck Squamous Cell Carcinoma Proteins 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 101700081979 IER2 Proteins 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229950009034 Indoximod Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010027059 Inotuzumab Ozogamicin Proteins 0.000 description 1
- 229950004101 Inotuzumab ozogamicin Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- 108010089187 Ipilimumab Proteins 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229950007752 Isatuximab Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- IQVRBWUUXZMOPW-PKNBQFBNSA-N Istradefylline Chemical compound CN1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1\C=C\C1=CC=C(OC)C(OC)=C1 IQVRBWUUXZMOPW-PKNBQFBNSA-N 0.000 description 1
- 229950009028 Istradefylline Drugs 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- FABUFPQFXZVHFB-PVYNADRNSA-N Ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-PVYNADRNSA-N 0.000 description 1
- 210000000281 Joint Capsule Anatomy 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levotetramisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 229910013596 LiOH—H2O Inorganic materials 0.000 description 1
- 229940040692 Lithium Hydroxide Monohydrate Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N Lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 210000003141 Lower Extremity Anatomy 0.000 description 1
- 208000003747 Lymphoid Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- NMQDFAIHBHQNGG-AYVPXZHZSA-L M-VAC protocol Chemical compound [NH2-].[NH2-].Cl[Pt+2]Cl.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 NMQDFAIHBHQNGG-AYVPXZHZSA-L 0.000 description 1
- 102100012572 MOBP Human genes 0.000 description 1
- 101700007176 MOBP Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L Magnesium hydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N Medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 229960003105 Metformin Drugs 0.000 description 1
- ZIYVHBGGAOATLY-UHFFFAOYSA-N Methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 210000004088 Microvessels Anatomy 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N Miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 229960000350 Mitotane Drugs 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 210000002200 Mouth Mucosa Anatomy 0.000 description 1
- 229940051866 Mouthwash Drugs 0.000 description 1
- 101700030819 Msx3 Proteins 0.000 description 1
- QAXZWHGWYSJAEI-UHFFFAOYSA-N N,N-dimethylformamide;ethanol Chemical compound CCO.CN(C)C=O QAXZWHGWYSJAEI-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HWYHDWGGACRVEH-UHFFFAOYSA-N N-methyl-N-(4-pyrrolidin-1-ylbut-2-ynyl)acetamide Chemical compound CC(=O)N(C)CC#CCN1CCCC1 HWYHDWGGACRVEH-UHFFFAOYSA-N 0.000 description 1
- PTGIMRMEAXZIGG-SRGAATOTSA-N N1=CC=C(C=C1)CC(C(=O)OCC)(C(=O)OCC)OC[C@H]1OC([C@@H]([C@]1(C#C)OC(C)=O)OC(C)=O)OC(C)=O Chemical compound N1=CC=C(C=C1)CC(C(=O)OCC)(C(=O)OCC)OC[C@H]1OC([C@@H]([C@]1(C#C)OC(C)=O)OC(C)=O)OC(C)=O PTGIMRMEAXZIGG-SRGAATOTSA-N 0.000 description 1
- UEBMIJOFAXSWAN-OVJZRAFVSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=CC=C(C=C1)C=1C(NC=CC=1)=O)(O)C#C)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=CC=C(C=C1)C=1C(NC=CC=1)=O)(O)C#C)O UEBMIJOFAXSWAN-OVJZRAFVSA-N 0.000 description 1
- UZSSDJGSFJEXFV-YGRIRRHQSA-N NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=CSC=C1)(O)C#C)O Chemical compound NC1=C2N=CN(C2=NC(=N1)Cl)[C@H]1[C@@H]([C@@]([C@H](O1)COC(C(=O)O)(C(=O)O)CC1=CSC=C1)(O)C#C)O UZSSDJGSFJEXFV-YGRIRRHQSA-N 0.000 description 1
- 238000006411 Negishi coupling reaction Methods 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000009025 Nervous System Disease Diseases 0.000 description 1
- 206010029305 Neurological disorder Diseases 0.000 description 1
- 229910003301 NiO Inorganic materials 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N Nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 108010019706 Nivolumab Proteins 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 229950006344 Nocodazole Drugs 0.000 description 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 1
- 229910004727 OSO3H Inorganic materials 0.000 description 1
- 229950009090 Ocaratuzumab Drugs 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 229960002700 Octreotide Drugs 0.000 description 1
- 229960002450 Ofatumumab Drugs 0.000 description 1
- LZMPYSIUWPEIRA-XFXZXTDPSA-N Ofatumumab Chemical compound N1=C2C=3COCCC=3N=CC2=N\C1=C1\NOC=C1 LZMPYSIUWPEIRA-XFXZXTDPSA-N 0.000 description 1
- 229940042125 Oral Ointment Drugs 0.000 description 1
- 229940041678 Oral Spray Drugs 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 102100005499 PTPRC Human genes 0.000 description 1
- 101700059076 PTPRC Proteins 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 235000003177 Panax trifolius Nutrition 0.000 description 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 1
- 241001135902 Peanut clump virus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229960002340 Pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229950010632 Perifosine Drugs 0.000 description 1
- SZFPYBIJACMNJV-UHFFFAOYSA-N Perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N Phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- XIPFMBOWZXULIA-UHFFFAOYSA-N Pivalamide Chemical compound CC(C)(C)C(N)=O XIPFMBOWZXULIA-UHFFFAOYSA-N 0.000 description 1
- 229960003171 Plicamycin Drugs 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241001272996 Polyphylla fullo Species 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N Pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- DTYWJKSSUANMHD-UHFFFAOYSA-N Preladenant Chemical compound C1=CC(OCCOC)=CC=C1N1CCN(CCN2C3=C(C4=NC(=NN4C(N)=N3)C=3OC=CC=3)C=N2)CC1 DTYWJKSSUANMHD-UHFFFAOYSA-N 0.000 description 1
- 229950008939 Preladenant Drugs 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N Propargyl alcohol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N Propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- 229940075579 Propyl Gallate Drugs 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N Pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N Retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- AEULVFLPCJOBCE-UHFFFAOYSA-N SCH-442,416 Chemical compound C1=CC(OC)=CC=C1CCCN1C(N=C(N)N2C3=NC(=N2)C=2OC=CC=2)=C3C=N1 AEULVFLPCJOBCE-UHFFFAOYSA-N 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 229940100996 SODIUM BISULFATE Drugs 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229950000106 Samalizumab Drugs 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N Selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 229950010746 Selumetinib Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 1
- 108020004459 Small Interfering RNA Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 229920001985 Small interfering RNA Polymers 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M Sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N Sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229940091252 Sodium supplements Drugs 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 229940032147 Starch Drugs 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N Suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 Suramin Drugs 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 229950004550 Talazoparib Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 229960003604 Testosterone Drugs 0.000 description 1
- HWCKGOZZJDHMNC-UHFFFAOYSA-M Tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 1
- 229960003433 Thalidomide Drugs 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N Thalidomide Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- 208000008732 Thymoma Diseases 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N Tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 108010010691 Trastuzumab Proteins 0.000 description 1
- 229950007217 Tremelimumab Drugs 0.000 description 1
- 229960001727 Tretinoin Drugs 0.000 description 1
- WVLBCYQITXONBZ-UHFFFAOYSA-N Trimethyl phosphate Chemical compound COP(=O)(OC)OC WVLBCYQITXONBZ-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 210000003708 Urethra Anatomy 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 229950011257 Veliparib Drugs 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- 229950003008 Vipadenant Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000004127 Vitreous Body Anatomy 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- QIJRTFXNRTXDIP-JIZZDEOASA-N [(1R)-1-carboxy-2-sulfanylethyl]azanium;chloride;hydrate Chemical compound O.Cl.SC[C@H](N)C(O)=O QIJRTFXNRTXDIP-JIZZDEOASA-N 0.000 description 1
- ASCUXPQGEXGEMJ-GPLGTHOPSA-N [(2R,3S,4S,5R,6S)-3,4,5-triacetyloxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(4-methylanilino)oxan-2-yl]methoxy]oxan-2-yl]methyl acetate Chemical compound CC(=O)O[C@@H]1[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@H]1OC[C@@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](NC=2C=CC(C)=CC=2)O1 ASCUXPQGEXGEMJ-GPLGTHOPSA-N 0.000 description 1
- GZZBZWITJNATOD-UHFFFAOYSA-N [4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanol Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(CO)C=C1 GZZBZWITJNATOD-UHFFFAOYSA-N 0.000 description 1
- PZRPBPMLSSNFOM-UHFFFAOYSA-N [4-(hydroxymethyl)phenyl]boronic acid Chemical compound OCC1=CC=C(B(O)O)C=C1 PZRPBPMLSSNFOM-UHFFFAOYSA-N 0.000 description 1
- YVJBCTFVENNIOV-UHFFFAOYSA-M [Br-].CC#C[Mg+] Chemical compound [Br-].CC#C[Mg+] YVJBCTFVENNIOV-UHFFFAOYSA-M 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- CEBXCCANICKCHP-MXHMCPQYSA-N [Si](C1=CC=CC=C1)(C1=CC=CC=C1)(C(C)(C)C)OC[C@@H]1[C@]([C@H](C(O1)O)O)(O)C#C Chemical compound [Si](C1=CC=CC=C1)(C1=CC=CC=C1)(C(C)(C)C)OC[C@@H]1[C@]([C@H](C(O1)O)O)(O)C#C CEBXCCANICKCHP-MXHMCPQYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- IKDXDQDKCZPQSZ-JHYYTBFNSA-N acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopro Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 IKDXDQDKCZPQSZ-JHYYTBFNSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 108091003858 adecatumumab Proteins 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- USNRYVNRPYXCSP-JUGPPOIOSA-N afatinib dimaleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 USNRYVNRPYXCSP-JUGPPOIOSA-N 0.000 description 1
- 229960002736 afatinib dimaleate Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 229940087168 alpha Tocopherol Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 150000004056 anthraquinones Chemical group 0.000 description 1
- 230000002744 anti-aggregatory Effects 0.000 description 1
- 230000003556 anti-epileptic Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 description 1
- 230000000949 anxiolytic Effects 0.000 description 1
- 108010062611 apolizumab Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- JSIYGGNTVMFDHJ-UHFFFAOYSA-N bicyclo[4.1.0]hept-5-ene Chemical compound C1CCC=C2CC21 JSIYGGNTVMFDHJ-UHFFFAOYSA-N 0.000 description 1
- RPZUBXWEQBPUJR-UHFFFAOYSA-N bicyclo[4.2.0]octane Chemical compound C1CCCC2CCC21 RPZUBXWEQBPUJR-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceuticals Drugs 0.000 description 1
- VRXYCDTWIOCJBH-UHFFFAOYSA-N bis(dichlorophosphoryl)methane Chemical compound ClP(Cl)(=O)CP(Cl)(Cl)=O VRXYCDTWIOCJBH-UHFFFAOYSA-N 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 230000003435 bronchoconstrictive Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 1
- 229960001573 cabazitaxel Drugs 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 125000005884 carbocyclylalkyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- STNNHWPJRRODGI-UHFFFAOYSA-N carbonic acid;N,N-diethylethanamine Chemical compound [O-]C([O-])=O.CC[NH+](CC)CC.CC[NH+](CC)CC STNNHWPJRRODGI-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 108090000758 catumaxomab Proteins 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- WRXDGGCKOUEOPW-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)NS(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 WRXDGGCKOUEOPW-UHFFFAOYSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 150000001925 cycloalkenes Chemical group 0.000 description 1
- IMYJOYAAVSFZMM-UHFFFAOYSA-L cyclopenta-1,3-diene;titanium(2+);dichloride Chemical compound [Cl-].[Cl-].[Ti+2].C1C=CC=[C-]1.C1C=CC=[C-]1 IMYJOYAAVSFZMM-UHFFFAOYSA-L 0.000 description 1
- 229960003843 cyproterone Drugs 0.000 description 1
- 230000001461 cytolytic Effects 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000000994 depressed Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 125000005131 dialkylammonium group Chemical group 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-M dichloroacetate Chemical compound [O-]C(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-M 0.000 description 1
- DAKIDYQCFJQMDF-UHFFFAOYSA-N dichloromethane;pyridine Chemical compound ClCCl.C1=CC=NC=C1 DAKIDYQCFJQMDF-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- BNKDGTGYTVFGBY-UHFFFAOYSA-N diethoxyphosphorylmethyl trifluoromethanesulfonate Chemical compound CCOP(=O)(OCC)COS(=O)(=O)C(F)(F)F BNKDGTGYTVFGBY-UHFFFAOYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 108010016436 durvalumab Proteins 0.000 description 1
- 108010047482 ectoATPase Proteins 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- 108010007604 epratuzumab Proteins 0.000 description 1
- 229960003649 eribulin Drugs 0.000 description 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-M ethyl carbonate Chemical compound CCOC([O-])=O CQDGTJPVBWZJAZ-UHFFFAOYSA-M 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 1
- NPTDXPDGUHAFKC-UHFFFAOYSA-N ethynylcyclopropane Chemical compound C#CC1CC1 NPTDXPDGUHAFKC-UHFFFAOYSA-N 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 239000000937 glycosyl acceptor Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000001867 hydroperoxy group Chemical group [*]OO[H] 0.000 description 1
- 230000001146 hypoxic Effects 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000266 injurious Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 238000006713 insertion reaction Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 108010011618 isatuximab Proteins 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- ZEABYRLMGDTEAI-UHFFFAOYSA-M lithium;methanol;hydroxide Chemical compound [Li+].[OH-].OC ZEABYRLMGDTEAI-UHFFFAOYSA-M 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000006439 lymphocytic leukemia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- GNRSAWUEBMWBQH-UHFFFAOYSA-N nickel(II) oxide Inorganic materials [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 108010045555 obinutuzumab Proteins 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 108091019562 ocaratuzumab Proteins 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108010052070 ofatumumab Proteins 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative Effects 0.000 description 1
- YWWARDMVSMPOLR-UHFFFAOYSA-M oxolane;tetrabutylazanium;fluoride Chemical compound [F-].C1CCOC1.CCCC[N+](CCCC)(CCCC)CCCC YWWARDMVSMPOLR-UHFFFAOYSA-M 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasites Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 108010026276 pembrolizumab Proteins 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000011528 polyamide (building material) Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 150000003152 propanolamines Chemical group 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N propyl 3,4,5-trihydroxybenzoate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108010026911 ramucirumab Proteins 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 230000001624 sedative Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- LIBWRRJGKWQFSD-UHFFFAOYSA-M sodium;2-nitrobenzenesulfonate Chemical compound [Na+].[O-][N+](=O)C1=CC=CC=C1S([O-])(=O)=O LIBWRRJGKWQFSD-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003595 spectral Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 230000000707 stereoselective Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 229960001663 sulfanilamide Drugs 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 150000003458 sulfonic acid derivatives Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- HSVFKFNNMLUVEY-UHFFFAOYSA-N sulfuryl diazide Chemical compound [N-]=[N+]=NS(=O)(=O)N=[N+]=[N-] HSVFKFNNMLUVEY-UHFFFAOYSA-N 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 201000000331 testicular germ cell cancer Diseases 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000007944 thiolates Chemical class 0.000 description 1
- 201000009365 thymic carcinoma Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 108010072993 tremelimumab Proteins 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cells Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000000989 vascularization Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000000261 vasodilator Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 1
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
- PGOLTJPQCISRTO-UHFFFAOYSA-N vinyllithium Chemical compound [Li]C=C PGOLTJPQCISRTO-UHFFFAOYSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Abstract
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
Description
Ectonucleotidase Inhibitors and Methods of Use Thereof
RELATED APPLICATIONS
This application claims the benefit of US. Provisional Application No. 62/688,225,
filed June 21, 2018, and US. Provisional Application No. ,505, filed April 1, 2019,
each of which is hereby incorporated by reference in its entirety.
BACKGROUND
CD73, also referred to as 5’-nucleotidase ) or ecto-5’-nucleotidase (Ecto
’NTase), is a ne-bound cell surface enzyme whose primary role is to ze the
conversion of extracellular nucleotides (e.g., AMP) to their corresponding nucleosides (e.g.,
adenosine), CD73 is found in most tissues and expressed on lymphocytes, endothelial cells,
and epithelial cells. It is also widely expressed in many tumor cell lines and, notably, is
upregulated in cancerous tissues (Antonioli er al., Nat. Rev. Cancer, 13: 842-857, 2013).
In tandem with CD39 (ecto-ATPase), CD73 generates adenosine from ATP/AMP,
which is often released from d or inflamed cells into the extracellular nment.
Extracellular adenosine produced by CD73 cts with G-protein coupled receptors on
target cells. An important downstream effect of this signaling is increased
immunosuppression via a number of pathways. For example, CD73 is a co-signaling
molecule on T cytes. Under normal circumstances, extracellular adenosine levels
promote a self-limiting immune response that prevents excessive inflammation and tissue
damage. For tumors, an advantage of ally increased CD73 is that the resulting
increased CD73-catalyzed adenosine levels yield inhibition of anti—tumor immune system
responses.
Even though CD73 plays a role in cancer immunosuppression, higher expression of
CD73 is associated with a variety of stages of tumor progression, including tumor
vascularization, veness, and metastasis, and with shorter breast cancer patient survival
time. Some of these observations result from CD73’s enzyme-independent function as an
on molecule required for lymphocyte binding to the endothelium.
Overall, CD73 has become an important target for developing new cancer therapies,
either as single agents or in combination with other cancer therapies. Indeed, combining
CD73 monoclonal dies with antibodies for other chemotherapy targets enhances
response and survival in animal cancer models (Allard et al., Clin. Cancer Res., 19:5626-35,
2013).
Many of the current cancer treatments and chemotherapeutic agents fail to
successfully treat all patients or all symptoms in treated patients, and many of these ies
are associated with rable side effects. As certain cancers develop resistance to various
chemotherapeutic agents, ate cancer therapies are needed. Thus, there is a need for
additional compounds and methods for treating cancer and other diseases.
SUMMARY
Disclosed herein are compounds of Formula (I):
Y 0 Het
R2b R1 b
R23 R1a
or a pharmaceutically acceptable salt and/or prodrug thereof, wherein
R4 o o
R5 || II
\P p_§_
5i R15/ V/
Y is R6 or R15
Het is heterocyclyl or heteroaryl;
Rlais ed from H, halo, hydroxy, cyano, azido, amino, C1-6alkyl, hydroxyCi-
6alkyl, amino-Ci-salkyl, -O-C(O)-O-C1-6alkyl, Cmacyloxy, C1-6alkoxy, C2.6alkenyl, and
kynyl;
R1b is selected from H, halo, C1-6alkyl, hydroxy-C1-6alkyl, amino-C1-6alkyl,
C2-6alkenyl, and C2-6alkynyl;
Rzais selected from halo, y, cyano, azido, amino, kyl, hydroxy-C1-6alkyl,
amino-Ci—salkyl, C1-6acyloxy, -O-C(O)-O-C1-6alkyl, C1-6alkoxy, C2-6alkenyl, and C2-6alkynyl;
R21) is selected from halo, C1-6alkyl, C2-6alkenyl, and C2.6alkynyl, preferably
substituted or tituted Czalkynyl, most preferably unsubstituted Czalkynyl;
R3 is selected from H and alkyl,
R4 is selected from H, alkyl, CN, aryl, heteroaryl, -C(O)OR9, RHR12, -
S(O)2R10, -P(O)(OR”)(OR12), and -P(O)(OR”)(NR13R14);
R5 is ed from H, cyano, alkyl, lkylalkyl, heterocyclylalkyl, aralkyl,
heteroaralkyl, and -C(O)OR9;
R6 is selected from —C(O)OR9, -C(O)NR16R17, and —P(O)(OR11)(OR12);
R9 is independently selected from H, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl,
heterocyclylalkyl, aryl, aralkyl, heteroaryl, and heteroaralkyl;
R10 is independently selected from alkyl, alkenyl, alkynyl, amino, lkyl,
cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, and heteroaralkyl;
each R11 and R12 is independently selected from H, alkyl, cycloalkyl, cycloalkylalkyl,
heterocyclyl, cyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or
R11 and R12, together with the en atom to which they are attached, form a 5- to
7-membered heterocyclyl,
R13 is H or alkyl,
R14 is alkyl or aralkyl,
each R15 is independently selected from y, alkoxy acyloxy and NR13R14,
each R16 and R17 is independently selected from H, hydroxy, alkyl, cycloalkyl,
cycloalkylalkyl, cyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or
R16 and R17, together with the nitrogen atom to which they are attached, form a 5- to
7-membered heterocyclyl.
In certain preferred embodiments of Formula I, the included compounds meet the
terms of a) and b); or a) and c);
wherein:
W0 46403
O NH2 NH2
0 GE </N '\N
EtO 0:0N
0 NA Nn
a) the compound is not To“
0 ”81:1 0
o v.
)LN Ho‘
HN\\)
\N o
N//'\CI
“1:56 /=N \N
0 O <’ I
Eto O N /
HO CAL-7‘NW N/kCI
“0 ”OH ”3/“ . .
Cl Ho‘ ’OH
, ,or
O NH2
b) if R4 and R6 are each -C(O)OH and R5 is benzyl substituted on the phenyl ring with
a heterocyclyl or heteroaryl substituent, then the phenyl ring substituent is selected from
unsubstituted or substituted pyrrolidinyl, piperazinonyl, piperidonyl, tetrahydropyrimidonyl,
nyl, and pyridyl; and
c) if R4 is H or tetrazolyl, R6 is -C(O)OH, and R5 is benzyl substituted on the
phenyl ring with a second phenyl ring, then either the benzyl phenyl ring or the second
phenyl ring is substituted with -C(O)OR9 where R9 is H or alkyl.
R6 In some embodiments, Y is . In other embodiments, Y is
O O
R” || II
> p—;—
R15 V/
In certain preferred embodiments:
W0 20192946403
O NH2 NH2
0 GE </N '\N
EtO 0:0N
0 NA Nn
a) the nd is not To“
0 ”81:1 0
o v.
)LN Ho‘
HN\\)
\N o
N//'\CI
N; \,N o NH2
N o OEt N O 0%O N/=N
NH </ l1
2 /
HO ”OH ”3/“ . .
Cl Ho‘ ’OH ,or
O NH2
0 OH N
</ 1‘”
b) R2b is selected from halo, C2-6alkyl, C2-6alkenyl, and kynyl, preferably
substituted or unsubstituted Czalkynyl, most preferably unsubstituted Czalkynyl, and either
c) R5 is benzyl substituted on the phenyl ring with a substituent selected from
unsubstituted or substituted piperidonyl, tetrahydropyrimidonyl, pyridonyl, and pyridyl, or
d) R5 is benzyl substituted on the phenyl ring with a second phenyl ring substituted
with -C(O)OR9 Where R9 is H or alkyl.
In certain embodiments, the present invention provides a ceutical composition
suitable for use in a subject in the treatment or prevention of cancer comprising an effective
amount of any of the compounds described herein (e. g., a nd of the invention, such as
a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and one or more
ceutically acceptable excipients. In certain embodiments, the pharmaceutical
preparations may be for use in treating or preventing a condition or disease as described
herein.
Disclosed herein are methods of treating diseases and conditions that benefit from the
inhibition of CD73, comprising administering to a subject in need thereof an effective amount
of a nd as disclosed herein (e.g., a compound of Formula (I) or any of the
embodiments thereof sed herein). In certain embodiments, the human t is in need
of such treatment. These diseases include, but are not limited to cancers, such as lung cancer,
WO 46403
kidney cancer, skin cancer, breast cancer, and ovarian cancer. Other diseases and conditions
that can be treated using the methods described herein include, but are not limited to,
neurological, neurodegenerative and CNS disorders and diseases such as sion and
son’s disease, cerebral and c ischemic diseases, sleep disorders, fibrosis, immune
and inflammatory disorders.
Provided herein are combination therapies of compounds of formula (I) with
onal antibodies and other chemotherapeutic agents that can enhance the therapeutic
benefit beyond the ability of the adjuvant therapy alone.
BRIEF DESCRIPTION OF THE FIGURES
depicts the increase in %CD8+ cells of CD45+ cells in EG7 tumors from
mice treated with Compound 9.
depicts the reversal of efficacy using Compound 9 when CD8+ cells are
ed with an anti-CD8 antibody.
depicts the al of AMP-mediated suppression of CD8+ T cells using the
CD73 inhibitor Compound 9, including the EC50=11.6nM for CD8+ T cell proliferation.
depicts the EC50=9.6 nM for CD8+ T cell activation.
depicts the .5 nM for [FN—gamma production.
depicts the ECso=5.6nM for Granzyme B tion.
depicts the effect of Compound 9 on proliferation of certain cell lines,
including the comparable % cell survival of EG7 cells, a mouse T cell lymphoma cell line.
depicts the comparable % cell al of A375 cells, a human melanoma
cell line.
depicts the comparable % divided cells of human CD8+ T cells.
depicts the potency of Compound 9 as evaluated against CD73 and CD73-
expressing SK-lVIEL—28 cells.
depicts the IC50=0.17 nM for human recombinant CD73.
depicts the ICso=0.38 nM for human plasma CD73.
depicts the 1C50=0.21 nM for human CD73 cell surface assay.
depicts the level of Compound 9 in mouse plasma.
depicts the inhibition of CD73 in mouse plasma.
s the efficacy of Compound 9 against EG7 tumors.
depicts the efficacy of Compound 9 against CT26 tumors.
depicts the reduction in tumor volume with single agent Compound 9 and
combination therapy with anti-PD—Ll antibody.
FIGs. 7B-7E show dual replications of this measurement for each dosing. is vehicle. is anti- PD-Ll antibody. is Compound 9. is
Compound 9 + Anti—PD-Ll.
depicts the reduction in tumor volume with single agent Compound 9 and
combination therapy with oxaliplatin.
FIGs. 8B-8E show individual ations of this ement for each dosing. is vehicle. is oxaliplatin. is Compound 9. FIG. SE is Compound 9 +
latin.
depicts the reduction in tumor volume with single agent Compound 9 and
combination therapy with doxorubicin.
FIGs. 9B-9E show individual replications of this measurement for each dosing. is vehicle. is doxorubicin. is Compound 9. is Compound 9 +
doxorubicin.
A depicts the sub-nanomolar inhibition of CD73 activity in head and neck
squamous cell oma (HNSCC) serum by Compound 9.
B s the sub—nanomolar tion of CD73 activity in ovarian cancer
serum by Compound 9.
C depicts the sub-nanomolar inhibition of CD73 activity in triple—negative
breast cancer (TNBC) serum by compound 9.
D depicts the sub-nanomolar inhibition of CD73 activity in esophageal cancer
serum by Compound 9.
depicts normalized mRNA expression levels of CD73 in tumor and normal
A depicts the reduction in tumor volume with single agent Compound 9 and
combination therapy with docetaxel in EG7 tumor model.
FIGs. 12B-12E depict individual replications of the reduction in tumor .
B shows vehicle. C is Compound 9. D is docetaxel. E is Compound 9 + docetaxel.
A depicts Compound 9 reduced the growth of established EG7 tumors.
FIGs. 13B-13D depict individual replications of the reduction in tumor growth.
B is vehicle. C is dosing of nd 9 started on day 1. D
is Compound 9 started on day 6.
DETAILED DESCRIPTION
Definitions
Unless defined otherwise, all technical and scientific terms used herein have the
meaning commonly understood by a person skilled in the art of the t disclosure. The
following references provide one of skill with a general definition of many of the terms used
in this disclosure: Singleton et al., Dictionary of Microbiology and Molecular y (2nd
ed. 1994), The Cambridge Dictionary of e and Technology (Walker ed, 1988), The
Glossary of Genetics, 5th Ed, R. Rieger et al. (eds.), Springer Verlag (1991); and Hale &
Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following
terms have the meanings ascribed to them below, unless specified otherwise.
In some embodiments, chemical structures are disclosed with a corresponding
chemical name. In case of conflict, the al structure controls the meaning, rather than
the name.
In this disclosure, "comprises, comprising, containing" and "having" and the like
" includes,"
can have the meaning ascribed to them in US. Patent law and can mean
"including," and the like, "consisting essentially of" or "consists ially" likewise has the
meaning ed in US. Patent law and the term is open-ended, allowing for the presence of
more than that which is recited so long as basic or novel characteristics of that which is
recited are not substantially changed by the presence of more than that which is recited, but
excludes prior art embodiments.
Unless specifically stated or obvious from context, as used herein, the term "or" is
understood to be inclusive. Unless specifically stated or obvious from context otherwise, as
used herein, the terms "a", "an", and "the" are understood to be ar or plural.
The term “acyl” is cognized and refers to a group represented by the l
formula arble(O)—, preferably alkle(O)-.
The term mino” is art-recognized and refers to an amino group substituted with
an acyl group and may be represented, for example, by the formula hydrocarble(O)NH-.
The term “acyloxy” is art-recognized and refers to a group represented by the general
formula hydrocarble(O)O-, preferably alkle(O)O-.
The term “alkoxy” refers to an alkyl group, preferably a lower alkyl group, having an
oxygen attached thereto. Representative alkoxy groups e methoxy, ethoxy, propoxy,
utoxy and the like.
The term “alkoxyalkyl” refers to an alkyl group substituted with an alkoxy group and
may be represented by the general formula alkyl-O-alkyl.
The term “alkenyl”, as used herein, refers to an aliphatic group containing at least one
double bond and is intended to include both "unsubstituted alkenyls" and "substituted
alkenyls", the latter of which refers to alkenyl moieties having substituents replacing a
hydrogen on one or more carbons of the alkenyl group. Such substituents may occur on one
or more s that are included or not included in one or more double bonds. Moreover,
such substituents include all those contemplated for alkyl groups, as discussed below, except
where stability is prohibitive. For example, substitution of alkenyl groups by one or more
alkyl, carbocyclyl, aryl, heterocyclyl, or heteroaryl groups is plated.
An “alkyl” group or “alkane” is a straight chained or branched non-aromatic
hydrocarbon which is completely ted. Typically, a straight chained or branched alkyl
group has from 1 to about 20 carbon atoms, preferably from 1 to about 10 unless otherwise
. Examples of straight chained and branched alkyl groups include , ethyl, n-
propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, hexyl, pentyl and octyl. A C1-C6
straight chained or branched alkyl group is also ed to as a "lower alkyl" group.
Moreover, the term " (or "lower ) as used throughout the specification,
examples, and claims is intended to include both "unsubstituted alkyls" and ituted
alkyls", the latter of which refers to alkyl moieties having substituents replacing a hydrogen
on one or more carbons of the hydrocarbon backbone. Such substituents, if not otherwise
specified, can include, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an
alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a
thioformate), an alkoxy, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino,
an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a
sulfate, a ate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an
aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the
es substituted on the hydrocarbon chain can themselves be substituted, if appropriate.
For instance, the tuents of a substituted alkyl may include substituted and unsubstituted
forms of amino, azido, imino, amido, oryl (including phosphonate and phosphinate),
sulfonyl (including sulfate, sulfonamido, sulfamoyl and ate), and silyl groups, as well
as ethers, alkylthios, yls (including ketones, des, carboxylates, and esters), -CF3,
-CN and the like. Exemplary substituted alkyls are described below. Cycloalkyls can be
further tuted with alkyls, ls, alkoxys, alkylthios, aminoalkyls, carbonyl-
substituted , —CF3, -CN, and the like.
The term “Cx.y” when used in conjunction with a chemical moiety, such as, acyl,
acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups that contain from X to y
s in the chain. For example, the term “Cx—yalkyl” refers to substituted or unsubstituted
saturated hydrocarbon , including straight-chain alkyl and branched-chain alkyl groups
that n from x to y carbons in the chain, including haloalkyl groups such as
trifluoromethyl and 2,2,2-tirfluoroethyl, etc. Co alkyl indicates a hydrogen where the group is
in a terminal position, a bond if internal. The terms “C2.yalkenyl” and “C2.yalkynyl” refer to
substituted or unsubstituted unsaturated aliphatic groups analogous in length and possible
substitution to the alkyls described above, but that contain at least one double or triple bond
respectively.
The term “alkylamino”, as used herein, refers to an amino group substituted with at
least one alkyl group.
The term “alkylthio”, as used herein, refers to a thiol group substituted with an alkyl
group and may be represented by the general formula alkylS-.
The term “alkynyl”, as used herein, refers to an aliphatic group containing at least one
triple bond and is intended to include both stituted alkynyls" and "substituted
alkynyls", the latter of which refers to alkynyl moieties having substituents replacing a
hydrogen on one or more carbons of the alkynyl group. Such substituents may occur on one
or more carbons that are included or not included in one or more triple bonds. Moreover,
such substituents include all those contemplated for alkyl groups, as sed above, except
where stability is prohibitive. For example, substitution of alkynyl groups by one or more
alkyl, carbocyclyl, aryl, heterocyclyl, or heteroaryl groups is contemplated.
The term “amide”, as used herein, refers to a group
WO 46403
wherein each R30 independently represents a hydrogen or hydrocarbyl group, or two R30 are
taken together with the N atom to which they are attached complete a heterocycle having
from 4 to 8 atoms in the ring structure.
The terms ” and “amino” are art-recognized and refer to both unsubstituted and
substituted amines and salts thereof, e.g., a moiety that can be ented by
R31 R31
/ /
é—N\ §—N{—R31
R31 or R31
wherein each R31 independently represents a hydrogen or a hydrocarbyl group, or two
R31 are taken together with the N atom to which they are attached complete a heterocycle
having from 4 to 8 atoms in the ring structure. The term “aminoalkyl”, as used herein, refers
to an alkyl group substituted with an amino group.
The term “aralkyl”, as used herein, refers to an alkyl group substituted with an aryl
group.
The term “aryl” as used herein include substituted or unsubstituted single-ring
aromatic groups in which each atom of the ring is carbon. Preferably, the ring is a 5- to 7-
membered ring, more preferably a 6—membered ring. The term “aryl” also includes
polycyclic ring systems having two or more cyclic rings in which two or more carbons are
common to two adjoining rings n at least one of the rings is aromatic, e.g., the other
cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or
heterocyclyls. Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and
the like.
The term “carbamate” is art-recognized and refers to a group
O O
fr‘\OJkN/R32 or 5‘:\NiO/R32
R53 [233
wherein R32 and R33 ndently represent hydrogen or a hydrocarbyl group, such as an
alkyl group, or R32 and R33 taken together with the intervening atom(s) te a
heterocycle having from 4 to 8 atoms in the ring structure.
WO 46403
The terms “carbocycle”, and cyclic”, as used herein, refers to a saturated or
unsaturated ring in which each atom of the ring is carbon. The term carbocycle includes both
aromatic carbocycles and non-aromatic carbocycles. Non-aromatic carbocycles include both
cycloalkane rings, in which all carbon atoms are saturated, and cycloalkene rings, which
contain at least one double bond.
The term “carbocycle” includes 5-7 membered clic and 8-12 membered
bicyclic rings. Each ring of a bicyclic ycle may be ed from saturated, unsaturated
and ic rings. Carbocycle includes bicyclic molecules in which one, two or three or
more atoms are shared n the two rings. The term “fused carbocycle” refers to a
bicyclic carbocycle in which each of the rings shares two adjacent atoms with the other ring.
Each ring of a fused carbocycle may be selected from saturated, unsaturated and aromatic
rings. In an exemplary embodiment, an aromatic ring, e.g., phenyl, may be fused to a
ted or unsaturated ring, e. g., cyclohexane, cyclopentane, or cyclohexene. Any
combination of saturated, unsaturated and aromatic bicyclic rings, as valence permits, is
included in the definition of carbocyclic. Exemplary “carbocycles” include cyclopentane,
cyclohexane, bicyclo[2.2. l]heptane, 1,5-cyclooctadiene, l,2,3,4-tetrahydronaphthalene,
o[4.2.0]octene, naphthalene and adamantane. Exemplary fused carbocycles include
decalin, naphthalene, l,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]octane, 4,5,6,7-tetrahydro-
lH—indene and bicyclo[4.1.0]heptene. “Carbocycles” may be tuted at any one or
more positions capable of bearing a hydrogen atom.
A “cycloalkyl” group is a cyclic hydrocarbon which is completely saturated.
“Cycloalkyl” includes monocyclic and bicyclic rings. Typically, a monocyclic cycloalkyl
group has from 3 to about 10 carbon atoms, more typically 3 to 8 carbon atoms unless
otherwise defined. The second ring of a bicyclic cycloalkyl may be selected from saturated,
unsaturated and aromatic rings. Cycloalkyl includes bicyclic molecules in which one, two or
three or more atoms are shared between the two rings. The term “fused cycloalkyl” refers to a
bicyclic cycloalkyl in which each of the rings shares two adjacent atoms with the other ring.
The second ring of a fused bicyclic cycloalkyl may be selected from saturated, unsaturated
and aromatic rings. A alkenyl” group is a cyclic hydrocarbon containing one or more
double bonds.
The term “carbocyclylalkyl”, as used , refers to an alkyl group substituted with
a carbocycle group.
The term “carbonate” is art—recognized and refers to a group —OC02—R34, wherein R34
represents a hydrocarbyl group.
The term “carboxy”, as used herein, refers to a group represented by the
formula -C02H.
The term “ester”, as used herein, refers to a group -C(O)OR35 wherein R35 represents
a hydrocarbyl group.
The term “ether”, as used herein, refers to a hydrocarbyl group linked through an
oxygen to another hydrocarbyl group. Accordingly, an ether substituent of a hydrocarbyl
group may be hydrocarbyl-O-. Ethers may be either symmetrical or unsymmetrical.
Examples of ethers e, but are not limited to, cycle-O-heterocycle and aryl-O-
heterocycle. Ethers include “alkoxyalkyl” groups, which may be represented by the general
formula alkyl-O-alkyl.
The terms “halo” and “halogen” as used herein means n and includes chloro,
fluoro, bromo, and iodo.
The terms “hetaralkyl” and oaralkyl”, as used herein, refers to an alkyl group
substituted with a l group.
The term "heteroalkyl", as used herein, refers to a saturated or unsaturated chain of
carbon atoms and at least one heteroatom, wherein no two heteroatoms are adjacent.
The terms “heteroaryl” and “hetaryl” include substituted or unsubstituted aromatic
single ring structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered
rings, whose ring structures include at least one heteroatom, preferably one to four
heteroatoms, more preferably one or two atoms. The terms “heteroaryl” and yl”
also include polycyclic ring systems having two or more cyclic rings in which two or more
carbons are common to two adjoining rings wherein at least one of the rings is
heteroaromatic, e. g., the other cyclic rings can be cycloalkyls, lkenyls, cycloalkynyls,
aryls, heteroaryls, and/or heterocyclyls. Heteroaryl groups include, for example, pyrrole,
furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and
pyrimidine, and the like.
The term “heteroatom” as used herein means an atom of any element other than
carbon or hydrogen. Preferred atoms are nitrogen, oxygen, and sulfur.
The terms “heterocyclyl”, “heterocycle”, and ocyclic” refer to substituted or
unsubstituted non-aromatic ring structures, preferably 3- to lO-membered rings, more
preferably 3— to 7-membered rings, whose ring structures include at least one heteroatom,
preferably one to four heteroatoms, more preferably one or two heteroatoms. The terms
“heterocyclyl” and “heterocyclic” also include clic ring systems having two or more
cyclic rings in which two or more carbons are common to two adjoining rings wherein at
least one of the rings is heterocyclic, e.g., the other cyclic rings can be cycloalkyls,
cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or cyclyls. Heterocyclyl groups
include, for e, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and
the like.
The term “heterocyclylalkyl”, as used herein, refers to an alkyl group substituted with
a heterocycle group.
The term “hydrocarbyl”, as used herein, refers to a group that is bonded through a
carbon atom that does not have a =0 or :8 substituent, and typically has at least one carbon-
hydrogen bond and a ily carbon backbone, but may optionally include heteroatoms.
Thus, groups like methyl, ethoxyethyl, 2-pyridyl, and trifluoromethyl are considered to be
hydrocarbyl for the es of this application, but tuents such as acetyl (which has a
=0 substituent on the linking carbon) and ethoxy (which is linked through oxygen, not
carbon) are not. Hydrocarbyl groups include, but are not limited to aryl, heteroaryl,
carbocycle, heterocyclyl, alkyl, alkenyl, alkynyl, and combinations f.
The term “hydroxyalkyl”, as used herein, refers to an alkyl group substituted with a
y group.
The term “lower” when used in conjunction with a chemical moiety, such as, acyl,
acyloxy, alkyl, alkenyl, l, or alkoxy is meant to e groups where there are ten or
fewer non-hydrogen atoms in the substituent, preferably six or fewer. A “lower alkyl”, for
example, refers to an alkyl group that contains ten or fewer carbon atoms, preferably six or
fewer. In n embodiments, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy substituents
defined herein are respectively lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower
alkynyl, or lower alkoxy, whether they appear alone or in combination with other
substituents, such as in the recitations hydroxyalkyl and aralkyl (in which case, for example,
the atoms within the aryl group are not counted when ng the carbon atoms in the alkyl
sub stituent).
The terms “polycyclyl”, “polycycle”, and “polycyclic” refer to two or more rings
(e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls) in
which two or more atoms are common to two adjoining Iings, e.g., the rings are “fused
rings”. Each of the rings of the polycycle can be substituted or unsubstituted. In certain
embodiments, each ring of the polycycle contains from 3 to 10 atoms in the ring, preferably
from 5 to 7.
The term “silyl” refers to a silicon moiety with three hydrocarbyl moieties attached
thereto.
The term “substituted” refers to moieties having tuents replacing a hydrogen on
one or more carbons of the backbone. It will be understood that “substitution” or “substituted
with” includes the it proviso that such substitution is in accordance with permitted
valence of the substituted atom and the substituent, and that the substitution results in a stable
compound, e.g., which does not spontaneously undergo transformation such as by
rearrangement, cyclization, ation, etc. As used herein, the term “substituted” is
contemplated to include all permissible tuents of organic nds. In a broad
aspect, the permissible substituents include acyclic and cyclic, ed and unbranched,
carbocyclic and cyclic, aromatic and omatic substituents of organic compounds.
The permissible substituents can be one or more and the same or different for appropriate
organic nds. For purposes of this invention, the heteroatoms such as nitrogen may
have hydrogen substituents and/or any permissible substituents of organic compounds
described herein which satisfy the valences of the heteroatoms. Substituents can include any
substituents described herein, for example, a halogen, a hydroxyl, a carbonyl (such as a
carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a
thioacetate, or a thioformate), an alkoxy, a phosphoryl, a ate, a phosphonate, a
phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a
sulfhydryl, an alkylthio, a sulfate, a sulfonate, a oyl, a sulfonamido, a sulfonyl, a
heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety. It will be understood by
those skilled in the art that substituents can themselves be substituted, if appropriate. Unless
specifically stated as “unsubstituted,” nces to chemical moieties herein are tood
to include substituted variants. For example, reference to an “aryl” group or moiety
implicitly includes both substituted and tituted variants.
The term “sulfate” is art-recognized and refers to the group -OSO3H, or a
pharmaceutically acceptable salt thereof.
The term “sulfonamide” is art—recognized and refers to the group represented by the
l formulae
0' IR36 OQSIR
é—S—N or , “O
.. s—N.
wherein R36 and R37 independently represent hydrogen or hydrocarbyl, such as alkyl, or R36
and R37 taken together with the intervening atom(s) complete a heterocycle having from 4 to
8 atoms in the ring structure.
The term “sulfoxide” is art—recognized and refers to the group -S(O)-R38, wherein R38
represents a hydrocarbyl.
The term “sulfonate” is art-recognized and refers to the group SO3H, or a
pharmaceutically acceptable salt thereof.
The term ne” is art-recognized and refers to the group -S(O)2-R39, wherein R39
represents a hydrocarbyl.
The term “thioalkyl”, as used herein, refers to an alkyl group substituted with a thiol
group.
The term “thioester”, as used herein, refers to a group -C(O)SR40 or -SC(O)R40
n R10 represents a hydrocarbyl.
The term “thioether”, as used , is equivalent to an ether, wherein the oxygen is
ed with a .
The term “urea” is art-recognized and may be represented by the general formula
s’S\NJLN,R42
R41 R41
wherein R41 and R42 independently represent hydrogen or a hydrocarbyl, such as alkyl, or
either occurrence of R41 taken together with R42 and the intervening atom(s)complete a
heterocycle having from 4 to 8 atoms in the ring structure.
The term “protecting group” refers to a group of atoms that, when attached to a
reactive functional group in a molecule, mask, reduce or prevent the reactivity of the
functional group. Typically, a protecting group may be selectively removed as desired during
the course of a synthesis. Examples of protecting groups can be found in Greene and Wuts,
Protective Groups in Organic Chemistry, 3rd Ed, 1999, John Wiley & Sons, NY and on
et al., Compendium ofSynthetic Organic Methods, Vols. 1—8, 1971—1996, John Wiley & Sons,
NY. Representative nitrogen protecting groups include, but are not limited to, formyl, acetyl,
trifluoroacetyl, benzyl, benzyloxycarbonyl ), tert-butoxycarbonyl (“Boo”),
trimethylsilyl (“TMS”), 2—trimethylsilyl—ethanesulfonyl (“TES”), trityl and substituted trityl
groups, allyloxycarbonyl, 9—fluorenylmethyloxycarbonyl (“FMOC”), nitro-
veratryloxycarbonyl (“NVOC”) and the like. Representative hydroxyl protecting groups
e, but are not limited to, those where the hydroxyl group is either acylated ified)
or alkylated such as benzyl and trityl ethers, as well as alkyl ethers, tetrahydropyranyl ethers,
trialkylsilyl ethers (e.g., TMS or TIPS ), glycol , such as ethylene glycol and
ene glycol derivatives and allyl ethers.
In certain embodiments, compounds of the invention may be racemic. In certain
embodiments, compounds of the invention may be enriched in one omer. For example,
a compound of the invention may have greater than about 30% ee, about 40% ee, about 50%
ee, about 60% ee, about 70% ee, about 80% ee, about 90% ee, or even about 95% or r
ee. In certain embodiments, nds of the invention may have more than one
stereocenter. In certain such embodiments, compounds of the invention may be enriched in
one or more diastereomer. For example, a compound of the ion may have greater than
about 30% de, about 40% de, about 50% de, about 60% de, about 70% de, about 80% de,
about 90% de, or even about 95% or greater de.
In certain embodiments, the therapeutic preparation may be enriched to provide
predominantly one enantiomer of a compound (e.g., of Formula (1)). An omerically
enriched mixture may comprise, for example, at least about 60 mol percent of one
enantiomer, or more preferably at least about 75, about 90, about 95, or even about 99 mol
percent. In certain embodiments, the nd enriched in one enantiomer is substantially
free of the other enantiomer, wherein substantially free means that the substance in question
makes up less than about 10%, or less than about 5%, or less than about 4%, or less than
about 3%, or less than about 2%, or less than about 1% as compared to the amount of the
other enantiomer, e.g., in the composition or compound mixture. For example, if a
ition or compound mixture contains about 98 grams of a first enantiomer and about 2
grams of a second enantiomer, it would be said to contain about 98 mol percent of the first
enantiomer and only about 2% of the second enantiomer.
In certain embodiments, the therapeutic preparation may be enriched to provide
predominantly one diastereomer of a compound (e.g., of Formula (1)). A diastereomerically
enriched mixture may comprise, for example, at least about 60 mol percent of one
diastereomer, or more preferably at least about 75, about 90, about 95, or even about 99 mol
percent.
The term "subject" to which administration is contemplated es, but is not
d to, humans (i.e., a male or female of any age group, e. g., a pediatric subject (e. g.,
infant, child, adolescent) or adult t (e.g., young adult, middle—aged adult or senior
adult)) and/or other primates (e. g., cynomolgus monkeys, rhesus monkeys); mammals,
including commercially relevant mammals such as cattle, pigs, horses, sheep, goats, cats,
and/or dogs; and/or birds, including commercially relevant birds such as chickens, ducks,
geese, quail, and/or turkeys. Preferred subjects are humans.
As used herein, a therapeutic that “prevents” a disorder or condition refers to a
compound that, in a statistical sample, reduces the occurrence of the er or condition in
the treated sample relative to an ted control sample, or delays the onset or reduces the
severity of one or more symptoms of the disorder or condition relative to the untreated
The term ing” includes prophylactic and/or therapeutic treatments. The term
ylactic or therapeutic” treatment is art-recognized and includes administration to the
subject of one or more of the disclosed compositions. If it is stered prior to clinical
station of the unwanted condition (e.g., disease or other unwanted state of the subject)
then the treatment is prophylactic (i.e., it protects the subject against developing the unwanted
condition), whereas if it is administered after manifestation of the unwanted condition, the
treatment is therapeutic, (i.e., it is intended to diminish, rate, or stabilize the existing
unwanted condition or side effects f).
The term ug” is intended to encompass compounds which, under physiologic
conditions, are converted into the therapeutically active agents of the present invention (e.g.,
a compound of Formula (1)). A common method for making a prodrug is to include one or
more selected moieties which are hydrolyzed under physiologic conditions to reveal the
desired molecule. In other embodiments, the prodrug is converted by an enzymatic activity of
the subject. For example, esters or carbonates (e,g., esters or carbonates of alcohols or
carboxylic acids) are preferred prodrugs of the present invention. In certain ments,
some or all of the compounds of Formula (I) in a formulation represented above can be
replaced With the corresponding suitable prodrug, e.g., wherein a hydroxyl in the parent
compound is presented as an ester or a carbonate or carboxylic acid.
An “effective amount”, as used herein, refers to an amount that is sufficient to achieve
a desired biological effect. A “therapeutically effective amount”, as used herein, refers to an
amount that is sufficient to achieve a desired therapeutic effect. For example, a
therapeutically effective amount can refer to an amount that is sufficient to improve at least
one sign or symptom of cancer.
A “response” to a method of ent can include a decrease in or amelioration of
negative symptoms, a decrease in the ssion of a disease or ms thereof, an
increase in beneficial symptoms or clinical outcomes, a lessening of side effects, ization
of disease, partial or complete remedy of e, among others.
In some embodiments, the ion provides a compound of formula (I):
Y 0 Het
R2b R1 b
RZa R1 a
or a pharmaceutically acceptable salt and/or prodrug thereof, n
R4 O O
R \IF!15
R5 L|_§_
555\ R15/ v/
Y is R6 or R15
Het is heterocyclyl or heteroaryl,
Rlais selected from H, halo, hydroxy, cyano, azido, amino, C1-6alkyl, hydroxyCi—
6alkyl, amino-C1-6alkyl, -O-C(O)-O—C1-6alkyl, C1-6acyloxy, C1-6alkoxy, C2-6alkenyl, and
C2-6alkynyl;
R11) is selected from H, halo, C1-6alkyl, hydroxy-C1-6alkyl, amino-Ci-salkyl,
Cmalkenyl, and C2-6alkynyl,
Rzais selected from halo, hydroxy, cyano, azido, amino, C1.6alkyl, hydroxy—Ci-salkyl,
amino-C1-6alkyl, C1-6acyloxy, -O-C(O)-O-C1-6alkyl, Cmalkoxy, C2-6alkenyl, and C2-6alkynyl,
R21) is ed from halo, C1-6alkyl, C2-6alkenyl, and C2.6alkynyl, preferably
substituted or unsubstituted Czalkynyl, most preferably unsubstituted Czalkynyl,
R3 is selected from H and alkyl;
R4 is selected from H, alkyl, CN, aryl, heteroaryl, R9, -C(O)NRHR12, -
S(O)2R10, OR”)(OR12), and OR”)(NR13R14);
R5 is selected from H, cyano, alkyl, cycloalkylalkyl, heterocyclylalkyl, aralkyl,
heteroaralkyl, and -C(O)OR9;
R6 is selected from —C(O)OR9, -C(O)NR16R17, and —P(O)(OR11)(OR12),
R9 is independently selected from H, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl,
heterocyclylalkyl, aryl, aralkyl, heteroaryl, and heteroaralkyl;
R10 is independently selected from alkyl, alkenyl, alkynyl, amino, cycloalkyl,
cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, and heteroaralkyl;
each R11 and R12 is independently selected from H, alkyl, cycloalkyl, lkylalkyl,
heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or
R11 and R12, together with the en atom to which they are attached, form a 5- to
7-membered heterocyclyl;
R13 is H or alkyl;
R14 is alkyl or aralkyl;
each R15 is independently selected from hydroxy, alkoxy acyloxy and NR13R14,
each R16 and R17 is independently selected from H, hydroxy, alkyl, cycloalkyl,
cycloalkylalkyl, heterocyclyl, cyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl; or
R16 and R17, er with the en atom to which they are attached, form a 5- to
7-membered heterocyclyl.
In certain preferred embodiments of Formula I, the included compounds meet the
terms of a) and b); or a) and c);
wherein:
W0 20192946403 2019/038245
O NH2 NH2
0 GE </N '\N
EtO 0:0N
0 NA Nn
a) the compound is not To“
0 ”81:1 0
o v.
)LN Ho‘
HN\\)
\N o
N//'\CI
“1:56 /=N \N
0 CAL-7‘NO <’ I
EtC) (3 “' /
fiC) PJ”L‘C:
C- TT/
“0 ”OH ”3/“ . .
Cl HO“ "OH
, ,or
O NH2
b) if R4 and R6 are each -C(O)OH and R5 is benzyl substituted on the phenyl ring with
a heterocyclyl or heteroaryl substituent, then the phenyl ring substituent is selected from
unsubstituted or substituted pyrrolidinyl, piperazinonyl, piperidonyl, tetrahydropyrimidonyl,
pyridonyl, and l; and
c) if R4 is -C(O)OH or tetrazolyl, R6 is -C(O)OH, and R5 is benzyl substituted on the
phenyl ring with a second phenyl ring, then either the benzyl phenyl ring or the second
phenyl ring is substituted with -C(O)OR9 where R9 is H or alkyl.
In some embodiments, the invention provides a compound of formula (11):
F24 F13
C3 flet
RZb R1 b
R23 R1 a
or a pharmaceutically acceptable salt and/or prodrug thereof, wherein
Het is heterocyclyl or heteroaryl,
Rlais selected from H, halo, hydroxy, cyano, azido, amino, C1-6alkyl, hydroxyCi-
, amino-C1-6alkyl, )-O-C1-6alkyl, C1-6acyloxy, C1-6alkoxy, C2.6alkenyl, and
Czsdkynyh
R1b is selected from H, halo, C1-6alkyl, hydroxy-Crsalkyl, C1-6alkyl,
C2-6alkenyl, and C2-6alkynyl;
Rzais selected from halo, hydroxy, cyano, azido, amino, C1.6alkyl, hydroxy-C1-6alkyl,
amino-Ci-salkyl, Cmacyloxy, -O-C(O)-O-C1-6alkyl, C1-6alkoxy, C2-6alkenyl, and C2-6alkynyl,
R21) is selected from H, halo, C1-6alkyl, C2-6alkenyl, and C2—6alkynyl,
R3 is selected from H and alkyl,
R4 is selected from alkyl, aryl, aryl, R9, -C(O)NR”R12, -S(O)2R10,
-P(O)(OR”)(OR12), and -P(O)(OR”)(NR13R14),
R5 is selected from H, cyano, alkyl, cycloalkylalkyl, heterocyclylalkyl, aralkyl,
heteroaralkyl, and -C(O)OR9,
R6 is ed from -C(O)OR9, -C(O)NR“R12 and -P(O)(OR”)(OR12),
R9 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl,
lkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, l, heteroaryl, and heteroaralkyl;
R10 is independently selected from alkyl, alkenyl, alkynyl, amino, cycloalkyl,
cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, and heteroaralkyl,
each R11 and R12 is independently selected from H, alkyl, cycloalkyl, cycloalkylalkyl,
heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, aralkyl, or
R11 and R12, together with the nitrogen atom to which they are attached, form a 5- to
7-membered heterocyclyl,
R13 is H or alkyl, and
R14 is alkyl or aralkyl,
provided that a), b) and c); or a), b) and d);
o NH2 NH2
0 GE <NI
EtO 'Nim
0:00 HO 0:2:o <IN<Nf:N*0 a) the compound is not H6 I
0 BEIf/im HZOHOO\é’ifikm
N C'
N 00 m oWit
</ I\N
HO 0 N
o CI
0 M No OWNAI<NfN1H2
ON C
b) sz is selected from halo, C2-6alkyl, C2-6alkenyl, and C2.6alkynyl, ably
substituted or unsubstituted Czalkynyl, most preferably unsubstituted Czalkynyl,
c) if R4 and R6 are each -C(O)OH and R5 is benzyl substituted on the phenyl ring with
a heterocyclyl or aryl substituent, then the phenyl ring substituent is selected from
unsubstituted or substituted piperidonyl, tetrahydropyrimidonyl, pyridonyl, and pyridyl; and
d) if R4 is -C(O)OH or tetrazolyl, R6 is -C(O)OH, and R5 is benzyl substituted on the
phenyl ring with a second phenyl ring, then either the benzyl phenyl ring or the second
phenyl ring is substituted with -C(O)OR9 where R9 is H or alkyl.
In certain preferred embodiments:
o NHZ NH2
0 CE
EtO o *0
a) the nd is not H0 0::0o (NjiqiN<N
HO OwN NACI HO [RE/km
o 0
_ V.
w H)“ F HN)LN Hd
H:{in
HoWt”:
HO OWN NACI 0 OH </N
0 [\N
F HO o N
~_ NA
OH O
“0 "0“ ”Y“ “0 '6“ ”Y“
Cl CI
O NH2 0 NH2
0 CE /N O OH
< \N /N \N
l A < l A
EIO 0—: N HO 0—: N
O N CI O N CI
Hd 90H or HOc I(OH
7 ; and
b) R2b is selected from halo, C2-6alkyl, C2-6alkenyl, and C2.6alkynyl, preferably
substituted or unsubstituted Czalkynyl, most preferably unsubstituted Czalkynyl; and either
c) R5 is benzyl substituted on the phenyl ring with a tuent selected from
unsubstituted or substituted piperidonyl, tetrahydropyrimidonyl, pyridonyl, and pyridyl, or
d) R5 is benzyl substituted on the phenyl ring with a second phenyl ring substituted
with -C(O)OR9 Where R9 is H or alkyl.
The following paragraphs describe various embodiments of compounds of Formula I
or II, which may be combined in any combination as consistent with the formulas as defined
above.
In certain embodiments, Rla is H or hydroxy. In certain embodiments, R113 is H or
yl. In other embodiments, R121 is hydroxy and R11) is H.
In some ments, R2a is hydroxy or C1.6alkyl. In certain embodiments, R2b is C2-
, C2-6alkenyl or C2-6alkynyl, preferably substituted or unsubstituted C2alkynyl, such as
ethynyl. In certain preferred ments, R2a is Me and R2b is ethynyl. In some
embodiments, R2a is hydroxy and R21) is ethyl or Vinyl. In other preferred embodiments, R221
is hydroxy and R21) is ethynyl. In some embodiments, R2b is yl, butynyl,
_ / \NH
% j, or unsubstituted or substituted /
In certain preferred embodiments, R3 is H.
In certain embodiments, the compound of Formula (I) has the ing structure:
Y X Het
R2b R1b
R23 R1a
In certain embodiments, the compound of Formula (II) has the following structure:
R5>1\
X Het
R2b R1b
R23 R13
In certain such embodiments, R1a is in the guration. For example, the compound of
Formula (I) may have the structure (IA):
RZb a, Rlb
R23 ’l/R1a
Further, the compound of Formula (II) may have the structure (IIAa):
R4 R3
R5>l\ Het
(IIAa)
In alternative embodiments, R1a is in the B-configuration. In some such ments,
the compound of Formula (I) has the structure (I3):
Y X Het
sz "’III/R1b
R22 R16
(113)
In some such ments, the compound of Formula (II) has the structure (IIBa):
(IIBa)
In further embodiments of nds of Formula (I), e.g., as described above, R221 is
in the u-configuration. For example, the compound of Formula (I) may have the structure
(IC):
(IICa)
In alternative embodiments, R2a is in the B-configuration. In some such embodiments,
the compound of Formula (I) has the structure (ID):
Y X Het
R2b\\“ R1b
R22 R13
(113)
In further preferred embodiments, the compound of Formula (II) has the structure
(IIDa):
R4 R3
R2b\\" R1b
R23 R13
(IIDa)
In certain red embodiments, the compound of Formula (I) has the structure (IE):
In further preferred embodiments, the compound of Formula (II) has the ure
(IIEa):
(IIEa)
In particularly preferred such embodiments, R1a is hydroxy and R2“1 is hydroxy and
R2b is selected from methyl, ethyl, Vinyl, and ethynyl, most preferably ethynyl. In most
preferred embodiments of the compound of Formula (IE), R1a is hydroxy, R2a is hydroxy, and
R21) is ethynyl. In some preferred embodiments of the nd of Formula (IIEa), R1a is
hydroxy, R2a is y, and R2b is ethynyl.
In certain embodiments, Y is R6
In n embodiments, R4 is selected from R9, -C(O)NR”R12, -S(O)2R10, and
-P(O)(OR”)(OR12). In some embodiments, R4 is -C(O)OR9 and R9 is H or alkyl. In other
embodiments, R4 is -C(O)NR”R12, In certain embodiments, each R11 and R12 is
independently selected from H and alkyl, or R11 and R12, together with the nitrogen atom to
which they are attached, form a 5- to 7-membered heterocyclyl. In other embodiments, R4 is
-S(O)2R10 and R10 is alkyl or aryl.
In some embodiments, R6 is -C(O)OR9 and R9 is H or alkyl, e.g., H or C1-6alkyl. In
other embodiments, R6 is -C(O)NR“R12. In certain such embodiments, each R11 and R12 is
independently selected from H and alkyl, or R11 and R12, er with the nitrogen atom to
which they are attached, form a 5- to 7-membered heterocyclyl.
In certain preferred embodiments, R4 and R6 are each -C(O)OH, most preferably
wherein R5 is benzyl, e. g., as discussed in greater detail below.
In certain embodiments, R5 is selected from H, alkyl, aralkyl and heteroaralkyl. In
certain such ments, each alkyl, aralkyl and aralkyl at R5 is unsubstituted or
substituted with one or more substituents selected from halo, alkyl, alkoxy, carbonyl, amino,
amido, cycloalkyl, heterocyclyl, and aryl. In other embodiments, the substituents on
the alkyl, aralkyl and heteroaralkyl at R5 are selected from halo, haloalkyl, alkoxy, carbonyl,
aryl, heterocyclyl, and aryl. In certain embodiments, R5 is aralkyl, e.g., substituted on
the aryl ring with a 5- to 7-membered heterocyclyl or a 5- to 7-membered heteroaryl. In
certain ular embodiments, R5 is selected from H, methyl, ethyl, -CH2—ethynyl, and -
CHz-Vinyl. In other embodiments, R5 is selected from benzyl, -CH2-pyridyl, -CH2-
pyridazinyl, -CH2-oxazolyl, -CH2-thiophenyl, -CH2-furanyl, -CH2-thiazolyl, and -CH2-
benzothiazolyl, preferably benzyl and -CH2-thiophenyl.
In certain preferred embodiments, R5 is benzyl tuted on the phenyl ring (e.g., at
a para position) with a heterocyclyl or heteroaryl sub stituent, preferably wherein the phenyl
ring substituent is selected from substituted piperidonyl, tetrahydropyrimidonyl, pyridonyl,
and pyn'dyl. In some embodiments, the phenyl ring substituent is piperazinonyl. In certain
such embodiments, the donyl, tetrahydropynmidonyl, pyridonyl, or pyridyl is
substituted with one or more of alkyl, hydroxyalkyl or alkoxyalkyl.
In certain embodiments, R5 is aralkyl or heteroaralkyl with a para substituent on the
aryl or heteroaryl ring selected from heterocyclyl, aryl, and aryl, and
R21) is methyl, ethyl, or C2-6alkynyl.
In certain preferred ments, R5 is benzyl substituted on the phenyl ring (e.g., at
o o
“be“be\| |
7 3
O O
“bkwax or\ OMe
I I
, ,Orl / ~
In certain embodiments, certain preferred embodiments, R5 is benzyl substituted on
O O
NELL/ HNiNk
the phenyl ring (e.g., at the 4—position) with v
, ,
W0 20192’246403 2019/038245
\Nifi; \/\NJ\N}{
K) K)
\N Hz/\N WES/Y
o 0
“ON\/\ \o/N
/O\/\N 3: N \ N \ ”I:
\ ,l / I
Insomeenmodhnmua
W0 46403
0 OH 0 NH2
HO HO
R6 represents 0 O
0 NH2 0 NH N
H2N jg HO 0 o3‘; HO 0%
O O
7 7
/OH /OH O
O 0 Me
\ \
P—OH P—OH O§s/
MeO jg EtO HO
O O}{
0 o o
j 7
H O OH
ph O OH
O§8/ HO
HO 0% HO oj;
O O
7 7
o OH
OH O OH
HO 0%
// o
W0 246403
o OEt 0 OH 0 0H
EtO ){ HO jg HO
O O Ojg
OH \\ //0 OH
o;%; HO o;%;
7 7
O OH
O O
9 3
F3C F30
O OH O OEt
HO HO
Ojg O}{
O 0
M60 CI
0 OH \ / O OH
W0 246403
0 (DH
W0 246403
W0 46403
In some embodiments, Y is R15
. In certain embodiments, each R15 is
hydroxy.
In certain ments, Het is selected from a 6- to bered aryl, a 5- to 8-
membered heterocyclyl, a 5— to 8-membered monocyclic or 5- to lO-membered bicyclic
heteroaryl, and may be unsubstituted or substituted with one or more substituents selected
from halo, alkyl, haloalkyl, alkoxy, yl, amino, amido, alkylthio, alkoxycarbonyl,
cycloalkyl, aryl, heterocyclyl and heteroaryl. In some embodiments, the Het substituents are
selected from halo, haloalkyl, amino, and heterocyclyl. In certain embodiments, Het is a
nitrogen-containing heterocyclyl or heteroaryl, preferably attached to the core ring Via a
nitrogen atom of the heterocyclyl or heteroaryl ring. In some ments, Het is
o NH2
/ /NH
NH /\N
7H0 :5; A
. In other embodiments, Het is
In other embodiments, Het is
{f2 Ra N( I\
75: NAijys N/
wherein
Z is CH or N;
Ra is ed from H, halo, hydroxy, alkyl, thiophenyl, -NR7R8, aralkyl, aryl, and
heteroaryl, preferably from H, Cl, -NR7R8, and phenyl;
Rb is selected from halo, alkyl, haloalkyl, hydroxyalkyl, alkylthio, amido, carbonyl,
amido, and heteroaryl,
R7 is selected from H, y, alkyl, aralkyl, heteroaralkyl, cycloalkyl, and
heterocyclyl; and
R8 is H or alkyl, or
R7 and R8, together with the nitrogen atom to which they are attached, form a 4- to 7-
membered cyclyl ring.
In some embodiments, Het is ~76: «Am
In certain embodiments, Z is CH. In other embodiments, Z is N.
In certain embodiments, Ra is selected from H, halo, alkyl, thienyl, -NR7R8, aryl, and
heteroaryl, preferably from H, Cl, —NR7R8, and . In some embodiments, R3 is -NR7R8.
In certain embodiments, Rb is selected from halo, alkyl, hydroxyalkyl, haloalkyl,
amido, carbonyl, amido, and aryl. In some embodiments, Rb is selected from C1, -CF3,
carbonyl and -CONH2.
NR7R8
</ \N
7‘» NA
In some embodiments, Het is Cl
In some embodiments, R7 is selected from H, alkyl, aralkyl, heteroaralkyl, cycloalkyl,
and heterocyclyl. In certain embodiments, R7 is alkyl or cycloalkyl, e. g, where the alkyl or
cycloalkyl is unsubstituted or substituted with one or more tuents selected from
hydroxy, alkoxy, aryl, amino, and cycloalkyl. In other embodiments, R7 is aralkyl or
heteroaralkyl, e.g., where the aralkyl or heteroaralkyl is unsubstituted or substituted with halo
or alkyl.
In some embodiments, R8 is ed from H, methyl, and ethyl.
In other embodiments, R7 and R8, together with the nitrogen atom to which they are
attached, form a heterocyclyl ring, e.g., selected from azetidinyl, morpholino, pyrrolidinyl,
and azepanyl.
Methods of Use
Provided herein are methods of inhibiting CD73 in a cell, comprising contacting the
cell with a compound of the invention, such as a compound of formula (I), or a
pharmaceutically acceptable salt thereof. In certain embodiments, contacting the cell occurs
in a subject in need thereof, thereby ng a disease or disorder mediated by ine.
Also, disclosed herein are methods of treating a disease or a disorder mediated by
adenosine comprising administering a compound the invention, such as a compound of
Formula (I), or a pharmaceutically acceptable salt thereof. In some embodiments, disclosed
herein are s of treating cancer comprising administering a compound the invention,
such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
Adenosine acts on a variety of immune cells to induce immunosuppression, and the
suppressive effects of cleotidases that enhance adenosine levels are also
associated with enhanced infections of mammalian cells by parasites, fungi, ia, and
viruses. Apart from immunosuppressive effects, adenosine also has a role in ting the
cardiovascular system (as a vasodilator and cardiac depressor), the l nervous system
(CNS) (inducing sedative, anxiolytic and antiepileptic effects), the respiratory system
(inducing bronchoconstriction), the kidney (having ic action; inducing vasoconstriction
at low concentrations and vasodilation at high doses), fat cells iting lipolysis), and
platelets (as an anti-aggregant). Furthermore, adenosine also promotes fibrosis (excess
matrix production) in a variety of tissues. Therefore, improved treatments targeting CD73
would provide therapies for treating a wide range of conditions in addition to cancer,
ing cerebral and cardiac ischemic disease, is, immune and inflammatory disorders
(e.g., atory gut motility disorder), ogical, neurodegenerative and CNS
disorders and diseases (e.g., depression, Parkinson’s disease), and sleep disorders.
In some embodiments, the disease or the disorder mediated by adenosine is selected
from cerebral ischemic e, cancer, cardiac ischemic disease, depression, s, an
immune er, an inflammatory disorder (e.g., inflammatory gut motility disorder),
neurological disorder or disease, neurodegenerative disorder or disease (e.g., Parkinson’s
disease), CNS ers and diseases, and sleep disorders.
The methods described herein are useful for the treatment of a wide variety of
cancers, ing bladder cancer, bone cancer, brain cancer (including glioblastoma), breast
cancer, cardiac cancer, cervical , colon , colorectal cancer, esophageal cancer,
f1brosarcoma, gastric cancer, gastrointestinal cancer, head & neck cancer, ’s sarcoma,
kidney cancer (including renal cell adenocarcinoma), leukemia, liver cancer, lung cancer
(including non-small cell lung cancer, small cell lung cancer, and mucoepidermoid
pulmonary carcinoma), lymphoma, melanoma, myeloma, ovarian cancer (including ovarian
adenocarcinoma), pancreatic cancer, penile , prostate cancer, testicular germcell
cancer, thymoma and thymic carcinoma.
In some embodiments, the subject has a cancer selected from breast cancer, brain
, colon cancer, f1brosarcoma, kidney cancer, lung cancer, melanoma, ovarian cancer,
and prostate . In certain embodiments, the subject has a cancer selected from breast
cancer, colon cancer, f1brosarcoma, melanoma, ovarian cancer, and prostate cancer. In other
embodiments, the subject has a cancer selected from brain cancer, breast cancer, kidney
cancer, lung cancer, melanoma, and ovarian cancer. In some embodiments, the subject has
head and neck squamous cell oma, ovarian cancer, breast cancer or esophageal cancer.
In other embodiments, the subject has atic cancer, esophageal cancer, stomach cancer,
head and neck cancer, colon cancer, lung cancer or kidney cancer. In yet other embodiments,
the subject has breast cancer. In some embodiments, the breast cancer is breast
adenocarcinoma. In n embodiments, the breast cancer is triple-negative breast cancer.
In certain embodiments, the methods for treating or preventing cancer can be
demonstrated by one or more responses such as increased apoptosis, inhibition of tumor
, reduction of tumor asis, tion of tumor metastasis, reduction of
microvessel density, decreased cularization, inhibition of tumor ion, tumor
regression, and increased survival of the subject.
In certain embodiments, the disease or the disorder mediated by adenosine is a disease
or er mediated by CD73 activity. In some ments, the compounds of the
invention, such as nds of Formula (I), are useful as inhibitors of CD73.
In some embodiments, the methods described herein treat or prevent cardiovascular
disease using inhibitors of CD73. Mutant genes encoding CD73 lead to extensive
calcification of lower-extremity arteries and small joint capsules, which is associated with
increased risk of cardiovascular disease (Hilaire et 51]., N. Engl. J. Med, 364(5): 432-442,
2011).
In some embodiments, the methods disclosed herein treat or prevent cancer using
inhibitors of CD73. A CD73 small interfering RNA and anti-CD73 onal antibodies
showed a significant effect in treating or preventing cancer (Antonioli el al., Nat. Rev.
Cancer, 13: 842-857, 2013). A tight correlation exists between CD73 expression and the
ability of cancer cells to e, invade, and adhere to the extracellular matrix (ECM)
(Antonioli 2013, Antonioli et 61]., Trends Cancer, 2(2): 95-109, 2016).
In some embodiments, the treatment or prevention of cancer by inhibitors of CD73
can be demonstrated by one or more responses selected from activation, clonal expansion,
and homing of specific T cells (Antonioli 2016). In other embodiments, the methods
sed herein increase the number of effector T lymphocytes (e.g., cytolytic effector T
lymphocytes).
Combination Treatments
In some embodiments, the method of treating or preventing cancer may comprise
administering a CD39 inhibitor conj ointly with one or more other chemotherapeutic agent(s).
In one embodiment, the CD73 inhibitor is a compound of the invention, such as a compound
of Formula (I). Other chemotherapeutic agents can include CD73-specific monoclonal
antibodies which enhance the effects of other dies and therapies because of increased
overall immune system activity (lower T-regulatory function and higher T-effector function,
etc.) (Antonioli 2016).
In certain embodiments, the method of treating or preventing cancer may se
administering a compound of the invention conjointly with one or more other
chemotherapeutic agent(s).
herapeutic agents that may be conjointly administered with compounds of the
invention include: 1—amino-4—phenylamino—9,10-dioxo-9,10—dihydroanthracene-2—sulfonate
(acid blue 25), l-amino[4-hydroxyphenyl-amino]-9, lO-dioxo-9,lO-dihydroanthracene-Z-
sulfonate, 1-amino[4-aminophenylamino]-9,10-dioxo-9,lO-dihydroanthracenesulfonate,
l-amino[l -naphthylamino]—9, lO—dioxo-9, lO-dihydroanthracene—2-sulfonate, l-amino[4-
fluorocarboxyphenylamino]-9,10-dioxo—9,10-dihydroanthracenesulfonate, 1-amino—4-
[2-anthracenylamino]-9, l 0-dioxo-9, l O-dihydroanthracene—2-sulfonate, ABT-263, afatinib
dimaleate, ib, aminoglutethimide, amsacrine, anastrozole, APCP, asparaginase,
AZD5363, Bacillus Calmette—Guérin vaccine (bcg), bicalutamide, bleomycin, omib, B-
methylene-ADP (AOPCP), buserelin, busulfan, cabazitaxel, ntinib, hecin,
capecitabine, carboplatin, carfilzomib, carmustine, ceritinib, chlorambucil, chloroquine,
cisplatin, bine, clodronate, cobimetinib, colchicine, crizotinib, hosphamide,
cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, demethoxyviridin,
dexamethasone, dichloroacetate, dienestrol, diethylstilbestrol, docetaxel, bicin,
epirubicin, eribulin, erlotinib, estradiol, estramustine, etoposide, everolimus, exemestane,
stim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gefltinib,
gemcitabine, genistein, goserelin, GSK1120212, hydroxyurea, idarubicin, ifosfamide,
imatinib, interferon, irinotecan, ixabepilone, lenalidomide, letrozole, leucovorin, leuprolide,
levamisole, lomustine, lonidamine, mechlorethamine, medroxyprogesterone, megestrol,
melphalan, mercaptopurine, mesna, metformin, rexate, miltefosine, mitomycin,
mitotane, mitoxantrone, MK-2206, mutamycin, N—(4-sulfamoylphenylcarbamothioyl)
pivalamide, NF279, NF449, nilutamide, nocodazole, octreotide, ib, oxaliplatin,
paclitaxel, pamidronate, pazopanib, pemexetred, pentostatin, perifosine, PF-O4691502,
plicamycin, pomalidomide, porflmer, PPADS, bazine, quercetin, rexed,
ramucirumab, reactive blue 2, rituximab, rolofylline, romidepsin, rucapaiib, selumetinib,
sirolimus, sodium nitrobenzenesulfonate, sorafenib, ozocin, sunitinib, suramin,
talazoparib, tamoxifen, temozolomide, temsirolimus, teniposide, testosterone, thalidomide,
thioguanine, thiotepa, titanocene dichloride, tonapofylline, topotecan, trametinib,
trastuzumab, tretinoin, veliparib, stine, vincristine, Vindesine, vinorelbine, and
vorinostat (SAHA). In other embodiments, chemotherapeutic agents that may be conjointly
administered with compounds of the invention include: ABT-263, dexamethasone, 5-
fluorouracil, PF-O4691502, romidepsin, and vorinostat (SAHA). In other embodiments,
chemotherapeutic agents that may be conjointly administered with compounds of the
invention include: l—amino-4—phenylamino—9,10-dioxo-9, 10—dihydroanthracene-2—sulfonate
(acid blue 25), o[4-hydroxyphenyl-amino]-9, lO-dioxo-9,lO-dihydroanthracene-Z-
sulfonate, 1-amino[4-aminophenylamino]-9,10-dioxo-9,10-dihydroanthracenesulfonate,
l-amino[1-naphthylamino]—9,lO—dioxo-9,10-dihydroanthracene—Z-sulfonate, l-amino[4-
fluoro-Z-carboxyphenylamino]-9,10-dioxo—9,10-dihydroanthracene-Z-sulfonate, 1-amino—4-
[2-anthracenylamino]-9,10-dioxo-9,lO-dihydroanthracene—2-sulfonate, APCP, B-methylene-
ADP (AOPCP), capecitabine, cladribine, cytarabine, fludarabine, doxorubicin, gemcitabine,
N-(4—sulfamoylphenylcarbamothioyl) pivalamide, NF279, NF449, PPADS, tin,
ve blue 2, rolofylline sodium 2,4-dinitrobenzenesulfonate, sumarin, and tonapofylline.
Many combination therapies have been developed for the treatment of cancer. In
certain ments, nds of the invention (e.g., compounds of Formula (I)) may be
ntly administered with a combination therapy. es of combination therapies with
which compounds of the invention may be conjointly stered are included in Table 1.
Table 1: Exemplary atorial therapies for the treatment of cancer
Therapeutic agents
V Doxorubicin, Bleomycin, Vinblastine
ABVD Doxorubicin, Bleomycin, Vinblastine, Dacarbazine
AC t) Doxorubicin, Cyclophosphamide
AC (Sarcoma) Doxorubicin, Cisplatin
AC blastoma) Cyclophosphamide, Doxorubicin
ACE Cyclophosphamide, Doxorubicin, Etoposide
ACe Cyclophosphamide, Doxorubicin
fififlfifilllllllll
fififififlflilllllll
wwwwwnllllllll
MMWK fiwwwwwulllllll
Eww fiwwmwwwwwmwwlll
BCVPP Carmustine, Cyclophosphamide, Vinblastine,
Procarbazine, Prednisone
P Bleomycin, ide, Doxorubicin, Cyclophosphamide,
Vincristine, Procarbazine, Prednisone, Filgrastim
EMMfiwwwwllllll
EWWWWWWWWWIIII
wwwwwwWMWIllO> flwwfiwwllllllll
00 O EWWWWWWWWWWIII
EWWWEWWWWWWIII
Cyclophosphamide, Daunorubicin, Vincristine,
Prednisone, Asparaginase
Cyclophosphamide, Doxorubicin, Methotrexate,
Procarbazine
E EWWWWWWWWWIIII
mv EWWWWWWWWWEIII
CMWD EWWWWIIIIIIIII
mww QWWWEWWWWWEIII
O0 EWWWEWWWIIIIII
cmmw EWWWWIIIIIIIII
cw EMWWWWWWWWEIII
CEPP(B) Cyclophosphamide, Etoposide, Prednisone, with or
Without/ cin
CEV hosphamide, Etoposide, Vincristine
CF Cisplatin, Fluorouracil or Carboplatin Fluorouracil
Name Therapeutic agents
CHAP Cyclophosphamide or Cyclophosphamide, Altretamine,
Doxorubicin, Cisplatin
ChlVPP mbucil V1nblast1ne Procarbazme Prednlsone
7 7
CHOP-BLEO Add Bleomycin to CHOP
CISCA Cyclophosphamide, Doxorubicin, Cisplatln
CLD-BOMP Bleomycin, tln Vlncristlne Mltomycm
CMF rexate, Fluorouracil, Cyclophosphamide
CMFP Cyclophosphamide, Methotrexate, Fluorouracil,
CMFVP Cyclophosphamide, Methotrexate, Fluorouracil,
Vincristine, Prednisone
COMLA Cyclophosphamide, Vincristine, Methotrexate,
Leucovorin, Cytarabine
COMP Cyclophosphamlde, stine Methotrexate Prednlsone
Cooper Regimen Cyclophosphamide, Methotrexate, Fluorouracil,
stine, Prednisone
COP Cyclophosphamide, Vincristine Prednisone
COPE Cyclophosphamide, Vlncrlstlne, Cisplatin, EtopOSIde
COPP Cyclophosphamide, Vincristine, Procarbazine, Prednisone
CP(Chronic mbucil, Prednisone
lymphocytic leukemia)
CP (Ovarian Cancer) Cyclophosphamide, Cisplatin
Cisplatin, Vinblastine, Dacarbazine
Carboplatin, Etoposide, Ifosfamide, Mesna
ilTherapeutic agentsCyclophosphamide, Vincristine, Prednisome
g Lornustine, Procarbazine, Prednisone
CYVADIC Cyclophosphamide, Vincristine, Doxorubicin,
Dacarbazine
Daunorubicin, bine
Daunorubicin, Cytarabine, Thioguanine
Daunorubicin, Cytarabine, Etoposide
Daunorubicin, Cytarabine, Thioguanine
Cisplatin, Cytarabine, Dexamethasone
IiillE Doxorubicin, Ifosfamide
DTIC/Tamoxifen Dacarbazine, fen
Daunorubicin, Vincn'stine, Prednisone
m Etoposide, Doxorubicin, Cisplatin
[T]O Etoposide, Carboplatin
Etoposie, Fluorouracil, Cisplatin
Etoposide, Leucovorin, uracil
Mitoxantrone, Etoposide, Cytarabine
ide, Cisplatin
Etoposide, Vinblastine
Fluorouracil, Doxorubicin, Cyclophosphamide
Fluorouracil, bicin, cin
Methotrexate, Leucovorin, Doxorubicin
’fi Fluorouracil, Doxorubicin, Cisplatin
Fluorouracil, Leucovorin
uracil, Cyclophosphamide, Epirubicin
Fluorouracil, Etoposide, Cisplatin
Flutamide, Leuprolide
Flutamide, Goserelin acetate implant
Methotrexate, Leucovorin
WO 46403
Altretamine, Cyclophosphamide, Methotrexate,
Fluorouracil
N Vincristine, Carmustine, Cyclophosphamide, Prednisone,
Melphalan
MAC-III Methotrexate, Leucovorin, Dactinomycin,
Cyclophosphamide
MACC Methotrexate, Doxorubicin, Cyclophosphamide,
Lomustine
MACOP-B Methotrexate, Leucovorin, Doxorubicin,
Cyclophosphamide, Vincristine, Bleomycin, Prednisone
Z>5 Mesna, Doxorubicin, Ifosfamide, Dacarbazine
Bleomycin, Doxorubicin, Cyclophosphamide, Vincristine,
Dexamethasone, rexate, Leucovorin
Methotrexate, Bleomycin, tin
Z0 Mitoxantrone, bine
rexate, Fluorouracil, Leucovorin
Ifosfamide, Carboplatin, Etoposide, Mesna
Mesna, Ifosfamide, Mitoxantrone, Etoposide
EAM Carmustine, Etoposide, Cytarabine, lan
MOBP Bleomycin, Vincristine, Cisplatin, Mitomycin
MOP Mechlorethamine, Vincristine, Procarbazine
MOPP Mechlorethamine, Vincristine, Procarbazine, Prednisone
MOPP/ABV Mechlorethamine, Vincristine, bazine, Prednisone,
Doxorubicin, Bleornycin, Vinblastine
MP (multiple Melphalan, Prednisone
myeloma)
g5 Therapeutic agents
VIP (prostate cancer) Mitoxantrone, Prednisone
Methotrexate, Mercaptopurine
?s:HP] E5)é Methotrexate, Mercaptopurine, Vincristine, Prednisone
UUfi-U>& Methotrexate, Leucovorin, Cisplatin, Doxorubicin
MV (breast ) Mitomycin, Vinblastine
VIV (acute myelocytic Mitoxantrone, Etoposide
M-VAC Methotrexate Vinblastine, Doxorubicin, Cisplatin
MVP cin Vinblastine, Cisplatin
MVPP Mechlorethamine, stine, Procarbazine, Prednisone
Mitoxantrone, Fluorouracil, orin
%é Mitoxantrone, Vinblastine, Vincn'stine
OPA Vincristine, Prednisone, Doxorubicin
OPPA Add Procarbazine to OPA.
PAC Cisplatin, Doxorubicin
PAC-I Cisplatin, Doxorubicin, Cyclophosphamide
PA-CI Cisplatin, Doxorubicin
PCV ine, Procarbazine, Vincristine
PFL Cisplatin, Fluorouracil, Leucovorin
POC Prednisone, Vincristine, Lomustine
ProMACE Prednisone, Methotrexate, Leucovorin, Doxorubicin,
Cyclophosphamide, Etoposide
ProMACE/cytaBOM sone, Doxorubicin, Cyclophosphamide, Etoposide,
Cytarabine, Bleomycin, Vincristine, Methotrexate,
Leucovorin, Cotrimoxazole
PROMACE/MOPP Prednisone, Doxorubicin, Cyclophosphamide, Etoposide,
Mechlorethamine, Vincristine, Procarbazine, Methotrexate,
Leucovorin
Cisplatin, Teniposide
sone, Vincristine, Asparaginase
Mechlorethamine, Doxorubicin, Vinblastine, stine,
cin, Etoposide, Prednisone
TTT Methotrexate, Cytarabine, Hydrocortisone
Topo/CTX Cyclophosphamide, Topotecan, Mesna
VAB-6 Cyclophosphamide, Dactinomycin, Vinblastine, Cisplatin,
Bleomycin
VACAdr stine, Cyclophosphamide, Doxorubicin,
Dactinomycin, Vincristine
Vincristine, Doxorubicin, Dexamethasone
Vinblastine, Doxorubicin, Thiotepa, Flouxymesterone
Vincn'stine, Carmustine, Doxorubicin, Prednisone
Vincristine, Camustine, Melphalan, Cyclophosphamide,
Prednisone
<O Vinorelbine, tin
Vincfistine, Cyclophosphamide, Doxorubicin, Prednisone
Vinorelbine, Doxorubicin
Vinblastine, Cisplatin, Ifosfamide, Mesna
Etoposide, Cisplatin, Ifosfamide, Mesna
Mitomycin, Vinblastine
tine, Melphalan, Cyclophosphamide, Prednisone
Etoposide, tin
< Etoposide, Thioguanine, Daunorubicin, bine
U‘I Cytarabine, Daunorubicin, Mitoxantrone
\] Cytarabine with/, Daunorubicin or Idarubicin or
Mitoxantrone
prednisolone, Vincristine, Lomustine,
Procarbazine, Hydroxyurea, Cisplatin, Cytarabine,
Dacarbazine
In some embodiments, the chemotherapeutic agents that may be conjointly
administered with nds of the invention, such as a compound of Formula (I), e a
CD39 inhibitor. CD39 or ecto-nucleoside triphosphate diphosphohydrolase 1 (E-NTPDasel
or ENTPD 1) is a membrane-bound enzyme that zes the conversion of extracellular
adenosine sphate (ATP) and/or ADP (adenosine diphosphate) to adenosine
monophosphate (AMP). In one embodiment, the CD39 inhibitor is polyoxometalate-l
(POM-l).
In other embodiments, the chemotherapeutic agents that may be conjointly
administered with compounds of the invention, such as a compound of Formula (I), include
known CD73 inhibitors. In some embodiments, the CD73 inhibitor is an anthraquinone
tive (Baqi el al., J. Med. Chem, 53(5): 2076-2086, 2010, herein incorporated by
reference). In other embodiments, the CD73 inhibitor is an sulfonic acid derivative (Raza et
al., Med. Chem, 8: 1133-1139, 2012, herein incorporated by reference). In yet other
embodiments, the CD73 inhibitor is selected from l-amino—4-phenylamino-9,lO-dioxo-9,lO-
dihydroanthracenesulfonate (acid blue 25), 1-amino[4-hydroxyphenyl-amino]-9,10-
dioxo-9, l 0—dihydroanthracenesulfonate, 1-amino[4-aminophenylamino]-9,10-dioxo—
9, l 0—dihydroanthracenesulfonate, l-amino[1—naphthylamino]—9,lO-dioxo-9,10-
dihydroanthracenesulfonate, 1-amino[4-fluorocarboxyphenylamino]-9,10-dioxo-
9, l droanthracenesulfonate, l-amino[2-anthracenylamino]-9,lO-dioxo-9,10-
dihydroanthracenesulfonate, sodium 2,4—dinitrobenzenesulfonate, N—(4—
oylphenylcarbamothioyl) pivalamide, APCP, B-methylene-ADP (AOPCP), PPADS,
NF279, NF449, quercetin, reactive blue 2, and sumarin (Baqi 2010, Raza 2012).
In certain ments, the combination of a compound of the invention, such as a
compound of Formula (I), with a second CD73 inhibitor or a CD39 inhibitor may have a
synergistic effect in the treatment of cancer and other diseases or disorders mediated by
adenosine. Without wishing to be bound by any theory, this synergy may be observed
because CD39 and CD73 are often on different cell types. The hypoxic tumor
microenvironment also s greater levels of CD39 and CD73.
In some embodiments, the chemotherapeutic agents that may be conjointly
stered with nds of the invention, such as a compound of Formula (I), include
an adenosine receptor tor. In other embodiments, the adenosine receptor inhibitor is
selected from rolofylline, tonapofylline, ATL-444, istradefylline, MSX-3, preladenant, SCH-
58,261, SCH-412,348, SCH-442,416, ST-1535, VER-6623, VER—6947, VER-7835,
vipadenant, and ZM-241,3 85. In some embodiments, the adenosine receptor tor targets
the AZA receptor as this subtype is inantly expressed in most immune cells.
In other embodiments, the chemotherapeutic agents that may be conjointly
administered with compounds of the invention, such as a compound of Formula (I), include a
nucleoside-based drug. In certain embodiments, the nucleoside-based drug is selected from
gemcitabine, capecitabine, bine, fludarabine and cladribine.
In further embodiments, the combination therapy comprises a nd of the
invention, such as a compound of Formula (I), conj ointly administered with an anthracycline.
In other ments, the combination therapy comprises a compound of the invention, such
as a compound of Formula (I), conj ointly administered with doxorubicin. Combination
treatment with an anti-CD73 antibody and doxorubicin has trated a significant
chemotherapeutic effect (Young et 61]., Cancer Discov., 4(8): 1-10, 2014, herein incorporated
by reference).
In certain embodiments, the combination therapy comprises a compound of the
invention, such as a compound of Formula (I), conj ointly administered with an A2A receptor
inhibitor and an anthracycline. In some embodiments, the anthracycline is doxorubicin.
Combination treatment with an anti—CD73 antibody, an A2A receptor tor, and
doxorubicin has demonstrated an increased chemotherapeutic effect (Antonioli 2013).
In certain embodiments, the nt therapies of the invention comprise conjoint
administration with other types of herapeutic agents, such as immuno-oncology
agents. Cancer cells often have c cell surface ns that can be recognized by the
immune system. Thus, -oncology agents, such as monoclonal antibodies, can
selectively bind to cancer cell antigens and effect cell death. Other immuno-oncology agents
can suppress tumor—mediated inhibition of the native immune response or otherwise activate
the immune response and thus facilitate recognition of the tumor by the immune system.
Exemplary antibody immuno—oncology agents, include, but are not limited to, omab,
adecatumumab, afutuzumab, alemtuzumab, anatumomab mafenatox, apolizumab,
umomab, EMS-936559, catumaxomab, durvalumab, epacadostat, epratuzumab,
indoximod, inotuzumab ozogamicin, intelumumab, ipilimumab, isatuximab, lambrolizumab,
MED1473 6, MPDL3280A, nivolumab, obinutuzumab, ocaratuzumab, ofatumumab,
olatatumab, pembrolizumab, zumab, rituXimab, ticilimumab, samalizumab, and
tremelimumab. In some embodiments, the antibody immune-oncology agents are selected
from anti-CD73 monoclonal antibody (mAb), anti—CD39 mAb, anti—PD-l mAb, and anti-
CTLA4 mAb. Thus, in some embodiments, the methods of the invention comprise conjoint
administration of one or more immuno-oncology agents, such as the agents mentioned above.
In some ments, the combination therapy comprises a compound of the
invention, such as a nd of Formula (I), conj ointly administered with anti-PD-l
therapy and anti-CTLA4 therapy. Combination treatment with an anti-CD73 monoclonal
dy (mAb), anti-PD-l mAb, and anti-CTLA4 mAb showed a significant
chemotherapeutic effect (Young 2014, Antonioli 2013).
In some embodiments, the combination therapy comprises conjoint administration of
a compound of the invention, such as a compound of Formula (I), with anti-PD-l therapy. In
certain embodiments, the combination therapy comprises conjoint stration of a
compound of the invention, such as a nd of Formula (I), with oxaliplatin. In other
embodiments, the combination therapy comprises conjoint administration of a compound of
the invention, such as a compound of Formula (I), with bicin.
In certain embodiments, a nd of the invention may be ntly administered
with non-chemical methods of cancer treatment. In certain embodiments, a compound of the
invention may be conjointly administered with radiation therapy. In n embodiments, a
compound of the invention may be conjointly administered with surgery, with
thermoablation, with focused ultrasound therapy, with cryotherapy, or with any ation
of these.
In certain embodiments, compounds of the invention may be conjointly administered
with one or more other compounds of the invention. Moreover, such combinations may be
conjointly stered with other therapeutic agents, such as other agents le for the
treatment of cancer, immunological or neurological diseases, such as the agents fied
above. In certain embodiments, conjointly administering one or more additional
chemotherapeutic agents with a compound of the invention provides a synergistic effect. In
certain embodiments, conjointly administering one or more additional chemotherapeutic
agents provides an additive effect.
Pharmaceutical Compositions
In certain embodiments, the present ion provides a pharmaceutical preparation
suitable for use in a human patient, comprising any of the compounds shown above (e. g., a
compound of the invention, such as a compound of formula (I), and one or more
pharmaceutically acceptable ents. In certain embodiments, the pharmaceutical
preparations may be for use in ng or preventing a condition or disease as described
herein. Any of the disclosed compounds may be used in the manufacture of medicaments for
the treatment of any diseases or conditions disclosed herein.
The compositions and methods of the present invention may be utilized to treat a
subject in need thereof. In certain embodiments, the subject is a mammal such as a human, or
a non—human . When administered to subject, such as a human, the composition or
the compound is preferably administered as a pharmaceutical composition comprising, for
example, a compound of the invention and a pharmaceutically acceptable carrier.
ceutically acceptable carriers are well known in the art and include, for e,
aqueous solutions such as water or physiologically buffered saline or other solvents or
vehicles such as glycols, glycerol, oils such as olive oil, or injectable organic esters. In a
preferred embodiment, when such pharmaceutical compositions are for human
administration, particularly for invasive routes of administration (i.e., routes, such as injection
or implantation, that circumvent transport or diffusion through an lial barrier), the
aqueous solution is pyrogen—free, or substantially pyrogen—free. The excipients can be
chosen, for example, to effect delayed release of an agent or to selectively target one or more
cells, tissues or organs. The pharmaceutical ition can be in dosage unit form such as
tablet, capsule ding sprinkle capsule and gelatin capsule), granule, lyophile for
reconstitution, powder, on, syrup, suppository, injection or the like. The ition
can also be present in a transdermal delivery , e. g., a skin patch. The composition can
also be present in a solution suitable for topical administration, such as an eye drop.
A pharmaceutically acceptable carrier can contain physiologically acceptable agents
that act, for example, to stabilize, increase solubility or to se the absorption of a
compound such as a compound of the invention. Such physiologically acceptable agents
include, for example, carbohydrates, such as glucose, sucrose or dextrans, antioxidants, such
as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other
stabilizers or excipients. The choice of a pharmaceutically acceptable carrier, including a
physiologically acceptable agent, depends, for example, on the route of administration of the
composition. The preparation or pharmaceutical composition can be a self—emulsifying drug
delivery system or a icroemulsifying drug delivery . The pharmaceutical
composition (preparation) also can be a liposome or other r matrix, which can have
incorporated therein, for example, a nd of the invention. Liposomes, for e,
which comprise phospholipids or other lipids, are nontoxic, logically acceptable and
metabolizable carriers that are vely simple to make and administer.
The phrase "pharmaceutically acceptable" is employed herein to refer to those
compounds, materials, compositions, and/or dosage forms which are, within the scope of
sound medical judgment, le for use in contact with the tissues of a t without
excessive ty, irritation, allergic response, or other problem or complication,
commensurate with a reasonable benefit/risk ratio.
The phrase "pharmaceutically acceptable carrier" as used herein means a
ceutically able material, composition or vehicle, such as a liquid or solid filler,
diluent, excipient, solvent or encapsulating material. Each carrier must be "acceptable" in the
sense of being compatible with the other ients of the formulation and not injurious to
the subject. Some examples of materials which can serve as pharmaceutically acceptable
carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn
starch and potato starch, (3) cellulose, and its derivatives, such as sodium carboxymethyl
cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin;
(7) talc, (8) excipients, such as cocoa butter and suppository waxes, (9) oils, such as peanut
oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols,
such as ene , (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene
glycol; (12) esters, such as ethyl oleate and ethyl laurate; (l3) agar; (l4) buffering agents,
such as magnesium hydroxide and aluminum hydroxide, (15) alginic acid; (16) pyrogen-free
water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol, (20) phosphate buffer
solutions; and (21) other non—toxic compatible substances employed in pharmaceutical
formulations.
A ceutical composition (preparation) can be administered to a subject by any
of a number of routes of administration including, for example, orally (for example, drenches
as in aqueous or non-aqueous solutions or suspensions, tablets, capsules (including sprinkle
capsules and gelatin capsules), boluses, powders, granules, pastes for application to the
tongue), absorption through the oral mucosa (e.g., sublingually); anally, rectally or vaginally
(for example, as a pessary, cream or foam); parenterally (including intramuscularly,
intravenously, subcutaneously or intrathecally as, for example, a sterile solution or
suspension); nasally; intraperitoneally; subcutaneously, transdermally (for example as a patch
applied to the skin); and topically (for example, as a cream, ointment or spray applied to the
skin, or as an eye drop). The compound may also be formulated for inhalation. In certain
embodiments, a compound may be simply dissolved or ded in sterile water. Details of
appropriate routes of administration and compositions le for same can be found in, for
example, US. Pat. Nos. 6,110,973, 5,763,493, 5,731,000, 5,541,231, 5,427,798, 5,358,970
and 4,172,896, as well as in patents cited therein.
The formulations may conveniently be presented in unit dosage form and may be
prepared by any methods well known in the art of pharmacy. The amount of active ingredient
which can be combined with a carrier al to produce a single dosage form will vary
depending upon the subject being d, the particular mode of administration. The amount
of active ingredient that can be combined with a carrier material to produce a single dosage
form will generally be that amount of the nd which produces a therapeutic effect.
lly, out of one hundred percent, this amount will range from about 1 percent to about
ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent,
most ably from about 10 percent to about 30 percent.
Methods of ing these formulations or compositions include the step of ng
into association an active compound, such as a compound of the invention, with the r
and, optionally, one or more accessory ingredients. In general, the formulations are prepared
by uniformly and intimately bringing into association a compound of the present ion
with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping
the product.
Formulations of the invention suitable for oral stration may be in the form of
capsules (including sprinkle capsules and gelatin capsules), cachets, pills, tablets, lozenges
(using a flavored basis, usually e and acacia or tragacanth), lyophile, powders,
granules, or as a on or a suspension in an aqueous or non-aqueous liquid, or as an oil—in-
water or water-in-oil liquid on, or as an elixir or syrup, or as pastilles (using an inert
base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the
like, each containing a predetermined amount of a compound of the present ion as an
active ingredient. Compositions or compounds may also be administered as a bolus, electuary
or paste.
To prepare solid dosage forms for oral administration (capsules (including sprinkle
capsules and gelatin capsules), tablets, pills, dragees, s, granules and the like), the
active ingredient is mixed with one or more ceutically acceptable rs, such as
sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders,
such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid, (2) binders, such as,
for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose
and/or acacia, (3) humectants, such as glycerol, (4) disintegrating agents, such as agar-agar,
calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium
carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as
quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol
and glycerol monostearate; (8) ents, such as kaolin and bentonite clay; (9) ants,
such a talc, m stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl
sulfate, and mixtures f; (10) xing agents, such as, modified and unmodified
extrins, and (l l) coloring agents. In the case of capsules (including sprinkle capsules
and gelatin capsules), s and pills, the pharmaceutical compositions may also comprise
buffering agents. Solid compositions of a similar type may also be employed as flllers in soft
and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as
high molecular weight polyethylene glycols and the like.
A tablet may be made by compression or molding, optionally with one or more
accessory ingredients. Compressed tablets may be prepared using binder (for example,
gelatin or hydroxypropylmethyl cellulose), lubricant, inert t, preservative, disintegrant
(for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose),
surface-active or dispersing agent. Molded tablets may be made by molding in a suitable
machine a mixture of the powdered compound ned with an inert liquid diluent.
The tablets, and other solid dosage forms of the ceutical compositions, such as
dragees, capsules (including sprinkle capsules and gelatin capsules), pills and granules, may
optionally be scored or prepared with coatings and shells, such as enteric gs and other
coatings well known in the pharmaceutical-formulating art. They may also be formulated so
as to provide slow or controlled release of the active ingredient therein using, for example,
hydroxypropylmethyl cellulose in varying proportions to provide the desired e profile,
other polymer matrices, liposomes and/or microspheres. They may be ized by, for
example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in
the form of sterile solid itions that can be dissolved in sterile water, or some other
sterile injectable medium immediately before use. These compositions may also optionally
contain opacifying agents and may be of a composition that they release the active
ient(s) only, or preferentially, in a certain portion of the gastrointestinal tract,
ally, in a delayed manner. Examples of embedding compositions that can be used
include polymeric substances and waxes. The active ingredient can also be in micro-
encapsulated form, if appropriate, with one or more of the above-described excipients.
Liquid dosage forms useful for oral administration include pharmaceutically
acceptable emulsions, lyophiles for reconstitution, microemulsions, solutions, suspensions,
syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain
inert diluents commonly used in the art, such as, for example, water or other solvents,
cyclodextrins and derivatives thereof, solubilizing agents and emulsifiers, such as ethyl
alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene , 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ,
olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and
fatty acid esters of sorbitan, and mixtures thereof.
Besides inert ts, the oral compositions can also include adjuvants such as
wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring,
ing and preservative agents.
Suspensions, in addition to the active compounds, may contain suspending agents as,
for example, ethoxylated isostearyl alcohols, polyoxyethylene ol and sorbitan ,
microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth,
and mixtures thereof.
Formulations of the pharmaceutical compositions for , vaginal, or urethral
administration may be presented as a itory, which may be prepared by mixing one or
more active compounds with one or more le nonirritating ents or carriers
comprising, for example, cocoa butter, hylene glycol, a suppository wax or a salicylate,
and which is solid at room temperature, but liquid at body ature and, therefore, will
melt in the rectum or vaginal cavity and release the active compound.
ations of the pharmaceutical compositions for administration to the mouth may
be presented as a mouthwash, or an oral spray, or an oral ointment.
Alternatively or additionally, compositions can be formulated for delivery via a
catheter, stent, wire, or other uminal device. Delivery via such devices may be
especially useful for delivery to the r, urethra, , rectum, or intestine.
Formulations which are suitable for vaginal administration also include pessaries,
tampons, creams, gels, pastes, foams or spray formulations containing such rs as are
known in the art to be appropriate.
Dosage forms for the topical or transdermal administration include powders, sprays,
ointments, pastes, , lotions, gels, solutions, patches and inhalants. The active
compound may be mixed under e ions with a pharmaceutically acceptable carrier,
and with any preservatives, buffers, or propellants that may be required.
The ointments, pastes, creams and gels may contain, in addition to an active
compound, excipients, such as animal and ble fats, oils, waxes, paraffins, starch,
tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc
and zinc oxide, or mixtures thereof
Powders and sprays can contain, in addition to an active compound, excipients such
as e, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or
mixtures of these substances. Sprays can additionally contain customary propellants, such as
chlorofluorohydrocarbons and le unsubstituted arbons, such as butane and
propane.
ermal patches have the added advantage of providing controlled delivery of a
compound of the present invention to the body. Such dosage forms can be made by
dissolving or dispersing the active compound in the proper medium. Absorption enhancers
can also be used to increase the flux of the compound across the skin. The rate of such flux
can be controlled by either providing a rate controlling membrane or dispersing the
compound in a polymer matrix or gel.
Ophthalmic formulations, eye ointments, powders, solutions and the like, are also
contemplated as being within the scope of this invention. Exemplary ophthalmic
formulations are described in US. Publication Nos. 2005/0080056, 2005/0059744,
2005/0031697 and 2005/004074 and US. Patent No. 6,583,124, the contents of which are
incorporated herein by reference. If desired, liquid lmic formulations have ties
similar to that of lacrimal fluids, aqueous humor or vitreous humor or are compatible with
such fluids. A preferred route of administration is local administration (e.g., topical
stration, such as eye drops, or administration via an implant).
The phrases "parenteral administration" and istered parenterally" as used
herein means modes of administration other than l and topical administration, usually
by injection, and includes, without limitation, intravenous, intramuscular, intraarterial,
intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal,
subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and
intrasternal injection and infusion.
Pharmaceutical compositions le for eral administration comprise one or
more active compounds in combination with one or more aceutically acceptable sterile
isotonic aqueous or eous solutions, dispersions, sions or emulsions, or e
powders which may be tituted into sterile injectable solutions or dispersions just prior
to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the
formulation isotonic with the blood of the intended recipient or suspending or thickening
agents.
Examples of suitable aqueous and nonaqueous carriers that may be employed in the
pharmaceutical compositions of the invention include water, ethanol, s (such as
glycerol, propylene glycol, polyethylene , and the like), and suitable mixtures thereof,
vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper
fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by
the maintenance of the required particle size in the case of dispersions, and by the use of
surfactants.
These compositions may also contain adjuvants such as preservatives, wetting agents,
emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be
d by the inclusion of various cterial and antifungal agents, for example, paraben,
chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic
agents, such as sugars, sodium chloride, and the like into the compositions. In addition,
prolonged absorption of the able pharmaceutical form may be brought about by the
inclusion of agents that delay absorption such as aluminum earate and gelatin.
In some cases, in order to prolong the effect of a drug, it is desirable to slow the
absorption of the drug from aneous or intramuscular injection. This may be
accomplished by the use of a liquid suspension of crystalline or amorphous material having
poor water solubility. The rate of absorption of the drug then depends upon its rate of
dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively,
d absorption of a parenterally administered drug form is accomplished by dissolving or
suspending the drug in an oil vehicle.
Injectable depot forms are made by forming microencapsulated matrices of the
subject compounds in biodegradable rs such as polylactide—polyglycolide. ing
on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of
drug release can be controlled. Examples of other biodegradable polymers include
poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by
entrapping the drug in liposomes or microemulsions that are compatible With body tissue.
For use in the methods of this invention, active nds can be given per se or as a
pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to
90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
Methods of introduction may also be provided by rechargeable or biodegradable
devices. Various slow release polymeric devices have been developed and tested in vivo in
recent years for the controlled ry of drugs, ing proteinacious biopharmaceuticals.
A variety of biocompatible polymers (including hydrogels), including both biodegradable and
non-degradable polymers, can be used to form an implant for the sustained release of a
compound at a particular target site.
Actual dosage levels of the active ingredients in the ceutical compositions may
be varied so as to obtain an amount of the active ingredient that is effective to achieve the
desired eutic response for a ular patient, composition, and mode of
administration, without being toxic to the patient.
The selected dosage level will depend upon a variety of factors including the ty
of the particular compound or combination of compounds employed, or the ester, salt or
amide thereof, the route of administration, the time of administration, the rate of excretion of
the particular compound(s) being employed, the duration of the treatment, other drugs,
compounds and/or als used in combination with the particular compound(s) employed,
the age, sex, weight, condition, l health and prior medical history of the subject being
treated, and like factors well known in the medical arts.
A physician or narian having ordinary skill in the art can readily determine and
prescribe the therapeutically effective amount of the pharmaceutical ition required
For example, the physician or veterinarian could start doses of the pharmaceutical
composition or nd at levels lower than that required in order to achieve the desired
therapeutic effect and gradually increase the dosage until the desired effect is achieved. By
“therapeutically effective amount” is meant the concentration of a compound that is sufficient
to elicit the desired therapeutic effect. It is generally understood that the ive amount of
the compound will vary according to the weight, sex, age, and medical history of the subject.
Other factors which influence the effective amount may include, but are not limited to, the
severity of the subject's ion, the disorder being treated, the stability of the compound,
and, if desired, another type of therapeutic agent being administered with the compound of
the invention. A larger total dose can be delivered by le administrations of the agent.
Methods to determine efficacy and dosage are known to those skilled in the art (Isselbacher el
al. (1996) Harrison’s Principles of Internal Medicine 13 ed., 1814-1882, herein incorporated
by reference).
In general, a suitable daily dose of an active compound used in the compositions and
methods of the invention will be that amount of the compound that is the lowest dose
effective to produce a eutic effect. Such an effective dose will generally depend upon
the factors described above.
If desired, the effective daily dose of the active compound may be administered as
one, two, three, four, five, six or more sub-doses administered separately at appropriate
intervals throughout the day, optionally, in unit dosage forms. In certain embodiments of the
present invention, the active compound may be administered two or three times daily. In
preferred embodiments, the active compound will be administered once daily.
In certain embodiments, the dosing follows a 3+3 . The traditional 3+3 design
requires no ng of the dose—toxicity curve beyond the classical assumption for
cytotoxic drugs that toxicity ses with dose. This rule-based design proceeds with
cohorts of three patients, the first cohort is treated at a starting dose that is considered to be
safe based on extrapolation from animal toxicological data, and the subsequent cohorts are
treated at increasing dose levels that have been fixed in advance. In some embodiments, the
three doses of a compound of formula (I) range from about 100 mg to about 1000 mg ,
such as about 200 mg to about 800 mg, such as about 400 mg to about 700 mg, such as about
100 mg to about 400 mg, such as about 500 mg to about 1000 mg, and further such as about
500 mg to about 600 mg. Dosing can be three times a day when taken with without food, or
twice a day when taken with food. In certain embodiments, the three doses of a compound of
formula (I) range from about 400 mg to about 800 mg, such as about 400 mg to about 700
mg, such as about 500 mg to about 800 mg, and further such as about 500 mg to about 600
mg twice a day. In n preferred embodiments, a dose of greater than about 600 mg is
dosed twice a day.
If none of the three patients in a cohort experiences a dose-limiting toxicity, r
three patients will be treated at the next higher dose level. However, if one of the first three
patients experiences a dose—limiting toxicity, three more ts will be treated at the same
dose level. The dose escalation continues until at least two patients among a cohort of three to
six ts experience dose—limiting toxicities (i.e., 2 about 33% of patients with a dose-
limiting toxicity at that dose level). The recommended dose for phase II trials is
conventionally defined as the dose level just below this toxic dose level.
In certain embodiments, the dosing schedule can be about 40 mg/m2 to about 100
mg/m2, such as about 50 mg/m2 to about 80 mg/m2, and further such as about 70 mg/m2 to
about 90 mg/m2 by IV for 3 weeks of a 4 week cycle.
In certain embodiments, compounds of the invention may be used alone or conjointly
administered with another type of therapeutic agent. As used , the phrase “conjoint
stration” refers to any form of administration of two or more different eutic
compounds such that the second compound is administered while the previously administered
therapeutic compound is still effective in the body (e.g., the two compounds are
simultaneously effective in the subject, which may include synergistic effects of the two
compounds). For example, the different therapeutic compounds can be administered either in
the same formulation or in a separate formulation, either itantly or sequentially. In
certain embodiments, the different therapeutic compounds can be administered within one
hour, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, or a week of one r. Thus, a
subject who receives such treatment can benefit from a combined effect of different
therapeutic compounds.
WO 46403
In certain ments, conjoint administration of compounds of the invention with
one or more additional therapeutic agent(s) (e.g., one or more additional chemotherapeutic
agent(s)) provides improved eff1cacy relative to each individual administration of the
compound of the invention (e.g., compound of formula I or Ia) or the one or more additional
therapeutic s). In certain such embodiments, the conjoint administration provides an
additive effect, wherein an additive effect refers to the sum of each of the effects of
individual administration of the compound of the invention and the one or more additional
therapeutic agent(s).
This invention includes the use of pharmaceutically acceptable salts of compounds of
the invention in the compositions and methods of the present invention. In certain
embodiments, contemplated salts of the invention include, but are not limited to, alkyl,
dialkyl, trialkyl or tetra-alkyl ammonium salts. In certain embodiments, contemplated salts
of the invention include, but are not limited to, L-arginine, benenthamine, benzathine,
betaine, calcium hydroxide, e, deanol, diethanolamine, lamine, 2-
ylamino)ethanol, ethanolamine, ethylenediamine, N—methylglucamine, amine,
lH-imidazole, lithium, ne, magnesium, 4-(2—hydroxyethyl)morpholine, piperazine,
potassium, 1-(2-hydroxyethyl)pyrrolidine, sodium, triethanolamine, hamine, and zinc
salts. In certain embodiments, contemplated salts of the invention include, but are not limited
to, Na, Ca, K, Mg, Zn or other metal salts.
The pharmaceutically acceptable acid addition salts can also exist as various solvates,
such as with water, methanol, ethanol, dimethylformamide, and the like. Mixtures of such
solvates can also be prepared. The source of such solvate can be from the solvent of
crystallization, inherent in the solvent of preparation or crystallization, or adventitious to such
solvent,
Wetting agents, emulsifiers and lubricants, such as sodium lauryl e and
magnesium stearate, as well as coloring agents, e agents, coating agents, ning,
flavoring and perfuming agents, preservatives and antioxidants can also be t in the
compositions.
Examples of pharmaceutically acceptable antioxidants include: (1) water-soluble
antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium
sulflte, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl
palmitate, butylated hydroxyanisole (BHA), ted hydroxytoluene (BHT), lecithin,
propyl gallate, alpha—tocopherol, and the like; and (3) metal—chelating agents, such as citric
acid, ethylenediamine cetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and
the like.
The invention now being generally described, it will be more readily understood by
reference to the ing examples which are ed merely for purposes of illustration of
certain aspects and embodiments of the present invention, and are not intended to limit the
invention.
General Synthetic Procedures
Compound numbers 1-129 as used in the general synthesis section below refer only to
genus ures in this section and do not apply to compounds sed elsewhere in this
application. nds disclosed herein can be made by methods depicted in the reaction
schemes below.
The starting materials and reagents used in ing these compounds are either
available from commercial supplier such as Aldrich Chemical Co., Bachem, etc., or can be
made by methods well known in the art. The schemes are merely illustrative of some
methods by which the compounds disclosed herein can be synthesized and various
modifications to these schemes can be made and will be suggested to POSITA having
referred to this disclosure. The starting materials and the intermediates and the final products
of the reacton may be isolated and purified if desired using convential ques, including
but not limited to filtration, distillation, crystallization, chromatography, and the like and may
be characterized using conventional means, including physical constants and spectral data.
Unless specified otherwise, the reactions described herein take place at atmospheric
re over a temperature range from about -78 0C to about 150 °C.
l Schemes
Compounds of Formula (I) having the structure:
0 Ru 0 R”
0V0R9 «#2 OR
N RV”? N N
< "i < "1
R90 R50 N NARV R50 N
0 0 N/ R" N/ V
HOS 30H HO‘ OH HO OH
('3) or (lb) of (IC)
where Z, R“, RV, RW, RX, R5, and R9 are analogous to variables Z, Ra, Rb, R”, R5, R9 and RK is
-CH2P(O)(OR15)2 or -OP(O)(OH)CH2P(O)(OR15)2 as defined in the Summary, can be
sized as illustrated and described in Scheme 1:
Scheme 1
HO:SDHO P0 P0 PO
0 deprotection 0
protection 0.,ng oxidation
”.0 OH
’OK ' )(RH— " '
o ,0 Ho~‘ :5’03< H6 ’OH
A-1 A-2 A-3 A-6
P= TBDPS,orTDMS R" =i-i,a|ky[.aryl,hetercycle
N \ u Li
(IflZ R R
0 0R9
N N R" N N
PO \i \
ion M1
GAO A-8 (I deprotection </ i R90 N2
_. P0 N
R' 0 N/ RV H0: 0 ,N N/ RV
—AcOI '
IOAc 9 lycosylation X 7 Rh2(OAc)4
RII ll
. ’ — ‘ 1
And bAc Acd bAC R9 = alkyl
A-7 A-9 A-10
0 Ru 0 R“ o R“
0Q0R9 N 0Q;0R9 N 0 OH
</ I 1 R5-X A-13 (l \Z
I deprotection m I NiRV
R90 0 R90 wi..N N/ N —, HO </NN
o R" R5 0 o N/ RV R5 0
base Rug—J_ / =—.0E
. R"
Ace“ 'bAc Acd 1’0Ac HO: ’OH
A42 A'14 formula (la)
Ketone A-3 is prepared from commercially available diol A-1 via selective protecting
the y alcohol with a suitable group such as TBDPS, TBDMS, Ac and B2, and followed
by oxidizing the secondary alcohol in A-2 where R” is H, alkyl, TMS, or heterocycles.
Stereoselective addition of the corresponding l nucleophile A-4, such as Grignard
reagents or Li ts, to ketone A-3 to provide propargylic alcohol A-5. Removal of the
acetonide protecting group is accomplished with d aq. acid, such as TFA, HCl, H2SO4,
HClO4, PPTS, CSA or other Lewis acids. Acylation of triol A-6 with reagents, such as AczO,
acetyl chloride, and BzCl, in the presence of a base, such as ne, and catalytic 4-DMAP
to provide tri-ester such as etate A-7. Glycosylation under conditions (N, O-
bis(trimethylsilyl)-acetamide and TMSOTf ) or (TfOH and DBU) in solvent (MeCN,
dichloroethane or toluene), between donor A-7 and acceptor A-8, such as 2-chloroadenine, 6-
aminochloroadenine, 2,6-dichloroadenine, 5,7—dichloro-1H-imidazo[4,5-b]pyridine, 5-
chloro-3H—imidazo[4,5-b]pyridine, uracil, thymine, cytosine or guanine, to provide the
nucleoside product A-9. In the case when R[1 is NH2, it is protected as N(Boc)2 with BoczO in
the presence of TEA and catalytic 4—DMAP. l of the protecting group in A-9, in the
case of P is TBDMS or TBDPS group, treatment with TBAF to give the y alcohol A-
which then is undergone an insertion on with diazo reagent A-11 in the presence of
catalyst such as Rh2(OAc)4 or Cu(OAc)2 to provide A-12. Alkylation with an ophile A-
13 such as alkyl , triflate, tosylate or mesylate in the presence of base such as CszCO3,
K2CO3, LiHMDS, DBU or NaH, to provide A-14. The ester groups in A-14 is finally
removed by base such as LiOH, NaOH, and KOH in water to provide A-15 in formula (Ia).
Alternatively, the alkynyl group at the 3’-position in intermediate A-5 can be
substituted with either alkyl or vinyl groups by using the corresponding alkyl or vinyl lithium
and Grignard reagents at Step 3 in Scheme 1.
Scheme 2
o 0
PO : : H0
0 o a A-11
--IO deprotection ”2
,,,o R90
R";—7 X0 O
R" _ . ’ ,Ok Ru ‘ . "'0
P10: bk Rh2(OAC)4
c ”
P10 0
3-1 B-2
R5-X A-13
0 OR9 0 0R9
acylation
9 9 deprotection
RORso 0 ‘—RORso O <—
0Ac A020 OH
7‘ for P‘ = A0
R" V . R" . .
A05 bAc AC5 ’OH P050 7'
3-6 B-5
Heterocycle B-7
glycosylation
o o
0 OR9 0 OH
deprotection
R90 R5 0 Het —> HO
o R5 o Het
R” E: S 7
R" E: E 7
AM? ’OAc Ho‘ bH
B-8 formula (la)
Compounds in formula (Ia) can also be prepared according to Scheme 2. The le
protecting group such as P is a silyl group (TBDPS or TBDMS) in precursor B-l can be
selectively removed by reagent such as TBAF or HF in THF while the P1 protecting group
such as Ac, B2 and MOM group remains. The resulting primary alcohol B-2 can react with
diazo reagent A-11 in solvent such as benzene, toluene, DCM and dichloroethane in the
WO 46403
presence of metal catalyst such as Rh2(OAc)4 to give intermediate B-3. Alkylation of B-3
with electrophile A-13 such as halide, triflate, mesylate or sulfonate is accomplished in the
presence of a base such as K2CO3, CszCO3, LiHMDS, NaH and DBU to give intermediate B-
4. Removing the acetonide protecting group in B-4 is done by an acid treatment such as aq.
TFA, HCl, H2804 or HClO4 in solvent such as DCM, acetone, THF or dioxane to provide
diol B-S. Acylation of B-S with t such as AczO or acetyl chloride in the presence of
pyridine, TEA or DIPEA and catalytic 4-DMAP to give tri-acetate B-6 (for P1 = OAc) as a
glycosylation donor. This intermediate B-6 is reacted with a glycosylation acceptor
heterocycle B-7 such as 2-chloroadenine, 6-aminochloroadenine, 2,6-dichloroadenine, 5,7-
dichloro- lH-imidazo[4,5-b]pyn'dine, 5-chloro-3H—imidazo[4,5-b]pyridine, uracil, thymine,
cytosine and guanine under the influence of conditions such as [N, 0-bis(trimethylsilyl)—
acetamide and TMSOTf ] or (TfOH and DBU) in t (MeCN, dichloroethane or DME) to
provide nucleoside intermediate B-8. Finally removal of the ester protecting groups in B—8
with the treatment of aq. LiOH, NaOH, and KOH in t such as THF, dioxane, MeOH or
EtOH to provide the desired final product in the formula (Ia).
Scheme 3
0 Cl 0 Ru
0W0}?9 9
</N \N philic
I OQOR (N \N
displacement I
R 0 R59 0 N / —> 9
mg, R 0 R5 0 N /
o N/kCI o N/kCI
C-2 WEZQ.
AGO: ~ ’
bAC x I
AcO OAc
‘34 C-3
Suzuki ng H)2 C-4
in"? fiupllnfin Ru—SNRQ C-5 deprotection
egs coup g
RU—ZnX C-6
0 Ru 0 Ru
0 0R9 /N o OH
< \N
I A deprotectlon. </N \N
R" : R“ :
‘. ,, ‘. ,,
Acd bAc Hd bH
C-7 formula (la)
Compounds in formula (Ia) can also be prepared according to Scheme 3. 2,6-
Dichloroadenine C-l prepared according to Scheme 1 can proceed into several tic
transformations. Selective nucleophilic displacement of the 6-chloro group in precursor 1
with nucleophile Ru—H (C-2) such as amines, alkoxides or thiolates in solvent such as DMF,
THF, dioxane, alcohols or NMP to provide intermediate C—3. Precursor C-1 also can
undergo a ng reaction such as Suzuki, Stille or Negishi reaction with the corresponding
reagent such as c acids (C-4), boronic , Tin reagents (C-S) or Zinc reagents (C-6)
to provide intermediate C-7, respectively. Treatment of both intermediates C-3 and C-7 with
aq. LiOH, NaOH, KOH, NaOMe, NaOEt or KOEt in solvent such as THF, dioxane, MeOH
or EtOH to provide the desired final products in the formula (Ia).
Scheme 4
Cl CI CI
N \ D-1 N N
N \N \N
P0; ’ | N/J\Cl <’ l NACI < l
N PO N deprotection HO N
0 0 NACI
: —>
Acd bAc glycosylation R"
,’ _ v,
Acd bAc Acd bAc
A-7 D-2 D-3
0 RW
c)4 R9OHN D-4
RlN R8 Cl CI
0 Rw 0 RW N 0 RW
H <N/ 1N1 \
/ N /
0'5 H H
R90 R5 0 <N I A
:0 'N R90 0 R90 0
CI HNR7RB R5 0 N Cl base,R5»X o:< 'Nim
‘— <—
R" amine R" R"
: a : -, A-13 : -,
Acd ’OAc dlsplacement Acd ’OAC A05 ,0Ac
D-7 C-1 D-S
i deprotectlonRLWR8
0 RW N
H < :1
HO R5 0wgs,, N
o N Cl
Ho‘ ’OH
formula (Ia)
Compounds in formula (Ia) can also be prepared via C-1 according to Scheme 4. In
this method, treatment of A-7 with 2,6-dichloropurine, TMSOTf and MO-
bis(trimethylsilyl)acetamide via the Vorbruggen reaction gives protected nucleoside D-2.
Selective removal of the tert-butyldiphenylsilyl moiety from the 5’-hydoxy1 group gives
alcohol D-3. Coupling with a desired substituted acyldiazo-reagent D-4 gives substituted
nucleoside D-5. A wide variety of diazo reagents can be used in this reaction. Some
examples include those where RW is C02R9, SOR9, S02R9, P(O)(OR9)2, and CN and R9 is
defined as in the Summary. If an alkyl substituent R5 is desired, it can be iently
introduced using an tion reaction where a phile such as RS-X (X = halide, OTf,
OMS or OTs) is used with a base like cesium carbonate in a polar aprotic solvent like THF or
DMF to give key intermediate C-l. A substituent such as an amine can be added to the
purine base by displacing the chlorine at the 6-position to give intermediate D-7 with variety
of amines D-6 in a solvent such as EtOH, THF or dioxane. Final deprotection of D-7 by
using an aqueous hydrolysis with a base such as lithium hydroxide gives target compound in
the structure of formula (1).
Scheme 5
\ / BOH( )2
Pd catalyst
acylation deprotection
‘— ‘—
Ac20 for P' = Ac
N glycosylalion
R\N/R7 a R\N,R7 s
\ - \
</ l N deprotectlon </ l N
—> NACI
formula (Ia)
Compounds in formula (Ia) can also be prepared according to Scheme 5. Alkylation
of sor B-3 from Scheme 2 above with an electrophile E-l such as 4—iodobenzyl halide
(Br, C1, or I) or the corresponding OTf, OMs or OTs with base such as K2CO3, CS2CO3, NaH
or LiHMDS in solvent like DMF or THF leads to ediate E-2 which can couple with
s boronic acids such as (2-oxo-l,2-dihydropyridinyl)boronic acid (E-3) illustrated
here. The resulting pyridone product E-4 is ted with various alkyl s (A-13) in the
presence of base such as K2CO3, CszCO3, NaH or LiHlVIDS in solvent like DMF and THF to
give E-S. The acetonide protecting group in E-S is removed with the treatment of aq. TFA,
HCl, H2804 or AcOH in a solvent such as DCM, acetone, e or THF to give diol E-6
which is acetylated with AczO or acetyl chloride with a catalytic amount of 4-DMAP and a
base such as pyridine, TEA or DIPEA in solvent like DCM to provide an anomeric mixture
E-7 as a glycosylation donor. Intermediate E-7 can either react With heterocyclic acceptor
2,6-dichloroadenine (D-l) or N—substituted ochloroadenine (E-9) which is formed
from displacing the 6-chloro group in D-1 with the suitable amines (D-7). Both glycosylation
can be done under the activation conditions such as [(N, O-bis(trimethylsilyl)-acetamide and
TMSOTf ] or (TfOH and DBU) in solvent (MeCN, roethane or toluene), between
donor E-7 and acceptors D-1 or E-9 to provide the corresponding nucleoside products, E-8 or
E-10 respectively. Nucleoside E-8 is converted into E-10 via a nucleophilic displacement
with s amines (D-7). Finally, desired compounds in formula (Ia) is produced from E-
via the deprotection of all its ester groups with treatment of aq. LiOH, NaOH, and KOH in
a t such as THF, dioxane, MeOH or EtOH.
Scheme 6
OTBDMS OH Br
0TBDMS
1 . 3—cNoropropy IsocyanaeI. t
TEA 1, Rs—X, base
2, NaH or NaOH 2. TBAF, THF 03% PPha, DCM
0 o 0
N4 N4 N4
NHz < NH < N—R5 < N—R5
F 1 F 2 F-3 F 4
glycosylation
R7\N,R5
9?:’CI,N \N F-11
Q formula (Ia)
Compounds in formula (Ia) can also be prepared according to Scheme 6. Alkylation
with benzyl halide F-4 with various alkyl side chains (R5) and precursor B-3 in the presence
of base such as K2CO3, CszCO3, LiHMDS or NaH in suitable solvent like DMF or THF leads
to intermediate F-S. Triacetate F-7 is formed via a two-step transformation from F—S via a
deprotection (aq. TFA in DCM) and acylation (AczO or acetyl chloride in pyridine) as
described aforementioned schemes. Glycosylation between F-7 and various acceptors such as
2,6-dichloroadenine (D-l) under an activation conditions [(N, 0-bis(trimethylsilyl)—acetamide
and TMSOTf ] or (TfOH and DBU) in solvent (MeCN, dichloroethane or toluene) to provide
nucleoside F-8 which is converted to amino analogs F-10 with various amines (F—9) in the
presence of base such as pyridine, TEA or DIPEA in appropriate solvent like dioxane, DMF,
or THF. Finally, desired molecules in formula (1) is obtained from F-10 with the treatment
of aq. LiOH, NaOH, and KOH in a solvent such as THF, dioxane, MeOH or EtOH.
Alternatively, intermediate F-10 can also directly produced from glycosylation between
donor F-7 and other acceptors such as N—substituted 6-aminochloroadenines (F—11).
The required benzyl s F-4 is prepared from 4-(((tert-butyldimethylsilyl)oxy)-
methyl)aniline (F-l) via a five-step transformation. The cyclic urea ring is initially formed
from aniline F-l reacting with 3-chloropropyl nate and followed by ation under
the influence of a base such as NaH, NaOH or LiHMDS in solvent like DMF or THF to
generate F-2. Intermediate F-2 is then led to F-3 by removal of the TBDMS group with
TBAF and proceeds to the final t by converting the primary alcohol to the bromide
with CBr4 and PPh3 in solvent such as DCM or THF.
Alternatively, key ediate F-5 is also prepared from precursor B-3 ing to
Scheme 7. Alkylation of sor B-3 with halides such as obenzyl bromide in the
presence of base such K2CO3 or Cs2CO3 in DMF to provide the nitro intermediate which is
then reduced to the aniline with Fe in aq. NH4Cl, Cyclic urea formation is carried out from
aniline with 3-chloropropyl isocyanate in the presence of base such as TEA in THF and
followed by olecular ring closure with the treatment of base such as NaH or LiHMDS
Introduction of the N—alkyl side chains is accomplished with electrophile such as A-13 to
provide key intermediate F-S.
Scheme 7
1. 3-chloropropyl isocyanate
TEA, THF
R 0 O
0 1. base, DMF 2. NaH or NaOH
-Ilo —>
R" 2. Fe, aq. NH4C|
R; X»:
Formula (1b) can be prepared ing to Scheme 8. The required diazo reagent G—2
which RW is an aryl or heteroaryl group, can be prepared from ester G—l with the suitable
sulfonyl azide reagent, such as midobenzenesulfonyl azide in the presence of a base,
such as Et3N and DBU, in MeCN or dioxane. Coupling of diazo reagent G—2 and alcohol A-
9 from Scheme 1 via the insertion reaction catalyzed by Rh or Cu catalyst such as Rh2(OAc)4,
in a solvent such as toluene, DCM or dichloroethane to give t G—3. Alkylation of G—3
with an electrophile A-13 such as alkyl halide, triflate, tosylate or mesylate in the presence of
base such as CszCO3, K2CO3, LiHMDS, DBU or NaH, to provide G—4. The ester groups in
G—4 is finally d by an aq. base such as LiOH, NaOH, and KOH to provide the desired
product in formula (Ib).
Scheme 8
o Ru
\ 0R9 N
o o </ j i Rw </ \z
RVKORQ diazoformation RW HO N
+ O N/ Rh2(OAC)4
mi?— Rv E—O N
0R9 O NARV
\. ., R" S 2
A05 IOAC Acd bAc
6-2 A-9 9-3
O R“ O Ru
“7?;0R9 N \ N
l NARV2 RW ’ Z
RS'X A43 72~OH l A
deprotection
—> R5 O O —> R5 O (N
0 v
R" _ . . R"
AcO aOAc H6 ’OH
G-4 formula (lb)
WO 46403
Compounds in formula (Ib) can also be prepared ing to Scheme 9. The y
alcohol B-2 can react with diazo reagent G—2 from Scheme 8 in the presence of a metal
catalyst such as Rh2(OAc)4 in a solvent such as benzene, toluene, DCM or dichloroethane to
give ediate H-1. Alkylation of H-1 with an electrophile A-13 such as halide, triflate,
mesylate or sulfonate is accomplished in the presence of base such as K2CO3, CszCO3,
LiHMDS, NaH and DBU to give intermediate H-2. Removing the acetonide protecting
group in H-2 is done by acid treatment such as aq. TFA, HCl, H2804, HClO4 or CSA in
solvent such as DCM, e, THF or dioxane to provide diol H-3. Acylation of H-3 with a
reagent such as AczO or acetyl chloride in the presence of pyridine, TEA or DIPEA and
catalytic 4-DMAP to give tri-acetate H-4 as a glycosylation donor. This intermediate H-4 is
reacted with a glycosylation or heterocycle B-7 such as 2-chloroadenine, 6-amino
chloroadenine, 2,6-dichloroadenine, 5,7-dichloro—1H—imidazo[4,5-b]pyridine, 5-chloro-3H—
imidazo[4,5-b]pyridine, uracil, thymine, cytosine and guanine under the conditions such as
[N, O-bis(trimethylsilyl)—acetamide and TMSOTf ] or (TfOH and DBU) in a solvent (MeCN,
dichloroethane or DME) to provide nucleoside intermediate H-5. Finally removal of the ester
protecting groups in H—S with the treatment of aq. LiOH, NaOH, and KOH in a solvent such
as THF, dioxane, MeOH or EtOH to provide the desired final product in the formula (Ib).
Scheme 9
4%; 0HO O N .
..lo 2 ‘ '
Rv-QQ—.O O
0 0 ection
R” " IO II IO
‘_ .’ base
.. k R;« ., k
¢ I ¢ I
P10 0 P10 0
B 2 H-1 H-2
O o 0
0R9 0R9 3—7 0R9 OH
R‘” RW Heterocycle R‘”
acylatlon' glycosylation Het
R5 O O Het RR5 O 0
O R5 0 0 O
OH OAc deprotection
—’ —>5R
Ac O l /
R” _=— 3 l R“ E— S R” __S
f Pa_A
P10‘ bH °' ‘ c Aco‘ OAc Ac0‘ ’OAc Riv$lcAcO OA
H-3 H-4 H-5 formula (lb)
Compounds in formula (Ic) can also be ed according to Scheme 10. Tertiary
alcohol I-2 where R1 is methyl (prepared according to the procedure reported by Franchetti,
P. et al. J. Med. Chem. 2005, 48, 4983—4989) or other alkyl groups; ethynyl (prepared
according to the procedure by Hulpia, F. et al. . Med. Chem. Lett. 2016, 26, 197O—
1972) or other l groups, and vinyl groups, was converted into L4 either directly by
treatment of acetylation reagent such as AczO and catalytic amount of H2804 in AcOH or vai
a 2-step process involving deprotetion of the acetonide group with treatment of aq. TFA or
other acid in DCM first and followed by acetylation of the resulting diol 1-3 with a reagent
such as AczO or acetyl chloride. Glycosylation of 1-4 with a heteroaromatic glycosyl
acceptor such as heterocycle B-7 described in Scheme 2 where R11 is H, Cl, NH2, N—alkyl
group such as 2-chloroadenine, 6-aminochloroadenine, 2,6-dichloroadenine, 5,7-dichloro-
lH-imidazo[4,5-b]pyridine, 5-chloro-3H—imidazo[4,5-b]pyridine, uracil, thymine, cytosine
and guanine under the conditions such as [N, trimethylsilyl)—acetamide and TMSOTf ]
or (TfOH and DBU) in a solvent (MeCN, dichloroethane or DME) to e nucleoside
intermediate [-5. Removal of the silyl protecting group in 1-5 with a source of fluoride such
as TBAF in THF to give primary alcohol 1-6 which was r converted into triol 1-7 with
aq. LiOH or NaOH in solvent such as THF, MeOH or EtOH. Finally, ent of 1-7 with
methylenebis(phosphonic dichloride) and trimethylphosphate before it is ed by
triethylammonium carbonate to provide the desired final product in the formula (1c).
Scheme 10
O o o
TBDPSO ...o R1-M TBDPSO mo aq.TFA,DCM TBDPso’mWOH
X _’ R1 ’
; X R1
_. .,
0 0 H6 0 Ac?) OH
H H2804 (cat) l-3
A020, AcOH
R” R” pyridine
N N 4-DMAP
<’ \N
l A </ \N
HO N
N TBDPSO N
0 N o
0 CI CI OAc
_ TBDPSO
TBAF THF glycosylatlon
R1 <—’ <— R1
. . R1 _ . a,
Acé éAc Aco bAc AcO
l-6 l-5 |.4
aq.LiOH,THF
(NIKN R”
CI—(IP? (lg—CI N \ N
N A CI/ V \CI 9 9
HO <’ l
o N CI HO—P P\
—> I \/ A
| O N
O N
HO 7’ CI
R1 P(O)(OMe)3, TEAB
.' .1 1 X
H5 OH RHd bH
l-7 formula (Ic)
nds in formula (Ic) can be prepared according to Scheme 11. Primary l
I-6 (where R“ = Cl) is alkylated with ophile J-l such as (diethoxyphosphoryl)methyl
trifluoromethanesulfonate or diethyl (iodomethyl)phosphonate in the presence of a base, such
as TEA, DIPEA, NaH and CszCO3 in a solvent such as THF, DMF, dioxane or NMP to give
intermediate J—2. Installation of the amino group in J-4 via nucleophilic displacement of the
chloro group in J-2 with R7R8NH (J—3) where R7 and R8 are H or alkyl , in the
presence of a base such as TEA or DIPEA in solvent such as dioxane, THF, or DMF. A two-
step deprotection sequence (TMSBr and aq. LiOH or NaOH) is required to convert J-4 to the
desired product in formula (Ic).
Scheme 11
gig,“ EtO-PVX
AC. EtO J"
”A MA R7JR8NH
base THF
OEt Egg,“ DIEA,dioxane
ACO OAc AcO OAc
I-G J-2
NR7R8 NR7R8
\ N N \
0| </ l 1. TMSBF, MeCN </ l N
/ 2. esterh drol sis
EtO-PA010,“ NJ\C| —.yy H0_'FI',/\o N
o “(km
OEt S 7
R1 OH
R1 . .
ACO OAC AC5 6A0
formula (lc)
Those having skill in the art will recognize that the starting als and reaction
ions may be varied, the sequence of the reactions altered, and additional steps
employed to produce compounds encompassed by the present invention, as demonstrated by
the following examples. In some cases, protection of certain reactive functionalities may be
necessary to achieve some of the above transformations. In l, the need for such
protecting groups as well as the conditions necessary to attach and remove such groups will
be apparent to enced organic chemists. The sures of all articles and references
ned in this application, including patents, are incorporated herein by reference.
The ation of the compounds of the present invention is illustrated further by the
following examples, which are not to be construed as limiting the invention in scope or spirit
to the specific procedures and compounds described in them.
Synthetic Examples
Example 1
Synthesis of 2—(((2R, 3S, 4R, 5R)—5-(6-amino-2—chloro-9H—purinyl)—3 -ethynyl-3 ,4-
dihydroxytetrahydrofuranyl)methoxy)benzylmalonic acid
TBDPSO
o _ TBDPSO TBDPSO TBDPSO
— M Br9 0
... 0
A020 0A5
THF . .
¢ ~‘ ’
O ”OK HO 0,0)(D HO AcO OAc
N \ TMSOTf
<’ f): DBU
n N c. MeCN
N(Boc)2 NH2
N(Boc)2 N \ N \
</NN TBAF,THF </ l 1 N
80620 </ I
I N10 <— TBDPSO
X j,No N/ l<— TBDPSO N
C o MAI
X 3/ C
HO—;‘»N-,I Eli/i: DMAP
Ach GOAc Ach “OAc
A06 OAc
0>—2_QB
toluene, 95 00
are N2
0 2 o N(Boc)2 o NH2
0 OEt {/NN BnBr K2003 0 CE 0 QB
] N1 DMF I N;\;. TFA DCM
E10 —>EtO (’NN
0:0 —A:OO:OIGO E10 0
CI 0<1|NiN10|
Acd bAc ACOC 90Ac
o NH2 0 NH2
0 OH OEt
/ lNHB,NMeOH
i Nlm /
LiOH (N 1%
HO O <: N
0N7 EtOH
HO: ’OH 0—H; Z‘OH
Example 1
Step 1:
To a e of (3aR, 5R, 6aS)—5-(((terz‘-butyldiphenylsilyl)oxy)methyl)—2,2-
yldihydrofuro[2,3-d][1,3]dioxol-6(3aH)—one (10 g, 23.44 mmol, 1 eq) in THF (100
mL) was added ethynylmagnesium bromide (0.5 M, 328.19 mL, 7 eq) at 15 0C under N2
atmosphere. The mixture was stirred for 16 h before additional ethynylmagnesium bromide
(0.5 M, 125mL, 3 eq) was added. The mixture was stirred further for 3 h before it was
diluted with saturated aq. NH4C1 (250 mL) and extracted with EtOAc (3 x 250 mL). The
combined organic layer was washed with brine (250 mL), dried over NazSO4, filtered and
amwmmwdmdwmw.Hmambmmhdwwpmmaflwflwhwmaghman
chromatography (petroleum ether: EtOAc = 1:0—4: 1) to provide (3aR, 5R, 6R, 6aR)(((tert—
butyldiphenylsilyl)oxy)methyl)ethynyl-2,2-dimethy1-tetrahydrofuro[2, 3 -d][1,3]dioxol—6-ol
(19.47 g, 92% yield) as a yellow solid.
Step 2:
To a solution of (3aR, 5R, 6R, 6aR)—5-(((lert—butyldiphenylsilyl)oxy)methyl)
l-2,2—dimethyltetrahydrofuro[2,3-d][1,3]dioxolol (9.47 g, 20.92 mmol, 1 eq) in
DCM (100 mL) was added H20 (10 mL) and TFA (100 mL) at 0 OC. The mixture was stirred
at 25 °C for l h before it was quenched with saturated aq. NaHCO3 to pH 7 and then
extracted with DCM (2 X 300 mL). The combined organic layer was washed with brine (200
mL), dried over NazSO4, filtered and concentrated to dryness. The crude product was
Imfimflbyflwhmhwgdcdmmumflmmwgqmy@amkwnemmflflOAc=10—Od)w
provide (3R, 4S, 5R)-5 -(((tert—butyldiphenyl silyl)oxy)methyl)ethynyltetrahydro—furan-2,3 ,4-
fim6wwbwawmmgmn
Step 3:
To a solution of (3R, 4S, 5R)—5—(((tert—butyldiphenylsilyl)oxy)methyl)—4-ethynyltetra—
hydrofuran-2,3,4-triol (5.17 g, 12.53 mmol, 1 eq) in pyridine (50 mL) at 15 °C was added 4-
DMAP (4.59 g, 37.60 mmol, 3 eq) and AczO (11.74 mL, 125.32 mmol, 10 eq). The mixture
was stirred at 15 0C for 16 h before H20 (500 mL) was added to the mixture. The reaction
emmmdmmEKMch2mnm)TMcmmmwogmmmWHW%WMMd
with brine (200 mL), dried over Na2S04, filtered and concentrated to dryness. The crude
product was purified by flash silica gel column chromatography (petroleum ether: EtOAc =
1:0 — 1:1) to provide (3R, 4R, 5R)—5-(((lert-butyldiphenylsilyl)oxy)methyl)—4—ethynyltetra-
mmfiMma3¢mflUMHmd7Dg7%flwwflwmflbwgm.
Step 4:
To a solution of (3R, 4R, (((lerz‘-butyldiphenylsilyl)oxy)methyl)—4-ethynyltetra-
hydrofuran—2,3,4-triyl tate (6.89 g, 12.79 mmol, 1 eq) in MeCN (5 mL) at 0 0C was
added 2-chloroadenine (2.39 g, 14.07 mmol, 1.1 eq), DBU (5.78 mL, 38.37 mmol, 3 eq) and
TBASOTf(11561nL,63961nnufl,5eq) Thennxuueumssfinedat0°Clbr05liandthen
stirred at 65 °C for 1 h before it was diluted with saturated aq. NaHCO3 solution (500 mL).
The aqueous phase was extracted with EtOAc (2 x 350 mL). The combined organic layer
was washed with brine (350 mL), dried over NazSO4, filtered and concentrated to dryness.
The crude product was purified by flash silica gel column chromatography (petroleum ether:
EtOAc = 1:0 — 0:1) to provide (2R, 3R, 4R, 5R)(6—amino—2-chloro—9H-purin-9—yl)(((tert—
butyldiphenylsilyl)oxy)methyl)—3-ethynyltetrahydrofuran-3,4-diyl diacetate (4.52 g, 44%
ymM)%aydbwde.
Step 5:
To a solution of (2R, 3R, 4R,5R)—5-(6-amino—2-chloro-9H—purinyl)(((ier2‘-
iphenylsilyl)oxy)methyl)—3-ethynyltetrahydrofuran-3,4-diyl diacetate (45 g, 6.94
mmol, 1 eq) in DMF (50 mL) at 20 0C was added TEA (4.83 mL, 34.71 mmol, 5 eq), 4-
DMAP (254 mg, 2.08 mmol, 0.3 eq) and BOC2O (7.58 g, 34.71 mmol, 5 eq). The mixture
was stirred at 20 0C for 1 h before H20 (250 mL) was added to the mixture. The reaction
mixture was ted with EtOAc (3 x 230 mL). The combined organic layer was washed
with brine (250 mL), dried over , filtered and concentrated. The crude product was
purified by flash silica gel column chromatography (petroleum ether: EtOAc = 1:0 — 1:1) to
provide (2R, 3R, 4R, 5R)-5 -(6—(bi s-(terl—butoxycarbonyl)amino)chloro-9H-purin—9-yl)-2—
(((tert—butyldiphenylsilyl)oxy)methyl)—3-ethynyltetrahydrofuran-3,4-diyl diacetate (3 .26 g,
46% yield) as a yellow foam.
Step 6:
To a solution of (2R,3R,4R,5R)—5-(6-(bis-(tert-butoxycarbonyl)amino)chloro-9H-
purinyl)—2-(((lert—butyldiphenylsilyl)oxy)methyl)ethynyltetrahydrofuran-3,4-diyl
diacetate (3.24 g, 3.82 mmol, 1 eq) in THF (35 mL) at 0 °C was added TBAF (1 M, 5.73 mL,
1.5 eq). The on mixture was stirred at 0 0C for 1 h before it was diluted with H20 (150
mL). The reaction mixture was ted with EtOAc (3 x 130 mL). The combined organic
layer was washed with brine (150 mL), dried over Na2SO4, filtered and concentrated. The
crude product was purified by flash silica gel column chromatography (petroleum ether:
EtOAc = 1:0 — 1:2) to provide (2R, 3R, 4R, (6-N,N’ (tert-butoxycarbonyl)amino)
chloro-9H-purinyl)—3 -ethynyl(hydroxymethyl)tetrahydrofuran-3 ,4-diyl diacetate (1 .5 1
g, 54% yield) as a yellow foam.
Step 7:
To a solution of (2R, 3R, —5-(6-N,N’ —(bis-(Zert—butoxycarbonyl)amino)chloro-
9H-purinyl)ethynyl-2—(hydroxymethyl)tetrahydrofuran-3,4-diyl diacetate (1.48 g, 2.43
mmol, 1 eq) in toluene (10 mL) at 20 0C under N2 atmosphere was added Rh2(OAc)4 (214
mg, 485.24 umol, 0.2 eq) and diethyl diazomalonate (903 mg, 4.85 mmol, 2 eq) in toluene (3
mL). The mixture was stirred at 95 0C for 2 h to give a green suspension before it was cooled
to room temperature and concentrated to dryness. The crude product was purified by flash
silica gel column chromatography (petroleum ether: EtOAc = 1:0 — 3: 1) to provide diethyl 2-
(((2R, 3R, 4R, 5R)-3 ,4-diacetoxy-5 -(6-N,N’ —(bi s-(tert—butoxycarbonyl)amino)chloro-9H—
purin—9-yl)-3—ethynyltetrahydrofuranyl)methoxy)malonate (517 mg, 20% yield) as a
yellow foam.
Step 8:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy-5—(6-N,N’ —(bis-(terl—butoxy-
carbonyl)amino)—2-chloro-9H—purinyl)ethynyltetrahydrofuranyl)methoxy)malonate
(497.00 mg, 647.00 umol, 1 eq) in DMF (5 mL) at 25°C was added K2CO3 (178.84 mg, 1.29
mmol, 2 eq). The reaction mixture was stirred for 30 min and followed by addition of benzyl
bromide (221.32 mg, 1.29 mmol, 153.69 uL, 2 eq). The mixture was stirred at 25°C for 15.5
h before additional K2CO3 (100 mg) and BnBr (100 uL) were added to the mixture. The
resulting mixture was stirred at 25°C for 24 h before H20 (50 mL) was added to the reaction.
The reaction mixture was extracted with EtOAc (2 x 50 mL). The combined organic layer
was washed with brine (50 mL), dried over NazSO4, filtered and concentrated. The crude
product was purified by flash silica gel column chromatography (petroleum ether: EtOAc =
1:0 — 3: 1) to provide diethyl 2-benzyl(((2R, 3R, 4R, 5R)—3,4-diacetoxy(6-(bis-(z‘erl—
butoxycarbonyl)amino)—2-chloro-9H—purinyl)ethynyltetrahydrofuranyl)methoxy)-
te (266 mg, 37% yield) as a yellow foam.
Step 9:
To a solution of diethyl 2-benzyl—2-(((2R, 3R, 4R, 5R)-3,4—diacetoxy(6—(bis-(tert-
butoxycarbonyl)amino)—2-chloro-9H-purin—9-yl)ethynyltetrahydrofuranyl)methoxy)-
malonate (266 mg, 309.92 umol, 1 eq) in DCM (3 mL) was added TFA (0.45 mL) at 0 °C.
The mixture was d at 25°C for 16 h before it was treated with saturated aq. NaHCO3
solution to pH 7. The reaction mixture was extracted with DCM (2 x 50 mL). The combined
c layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated to
provide crude l 2-benzyl(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-aminochloro-9H—
purinyl)—3-ethynyltetrahydrofuranyl)methoxy)malonate (195 mg) as a yellow foam.
Step 10:
The mixture of crude diethyl 2-benzyl(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-amino-
2-chloro-9H-purinyl)ethynyltetrahydrofuranyl)methoxy)malonate (195 mg, 296.33
umol, 1 eq) in saturated NH3 in MeOH (3 mL) was stirred at 10 °C for 16 h before it was
concentrated to dryness directly. The crude product was purified by preparative TLC
(EtOAc) to provide l R, 3S, 4R, 5R)(6—aminochloro-9H-purinyl)—3-
ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)benzylmalonate (91.7 mg, 49%
yield) as a yellow foam.
Step 11:
To a solution of diethyl 2-(((2R, 3S, 4R, (6-aminochloro-9H—purin—9—yl)-3—
ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)benzylmalonate (81 mg, 141.12
umol, 1 eq) in EtOH (2 mL) was added zO (30 mg, 705.60 umol, 5 eq) in H20 (02
mL) at 10°C. The mixture was stirred at 50°C for 4 h before it was concentrated to dryness.
The residue was dissolved in H20 (50 m1) and extracted with EtOAc (2 x 50 mL). The
organic layers were discarded and the aqueous phase was acidified to pH ~25 with 1N aq.
HCl solution. The aqueous phase was extracted with EtOAc (3 x 50 mL). The combined
organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated to
provide the title compound (55.4 mg, 74% yield) as a white solid.
1H NMR (400 MHz, DMSO-ds) 8 ppm 8.39 (s, 1H), 7.79 (br s, 2H), 7.20 (br d, J=7.03 Hz,
2H), 7.01 - 7.12 (m, 3H), 5.82 (d, J=7.53 Hz, 1H), 4.87 (d, J=7.78 Hz, 1H), 4.16 (dd, J=5.27,
2.51 Hz, 1H), 3.99 - 4.07 (m, 2H), 3.83 (br d, J=8.03 Hz, 1H), 3.56 (s, 1H), 3.25 (dd, J=6.78
Hz, 2H), LC/MS [M + H] = 518.0.
Example 2
sis of 2-(((ZS, 3R, 4R, 5R)(6-aminochloro-9H-purinyl)ethynyl
ytetrahydrofuranyl)methoxy)benzylmalonic acid
N(Boc)2 NHBoc NHBoc NHBoc
\ \ N \ N \ N
/ N NH3, MeOH <,N TCDI </N (n-Bu)38nH /N
TBDPSO N N’ TBDPSO N
o N/ DMAP O N
o CI Cl o N/ CI 133er TBDPSO N
o N/
X 7’ X 7 CI
DCM X 7’ X 7’
mi ”OAc Hcf ’OH 6Tb 6H
N 800 N Bee 0 05'
NH: ( )2 ( )2 o N(Boc)2
TFA B0020, TEA TBAF
DCM /N \ DMAP, DMF /N \ N THF /N \ N ao 0 QB
I AN I A I A ' <IN l A
N TBDPSO <N HO <N
TBDPSO; Rh (0A6)
o N CI ; 0 N CI ; o N on tozluene‘: E10 0; N
o N CI
10H bBoc 68°C 90809
0 N(Boc)2 o NH2 0 NH2
C 0 CB N 0 QB N O OH
\ \ N \
<’ l i TFA,DCM </ | i aq.LiOH,THF </ l i
—> EtO o N
o N/ —> EC 0 N HO 0 N
CI o N/ CI o N/ Cl
K2803,DMF
r’OBoc "OH ’IOH
Examplez
Step 1:
To a solution of (2R, 3R, 4R,5R)(6—(bis-(terl-butoxycarbonyl)amino)chloro-9H—
purinyl)—2-(((lert—butyldiphenylsilyl)oxy)methyl)ethynyltetrahydrofuran-3,4-diyl
diacetate (5 g, 5.89 mmol, 1 eq) was added 2M NH3 in MeOH (50 mL) at 0 °C. The reaction
mixture was stirred at 25 0C for 16 h before it was concentrated. The crude was purified by
flash silica gel column chromatography (0—50% EtOAc in petroleum ether) to provide tert—
butyl (9-((2R, 3R, 4S, 5R)(((lerZ-butyldiphenylsilyl)oxy)methyl)ethynyl-3 ydroxy-
tetrahydrofuran-Z-yl)ch1oro-9H-purinyl)carbamate (3.78 g, 90% yield) as a yellow
foam.
Step 2:
To a solution of utyl (9—((2R, 3R, 4S, 5R)—5-(((terl—butyldiphenylsilyl)oxy)-
methyl)ethynyl-3,4-dihydroxytetrahydrofuranyl)chloro-9H-purinyl)carbamate
(3.78 g, 5.29 mmol, 1 eq) in DCM (40 mL) at 0 °C under N2 atmosphere was added 4-DMAP
(258.63 mg, 2.12 mmol, 0.4 eq) and TCDI (4.72 g, 26.46 mmol, 5 eq). The on mixture
was stirred at 25 CC for 16 h before it was concentrated. The crude was purified by flash
silica gel column chromatography (0—33% EtOAc in petroleum ether) to provide terl-butyl
(9-((3aR, 4R, 6R, 6aR)(((terZ-butyldiphenylsilyl)oxy)methyl)-6a—ethynyl—2-thioxotetra-
hydrofuro[3,4-d][1,3]dioxol—4-yl)chloro—9H—purinyl)carbamate (1.4 g, 37% yield) as a
yellow foam.
Step 3:
To a solution of lert—butyl (9—((3aR, 4R, 6R, 6aR)—6-(((Zerl-butyldiphenylsilyl)oxy)-
methyl)-6a-ethynylthioxotetrahydrofuro[3 1,3]dioxolyl)chloro-9H—purin
yl)carbamate (500 mg, 707.93 umol, 1 eq) in toluene (5 mL) was added AIBN (11.62 mg,
70.79 umol, 0.1 eq) at 20—25°C. The reaction mixture was then heated to 60 oC and followed
by addition of (n-Bu)3SnH (561.96 uL, 2.12 mmol, 3 eq). The reaction mixture was stirred at
60 °C for 1.5 h before it was concentrated. The crude was purified by flash silica gel column
chromatography (0—33% EtOAc in petroleum ether) to e tert—butyl (9-((2R, 3R, 4R, 5S)-
-(((l‘erl—butyldiphenylsilyl)oxy)methyl)ethynyl—3 -hydroxytetrahydro-furanyl)
chloro-9H-purinyl)carbamate (220 mg, 47% yield) as a white foam.
Step 4:
To a solution of lert-butyl (9-((2R, 3R, 4R, (((terZ-butyldiphenylsilyl)oxy)-
methyl)ethynylhydroxytetrahydrofuranyl)chloro-9H-purinyl)carbamate (220
mg, 339.39 umol, 1 eq) in DCM (1.4 mL) at 0 CC was added TFA (0.7 mL, 9.45 mmol, 28
eq). The reaction mixture was d at 25 CC for l h before it was diluted with saturated
aq. NaHCO3 solution (15 mL) and extracted with DCM (3 x 5 mL). The combined organic
layer was washed with brine (10 mL), dried over Na2S04, filtered and concentrated to
WO 46403 2019/038245
provide crude (2R, 3R, 4R, 5.5)—2-(6-amino-2—chloro—9H—purin—9-yl)—5—(((tert—butyldiphenyl—
silyl)oxy)methyl)ethynyltetrahydrofuranol (260 mg) as a yellow foam.
Step 5:
To a solution of (2R, 3R, 4R,5S)(6-amino—2-chloro-9H—purinyl)—5-(((lert—
butyldiphenylsilyl)oxy)methyl)-4—ethynyltetrahydrofuranol (260 mg, 474.36 umol, 1 eq,
crude) in DMF (2.5 mL) was added BOC2O (931.75 mg, 4.27 mmol, 9 eq), TEA (660.25 uL,
4.74 mmol, 10 eq) and 4-DMAP (5.80 mg, 47.44 umol, 0.1 eq) at 0 oC. The reaction mixture
was stirred at 25 °C for 1.5 h before it was diluted with H20 (20 mL) and extracted with
EtOAc (3 x 5 mL). The combined organic layer was washed with brine (10 mL), dried over
Na2SO4, filtered and concentrated to provide crude (2R, 3R, 4S, 5S)(6-(N,N’ -bis-((tert-
butoxycarbonyl)amino)chloro-9H-purin—9-yl)-5—(((lert—butyldiphenylsilyl)oxy)methyl)—4-
ethynyltetrahydrofuranyl utyl carbonate (560 mg) as an orange gum.
Step 6:
To a solution of crude (2R, SR, 45, 5S)—2-(6-(N,N’ -bis-((lert-butoxycarbonyl)amino)
chloro-9H-purinyl)(((terl—butyldiphenylsilyl)oxy)methyl)ethynyltetrahydrofuran—3 -yl
lert—butyl carbonate (560 mg, 660.02 umol, 1 eq, crude) in THF (6 mL) at 0 0C was added
TBAF in THF (1 M, 1 mL, 1.52 eq). The reaction mixture was stirred at 0 °C for l h. The
on mixture was diluted with H20 (10 mL) and extracted with EtOAc (3 x 5 mL). The
combined organic layer was washed with brine (10 mL), dried over Na2SO4, filtered and
trated. The crude was d by preparative TLC leum ether : EtOAc = 2: 1) to
provide (2R, SR, 45, 5S)(6—(N,N’ —bis-((lert—butoxycarbonyl)amino)chloro-9H—purinyl)—
4-ethynyl-5—(hydroxymethyl)tetrahydrofuranyl terZ-butyl carbonate (93 mg, 45% yield
over 3 steps) as a yellow foam.
Step 7:
To a solution of (2R, 3R, 4S, 5S)—2-(6-(N,N’ -bis-((Zert—butoxycarbonyl)amino)chloro-
9H-purinyl)ethynyl(hydroxymethyl)tetrahydrofuran-3 -yl tert—butyl carbonate (93
mg, 152.45 umol, 1 eq) in toluene (1 mL) at 25 0C under N2 atmosphere was added
Rh2(OAc)4 (6.74 mg, 15.24 umol, 0.1 eq). The reaction mixture was heated to 90 oC and
followed by addition of diethyl 2-diazomalonate (85.14 mg, 457,34 umol, 3 eq) in toluene (1
mL). The reaction mixture was stirred at 90°C for 3 h before it was concentrated. The crude
residue was purified by flash column tography on silica gel to provide diethyl 2-
(((2S, 3S, 4R, 5R)—5-(6-(N,N’ -bis-((Zerz‘-butoxy-carbonyl)amino)chloro-9H-purinyl)
WO 46403
((tert—butoxycarbonyl)oxy)—3—ethynyltetrahydro-furanyl)methoxy)malonate (180 mg) as a
Step 8:
To a solution of crude diethyl S, 3S, 4R, 5R)(6-(N,N’ -bis-((terl—butoxy-
carbonyl)amino)—2—chloro—9H—purinyl)((2‘ert—butoxycarbonyl)oxy)ethynyltetrahydrofuranyl
)methoxy)malonate (117.11 mg, 152.45 umol, 1 eq) in DMF (3 mL) was added
K2C03 (421.39 mg, 3.05 mmol, 20 eq) at 20—25 °C. The reaction mixture was stirred for 0.5
h and followed by addition of benzyl bromide (271.61 uL, 2.29 mmol, 15 eq). The on
was then stirred further for 16 h before it was d with H20 (20 mL) and extracted with
EmAd3xmmD.wamMmdmymdwflW%W%Mdmmbmw05mmgmwowr
hhfiOgmwmdmdamWmed7meambwupmmaflwflwhwmagflwbmn
chromatography (petroleum ether : EtOAc = 1:0 — 2:1 gradient) to provide diethyl 2-
(((2S, 3S, 4R, 5R)(6-(N,N’ —bis-((tert—butoxycarbonyl)amino)chloro-9H—purinyl)
((lert—butoxycarbonyl)oxy)—3-ethynyltetrahydrofuranyl)methoxy)benzylmalonate (90
rng)asanofl?whfiegunr
Step 9:
To a solution of diethyl 2-(((ZS,3S,4R,5R)—5-(6-(N,N’ -bis-((tert-butoxycarbonyl)-
amino)—2-chloro-9H-purinyl)((ZerZ-butoxycarbonyl)oxy)ethynyltetrahydrofuran-Z-
yl)methoxy)benzylmalonate (90 mg, 104.86 umol, 1 eq) in DCM (0.6 mL) at 0 CC was
added TFA (0.3 mL, 4.05 mmol, 39 eq). The reaction mixture was stirred at 25 °C for l h
before it was diluted with saturated aq. NaHC03 solution (5 mL) and extracted with DCM (3
x 3 mL). The combined c layer was washed with brine (5 mL), dried over Na2SO4,
wmmmmw.HmammmmmwwwmmfiwbymwMMWEHLXmmdwm
ether : EtOAc = 1:1) to provide diethyl 2-(((ZS, 3R, 4R, 5R)-5—(6-aminochloro-9H—purin-9—
yl)ethynylhydroxytetrahydrofuranyl)methoxy)benzylmalonate (19 mg, 13% yield
for 3 steps) as a yellow gum.
Step 10:
To a solution of diethyl 2-(((ZS, 3R, 4R, 5R)(6-aminochloro-9H-purinyl)
ethynylhydroxytetrahydrofuranyl)methoxy)-2—benzylmalonate (19 mg, 3405 umol, 1
eq) in THF (0.2 mL) was added LiOH'H20 (7.14 mg, 170.26 umol, 5 eq) in H20 (70 uL) at
°C. The on mixture was stirred for 5.5 h before it was diluted with H20 (5 mL) and
then acidified to pH 2—3 with 1N aq. HCl. The mixture was extracted with EtOAc (3 x 5
mL). The combined organic layer was washed with brine (15 mL), dried over anhydrous
NazSO4, filtered, and concentrated. The crude e was dissolved in a mixture of H20 (3
mL) and MeCN (2 mL) and then lyophilized to provide the title compound as a white solid.
1H NMR (400 MHz, CD30D) 6 ppm 8.30 (s, 1H) 7.27 (br d, J=5.27 Hz, 2H) 7.17 — 7.24 (m,
1H) 7.15 (br d, J=6.78 Hz, 2H) 5.87 — 5.96 (m, 1H) 4.94 (br s, 1H) 4.68 (br s, 1H) 3.96 — 4.11
(m, 2H) 3.34 = 5020.
— 3.40 (m, 2H) 2.57 (d, J=2.51 Hz, 1H) 2.32 (s, 1H); LC/MS [M + H]
Example 3
Synthesis of 2-(((2R, SS, 4R, 5R)(6-aminochloro-9H-purinyl)-3,4-dihydroxy(prop-
l-yn— l -yl)tetrahydrofuranyl)methoxy)-2—benzylmalonic acid
4DMAP
TBDPSO3—7.40—_—MgBr $§fTBDPSO TBDPSO
o pyridine $gk TBAF AcOH Qj
0 "0k THF 40°C
0 o
—N>Eio
3—3.“:03 OWOEO BnBrCsQCOE
NH2 O NH
0 ””2 2
ACQO o OEt
4DMAF (HN’N10</ O OH
I 0 CE N
[\N </ 1*\N _'d' aq'LiOH
mm Ine EtO o
0 THF HO O N
_, OAc BO 0 N o N/
o NAG—p oi
BSA,TMSOTf
. .
C 9 MeCN Q1, . .
AcO OAc : 3/ : 'r
AC6 OH
OAc HO
Examples
Step 1:
To a solution of (3aR,5R,6aS)(((terZ-butyldiphenylsilyl)oxy)methyl)-2,2—dimethyl-
dihydrofuro[2,3-d][l,3]dioxol-6(3ahO-one (10 g, 23.44 mmol, 1 eq) in THF (100 mL) at 20
°C under N2 atmosphere was added (prop-l-ynyl)magnesium bromide (0.5 M, 93.77 mL, 2
eq). The mixture was stirred at 40 °C for 2 h before it was diluted with saturated aq. NH4Cl
on (250 mL). The aqueous phase was ted with EtOAc (3 x 200 mL). The
combined organic layer was washed with brine (200 mL), dried over , filtered and
W0 20191246403
concentrated to give crude (3aR,5R,6R,6aR)—5-(((tert—butyldiphenylsilyl)oxy)methyl)—2,2-
dimethyl(propynyl)tetrahydrofuro[2,3-d][1,3]dioxolol (11.81 g) as a yellow gum.
Step 2:
To a on of crude (3aR, 5R, 6R, 6aR)(((Zert—butyldiphenylsilyl)oxy)-methyl)—
2,2-dimethyl(propyn—1-yl)tetrahydrofuro[2,3-d][1,3]dioxolol (12.2 g, 26.14 mmol, 1
eq) in pyridine (120 mL) at 20 CC was added 4-DMAP (3.51 g, 28.76 mmol, 1.1 eq) and
AC2O (4.90 mL, 5229 mmol, 2 eq), The mixture was d at 20 0C for 16 h before it was
diluted with H20 (200 mL) and extracted with EtOAc (3 X 100 mL). The ed organic
layer was washed with brine (250 mL), dried over Na2SO4 and filtered. The filtrate was
concentrated to give crude (3aR,5R,6R,6aR)—5-(((tert-butyldiphenylsily1)oxy)methyl)-2,2-
dimethyl(propynyl)tetrahydrofuro[2,3-d][1,3]dioxolyl acetate (15 g) as a yellow
Step 3:
To a solution of crude (3aR, 5R, 6R, 6aR)(((ZerZ-butyldiphenylsilyl)oxy)-methyl)—
2,2—dimethyl(prop-l-yn—l-yl)tetrahydrofuro[2,3-d][l,3]dioxol—6-yl acetate (15 g, 29.49
mmol, 1 eq) in THF (300 mL) at 0 °C under N2 here was added a mixture of TBAF (1
M, 44.23 mL, 1.5 eq) and AcOH (1.26 mL, 22.12 mmol, 0.75 eq). The mixture was stirred at
°C for 7 h before it was diluted with saturated aq. NH4Cl solution (300 mL) and extracted
with EtOAc (3 x 200 mL). The combined organic layer was washed with brine (300 mL),
dried over Na2SO4, filtered and concentrated. The crude product was purified by flash silica
gel column chromatography leum ether : EtOAc=1 :0—1 : 1) to provide (3aR, 5R, 6R, 6aR)(hydroxymethyl)—2,2-dimethyl(prop—1-ynyl)tetrahydrofuro[2, 3 -d] [ l ,3 ] dioxolyl
acetate (5.78 g, 72.5% yield) as a white solid.
Step 4:
To a solution of (361R, 5R, 6R, 6aR)-5—(hydroxymethyl)-2,2-dimethyl—6-(prop—1-yn-l—
yl)tetrahydrofuro[2,3-d][1,3]dioxolyl acetate (5.78 g, 21.39 mmol, 1 eq) in dichloroethane
(60 mL) at 15 °C under N2 atmosphere was added Rh2(OAc)4 (945.21 mg, 2.14 mmol, 0.1
eq) and diethyl diazomalonate (7.96 g, 42.77 mmol, 2 eq). The mixture was stirred at 40 °C
for 7 h before it was concentrated to dryness. The crude product was d by flash silica
gel column chromatography (0—25% EtOAc in petroleum ether) to provide diethyl 2-
W0 20191246403
(((3aR,5R, 6R, 6aR)-6—acetoxy—2,2-dimethyl—6—(prop—1-yn-1—yl)tetrahydrofuro[2,3 -d] [1 , 3 ]-
yl)methoxy)malonate as a yellow gum.
Step 5:
To a on of diethyl 2-(((3aR,5R, 6R, 6aR)acetoxy-2,2—dimethyl(propyn—1-
yl)tetrahydrofuro[2,3-d][1,3]dioxolyl)methoxy)malonate (7.28 g, 16.99 mmol, 1 eq) in
DMF (70 mL) at 20 0C was added CS2CO3 (11.07 g, 33.98 mmol, 2 eq) and BnBr (3.03 mL,
.49 mmol, 1.5 eq). The e was stirred at 20 0C for 2 h before it was diluted with H20
(300 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layer was washed
with brine (200 mL), dried over Na2SO4, filtered and concentrated. The crude product was
purified by flash silica gel gel column chromatography (petroleum ether : EtOAc = l:0—3:l)
to provide diethyl 2—(((3aR, 5R, 6R, 6aR)acetoxy-2,2-dimethyl-6—(prop- 1 —yn
yl)tetrahydrofuro[2,3-d][1,3]dioxolyl)methoxy)benzylmalonate (7.67 g, 87% yield) as a
yellow gum.
Step 6:
To a solution of l 2-(((3aR,5R, 6R, 6aR)acetoxy-2,2-dimethyl(propyn-l-
yl)tetrahydrofuro[2,3-d][1,3]dioxol—5-yl)methoxy)—2-benzylmalonate (7.67 g, 14.79 mmol, 1
eq) in TFA (80 mL) at 20 °C was added H2O (6.97 mL, 387.05 mmol, 26 eq). The e
was stirred at 20 °C for 8 h before it was quenched with saturated aq. NaHCOs solution to pH
7 and partitioned with EtOAc (3 x 100 mL). The combined organic layer was washed with
brine (200 mL), dried over Na2SO4 and filtered. The e was concentrated to dryness to
provide crude diethyl 2-benzyl(((2R,3S,4R)-3,4,5-trihydroxy-3 -(prop-1—ynyl)tetra-
hydrofuranyl)methoxy)malonate (5.95 g) as a yellow gum.
Step 7:
To a solution of crude diethyl 2-benzyl(((2R, 3S, 4R)-3,4,5-trihydroxy(propyn-
1-yl)tetrahydrofuranyl)methoxy)malonate (5.95 g, 13.63 mmol, 1 eq) in pyridine (60
mL) at 20 0C was added 4-DMAP (5.00 g, 40.90 mmol, 3 eq) and A020 (6.38 mL, 68.16
mmol, 5 eq). The mixture was stirred at 20 0C for 16 h tbefore it was diluted with H20 (300
mL) and extracted with EtOAc (3 x 150 mL). The combined organic layer was washed with
brine (300 mL), dried over Na2SO4, d and concentrated. The crude product was
purified by flash silica gel column chromatography (petroleum ether : EtOAc = 1:0—3 : 1) to
provide diethyl 2-benzyl(((2R, 3R, 4R)-3,4,5-triacetoxy-3—(prop-1—yn-1 -yl)tetrahydrofuran-
2-yl)methoxy)malonate (5.76 g, 66% yield) as a yellow gum.
Step 8:
To a solution of diethyl 2-benzyl(((2R, 3R, 4R)-3,4,5-triacetoxy-3—(propyn
rahydrofuranyl)methoxy)malonate (1 g, 1.78 mmol, 1 eq) in MeCN (10 mL) at 20 0C
was added N,O-bis(trimethylsilyl)acetamide (BSA) (1.32 mL, 5.33 mmol, 3 eq) and 2-chloro-
adenine (301.43 mg, 1.78 mmol, 1 eq). The mixture was d at 65 CC for 30 min before it
was cooled to 0 °C and followed by addition of TMSOTf (642 uL, 3.56 mmol, 2 eq)
dropwise. The mixture was stirred at 0 0C for 10 min and then at 65 0C for 2 h before it was
ed with saturated aq. NaHCO3 (100 mL) and extracted with EtOAc (2 x 60 mL). The
combined organic layer was washed with brine (100 mL) and dried over Na2S04, filtered and
concentrated. The crude product was purified by flash silica gel column chromatography (0—
33% EtOAc in petroleum ether) to provide diethyl 2-benzyl—2-(((2R, 3R, 4R, 5R)-3,4—
diacetoxy(6-aminochloro-9H—purinyl)-3 ynyl)tetrahydrofuran
yl)methoxy)malonate (218 mg, 18% yield) as a yellow foam.
Step 9:
To a solution of diethyl 2-benzyl-2—(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-amino
chloro—9H-purinyl)—3-(propyn—1-yl)tetrahydrofuran-2—yl)methoxy)malonate (218 mg,
324.37 umol, 1 eq) in THF (2 mL) was added LiOH‘HzO (136.12 mg, 3.24 mmol, 10 eq) in
H20 (2 mL) at 20 °C. The mixture was heated at 45°C for 2 h before it was diluted with H20
(10 mL) and extracted with EtOAc (10 mL). The c layer was discarded and the
aqueous phase was acidified with 2 N aq. HCl to pH 2—3. Then the aqueous phase was
extracted with EtOAc (3 x 20 mL). The combined c layer was washed with brine (30
mL), dried over NazSO4, filtered and concentrated. The crude product was purified by
preparative HPLC to provide the title compound (39.8 mg, 23% yield) as a white solid.
1H NMR (011480—016, 400 MHz) 5 ppm 412 (m, 2H), 8.37 (s, 1H), 7.80 (br s, 2H),
7.19 (br d, J=7.03 Hz, 2H), 7.00—7.11 (m, 3H), 5.88—6.03 (m, 2H), 5.81 (d, J=7.53 Hz, 1H),
4.78 (br s, 1H), 4.12 (dd, J=4.52, 3.01 Hz, 1H), 3.95 (br dd, J=9.91, 4.89 Hz, 1H), 3.82 (br d,
J=8.53 Hz, 1H), 3.25 (s, 2H), 1.81 (s, 3H), LC/MS [M + H] = 532.0.
Synthesis of 2-(((2R, 3S, 4R, (6-aminochloro-9H-purinyl)(cyclopropylethynyl)-
3,4-dihydroxytetrahydrofuranyl)methoxy)benzylmalonic acid
TBDPSO A OHC
3:7“) _\<j— 0 o 0
TBDPSO TBDPSO HO
ne THF Bo N2
'0 "'0
—> —> —>
Rh2(OAC)4
O "IO)(n-BUL1,THF 0:"0/%—> ACO ’O/k /ACO
O BnBr O O A620, 0
OMOE‘ (332003 0 05* 0 0E! 4—DMAP o OEt
DMF TFA, DCM pyridine
EtO o —>BO 0 EC 0
o o —> o OH—> EC 0
"'0 Ph ...0 Ph OAc
_ :
.0OK 5 ubk :
., =
’0“ .- .0
A00 AcO A00 Aco‘ OAc
(grid NH2
0 30(31):!“N/kCI aq. LiOH THF
”Oh 0< NH2
TMSOTf, BSA Etoh
AcO HO
Examp|e4
Step 1:
To a solution of ethynylcyclopropane (4.96 g, 75.02 mmol, 6.22 mL, 2 eq) in THF (80
mL) at —78°C under N2 atmosphere was added n-BuLi (2.5 M, 3001 mL, 2 eq) dropwise.
The solution was stirred at —78 °C for 0.5 h and followed by addition of a solution of
(3aR, 5R, 6aS)—5-(((terZ-butyldiphenylsilyl)oxy)methyl)-2,2—dimethyldihydrofuro[2,3 -d][1,3]—
dioxol-6(3aH)-one (16.0 g, 37.51 mmol, 1 eq) in THF (60 mL) dropwise. Then the solution
was allowed to warm to 20 °C and stirred for 1 h before it was then cooled to 0 °C and
quenched with water (120 mL). The mixture was extracted with EtOAc (2 X 120 mL). The
combined organic layer was washed with brine (200 mL), and dried by Na2S04, filtered and
concentrated. The crude was purified by Combi-flash on silica gel (0—15% ethyl acetate in
petroleum ether) to give (30R, 5R, 6R, 6aR)—5-(((tert—butyldiphenylsilyl)oxy)-methyl)
(cyclopropylethynyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxolol (15.8 g, 86% yield)
as a syrup.
Step 2:
To a solution of (301R, 5R, 6R, 6aR)—5-(((lert-butyldiphenylsilyl)oxy)methyl)(cyclo-
propylethynyl)—2,2—dimethyltetrahydrofuro[2,3-d][l,3]dioxolol (15.8 g, 32.07 mmol, 1 eq)
in pyridine (160 mL) at 20 °C was added 4—DMAP (4.70 g, 38.48 mmol, 1.2 eq) and A020
(9.01 mL, 9621 mmol, 3 eq). The solution was stirred for 3 h before it was diluted with
water (200 mL) and extracted with ethyl acetate (2 X 200 mL). The combined organic layer
w&wwkdmmbmwmmmmlmmeNmQMJmflwaMcM%MmmlTMcm®
residue was purified by Combi-flash on silica gel ethyl acetate in petroleum ether) to
give (3aR, 5R, 6R, 6aR)—5-(((tert—butyldiphenylsilyl)oxy)methyl)-6—(cyclopropylethynyl)—2,2-
dimethyltetrahydrofuro[2,3—d][1,3]dioxol-6—yl acetate (14.7 g, 86% yield) as a clear syrup.
Step 3:
To a solution of (361R, 5R, 6R, 6aR)-5—(((Zert—butyldiphenylsilyl)oxy)methyl)—6-
(cyclopropylethynyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxolyl acetate (14.7 g,
27.49 mmol, 1 eq) in THF (150 mL) at 0 °C was added a solution of TBAF (1 M, 41.24 mL,
1.5 eq) and AcOH (1.18 mL, 20.62 mmol, 0.75 eq). The solution was stirred at 20 °C for 16
h before it was diluted with water (300 mL) and extracted with ethyl acetate (2 X 200
mL). The combined organic layer was washed with water (400 mL), brine (400 mL), dried
bflMMMmmmemwmmdmeMwwwfifiMfimfiflMmmme
(20—60%ethyl acetate in petroleum ether) to give (3aR, 5R, 6R, 6aR)—6-(cyclopropylethynyl)—5-
(hydroxymethyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxolyl e (8.15 g, 100%
yield) as a white solid.
Step 4:
To a solution of (3aR,5R,6R,6aR)—6-(cyclopropylethynyl)(hydroxymethyl)-2,2—
dimethyltetrahydrofuro[2,3-01][1,3]dioxol-6—yl acetate (8.15 g, 27 .50 mmol, 1 eq) in
dichloroethane (80 mL) at 20 °C under N2 atmosphere was added Rh2(OAc)4 (1.00 g, 2.26
mmol, 0.08 eq) and a on of diethyl diazomalonate (10.24 g, 55.01 mmol, 2 eq) in
mdewmmeaomD.flwgmmmdenwwsmmdbrMhbfiMefiwmammewd
The crude was purified by Combi-flash on silica gel (15—50% ethyl acetate in petroleum
ether) to give diethyl 2-(((3aR, 5R, 6R, 6aR)—6-acetoxy(cyclopropylethynyl)-2,2-dimethyl-
tetrahydrofuro[2,3-d][1,3]dioxolyl)methoxy)malonate (9.52 g, 76% yield) as a yellow oil.
Step 5:
To a solution of l 2-(((3aR, 5R, 6R, 6aR)acetoxy-6—(cyclopropylethynyl)-2,2-
yltetrahydrofuro[2,3—d][1,3]dioxol-5—yl)methoxy)malonate (4.50 g, 9.90 mmol, 1 eq)
in DMF (50 mL) at 20 0C was added CszCO3 (9.68 g, 29.71 mmol, 3 eq) and benzyl bromide
(1%anM85mde5eQ.finamwmbnwwstdfirMhbfimefiwmeWd
with water (80 mL) and extracted with ethyl e (3 x 80 mL). The combined organic
layer was washed with water (200 mL), brine (200 mL), dried by Na2SO4, d and
concentrated. The crude was purified by Combi-fiash on silica gel (15—50% ethyl acetate in
petroleum ether) to give diethyl 2-(((3aR, 5R, 6R, 6aR)acetoxy(cyclo-propylethynyl)—2,2-
dimethyltetrahydrofuro[2,3—d][l,3]dioxolyl)methoxy)-2—benzyl—malonate (4.10 g, 76%
yield) as a colorless syrup.
Step 6:
To a solution of diethyl aR, 5R, 6R, 6aR)acetoxy-6—(cyclopropylethynyl)-2,2-
dimethyltetrahydrofuro[2,3—d][1,3]dioxol-5—yl)methoxy)-2—benzylmalonate (4.10 g, 7.53
mmol, 1 eq) in DCM (50 mL) at 0 °C was added H20 (10 mL) and TFA (50 mL). The
solution was stirred at 20 °C for 2 h before it was quenched with saturated aq. NaHCO3 (80
mL) to pH ~7. The on mixture was exacted with DCM (100 mL). The organic layer
was washed with brine (10 mL), dried by NazSO4, filtered and concentrated to give crude
diethyl 2-(((2R, 3S, 4R)-3 -acetoxy-3 —(cyclopropylethynyl)-4, 5 -dihydroxytetrahydrofuran-2—
hoxy)benzylmalonate (3.80 g) as a yellow gum.
Step 7:
To a solution of crude l diethyl 2-(((2R,3S,4R)acetoxy-3 opropyl-
ethynyl)-4,5-dihydroxytetrahydrofuranyl)methoxy)benzylmalonate (3.80 g, 7.53 mmol,
1 eq) in pyridine (40 mL) at 20 CC was added 4-DMAP (2.76 g, 22.60 mmol, 3 eq) and AczO
(5.64 mL, 60.25 mmol, 8 eq). The solution was d for 16 h before it was diluted with
water (80 mL) and extracted with ethyl acetate (2 x 80 mL). The combined organic layer was
washed with water (150 mL), brine (150 mL), dried by Na2SO4, filtered and concentrated.
The crude was d by Combi-flash on silica gel (10—50% ethyl acetate in petroleum
ether) to give diethyl 2-benzyl(((2R, 3R, 4R)-3,4,5-triacetoxy(cyclopropylethynyl)—
tetrahydro-furanyl)methoxy)malonate (2.91 g, 66% yield) as a yellow gum.
Step 8:
To a solution of diethyl 2-benzyl(((2R, 3R, 4R)-3,4,5-triacetoxy
(cyclopropylethynyl)tetrahydrofuranyl)methoxy)malonate (980 mg, 1.66 mmol, 1 eq) in
MeCN (24 mL) at 25 °C was added 2-chloroadenine (338.80 mg, 2.00 mmol, 1.2 eq) and
BSA (987,71 uL, 4.00 mmol, 2.4 eq). The suspension was stirred at 65 °C for 0.5 h as it
turned clear. The resulting solution was cooled down to 0°C and followed by addition of
TMSOTf (444.06 mg, 200 mmol, 361.03 uL, 1.2 eq) dropwise. The reaction mixture was
stirred at 40 0C for 4 h before it was allowed to cool to room temperature. The reaction
mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 x 20 mL). The
ed organic layer was washed with brine (50 mL), dried by NazSO4, filtered and
concentrated. The crude was purified by Combi-flash on silica gel (30—80% ethyl acetate in
petroleum ether) to give diethyl 2-benzyl-2—(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-amino
chloro-9H—purin-9—yl)(cyclopropylethynyl)tetrahydrofuran-Z-y1)methoxy)malonate (270
mg, 23% yield) as a yellow gum.
Step 9:
To a solution of diethyl 2-benzyl-2—(((2R, 3R, 4R, 5R)—3,4-diacetoxy—5-(6-amino
chloro-9H—purinyl)(cyclopropylethynyl)tetrahydrofuranyl)-methoxy)malonate (270
mg, 386.75 umol, 1 eq) in THF (8 mL) was added aq. LiOH solution (1 M, 5.80 mL, 15 eq).
The mixture was stirred at 20 0C for 16 h before it was treated with 1N HCl to adjust the pH
to 5. The mixture was trated. The crude residue was purified by preparative HPLC to
give the title compound (23 mg, 11% yield) as a white solid.
1H1\H\1R (400 MHz, CD30D) 5 ppm 8.04 (s, 1H) 7.14 — 7.27 (m, 2H) 7.01 — 7.08 (m, 3H)
.92 (d, J=6.63 Hz, 1H) 4.70 — 4.83 (m, 1H) 4.24 (t, J=3.50 Hz, 1H) 4.02 (t, J=3.31 Hz, 2H)
3.31— 3.45 (m, 2H) 1.25 — 1.33 (m, 1H) 0.72 — 0.79 (m, 2H) 0.63 — 0.71 (m, 2H), LC/MS [M +
H] = 559.0.
Example 5
sis of 2—(((2R, 3S, 4R, (6-amino-2—chloro—9H—purinyl)—3 yl-3 ,4-
dihydroxytetrahydrofuran-Z-yl)methoxy)((2—chloropyridinyl)methyl)malonic acid
0 N<Boc>2
o N(Boc)2 c1 0E1
0 QB N
N 016) </r
</ I A 5‘0 N
o TFA DCM
BO 0 N
o N/ \
K2003 DMF \
A00: GOAC
o NH2 0 2
O 0E1 N CH
<’ ‘”
l aq.LIOH,THF~ </N 1N1
E10 A
,N N ”0
\ 0; o CI \
N / ~‘ '9 /
Aco‘ OAc 0H;:0;OH,N
Example 5
Proceeding as described in Example 1 above by substituting BnBr with 2-chloro
(chloromethyl)py1idine provided the title compound as a white solid.
1H NMR (CD3OD, 400 MHz) 5 ppm 8.40 (s, 1H), 8.00 (d, J=5. 13 Hz, 1H), 7.36 (s, 1H),
7.23 (d, J=5.13 Hz, 1H), 6.01 (d, J=7.63 Hz, 1H), 5.08 (d, J=7.63 Hz, 1H), 4.39 (dd, J=4.88,
2.75 Hz, 1H), 4.16 (dd, J=10.07, 5.19 Hz, 1H), 4.05 (dd, J=10.01, 2.63 Hz, 1H), 3.47 (s, 2H),
3.05 (s, 1H); LC/MS [M + H] = 553.1.
Example 6
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)—5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)
ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
TBDPSO HO O OH
0 0 Rh2(OAc)4
"'0 "'0
0* TBAF, THF DCE, 25 °c
: —> : E10 0
.~ .,I 1- .,l 0
Ho‘ Ho‘ 0*
S 7"'0
—Ho- (K
JCSZCOS, BnBr
0 CE OEt
Ac20,4-DMAP
O: 0 OAc pyridine, DCM O: 0 mo
Acd ’OAc —HO¢- ”OX
</_<NH, BSA, TMSOTf, MeCN
aq. LiOH, MeOH
Step 1:
To a mixture of (3aR, 5R, 6R, 6aR)-5—(((Zert-butyldiphenylsilyl)oxy)methyl)—6-ethynyl-
2,2-dimethyltetrahydrofuro[2,3-d][l,3]dioxolyl acetate (27.4 g, 55.39 mmol, 1 eq) in THF
(250 mL) at 0 °C was added AcOH (2.38 mL, 41.54 mmol, 0.75 eq) in TBAF (1 M, 83.09
mL, 1.5 eq). The mixture was d at 15 CC for 15 h before it was partitioned between
water (800 mL) and EtOAc (300 mL). The s phase was r extracted with EtOAc
(3 x 200 mL). The combined organic layer was washed with brine (300 mL), dried over
anhydrous NazSO4, filtered and concentrated under reduced pressure to give a residue. The
residue was purified by column chromatography on Si02 (1 1—33% EtOAc in petroleum
ether) to give (3aR, 5R, 6R, 6aR)ethynyl-5—(hydroxymethyl)—2,2-dimethyltetrahydrofuro—
[2,3-d][1,3]dioxolyl acetate (15.2 g, 91% yield) as a light yellow solid.
Step 2:
To a mixture of (3aR, 5R, 6R, 6aR)-6—ethynyl(hydroxymethyl)—2,2-dimethyltetra—
hydrofuro[2,3-d][1,3]dioxolyl acetate (15.2 g, 59.32 mmol, 1 eq) in dichloroethane (150
mL) at 0 0C was added Rh2(OAc)4 (1.31 g, 2.97 mmol, 0.05 eq) and diethyl diazomalonate
(13.25 g, 71.18 mmol, 1.2 eq) in dichloroethane (30 mL). The mixture was stirred at 15 0C
under N2 atmosphere for 15 h before additional amount of diethyl diazomalonate (6 g) in
dichloroethane (15 mL) was added. The mixture was stirred further at 15°C for 2 h before it
was concentrated under d pressure. The e was d by column
chromatography on silica gel (11—33% EtOAc in petroleum ether) to give diethyl 2-
(((3aR, 5R, 6R, 6aR)—6-acetoxyethynyl-2,2-dimethyltetra—hydrofuro-[2,3—d] [ 1 ,3 ]dioxol
yl)methoxy)malonate (15 g, 61% yield) as a white solid.
Step 3:
To a mixture of diethyl 2-(((3aR, 5R, 6R, -acetoxyethynyl—2,2-dimethyltetra-
hydrofuro[2,3-d][1,3]dioxolyl)methoxy)malonate (14 g, 33.78 mmol, 1 eq) in DMF (140
mL) at 25 °C was added CS2CO3 (22.01 g, 67.57 mmol, 2 eq) and BnBr (6.02 mL, 50.68
mmol, 1.5 eq). The mixture was stirred at 25 0C for 3 h before it was d and the filter
cake was washed with EtOAc (50 mL). The filtrate was diluted with water (400 mL) and
extracted with EtOAc (3 x 150 mL). The combined organic layer was washed with brine
(200 mL), dried over anhydrous Na2SO4, filtered and trated under reduced pressure.
The residue was purified by flash silica gel column chromatography (O—33% EtOAc in
petroleum ether) to give l 2-(((3aR, 5R, 6R, 6aR)—6-acetoxyethynyl-2,2-dimethyltetra-
hydrofuro[2,3—d][1,3]dioxol—S—yl)methoxy)—2—benzylmalonate (13.3 g, 78% yield) as a
colorless oil.
Step 4:
To a mixture of diethyl 2-(((3aR, 5R, 6R, 6aR)—6-acetoxyethynyl-2,2-dimethyltetra-
hydrofuro[2,3-d][1,3]dioxolyl)methoxy)benzylmalonate (13.20 g, 26.16 mmol, 1
eq) in DCM (100 mL) and H20 (20 mL, 111 mol, 42 eq) was added TFA (100 mL, 1.35
mol, 52 eq). The mixture was stirred at 15 0C for 12 h before water (200 mL) was added.
The aqueous phase was extracted with DCM (2 x 100 mL). The combined organic extract
was washed with saturated aq. NaHCO3 (2 x 100 mL), brine (100 mL), dried over anhydrous
NazSO4, filtered and concentrated under reduced re. The residue was purified by flash
column chromatography (SiOz, eum ether : Ethyl acetate = 10:1 to 1:3) to give l
2-benzyl(((2R, SS, 4R)-3 -ethynyl-3 ,4, 5 -trihydroxytetrahydrofuran-Z-yl)methoxy)malonate
(7.8 g, 71% yield) as a ess oil.
Step 5:
To a mixture of diethyl 2-benzyl(((2R, 3S, 4R)—3-ethynyl—3,4,5-trihydroxytetra-
hydrofuran—2-yl)methoxy)malonate (7.8 g, 18.46 mmol, 1 eq) in pyridine (70 mL) at 15 °C
was added 4—DMAP (6.77 g, 5539 mmol, 3 eq) and AczO (17.29 mL, 184.65 mmol, 10 eq).
The mixture was stirred for 15 h before water (400 mL) was added. The mixture was
ted with EtOAc (3 x 200 mL). The combined organic layer was washed with 1N aq.
HCl (2 x 200 mL), saturated aq. NaHCO3 (300 mL), brine (300 mL), dried over anhydrous
NazSO4, filtered and concentrated under reduced pressure. The residue was purified by flash
silica gel column tography (petroleum ether : Ethyl acetate = 1:0 to 2: 1) to give the
desired product (7 g). This product was triturated with EtOH (10 mL) and d to give
diethyl 2-benzyl(((2R, 3R, 4R)-3 ,4, 5 -t1iacetoxy-3 —ethynyltetrahydrofuran—2-yl)methoxy)—
malonate (3.79 g, 37% yield) as a white solid. The filtrate was concentrated under reduced
pressure to give slightly impure additional product (3 g).
Step 6:
To a solution of diethyl 2-benzyl-2—(((2R, 3R, 4R)-3,4,5-triacetoxy—3-ethynyltetra-
hydrofuran-2—yl)methoxy)malonate (116 mg, 0.21 mmol, 1.0 eq) in MeCN (3 mL) at 25 0C
was added uracil (28 mg, 0.25 mmol, 1.2 eq) and followed by N,O-bis(trimethylsilyl)—
acetamide (BSA) (124 uL, 0.51 mmol, 2.4 eq). The resulting suspension was heated at 65 °C
for 30 min as it became clear. The reaction mixture was cooled to 0 0C and followed by
dropwise addition of TMSOTf (46 uL, 0.25 mmol, 1.2 eq). The reaction mixture was
allowed to warm up and heated at 65 0C for 3 h as all of the starting material was consumed.
The reaction was quenched with cold ted aq. NaHCO3 solution (3 mL) and diluted with
EtOAc (15 mL). The organic layer was separated, washed with H20 (2 x 10 mL), brine,
dried (MgSO4), filtered and concentrated. The crude residue was purified by flash silica gel
column chromatography (0—75% EtOAc in hexanes) to provide the product l 2-benzyl-
2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy(2,4-dioxo-3 ,4-dihydro—pyrimidin- 1 (2]10-yl)ethynyl-
tetrahydrofuran-2—yl)methoxy)malonate (104 mg, 82% yield).
Step 7:
To a solution of diethyl 2-benzyl-2—(((2R, 3R, 4R, 5R)—3,4-diacetoxy—5—(2,4-dioxo-3,4—
dihydropyrimidin- 1 (2]10-yl)-3 yltetrahydrofuranyl)methoxy)-malonate (100 mg,
0.166 umol, 1 eq) in a mixture of THF (1 mL) and MeOH (2 mL) was added aq. LiOH
solution (1 M, 3 mL). The mixture was stirred at 40 0C for 24 h before the organic volatile
was removed under reduced pressure. The residue was diluted with water (2 mL) and treated
with 1N HCl to adjust the pH to 4. The mixture was extracted with EtOAc (3 x 10 mL), The
combined c layer was washed with brine, dried (MgSO4), filtered and concentrated to
provide the title compound (67 mg) as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.09 (bs, 1H), 7.86 (d, J=8 Hz, 1H), 733—7. 16 (m, 5H), 6.01
(d, J=7 Hz, 1H), 5.07 (d, J=8 Hz, 1H), 4.45 (d, J=7 Hz, 1H), 4.22 (bs, 1H), 4.11—3.94 (m,
2H), 3.55—3.31 (m, 2H), 2.95 (s, 1H), , LC/MS [M + H] = 461.0.
Example 7
Synthesis of 2-(((2R, 3S, 4R, 5R)(6-aminochloro-9H—purinyl)-3 yl-3 ,4-
dihydroxytetrahydrofuranyl)methoxy)(pyridinylmethyl)malonic acid
0 Cl 0 O A020
OWOB Q) 0 TFA O 4—DMAP
N / DCM 10% H20 pyridine
EtO O —> EtO —2>
...o 052CO3 :10 El\O
Q DMF. 20°C
. 5
Acd IO
O NH2
(LN, 0 CE N
EtO </ [A aq.LiOH,THF f @om <N
E10 0 N 0
o N Acn
BSA TMSOTf \\ \
MeCN \
N / 5 .9
AcO OAC
Example7
Step 1:
To a e of diethyl 2-(((3aR, 5R, 6R, 6aR)—6-acetoxyethynyl-2,2-dimethyltetra-
hydrofuro[2,3-d][1,3]dioxol—5-yl)methoxy)malonate (1.2 g, 2.90 mmol, 1 eq) in DMF (20
mL) at 20 °C was added CS2CO3 (6.60 g, 20.27 mmol, 7 eq) and oromethyl) pyridine
hydrochlon'de (1.90 g, 11.58 mmol, 4 eq). The mixture was stirred for 2 h before it was
filtered and the filter cake was washed with EtOAc (20 mL). The filtrate was diluted with
water (60 mL) and extracted with EtOAc (3 x 50 mL). The combined extract was washed
with water (2 x 50 mL), saturated aq. NH4Cl (50 mL), brine (50 mL), dried over anhydrous
W0 20191246403
NazSO4, filtered and concentrated under reduced pressure. The residue was purified by
column tography on SiO2 (14—33% EtOAc in petroleum ether) to give diethyl 2-
(((3Q‘R, 5R, 6R, 6aR)—6-acetoxyethynyl—2,2-dimethyltetrahydrofuro[2,3 —d][1,3]—dioxol—5-
yl)methoxy)—2-(pyridinylmethyl)malonate (900 mg, 61% yield) as a yellow oil.
Step 2:
To a mixture of diethyl 2-(((3aR, 5R, 6R, 6aR)—6-acetoxyethynyl-2,2-dimethyltetra-
hydrofuro[2,3-d][1,3]dioxolyl)methoxy)(pyridinylmethyl)-malonate (900 mg, 1.78
mmol, 1 eq) in DCM (5 mL) and H20 (1 mL, 55.51 mmol, 31.18 eq) was added TFA (5 mL,
67.53 mmol, 37.93 eq). The mixture was stirred at 20 0C for 12 h before it was concentrated
under reduced pressure. The crude residue was azeotroped with DCM (3 x 10 mL) under
d pressure to provide crude diethyl 2-(((2R,3S,4R)ethynyl-3,4,5-trihydroxytetra-
hydrofuranyl)methoxy)(pyridinylmethyl)malonate (1.1 g) as a brown oil.
Step 3:
To a mixture of crude diethyl R,3S,4R)ethynyl-3,4,5-trihydroxy-tetrahydro-
furan—2-yl)methoxy)—2-(pyridinylmethyl)malonate (1.1 g, 2.60 mmol, 1 eq) in pyridinie (8
mL) at 20 °C was added 4-DMAP (952.17 mg, 7.79 mmol, 3 eq) and A020 (2.43 mL, 25.98
mmol, 10 eq). The mixture was stirred for 12 h before it was partitioned between
water (30 mL) and EtOAc (20 mL). The s phase was further ted with EtOAc (2
x 20 mL). The combined t was washed with water (20 mL), 0.5 N aq. HCl (2 x 10
mL), and brine (20 mL), dried over anhydrous Na2804, filtered and concentrated under
reduced pressure. The e was purified by flash column tography on SiO2 (25—
50% EtOAc in petroleum ether) to give diethyl 2-(pyridinylmethyl)(((2R,3R,4R)—3,4,5-
triacetoxyethynyl-tetrahydrofuranyl)methoxy)malonate (640 mg, 45% yield) as a
brown syrup.
Step 4:
To a mixture of diethyl 2-(pyridin—4-ylmethyl)-2—(((2R, 3R, 4R)—3,4,5-triacetoxy—3-
ethynyltetrahydrofuranyl)methoxy)malonate (40 mg, 72.79 umol, 1 eq) and 2-chloro-
adenine (13.58 mg, 80.07 umol, 1.1 eq) in MeCN (1.5 mL) was added BSA (44.98 uL,
181.98 umol, 2.5 eq) at 25 °C under N2 atmosphere. The mixture was stirred at 65 0C for 0.5
h before it was cooled to 0 OC and followed by dropwise addition of TMSOTf (26.31 uL,
145.58 umol, 2 eq). The mixture was stirred at 0 °C for 0.5 h and then at 65 °C for 2 h. The
reaction mixture was cooled to room temperature and quenched with saturated aq.
NaHC03 (6 mL). The mixture was extracted with EtOAc (3 x 8 mL). The ed organic
layer was washed with brine (5 mL), dried over anhydrous NazSO4, filtered and concentrated
under reduced pressure. The residue was purified by preparative TLC (EtOAc) to provide
diethyl 2-(((2R, 3R, 4R, 5R)—3,4-diacetoxy-S—(6-aminochloro-9H—purin-9—yl)-3 -
ethynyltetrahydrofuran-Z-yl)methoxy)(pyridinylmethyl)-malonate (13 mg, 26% yield)
was obtained as a yellow gum.
Step 5:
To a mixture of diethyl R, 3R, 4R, 4-diacetoxy-5—(6-aminochloro-9H—
purinyl)—3-ethynyltetrahydrofuranyl)methoxy)(pyridinylmethyl)—malonate (50
mg, 75.87 umol, 1 eq) in THF (1 mL) was added 1N aq. LiOH (1 mL). The mixture was
stirred at 50 0C for 1 h before it was cooled to room temperature and adjusted the pH 6—7
with 2N aq. HCl solution. The mixture was concentrated under reduced pressure and the
residue was purified by ative reverse—phase HPLC to provide the title nd (34
mg) as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.50 (bs, 1H), 8.32 (d, J=4 Hz, 2H), 7.50 (d, J=5 Hz, 2H),
6.01 (d, J=7 Hz, 1H), 4.80 (d, J=6 Hz, 1H), 4.38 (q, J=3 Hz, 1H), 4.10—3.95 (m, 2H), 3.45
(bs, 2H), 3.06 (s, 1H), LC/MS [M + H] = 519.0.
Example 8
Synthesis of 2-(((2R, SS, 4R, 5R)(6—amino—2-chloro-9H—purinyl)-3 -ethynyl-3 ,4-
dihydroxytetrahydrofuran—2-yl)methoxy)—2-(furanylmethyl)malonic acid
510%?0Q O
o OEt
Q/OH—’PPh3 CBr4 0 TFA H20
\\ EC 0
B o
’ 0“
052003 DMF / \
—AcO 0 Ho: OH
0 gig”: o NH2 0 NH2
0 DE! <’ 0 OEt ,N 0 OH
km N
\N \N
A020.4—DMAP < l X LIOH I X
EtO o H—C> /
_ o BO 0 N
o N/ HO 0 N
OAc Cl 0 N
' - 0|
”mime / \ BSA, TMSOTf / H20,THF
\ / \
_ MeCN : =
,5 O : a, O ‘1 ,,
AcO OAc Aco‘ OAc Ho‘ ’OH
Example8
-lOO-
Step 1:
To a mixture of PPh3 (4.28 g, 16.31 mmol, 1.6 eq) and CBr4 (4.06 g, 12.23 mmol, 1.2
eq) in DCM (20 mL) at 0 °C under N2 atmosphere was added furanylmethanol (1 g, 10.19
mmol, 1 eq) in DCM (5 mL) dropwise. The mixture was stirred at 20 0C for 2 h before it was
quenched with saturated aq. NaHCO3 (30 mL) and then extracted with EtOAc (2 x 15 mL).
The combined c layer was washed with brine (30 mL), dried over anhydrous Na2S04,
filtered and concentrated under reduced pressure to provide crude 3-(bromomethyl)furan (2.9
g) as yellow gum which was used in the next step directly t further purification.
Step 2:
To a solution of diethyl 2-(((3aR, 5R, 6R, 6aR)acetoxyethynyl-2,2-dimethyltetra-
hydrofuro[2,3-d][l,3]dioxolyl)methoxy)malonate (l g, 2.41 mmol, 1 eq) in DMF (5 mL)
at 20 °C was added CszCO3 (2.36 g, 7.24 mmol, 3 eq) and crude 3-(bromomethyl)furan (2.9
g) in DMF (6 mL). The mixture was stirred for 2 h before it was partitioned between water
(30 mL) and EtOAc (30 mL). The aqueous phase was extracted with EtOAc (3 x 15mL).
The combined organic extract was washed with water (20 mL), saturated aq. NH4Cl (2 x 20
mL), brine (20 mL), dried over anhydrous Na2S04, filtered and concentrated under d
pressure. The residue was purified by column chromatography on Si02(10—25% EtOAc in
petroleum ether) to give diethyl 2-(((3aR, 5R, 6R, -acetoxyethynyl-2,2-dimethyltetra-
hydrofuro[2,3-d][l,3]dioxolyl)methoxy)(furanylmethyl)malonate (375 mg, 31%
yield) as a light yellow oil,
Step 3:
To a mixture of diethyl aR, 5R, 6R, 6aR)—6-acetoxyethynyl-2,2-dimethyltetra-
uro[2,3-d][1,3]dioxolyl)methoxy)(furanylmethyl)-malonate (375 mg, 758.36
umol, 1 eq) in DCM (2 mL) and H20 (0.4 mL, 2220 mmol, 29 eq) was added TFA (2 mL,
27.01 mmol, 36 eq). The mixture was stirred at 20 0C for 12 h before it was concentrated
under reduced pressure to provide crude diethyl 2-(((2R,SS, 4R)ethynyl-3,4,5-trihydroxy-
ydrofuranyl)methoxy)(furanylmethyl)malonate (420 mg) as an oil which was
used in next step without further purification.
Step 4:
To a mixture of crude diethyl 2-(((2R, 3S, 4R)ethynyl-3,4,5-trihydroxytetrahydro—
furan—2-yl)methoxy)—2-(furan—3-ylmethyl)malonate (420 mg, 1.02 mmol, 1 eq) in pyridine (4
mL) at 20 °C was added AczO (954 uL, 10.18 mmol, 10 eq) and 4-DMAP (373 mg, 3.06
WO 46403
mmol, 3 eq). The mixture was stirred for 12 h before it was partitioned between water (15
mL) and EtOAc (10 mL). The aqueous phase was extracted with EtOAc (2 X 20 mL). The
combined organic extract was washed with water (10 mL), 0.5N aq. HCl (2 x 5 mL), brine
(10 mL), dried over anhydrous NazSO4, filtered and concentrated, The e was purified
by preparative TLC (petroleum ether : EtOAc =3: 1) to give diethyl 2-(furan-3 -ylmethyl)
(((2R, 3R, 4R)—3,4,5-triacetoxyethynyltetrahydrofuranyl)methoxy)malonate (95 mg, 17%
yield) as a yellow oil.
Step 5:
To a mixture of diethyl 2-(furanylmethyl)(((2R, 3R, 4R)—3,4,5-triacetoxy
ethynyltetrahydrofuranyl)methoxy)rnalonate (50 mg, 92.85 umol, 1 eq) and 2-chloro-
addenine (17.32 mg, 102.14 umol, 1.1 eq) in MeCN (1.2 mL) was added BSA (57.38 uL,
232.13 umol, 2.5 eq) at 25 CC under N2 atmosphere. The mixture was stirred at 65 CC for 0.5
h before it was cooled to 0 °C and followed by dropwise addition of TMSOTf (33.56 uL,
185.70 umol, 2 eq). The mixture was d at 0 °C for 0.5 h and then at 65 0C for 2 h before
it was cooled to room temperature and quenched with saturated aq. NaHCO3 solution (2 mL).
The mixture was extracted with EtOAc (3 x 2 mL). The combined organic layer was washed
with brine (2 mL), dried over anhydrous Na2SO4, filtered and concentrated under d
re. The residue was purified by preparative TLC (petroleum ether : EtOAc = 1:1) to
provide diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy—5-(6-aminochloro-9H—purin—9-yl)—3—
ltetrahydrofuranyl)methoxy)(furanylmethyl)malonate (17 mg, 29% yield) as a
yellow gum.
Step 6:
To a mixture of diethyl 2-(((2R, 3R, 4R, 5R)—3,4-diacetoxy-5—(6-aminochloro-9H—
purinyl)—3 -ethynyltetrahydrofuranyl)methoxy)(furan-3 -ylmethyl)-malonate (3 3 mg,
50.92 umol, 1 eq) in THF (1 mL) was added 1N aq. LiOH (1 mL). The mixture was stirred at
°C for 3 h before it was extracted with EtOAc (2 mL). The organic layer was ded.
The aqueous phase was adjusted the pH 2—3 with 2N aq, HCl before it was extracted with
EtOAc (4 x 5 mL). The combined organic extract was washed with brine (3 mL), dried over
anhydrous Na2SO4, filtered and concentrated under reduced pressure. The e was
dissolved in a mixture of MeCN (1 mL) and H20 (1 mL) and then dried by lyophilization to
provide the title compound (10.0 mg, 37% yield) as a white solid.
-lO2-
1H NMR (400 MHz, DMSO—dd) 6 ppm 8.48 (s, 1H) 7.81 (br s, 2H) 7.35 (s, 2H) 6.29 (s, 1H)
6.22 (br s, 1H) 6.02 (br d, J=6.50 Hz, 1H) 5.83 (d, J=7.50 Hz, 1H) 4.75 — 4.90 (m, 1H) 4.16
(dd, J=4.75, 2.75 Hz, 1H) 3.92 (br dd, J=10.07, 5.07 Hz, 1H) 3.77 (br d, J=8.00 Hz, 1H) 3.48
(s, 1H) 3.08 (s, 2H); LC/MS [M + H] = 507.9.
Synthesis of 2-(((2R, 3S, 4R, 5R)(6-aminochloro—9H—purinyl)—3-ethynyl-3,4-
dihydroxytetrahydrofuranyl)methoxy)(4—(2-oxotetrahydropyrimidin- 1 (2H)-
yl)benzyl)malonic acid
NHBoc NHBoc
o 2 0 o
oWOE 0 GE 0 GE N
<N<Nf\N OZrN/Qj </N IN:J\Cl_>Fe,NH4C| </ l 1
N/cCI E10 0 N EtO O N / CIMN‘C9O
E10 0
o o o N CI
K24303 DMF EtOH, H20 DCM
Acd bAc ACG bAC
OZN HzN
o NHBoc o NHBoc o NH2
OEt <N OH 0 OH
’ 1 N10 <N’ 1 N10 (N/ \N
o NaH THF N
0 TFA DCM HO 0 N
o NAG
“Ow )LN Ho‘ )LN Ho‘ ’OH
HNQ HN\J
Examples
Step 1:
To a solution of l 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-N,N’ -(bis-(ter2‘-
butoxycarbonyl)amino)—2-chloro-9H—purinyl)ethynyltetrahydrofuran—2-y1)methoxy-
)malonate (7.26 g, 4.92 mmol, 1 eq) in DMF (80 mL) at 25°C was added K2CO3 (13.60 g,
98.40 mmol, 20 eq). The reaction mixture was stirred for 0.5 h and followed by addition of
1-(bromomethyl)nitro-benzene (15.94 g, 73.80 mmol, 15 eq). The reaction e was
stirred for 24 h before it was diluted with H20 (3 00 mL) and extracted with EtOAc (3 x 60
mL). The combined organic layer was washed with brine (100 mL), dried over Na2S04,
filtered and concentrated. The crude residue was purified by flash silica gel column
chromatography (petroleum ether : EtOAc = 10: 1—2: 1) to provide diethyl R, 3R, 4R, 5R)-
3,4-diacetoxy(6-((z‘erl—butoxycarbonyl)amino)chloro-9H-purinyl)—3-ethynyltetra—
hydrofuranyl)methoxy)(4-nitrobenzyl)malonate (2.36 g) was obtained as a brown gum.
Step 2:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)—3,4-diacetoxy(6-((tert—butoxycarbonyl)-
amino)—2-chloro-9H-purinyl)—3-ethynyltetra-hydrofuran—2-yl)methoxy)—2-(4-nitrobenzyl)-
W0 20191246403
malonate (2.26 g, 2.81 mmol, 1 eq) in EtOH (23 mL) at 0 °C was added Fe (786 mg, 14.07
mmol, 5 eq) and NH4C1 (151 mg, 2.81 mmol, 1 eq) in H20 (8.5 mL). The reaction mixture
was stirred at 50 °C for 4 h before it was filtered and the filtrate was concentrated. The crude
residue was purified by flash silica gel column chromatography (petroleum ether : EtOAc =
1:0 — 1:1) to provide diethyl 2-(4-aminobenzyl)-2—(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-((tert—
butoxycarbonyl)-amino)chloro-9H-purin—9-yl)-3—ethynyltetra-hydrofuranyl)methoxy)-
malonate (280 mg) as a yellow foam.
Step 3:
To a solution of diethyl 2-(4-aminobenzyl)—2-(((2R, 3R, 4R,5R)—3,4-diacetoxy(6—
((tert—butoxycarbonyl)amino)chloro-9H-purinyl)—3-ethynyltetrahydrofuran—2-yl)-
methoxy)malonate (280 mg, 362.14 umol, 1 eq) in DCM (3 mL) at 0 0C was added 1-chloro-
3-isocyanatopropane (86.59 mg, 724.28 umol, 2 eq). The reaction mixture was stirred at
°C for 16 h before it was trated. The crude residue was purified by preparative TLC
(petroleum ether : EtOAc = 1:0—1 : 1) to provide diethyl 2-(4-(3 -(3-chloropropy1)ureido)-
)—2—(((2R, 3R, 4R, 5R)-3,4-diacetoxy—5-(6-((tert-butoxycarbonyl)amino)-2—chloro—9H—
purinyl)—3-ethynyltetrahydrofurany1)methoxy)ma1onate (120 mg, 33% yield) as a foam.
Step 4:
To a on of diethyl 2-(4—(3 -(3 -ch1oropropyl)ureido)benzyl)—2-(((2R, 3R, 4R, 5R)—
acetoxy(6—((lerl—butoxycarbonyl)amino)ch1oro-9H—purinyl)—3-ethynyltetra—
uran-2—yl)methoxy)malonate (120 mg, 134.42 umol, 1 eq) in THF (1.2 mL) at 0 °C
was added NaH (11 mg, 268.84 umol, 60% in mineral oil, 2 eq). The reaction mixture was
stirred at 25 °C for 2 h before it was quenched with H20 (0.2 mL) at 0 °C. The reaction
mixture was then stirred at 25 0C for 16 h. The reaction mixture was ed to pH 3—4
with 1N aq. HCl solution and then extracted with EtOAc (3 x 5 mL). The combined organic
layer was washed with brine (15 mL), dried over anhydrous Na2S04, filtered and
concentrated to provide crude 2-(((2R, 3S, 4R, 5R)(6-((tert—butoxycarbonyl)amino)
chloro-9H-purinyl)ethyny1-3,4—dihydroxytetrahydrofuran-Z-yl)methoxy)(4-(2-oxo—
tetrahydropyrimidin-1(2hO-yl)benzyl)malonic acid (77 mg, 73% yield) as a white solid.
Step 5:
To a solution of crude 2-(((2R, 3S, 4R, 5R)(6-((lert—butoxycarbonyl)amino)chloro-
9H—pu1in-9—yl)ethyny1—3,4-dihydroxytetrahydrofuranyl)methoxy)(4-(2-oxotetra—
hydropyrimidin-1(2110-y1)benzyl)malonic acid (76 mg, 106.13 umol, 1 eq) in DCM (0.5 mL)
—104—
W0 20191246403
) at 0 °C was added TFA (0.25 mL, 338 mmol, 32 eq). The reaction mixture was stirred at
°C for 2 h before it was concentrated. The residue was re-dissolved with saturated aq.
NaHCO3 solution (5 mL) and extracted EtOAc (3 x 5 mL). The combined c layer
was washed with brine (15 mL), dried over anhydrous NazSO4, filtered and concentrated.
The crude residue was purified by ative reversed-phase HPLC to provide the title
compound (8.6 mg, 12% yield) as a white solid.
1H NMR (CD3OD, 300 MHz) 6 8,28 (s, 1H), 7.11 (d, J=8.52 Hz, 2H), 7.02 (d, J=8.52 Hz,
2H), 5.99 (d, J=7.44 Hz, 1H), 4.79 (d, J=7.41 Hz, 1H), 4.29 (t, J=2.76 Hz, 1H), 4.01—3.91
(m, 2H), 3.54—3.41 (m, 4H), .32 (m, 2H), 3.05 (s, 1H), 2,03—1.94 (m, 2H); LC/MS [M
+ H] = 616.2.
Example 10
Synthesis of 2—(((2R, 3S, 4R, 5R)(6-amino-2—chloro-9H—purinyl)-3 -ethynyl-3 ,4-
dihydroxytetrahydrofurany1)methoxy)(4—(2-oxopiperidin— 1 -yl)benzyl)malonic acid
NHBoc
O o o NHBoc
O NHB°°
o 0E1 0 OH
0 CB N \N
/ \N @ </N I
<N INA NaH THF
0' v
E10 0 N NAG —> HO o «Mfr:N
o o NAG
‘0 O
0 0| TEA, DCM, 25°C
o 0 _
: ., .- a
_ X 7
a, Acd bAc
H6 ”OH
N N
AcO OAc
H2N H
Step 1:
To a solution of crude diethyl 2-(4-aminobenzyl)-2—(((2R, 3R, 4R, 5R)-3,4-diacetoxy—5-
(6-((terZ-butoxycarbonyl)amino)-2—chloro-9H—purinyl)ethynyltetrahydrofuranyl)-
methoxy)malonate (140 mg, 160 umol, 1 eq) in DCM (2 mL) at 25°C was added TEA (107
mg, 1.06 mmol, 147 uL, 6.59 eq) and followed by 5-chloropentanoyl chloride (24.9 uL, 192
umol, 1.2 eq). The mixture was stirred for 1 h before it was partitioned between DCM (20
mL) and H20 (20 mL). The organic phase was washed with H20 (10 mL), dried over
NazSO4, filtered and concentrated under reduced pressure. The residue was d by
ative TLC (petroleum ether : EtOAc = 1:1) to give l 2—(4-(5-chloropentanamido)—
benzyl)(((2R, 3R, 4R, 5R)—3,4-diacetoxy(6-((lert—butoxycarbonyl)amino)chloro-9H—
purin—9-yl)-3—ethynyltetrahydrofuran—2-yl)methoxy)malonate (130 mg, 69% yield) as a
yellow gum.
Step 2:
To a solution of diethyl 2-(4-(5-chloropentanamido)-benzy1)—2-(((2R, 3R, 4R, 5R)-3,4-
diacetoxy(6-((tert—butoxycarbonyl)amino)chloro-9H—purin—9-yl)—3—ethynyltetrahydrofuranyl
)methoxy)malonate (104 mg, 105 umol, 1 eq) in THF (2 mL) at 25 °C was added
NaH (25.2 mg, 630 umol, 60% in mineral oil, 6 eq). The mixture was d for 4 h before it
was quenched with H20 (1 mL), The reaction mixture was stirred at 20 °C for 14 before it
was partitioned between EtOAc (10 mL) and water (20 mL). The aqueous phase was
acidified to pH 5—6 with 2N aq. HCl solution before it was partitioned between EtOAc (20
mL) and brine (10 mL), dried over anhydrous NazSO4, d and concentrated under
reduced pressure to give crude 2-(((2R,3S,4R,5R)(6-((tert—butoxycarbonyl)amino)
-9H—purinyl)ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)(4-(2-
oxopiperidin-l-yl)benzyl)malonic acid (58 mg) as a ess gum.
Step 3:
To a mixture of crude 2-(((2R, 3S, 4R, 5R)-5—(6-((lert—butoxycarbonyl)amino)chloro-
9H-purinyl)ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)(4-(2-oxopiperidin-
1-yl)benzyl)malonic acid (58 mg, , 1 eq) in DCM (500 uL) was added TFA (400 uL,
.40 mmol, 67 eq). The mixture was stirred at 20 CC for 2 h before it was quenched with 2N
aq. LiOH (500 uL). The mixture was partitioned between EtOAc (10 mL) and water (10
mL). The aqueous phase was adjusted to pH 5—6 with 2M aq. HCl solution. The aqueous
phase was partitioned between EtOAc (2 x 20 mL) and brine (5 mL), dried over anhydrous
NazSO4, d and concentrated under reduced pressure. The crude product was purified by
preparative HPLC and lyophilized to give the title compound (6.9 mg, 14% yield) as a white
solid.
1H NMR (400 MHz, DMSO-dé) 5 ppm 8.32 (s, 1H) 7.33 (d, J=8.53 Hz, 2H) 6.98 (d, J=8.28
Hz, 2H) 5.98 (d, J=7.53 Hz, 1H) 4.79 (m, 1H) 4.28 (t, J=2.76 Hz, 1H) 4.04 (br s, 2H) 3.39 -
3.54 (m, 4H) 3.05 (s, 1H) 2.43 (m, 2H) 1.88 (br t, J=2.89 Hz, 4H); LC/MS [M + H] = 615.3.
Example 11
Synthesis of R, 3S, 4R, 5R)(6-aminochloro-9H-purinyl)ethynyl-3,4-
oxytetrahydrofuranyl)methoxy)(4-(1 —(methoxymethy1)oxo— 1 ,2-
dihydropyridinyl)benzyl)malonic acid
0 N030C)2
O O :dB’OfiOH arkINAm
Br Boy? 0
Br MOMVCI,K2003 Br 0
—, —> C—>Br4Pphs
HN \ acetone \0/\N \
Pd(dppf)C|2, K2003 DCM ’0
\ \ \
dioxane, H20 \0
\ K2003 DMF
N OEt N OH N
\ \
</ l N l </ I N
0 N
o NAG 0
TFA,DCM O</N NJ\CI O N
aq.LiOH o NACI
_ . _ _ _ .
“ ’OAc Aco¢ ’OAc HO\‘ ”OH
\o/‘N \OPN
Example 11
Step 1:
To a solution of 3-bromopyridin-2(1110-one (2.25 g, 12.93 mmol, 1 eq) in acetone (40
mL) at 25 0C was added K2CO3 (4.47 g, 32.33 mmol, 2.5 eq). The suspension was stirred for
0.5 h and followed by addition of MOM-Cl (2.79 mL, 36.76 mmol, 2.84 eq) dropwise. The
mixture was stirred at 25 °C for 15 h before it was diluted with water (40 mL) and extracted
with ethyl acetate (2 X 30 mL). The combined organic layer was washed with brine (50 mL),
dried by Na2SO4, filtered and trated. The crude residue was purified by flash
on silica gel (20—60% ethyl acetate in petroleum ether) to e 3-bromo(methoxy-
methyl)-pyridin-2(1}D-one (1.22 g, 43% yield) as a clear oil.
Step 2:
To a solution of 3-bromo(methoxymethyl)pyridin-2(11-D—one (1.38 g, 6.33 mmol, 1
eq) and (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)phenyl)methanol (1.06 g, 6.96 mmol,
1.1 eq) in dioxane (12 mL) was added K2CO3 (2.62 g, 18.99 mmol, 3 eq), Pd(dppf)Cl2 (463
mg, 632.89 umol, 0.1 eq) and H20 (4 mL). The mixture was de-gassed with N2 for 10 min
before it was then heated at 80 °C for 16 h under N2 atmosphere. The reaction was d
with water (10 mL) and extracted with ethyl acetate (3 x 10 mL). The ed organic
layer was washed with brine (25 mL), dried by Na2SO4, filtered and concentrated. The crude
residue was purified by Combi-flash on silica gel (SO—100% ethyl acetate in petroleum ether)
to provide 3—(4-(hydroxymethyl)phenyl)—1—(methoxymethyl)py1idin—2(MED—one (1.30 g, 84%
yield) as a yellow gum.
Step 3:
To a solution ofPPh3 (8.34 g, 31.80 mmol, 6 eq) in DCM (50 mL) at —25 °C was
added CBr4 (10.55 g, 31.80 mmol, 6 eq) . The yellow suspension was stirred at —25 °C for 1
h and followed by addition of a solution of 3-(4-(hydroxymethyl)phenyl)—1-
(methoxymethyl)-pyridin-2(MED-one (1.30 g, 5.30 mmol, 1 eq) in DCM (10 mL) dropwise.
The yellow suspension was stirred at —25 °C for 0.5 h before it was diluted with MTBE (180
mL). The precipitate was filtered off and the e was concentrated to give crude (2.8 g) as
a yellow gum. The crude residue was purified by Combi-flash on silica gel (30—100% ethyl
acetate in petroleum ether) to provide 3-(4-(bromomethyl)phenyl)—1-(methoxymethyl)-
pyridin-2(1H)—one (760 mg, 46% yield) as a white solid.
Step 4:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-N,N’ -(bis-(ter2‘-
butoxycarbonyl)amino)—2-chloro-9H—pu1inyl)ethynyltetrahydrofuran—2-yl)-methoxy)—
malonate (100 mg, 130.18 umol, 1 eq) in DMF (1.5 mL) at 20 °C was added K2CO3 (53.97
mg, 390.54 umol, 3 eq). The suspension was stirred for 0.5 h and followed by addition of 3-
(4-(bromomethyl)phenyl)(methoxymethyl)pyridin-2(1H)-one (44.13 mg, 143.20 umol, 1.1
eq). The sion was stirred at 20 °C for 16 h before it was diluted with water (2 mL) and
extracted with ethyl acetate (3 X 2 mL). The combined organic layer was dried by Na2S04,
filtered and concentrated. The crude residue was d by preparative TLC (petroleum
ether : ethyl acetate = 1:1) to e diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-(N,N’ —
bis-(terZ-butoxy-carbonyl)amino)chloro—9H—purinyl)—3-ethynyltetrahydro-furan
yl)methoxy)—2—(4-(1—(methoxymethyl)—2-oxo—1,2-dihydropyridin-3—yl)benzyl)-malonate (71
mg, 55% yield) as a clear syrup.
Step 5:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy-5—(6-(N,N’ -bis-(terZ-butoxy-
yl)amino)—2—chloro—9H-purinyl)ethynyltetrahydrofuranyl)—methoxy)—2-(4—( l -
(methoxymethyl)-2—oxo-1,2—dihydropyridin—3-yl)benzyl)-malonate (68 mg, 68.31 umol, 1 eq)
in DCM (1.7 mL) at 0 CC was added TFA (0.3 mL, 4.05 mmol, 59 eq). The mixture was
stirred at 20 0C for 2 h before it was quenched with ted aq. NaHCO3 on to adjust
the pH to 9. The mixture was extracted with ethyl acetate (3 x 8 mL). The combined organic
layer was concentrated to give crude (98 mg) as a yellow gum. The crude residue was
purified by preparative TLC (ethyl acetate) to provide l 2-(((2R, 3R, 4R, 4-
diacetoxy—5—(6-aminochloro-9H-purin—9-yl)ethynyltetrahydrofuranyl)-methoxy)
(4-(1-(methoxymethyl)—2-oxo-1,2-dihydropyridin-3 -yl)benzyl)-malonate (21 mg, 38% yield)
as a colorless syrup.
Step 6:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)—3,4-diacetoxy(6-aminochloro-9H—
purin—9-yl)—3 —ethynyltetrahydrofuran—2-yl)methoxy)—2-(4-( l —(methoxy-methyl)-2—oxo- 1 ,2—
dihydropyridinyl)benzyl)malonate (20 mg, 25.15 umol, 1 eq) in THF (1 mL) was added
1M aq. LiOH (503 uL, 20 eq). The mixture was stirred at 18 °C for 22 h before it was
acidified to pH 2 with 1N aq. HCl and concentrated. The crude residue was d by
preparative HPLC and the fraction was dried by lyophilization to provide the title compound
(2.1 mg, 13% yield) as a white solid.
1H NMR (400 MHz, DMSO-d6) 6 ppm 8.45 (br s, 1H), 7.81 (br s, 2H), 7.67 (dd, J=6.75, 1.75
Hz, 1H), 7.51 (br d, J=6.75 Hz, 1H), 7.36 (br d, J=6.88 Hz, 2H), 7.20 (br d, J=7.50 Hz, 2H),
6.33 (t, J=6.75 Hz, 1H), 6.20 (br s, 1H), 6.01 (br d, J=6.88 Hz, 1H), 5.82 (d, J=7.50 Hz, 1H),
.28 (s, 2H), 4.65—4.89 (m, 1H), 4.06—4.23 (m, 1H) .06 (m, 1H), 3.67—3.86 (m, 1H),
3.40—3.52 (m, 3H), 3.18—3.30 (m, 2H), LC/MS [M + H] = 655.1.
Example 12
Synthesis of 2—(((2R, 3S, 4R, 5R)—5-(6-amino-2—chloro—9H—purin—9-yl)—3—ethynyl—3,4-
dihydroxytetrahydrofuranyl)methoxy)—2-(4-(2-oxo-1,2-dihydropyridin-3 -
yl)benzyl)malonic acid
o N(Boc)2 O 2 N(Boc)2
OQOB NfN Br (NfN BOH( )2
<:> o 0151 HN
</ I
l l I
E10 0 N E10 0 N
o N¢kc1 o Nékm
K2003, DMF Pd(dppf)C|2, K2C03
, . dioxane,H20
o N(Boc)2
<’Mfgl N
TFA, DOM O : o ,N NAG aq.LiOH,THF
—> —>
And bAc
Exam ple 12
Step 1:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy-5—(6-N,N’ —(bis-(terl—butoxy-
carbonyl)amino)—2-chloro-9H—purinyl)ethynyltetrahydrofuranyl)-methoxy)-malonate
(12.59 g, 16.39 mmol, 1 eq) and 1-(bromomethyl)iodo-benzene (48.67 g, 163.90 mmol, 10
eq) in DMF (120 mL) at 20 °C was added K2CO3 (33.98 g, 245.85 mmol, 15 eq). The
solution was stirred for 16 h before it was diluted with water (200 mL) and extracted with
ethyl acetate (3 X 200 mL). The ed organic layer was washed with water (400 mL),
brine (400 mL), dried by Na2SO4, filtered and concentrated. The crude residue was purified
by Combi-flash on silica gel % ethyl acetate in petroleum ether) to give diethyl 2-
(((2R, 3R, 4R, 5R)—3 ,4-diacetoxy-5 -(6-N,N’ -(bi t-butoxycarbonyl)-amino)chloro-9H-
purinyl)—3-ethynyltetra-hydrofurany1)methoxy)(4-iodobenzyl)—malonate (2.94 g,
18% yield) as a yellow solid.
Step 2:
To a solution of diethyl R, 3R, 4R, 5R)-3,4-diacetoxy-5—(6-N,N’ (terZ-butoxy-
carbonyl)amino)—2-chloro-9H-purinyl)ethynyltetrahydrofuranyl)—methoxy)(4—
iodobenzyl)malonate (1.10 g, 1.12 mmol, 1 eq) and (2-oxo—1,2-dihydropyridinyl)boronic
acid (310.53 mg, 2.24 mmol, 2 eq) in dioxane (12 mL) was added K2CO3 (463.41 mg, 3.35
mmol, 3 eq), Pd(dppf)Cl2 (81.78 mg, 111.77 umol, 0.1 eq) and H20 (4 mL). The mixture
was degassed with N2 for 10 min and then stirred at 80 0C for 1 h under N2 atmosphere. The
dark mixture was diluted with water (10 mL) and extracted with ethyl acetate (3 x 10 mL).
The combined organic layer was washed with brine (30 mL), dried by Na2804, filtered and
concentrated. The crude residue was purified by Combi-flash on silica gel (40—100%ethyl
acetate in petroleum ether) to give diethyl 2—(((2R, 3R, 4R, 5R)-3,4-diacetoxy—5-(6-N,N’ -(bis—
(Zert-butoxy-carbonyl)amino)chloro-9H-purinyl)—3-ethynyltetrahydrofuranyl)-
methoxy)-2—(4—(2-oxo—1,2-dihydropyridin-3—yl)benzyl)malonate (220 mg, 21% yield) as a
yellow gum.
Step 3:
To a solution of diethyl R, 3R, 4R, 5R)-3,4-diacetoxy-5—(6-N,N’ -(bis-(terZ-butoxy-
carbonyl)amino)—2—chloro—9H-purinyl)—3-ethynyltetrahydrofuranyl)—methoxy)—2-(4—(2-
oxo—1,2-dihydropyridinyl)benzyl)malonate (180 mg, 189.20 umol, 1 eq) in DCM (2.4 mL)
was added TFA (0.6 mL, 8.10 mmol, 43 eq). The yellow solution was stirred at 20 0C for 2.5
h before it was quenched with saturated aq. NaHCO3 (5 mL) and extracted with ethyl acetate
(3 x 4 mL). The combined c layer was concentrated to give crude (108 mg) as a
yellow gum. The crude residue was purified by preparative TLC (ethyl acetate) to give
diethyl 2-(((2R, 3R, 4R, 5R)—3 ,4-diacetoxy(6-aminochloro-9H-purinyl)-3 yltetra-
hydrofuranyl)methoxy)—2-(4-(2—oxo-1,2—dihydropyridin-3 -yl)benzyl)—malonate (23 mg,
16% yield) as a yellow solid.
Step 4:
To a solution of diethyl R, 3R, 4R, 5R)-3,4-diacetoxy-5—(6-aminochloro-9H—
purinyl)—3-ethynyltetrahydrofuranyl)methoxy)(4-(2-oxo-1,2-dihydropyridin
yl)benzyl)malonate (23 mg, 30.62 umol, 1 eq) in THF (2.5 mL) was added 1M aq. LiOH (0.6
mL, 20 eq). The reaction mixture was stirred at 20 °C for 4 h before it was acidified to pH 6
with 1N aq. HCl and trated to give crude (32 mg) as a yellow gum. The crude residue
was purified by preparative HPLC (column: YMC-Triart Prep C18 150*40mm*7um, Mobile
phase: [water (O.225%FA)—CAN]; B%: 15%-3 5%, 10min). The product was dried by
lyophilization to give the title compound (21 mg, 11% yield) as a white solid.
1H NMR (400 MHz, CD30D) 5 ppm 8.24 (s, 1H), 7.46 (dd, J=6.88, 1.63 Hz, 1H), 7.28—7.34
(m, 5H), 6.39 (t, J=6.75 Hz, 1H), 5.96 (d, J=7.38 Hz, 1H), 4.77—4.84 (m, 1H), 4.29 (t, J=2.88
Hz, 1H), 4.03 (d, J=2.75 Hz, 2H), 3.38—3.51 (m, 2H), 3.04 (s, 1H); LC/MS [M + H] = 611.0.
Example 13
Synthesis of 2—(((2R, 3S, 4R, 5R)(6-amino-2—chloro-9H—purinyl)—3 -ethynyl-3 ,4-
dihydroxytetrahydrofuranyl)methoxy)—2-((2-carboxy-[ 1 , 1'-biphenyl]yl)methyl)malonic
N(Boc)2
1 NAG
TFA, DCM
Example 13
Step 1:
To a mixture of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy-5—(6-N,N’ —(bis-(ierl—
butoxycarbonyl)amino)chloro-9H-purinyl)ethynyltetrahydrofuranyl)methoxy)-
malonate (99.87 mg, 130.01 umol, 1 eq) in DMF (0.5 mL) was added K2CO3 (53.90 mg,
390.03 umol, 3 eq). The mixture was stirred at 40 °C for 0.5 h and followed by on of
methyl 4-(bromomethyl)—[1,l'-biphenyl]carboxylate (79.35 mg, 260.02 umol, 2 eq) which
was prepared according to the reported procedure by D. Stoermer et al (J. ofMed. Chem.
2012, 55, 5922-5932). The mixture was stirred at 40 0C for 15.5 h before it was diluted with
water (4 mL) and extracted with EtOAc (3 x 5 mL). The combined organic layer was washed
with water (2 x 5 mL) and brine (5mL), dried over anhydrous NazSO4, d and
concentrated. The crude residue was d by preparative TLC (petroleum ether : EtOAc
= 1:1) to give diethyl 2-(((2R, 3R, 4R, 4-diacetoxy(6-N,N’ -(bis-(ZerZ-butoxycarbonyl)-
amino)—2-chloro-9H—purinyl)-3 —ethynyltetrahydrofuranyl)methoxy)((2-(methoxy-
carbonyl)-[1,1'-biphenyl]yl)methyl)malonate (70 mg, 53% yield) as a colorless syrup.
Step 2:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-N,N’ -(bis-(2‘erl-
butoxycarbonyl)amino)chloro-9H-purin—9-yl)ethynyltetrahydrofuranyl)methoxy)
((2—(methoxycarbonyl)—[1,1'-biphenyl]—4—yl)methyl)malonate (70 mg, 7053 umol, 1 eq) in
DCM (2 mL) was added TFA (0.5 mL, 6.75 mmol, 96 eq). The mixture was stirred at 20 °C
for 2 h before it was quenched with saturated aq. NaHCO3 to pH 7—8 and extracted with
EtOAc (3 x 10 mL). The combined organic layer was washed with water (2 x 8 mL) and
brine (8 mL), dried over anhydrous NazSO4, filtered and trated. The crude residue
was purified by preparative TLC (petroleum ether : EtOAc = 1:1) to give diethyl 2—
(((2R, 3R, 4R, 5R)-3 ,4-diacetoxy-5 -(6-amino—2-chloro-9H—purinyl)-3 -ethynyltetrahydro-
furanyl)-methoxy)((2-(methoxycarbonyl)-[1,l'-biphenyl]yl)methyl)malonate (40 mg,
71% yield) as a colorless syrup.
Step 3:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy-5—(6-aminochloro-9H—
purinyl)—3 -ethynyltetrahydrofuranyl)methoxy)((2-(methoxy-carbonyl)-[1, 1 '-
yl]-4—yl)methyl)malonate (30 mg, 3787 umol, 1 eq) in THF (1 mL) was added 1M aq.
LiOH (568 uL, 15 eq). The mixture was stirred at 25 0C for 20 h before it was diluted with
water (1 mL) and extracted with EtOAc (3 x 2 mL). The organic layer was discarded. The
pH of the water phase was adjusted to 2 with 2N aq. HCl to produce a precipitate. The
-ll2-
precipitate was collected by filtration to give desired product (28 mg) as the first crop. The
aq. phase was further extracted with EtOAc (4 X 2 mL). The combined organic layer was
dried over anhydrous NazSO4, filtered and concentrated to provide the second crop (10 mg)
as a white solid. These two crops were ed and d by preparative HPLC and the
fraction was lyophilized to give the title compound (8.0 mg, 33% yield) as a white solid.
1H NMR (400 MHz, CD3OD) 5 ppm 8.21 (s, 1H), 7.66 (s, 1H), 7.46 (br d, J=7.6 Hz, 1H),
7.24—7.32 (m, 3H), 7.12 (dd, J=7. 1, 2.3 Hz, 2H), 7.07 (d, J=7.9 Hz, 1H), 5.99 (d, J=7.4 Hz,
1H), 4.84 (br s, 1H), 4.33 (br s, 1H), .16 (m, 2H), 3.43—3.60 (m, 2H), 3.03 (s, 1H);
LC/MS [M + H] = 638.2.
Example 14
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)—5-(2-chlorophenyl-9H-purin—9-yl)-3 -ethynyl-3,4-
dihydroxytetrahydrofuranyl)methoxy)malonic acid
O‘B(OH)2 0
Cl 0 OH
1>d(0Ac)2 052003 / £11
P(05H4SO3Na)3 (N I A
(N m—>MeCN::H20(21) HO 0 ONNC|
H6 ”OH
Example 14
Step 1:
To a on of 2,6—dichloroadenine (0.8 g, 4.23 mmol, 1 eq) in H20 (10 mL) and
MeCN (5 mL) was added phenylboronic acid (464.49 mg, 3.81 mmol, 0.9 eq), CS2CO3 (3.45
g, 10.58 mmol, 2.5 eq), Pd(OAc)2 (47.51 mg, 211.64 umol, 0.05 eq) and trisodium;3-bis(3—
sulfonatophenyl)phosphanylbenzenesulfonate (601.50 mg, 1.06 mmol, 0.25 eq) at 20 0C
under N2 atmosphere. The mixture was stirred at 110 °C for 2 h before it was allowed to cool
and diluted with H20 (50 mL). The on mixture was extracted with EtOAc (5 x 50 mL).
The combined organic layer was washed with brine (50 mL), dried over NazSO4, filtered and
concentrated. The crude product was triturated with a mixture of petroleum ether (9 mL) and
EtOAc (3 mL) to provide 2-chloro—6-phenyl-9H—purine (140 mg, 14% yield) as a yellow
solid.
Step 2:
To a solution of 2-chlorophenyl—9H-purine (321.05 mg, 585.30 umol, 1 eq) in
MeCN (0.5 mL) was added diethyl 2-benzyl(((2R, 3R, 4R)-3,4,5—triacetoxyethynyltetra-
-ll3-
W0 20191246403
hydrofuran-2—yl)methoxy)malonate (135 mg, 585.30 umol, 1 eq) and BSA (347 uL, 1.40
mmol, 2.4 eq) at 15°C. The mixture was stirred at 65°C for 30 min as it became clear. The
mixture was cooled to 0 °C and followed by dropwise addition of TMSOTf (126.91 uL,
702.35 umol, 1.2 eq) . The e was stirred for 0 °C 10 min and then at 65 °C for 3
h before it was cooled and quenched with saturated aq. NaHCO3 (40 mL). The reaction
mixture was extracted with EtOAc (2 x 30 mL). The combined organic layer was washed
with brine (40 mL) and dried over Na2SO4, filtered and concentrated. The crude t was
purified by flash silica gel column chromatography (petroleum : EtOAc = 1:0 — 1:1) first and
then by preparative TLC (petroleum : EtOAc = 1:1) to provide diethyl 2-benzyl
(((2R,3R,4R,5R)—3,4-diacetoxy(2-chloropheny1-9H-purinyl)
ethynyltetrahydrofuranyl)methoxy)malonate (135 mg) as a yellow gum.
Step 3:
To a solution of diethyl 2-benzyl(((2R, 3R, 4R, 5R)—3,4-diacetoxy—5-(2-chloro
phenyl-9H—purinyl)ethynyltetrahydrofuranyl)methoxy)malonate (135 mg, 187.73
umol, 1 eq) in THF (2 mL) was added LiOH'H2O (78.77 mg, 1.88 mmol, 10 eq) in H2O (0.2
mL) at 20 °C. The mixture was stirred at 45°C for 2 h before it was diluted with H20 (10
mL) and with EtOAc (2 mL). The organic layer was ded and the aqueous phase was
acidified with 2N aq. HCl to pH 2—3. Then the aqueous phase was extracted with EtOAc (3 x
mL). The combined organic layer was washed with brine (30 mL), dried over Na2SO4,
filtered and concentrated. The crude product was purified by ative HPLC to provide
the title compound (27.6 mg, 24% yield) as a white solid.
1H NMR (400 MHz, e) 5 ppm 9.23 (s, 1H), 8.75 - 8.81 (m, 2H), 7.61 — 7.68 (m, 3H),
7.07 — 7.22 (m, 5H), 6.03 (d, J=6.53 Hz, 1H), 4.62 (d, J=6.53 Hz, 1H), 4.20 (dd, J=6.90, 2.64
Hz, 1H), 3.72 (br dd, J=9.91, 7.15 Hz, 2H), 3.55 (s, 1H), 3.03 (br d, J=1.51 Hz, 2H); LC/MS
[M +H] = 579.1.
Example 15
Synthesis of 2-allyl(((2R, 3S, 4R, 5R)—5—(6-aminochloro-9H—purinyl)ethynyl-3,4-
dihydroxytetrahydrofuranyl)methoxy)malonic acid
—114—
0 allyl bromide O 0 ACZO
0 CE! 052co3 O TFA O 4DMAP
DMF 20°C DCM 10% H20 pyridine
E10 0Q10 —> EtO —>EtO
O A) A)
of ,
AcO AcO\
0 (IHNfN:N O NH2
0 CB *C' 0 0H
0 QB N N
(x l aq.LiOH </ i 1
E10 0 —> HO /
$4.0M Eto O N :Nk 0 N
0 N
BSA TMSOTf O N/ CI THF
\ \ MeCN \ _
_ . \ _
Acd ”OAc Ho‘ OH
Step 1:
To a solution of diethyl 2-(((3aR, 5R, 6R, 6aR)acetoxyethynyl—2,2-dimethyltetra-
hydrofuro[2,3-d][1,3]dioxolyl)methoxy)malonate (600 mg, 1.45 mmol, 1 eq) in DMF (1
mL) was added allyl bromide (263 mg, 2.17 mmol, 15 eq) and CszCOs (943 mg, 2.90 mmol,
2 eq). The mixture was stirred at 20 0C for 2 h before it was diluted with water (15 mL) and
extracted with EtOAc (4 X 10 mL). The combined organic phase was washed with water (10
mL), brine (10 mL), dried over anhydrous Na2S04, filtered and concentrated to provide crude
diethyl aR, 5R, 6R, 6aR)—6-acetoxy-6—ethynyl—2,2-dimethyltetrahydro-furo[2,3 -d] [1 3 ]-
dioxolyl)methoxy)—2-allylmalonate (685 mg) as a colorless gum.
Step 2:
To a solution of crude diethyl 2-(((3aR, 5R, 6R, 6aR)—6-acetoxyethynyl-2,2-
dimethyltetrahydrofuro[2,3-d][1,3]dioxolyl)methoxy)—2-allylmalonate (685 mg, 1.51
mmol, 1 eq) in DCM (5 mL) was added TFA (5 mL, 6753 mmol, 45 eq) and H20 (1 mL,
55.51 mmol, 37 eq). The mixture was stirred at 20 0C for 16 h before it was diluted with
water (15 mL) and adjusted the pH to 7—8 with solid NaHCO3. The reaction mixture was
extracted with a mixture of DCM and MeOH (4 x 12 mL, 10: l/Vzv). The combined extract
was washed with saturated aq. NaHCO3 (8 mL), brine (8 mL), dried over anhydrous NazSO4,
filtered and concentrated under reduced pressure to give crude l 2-(((2R,3S,4R)
yethynyl-4,5-dihydroxytetrahydrofuranyl)methoxy)allylmalonate (580 mg) as
a yellow gum.
Step 3:
To a solution of crude diethyl 2-(((2R,SS,4R)—3-acetoxyethyny1-4,5-dihydroxytetra-
hydrofuranyl)methoxy)allylmalonate (580 mg, 1.40 mmol, 1 eq) in ne (5 mL) was
added A020 (1.31 mL, 14.00 mmol, 10 eq) and 4—DMAP (513 mg, 4.20 mmol, 3 eq). The
mixture was stirred at 20 °C for 15 before it was d with water (15 mL) and extracted
with EtOAc (3 x 10 mL). The combined extract was washed with 0.5 N aq. HCl (2 X 8 mL),
NaHCO3 (2 x 8 mL), brine (8 mL), dried over anhydrous Na2SO4, filtered and concentrated
under reduced pressure. The crude product was purified by silica gel column
chromatography (petroleum ether : EtOAc = 5:1 — 2:1) to give (420 mg, 60% yield) as a
colorless gum.
Step 4:
To a mixture of diethyl 2-allyl(((2R, 3R, 4R)—3,4,5-triacetoxyethynyltetra-
hydrofuran-2—yl)methoxy)malonate (360 mg, 722.20 umol, 1 eq) and 2-chloro-9H—purin-6—
amine (135 mg, 794.42 umol, l.l eq) in MeCN (5 mL) was added BSA (446.28 uL, 1.81
mmol, 2.5 eq) at 25 °C under N2 atmosphere. The mixture was d at 65 °C for 0.5 h.
The reaction mixture was cooled to O 0C and followed by dropwise addition of TMSOTf
(261.00 uL, 1.44 mmol, 2 eq) in MeCN (1 mL). The e was stirred at 65 CC for 3 h
before it was allowed to cooled and quenched with saturated aq. NaHCO3 solution (15 mL).
Then the mixture was extracted with EtOAc (4 x 10 mL), washed with saturated brine (8
mL), dried over ous , filtrated and concentrated. The crude product was
d by Combi-flash on silica gel (20—40% EtOAc in petroleum ether) to give diethyl 2-
allyl(((2R,3R,4R,5R)-3,4-diacetoxy(6-aminochloro-9H-pu1inyl)ethynyltetra-
hydrofuranyl)methoxy)malonate (190 mg) as a colorless gum.
Step 5:
To a solution of diethyl 2-allyl(((2R, 3R, 4R, 5R)-3,4-diacetoxy-5—(6-amino
chloro-9H—purin-9—yl)ethynyltetrahydrofuranyl)methoxy)malonate (100 mg, 164.47
umol, 1 eq) in THF (0.5 mL) was added LiOH'HzO (6.90 mg, 164.47 umol, 1 eq). The
mixture was stirred at 50 °C for l h before it was diluted with water (6 mL) and extracted
with EtOAc (3 x 4 mL). The organic layer was discarded. The pH of the aq. phase was
adjusted to 2 with 2N aq. HCl solution. The aq. phase was then extracted with EtOAc (4 x 6
mL). The combined organic phases was washed with brine (6 mL), dried over ous
Na2SO4, filtered and concentrated to provide a solid. The solid was dissolved in a e of
MeCN (1 mL) and water (1 mL) and then lyophilizied directly to give the title compound
(65.2 mg, 83% yield) as a white solid.
1H NMR (400 MHz, CD30D) 5 ppm 8.83 (s, 1H) 6.05 (d, J=7.5 Hz, 1H) 5.84 (br dd, J=17.2,
.2 Hz, 1H) 5.15 (dd, J=17.2, 1.6 Hz, 1H) 4.99 - 5.05 (m, 2H) 4.27 (t, J=2.5 Hz, 1H) 4.00
-ll6-
(dd, J=10.2, 2.6 Hz, 1H) 3.79 (dd, J=10.3, 2.8 Hz, 1H) 3.06 (s, 1H) 2.88 (d, J=7.3 Hz, 2H),
LC/MS [M + H] = 467.9.
Example 16
Synthesis of 2-(((2R, 35, 4R, 5R)(6-amino-Z-chloro-9H-purin-9—yl)-3 -ethyny1-3 ,4-
oxytetrahydrofuran-Z-yl)methoxy)-2—ethy1malonic acid
0 NH2
3%:0 OH
O 'NACI
H6 ’OH
Example 16
Proceeding as described in Example 15 above but substituting allyl bromide with EtBr
provided the title compound as a white solid.
1H NMR (400 MHz, DMSO-d6) 6 ppm 8.53 — 8.83 (m, 1H) 7.81 (br s, 2H) 5.91 — 6.40 (m,
2H) 5.83 (d, J=7.88 Hz, 1H) 4.91 (d, J=7.75 Hz, 1H) 4.14 (t, J=2.88 Hz, 1H) 3.75 (dd,
J=10.26, 3.25 Hz, 1H) 3.56 (s, 1H) 3.47 — 3.51 (m, 1H) 1.93 — 2.04 (m, 2H) 0.76 (t, J=7.38
Hz, 3H), LC/MS [M + H] = 4559.
Example 17
Synthesis of 2—(((2R, 3S, 4R, 5R)(6-aminoch1oro-9H—purin-9—yl)-3 -ethyny1-3 ,4-
oxytetrahydrofurany1)methoxy)methylmalonic acid
0 NH2
0>7?OH N
<’ fN
HO 0: N
o NAG
—Ho‘: ”0H
Example 17
Proceeding as described in Example 15 above but substituting allyl bromide with
methyl bromide provided the title compound as a white solid.
1HWR (400 MHz, DMSO-d6) 5 ppm 13.38 (br s, 2H) 8.69 (s, 1H) 7.82 (br s, 2H) 6.17 (br
s, 1H) 5.98 (br d, J=7.25 Hz, 1H) 5.82 (d, J=7.63 Hz, 1H) 4.85 (br t, J=6.94 Hz, 1H) 4.15 (t,
J=2.75 Hz, 1H) 3.83 (dd, J=10.13, 3.25 Hz, 1H) 3.53 — 3.65 (m, 2H) 1.52 (s, 3H); LC/MS [M
+ H] = 441.8.
W0 20191246403
Example 18
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)—5-(2-chloro(thiophenyl)-9H—purinyl)
ethyny1-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
\S _S_ 0?: 0 CE N
\N —AcO ’o </ l
l A BC 0 N
o NACI
N Cl Pd(OAc)2. 052003 DBU TMSOTf MeCN
P(C6H4803Na)3 :
‘. .9
MeCN H20 AcO OAc
aq. LiOH, THFi _
O OH N
</ :1
HO O N
O N/ Cl
H6 "0H
Step 1:
To a mixture of 2-chloroadenine (800 mg, 4.23 mmol, 1 eq) in MeCN (5 mL) and
H20 (10 mL) at 20 °C under N2 atmosphere was added 4,4,5,5-tetramethyl(thiophenyl)-
1,3,2-dioxaborolane (800.37 mg, 3.81 mmol, 0.9 eq), Pd(OAc)2 (47.51 mg, 211.64 umol,
0.05 eq), CS2CO3 (3.45 g, 10.58 mmol, 2.5 eq) and triphenylphosphine-3,3’-3”-trisulfonic
acid ium salt (601.50 mg, 1.06 mmol, 0.25 eq). The mixture was stirred at 110 CC for 3
h before it was allowed to cool and partitioned between EtOAc (3 x 20 mL) and H20 (10
mL). The combined organic phase was washed with H20 (2 x 10 mL), dried over Na2SO4,
filtered and concentrated under reduced pressure. The crude product was triturated with
leum ether : EtOAc = 3: 1) and left standing for for 14 h. The precipitate was collected
by suction filtration and dried to provide 2-chloro(thiophenyl)-9H—purine (190 mg, 19%
yield) as a yellow solid.
Step 2:
To a e of 2-chloro(thiophenyl)-9H-purine (140 mg, 591.51 umol, 1 eq)
and diethyl 2-benzyl(((2R, 3R, 4R)—3 ,4, 5 -triacetoxy-3 -ethynyltetrahydrofuran
yl)methoxy)malonate (324.47 mg, 591.51 umol, 1 eq) in MeCN (3 mL) at 0° C was added
DBU (267 uL, 1.77 mmol, 3 eq). The e was stirred at 0°C for 10 min and followed by
dropwise addition of TMSOTf (481 uL, 2.66 mmol, 4.5 eq). The mixture was stirred at 0 0C
-ll8-
for 30 min and then at 65 °C under N2 atmosphere for 14 h. The reaction mixture was
d to cool and partitioned between EtOAc (3 X 20 mL) and saturated aq. NaHCO3 (2 x
mL). The combined organic phase was washed with brine (2 X 20 mL), dried over
NazSO4, d and concentrated. The crude product was purified by preparative TLC
leum ether : EtOAc = 2:1) to provide diethyl 2-benzyl(((2R, 3R, 4R, 5R)-3,4-
diacetoxy-5—(2-chloro(thiophenyl)-9H—purinyl)—3-ethynyltetrahydrofuran—2-
yl)methoxy)-malonate (150 mg, 31% yield) as a white solid.
Step 3:
To a mixture of diethyl 2-benzyl(((2R, 3R, 4R, 5R)-3,4-diacetoxy(2-chloro
(thiophenyl)—9H-purinyl)—3-ethynyltetrahydrofuranyl)methoxy)malonate (150 mg,
206.85 umol, 1 eq) in THF (2 mL) was added LiOH'H2O (2 M, 2 mL, 19.34 eq). The mixture
was stirred at 25 CC for 2 h before it was partitioned between EtOAc (10 mL) and water (10
mL). The aqueous phase was adjusted to pH ~2 with 2M aq. HCl solution. The aqueous
phase was partitioned between EtOAc (40 mL) and brine (20 mL), dried over anhydrous
NazSO4, filtered and concentrated under reduced pressure. The crude product was purified
by preparative HPLC (column: YMC-Triart Prep C18 150*40mm*7um, mobile phase:
[water(0.225%FA)-ACN];B%: 43%-63%, 10min) and lyophilized to provide the title
compound (31.6 mg, 26% yield) as a white solid.
1H NMR (400 MHz, DMSO-dd) 5 ppm 8.87 (s, 1H) 8.60 (dd, J=3.76, 1.25 Hz, 1H) 8.02 (dd,
J=5.02, 1.00 Hz, 1H) 7.36 (dd, J=4.89, 3.89 Hz, 1H) 7.16 — 7.28 (m, 2H) 6.93 — 7.10 (m, 3H)
6.31 (br s, 1H) 6.11 (br d, J=6.02 Hz, 1H) 5.99 (d, J=7.53 Hz, 1H) 4.88 — 4.97 (m, 1H) 4.23
(dd, , 2.76 Hz, 1H) 3.99 (br dd, J=10.42, 4.39 Hz, 1H) 3.84 (br d, J=8.53 Hz, 1H) 3.56
(s, 1H) 3.26 (s, 2H); LC/MS [M + H] = 585.0.
Example 19
Synthesis of 2-(((2R, 3S, 4R, (6-aminochloro-9H—purinyl)-3 yl-3 ,4-
dihydroxytetrahydrofuranyl)methoxy)(4-(2-oxo- l l- l ,2-dihydropyridin-3 -
yl)benzyl)malonic acid
-ll9-
N(Boc)2
o OEt N
/\/rB A
O o OH Br 9000qu
HN5BI' K2C03,K|, Br HO L.
acetone, 20 °C \PNb \OBWH); O CBr4. PPha 0 A05 IOAC
—> —> —> —>
\ \ Pd(dppf)Cl2, K2C03 \PN
dioxane, H20, so °c \
\ \/\N\ \ 535583132":
Step 1:
To a solution of 3-bromopyridin-2(1110-one (3 g, 17.24 mmol, 1 eq) in acetone (100
mL) was added K2CO3 (11.91 g, 86.21 mmol, 5 eq). The suspension was d at 20 0C for
0.5 h and followed by addition of 1—bromopropane (4.71 mL, 51.73 mmol, 3 eq) and K1 (859
7rnnufl,03eq) Thenfixunenmssfinedat20OCfor16lL.Admfionalmnountofl-
bromopropane (1.0 g) was added to the reaction mixture and the mixture was stirred further at
°C for 3 h. The on was d with water (50 mL) and extracted with EtOAc (3 x
40 mL). The combined organic layer was washed with brine (100 mL), and dried over
anhydrous Na2SO4, filtered and concentrated. The residue was purified by Combi—Flash
(silica gel, 20—60% EtOAc in petroleum ether) to provide 3-bromopropylpyridin-2(1H)—
one (123 g, 33% yield) as a clear oil.
Step 2:
To a solution of 3-bromopropy1pyridin-2(1H)—one (1.79 g, 8.28 mmol, 1 eq) and
(4-(hydroxymethyl)phenyl)boronic acid (1.38 g, 9.11 mmol, 1.1 eq) in dioxane (18 mL) was
added K2CO3 (3.43 g, 24.84 mmol, 3 eq), Pd(dppf)Cl2 (606 mg, 828.00 umol, 0.1 eq) and
H20 (6 mL). The mixture was ed with N2 for 10 min and then stirred at 80°C for 16 h
under N2 atmosphere. The reaction mixture was cooled and filtered. The filtrate was
wmmmmw.UmmfiflwwwpmfiuflowflfiHwhfimwgd30flfithOAMn
petroleum ether) to provide 3-(4-(hydroxymethyl)phenyl)—1-propy1pyridin-2(1hO-one (1.84 g,
91% yield) as a brown solid.
Step 3:
To a solution of PPh3 (1.94 g, 7.40 mmol, 6 eq) in DCM (15 mL) was added CBr4
(245g,740nnnd,6eq)M—25°C.Theydhnysdufionumssfinaim—QS°Clbr1hand
followed by addition of 3-(4-(hydroxymethyl)phenyl)propylpyridin-2(lhO-one (300 mg,
-l20-
1.23 mmol, 1 eq) in DCM (3 mL) dropwise. The yellow suspension was stirred at —25 °C for
0.5 h to e a yellow suspension. The reaction mixture was diluted with MTBE (50 mL)
to produce more itate. The precipitate was d off and the filtrate was
concentrated. The residue was purified by CombiFlash a gel column, 10—100 % of
EtOAc in petroleum ether) to provide 3-(4-(bromomethy1)pheny1)—1-propylpyridin-2(1H)—one
(243 mg, 64% yield) as a clear oil.
Step 4:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy-5—(6-N,N’ —(bis-(terl—
carbonyl)amino)—2-chloro-9H-purinyl)ethynyltetrahydrofuranyl)methoxy)-
malonate (554 mg, 721.20 umol, 1 eq) in DMF (5 mL) was added K2CO3 (299.03 mg, 2.16
mmol, 3 eq). The mixture was stirred at 20 0C for 0.5 h and followed by addition of 3-(4-
(bromomethyl)phenyl)—1-propylpyridin-2(1H)—one (242.91 mg, 793.32 umol, 1.1 eq). The
mixture was stirred at 20 °C for 16 h before it was diluted with water (30 mL) and extracted
by EtOAc (4 x 20 mL). The combined organic layer was washed with water (100 mL), dried
over anhydrous NazSO4, filtered and concentrated. The residue was purified by Combi Flash
(silica gel, 20—30% of EtOAc in petroleum ether to provide l 2-(((2R, 3R, 4R,5R)—3,4-
diacetoxy(6-N,N’ -(bis-(terl-butoxycarbonyl)amino)chloro-9H-purinyl)-3 -ethynyl-
tetrahydrofuranyl)methoxy)(4-(2-oxo— l -propyl- l ,2-dihydropyridinyl)benzyl)-
malonate (209 mg) as a colorless gum.
Step 5:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-N,N’ -(bis-(terl‘-butoxy-
carbonyl)amino)—2-chloro-9H-pu1in—9-yl)-3—ethynyltetrahydrofuranyl)methoxy)—2-(4-(2—
oxo—1-propyl-1,2-dihydropyridinyl)benzyl)malonate (209 mg, 210.38 umol, 1 eq) in DCM
(2 mL) at 0 0C was added TFA (0.7 mL, 9.45 mmol, 44.94 eq). The solution was d at 20
0C for 2 h before it was quenched by ted aq. NaHCO3 (5 mL) and extracted with EtOAc
(4 x 10 mL). The combined organic layer was dried over anhydrous NazSO4, filtered and
trated. The residue was purified by Combi Flash (silica gel, 30—70% of EtOAc in
petroleum ether) to provide diethyl 2-(((2R,3R,4R,5R)—3,4-diacetoxy(6-aminochloro-
9H-purinyl)—3-ethynyltetrahydrofuran-2—yl)methoxy)-2—(4-(2-oxo-l-propyl-1,2—dihydropyridinyl
)benzyl)malonate (91 mg, 55% yield) as a white solid.
Step 6:
-l2l-
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy-S—(6-aminochloro-9H—
purinyl)—3 -ethynyltetrahydrofuranyl)methoxy)(4-(2-oxopropyl-1,2-dihydro-
pyridin-3—y1)benzy1)malonate (91 mg, 114.72 umol, 1 eq) in THF (1 mL) was added 1N aq.
LiOH (1 mL). The mixture was stirred at 20 0C for 2.5 h before it was diluted with water (5
mL) and the ing on was washed with EtOAc (2 x 10 mL). The c extract was
discarded. The aqueous layer acidified to pH 2 with 2N aq. HCl and then extracted with
EtOAc (4 x 8 mL). The combined organic layer was dried over anhydrous NazSO4, filtered
and concentrated. The residue was dissolved in a mixture ofMeOH (5 mL) and water (20
mL) and was dried by lyophilization to provide thet title compound (51 mg, 67% yield) as a
white solid.
1HWR (400 MHz, CD30D) 5 ppm 8.08 (s, 1H), 7.53 (dd, J=6.80, 2.0 Hz, 1H), 7.28—7.39
(m, 5H), 6.34 (t, J=6.9 Hz, 1H) ,5.96 (d, J=7.6 Hz, 1H), 4.77 (d, J=7.6 Hz, 1H), 4.28 (s, 1H),
4.07—4.15 (m, 1H), 4.01 (dd, J=10.3, 2.8 Hz, 1H), 3.92 (t, J=7.4 Hz, 2H), 3.39—3.58 (m, 2H),
3.06 (s, 1H), 1.65—1.80 (m, 2H), 0.94 (t, J=7.4 Hz, 3H), LC/MS [M + H] = 653.1.
Example 20
Synthesis of 2—(((2R, 3S, 4R, 5R)(6-amino-2—chloro-9H—purinyl)—3 yl-3 ,4-
dihydroxytetrahydrofuranyl)methoxy)—2-(4-(1 -ethyloxo-1 ,2-dihydropyridin-3 -
yl)benzyl)malonic acid
N(Boc2)
0%?—0E!Off
\,Br Eloy—2— I
Br K2C03 Kl Br HO o
HN\5—.acetone 20 °C G B(OH)2 O
/‘N\ CBr4 PPhs AcO OAc
Pd(dppf)CI2 K2003
dioxane H20, 80 ”C /\N\§éCCO31,éD;V|:
o NH2 0 NH;
0 CE N CH
</ ‘N
- </ I
TFA DCM A aq. LIOH,THF Y—b O I‘- ,0. 'N N CI —> NACI
— O
Acd bAC
Example 20
Proceeding as described in Example 19 above but substituting propyl bromide with
ethyl bromide provided the ttitle compound as a white solid.
1H NMR (400 MHz, CD30D) 5 ppm 8.15 (s, 1H), 7.53 (dd, J=6.6, 1.3 Hz, 1H), 7.25—7.38
(m, 5H), 6.32 (t, J=6.9 Hz, 1H), 5.96 (d, J=7.6 Hz, 1H), 4.78 (d, J=7.5 Hz, 1H), 4.30 (s, 1H),
-l22-
WO 46403
4.09—4.15 (m, 1H), 3.95—4.04 (m, 3H), 3.39—3.58 (m, 2H), 3.06 (s, 1H), 1.28—1.32 (m, 3H);
LC/MS [M + H] = 639.1.
Example 21
sis of 2—(((2R, 3S, 4R, 5R)(6-amino-2—ch1oro-9H-purinyl)—3 -ethyny1-3 ,4-
dihydroxytetrahydrofurany1)methoxy)(4-(1-(2-hydroxyethy1)oxo-1,2-
dihydropyridin-3—y1)benzy1)malonic acid
0 /\,Br 0 O HO OH
Br 3’ Br
TBDPSCI
HN \ K2C03. acetone TBDPSOfN \ Imldazoli DMF TBDPSOJ‘N \ L©_B(OH)Z
—> —.
\ \
\ Pd(dppf)C|2, K2003 TBDPSO\/\N \
dioxane, H20 \
0 (HA
_i\l.o N CI
0 Br Accf ’OAc
CBC“ PPh3 TFA, DCM
—’ — ¢ 9 —>
TBDPSO AGO OAC
DCM \/\N
l K2003, DMF TBDPSO\/\N
0 “Hz
OEt N 0 NH2 0 NH2
</ i AN o 0E1 /N OH
\N /N \N
o N
o N 0| < l A < 1 A
TBAF,THF o ,N N CI aq.LiOH,THF ,N N c:
A06 bAC 0; 1:0
: ‘4, 5 '3
TBDPSO\/\N H6 OH HO OH
Exampiem
Step 1:
To a mixture of 3-bromopyridin-2(lhO-one (3 g, 17.24 mmol, 1 eq) in e (100
mL) at 20 °C was added KI (859 mg, 5.17 mmol, 03 eq), K2CO3 (5.96 g, 43.10 mmol, 25
eq) and 2-bromoethanol (4.90 mL, 68.97 mmol, 4 eq). The mixture was d for 4 before it
was filtered and the filter cake was washed with EtOAc (100 mL). The filtrate was
concentrated under reduced pressure to give a residue. The residue was purified by flash
silica gel column chromatography (petroleum ether : EtOAc = 5:1 to 0:1) to provide 3-
bromo(2-hydroxyethyl)pyridin-2(lib-one (2.2 g, 59% yield) as a yellow gum.
Step 2:
To a mixture of 3-bromo(2-hydroxyethyl)pyridin-2(1H)-one (2.2 g, 10.09 mmol, 1
eq) in DMF (15 mL) at 20 °C was added imidazole (1.72 g, 25.22 mmol, 2.5 eq) and
TBDPSCl (5.18 mL, 20.18 mmol, 2 eq). The mixture was stirred for 2 h before it was diluted
with H20 (60 mL) and extracted with EtOAc (3 x 30 mL). The combined extract was
washed with saturated aq. NH4C1 (2 x 30 mL), brine (30 mL), dried over anhydrous Na2S04,
WO 46403
filtered and concentrated under reduced pressure. The residue was d by flash silica gel
column chromatography (petroleum ether : EtOAc = 1:0 to 6: 1) to provide 3-bromo(2-
((tert-butyldiphenylsilyl)oxy)ethyl)-pyridin-2(1H)-one (3.75 g, 79% yield) as a light yellow
Steps 3 — 8:
Proceeding as described in Example 19 above but substituting 3-(4—(bromomethyl)—
phenyl)propylpy1idin-2(lhO-one with 3—bromo(2-((terz‘-butyldiphenylsilyl)oxy)ethyl)-
pyridin-2(1H)—one provided the title compound as a white solid.
1H NMR (400 MHz, CD3OD) 5 ppm 8.33 (s, 1H), 7.50—7.57 (m, 1H), 7.41—7.47 (m, 1H),
7.39 (d, J=8.13 Hz, 2H), 7.29 (br d, J=8.13 Hz, 2H), 6.35 (t, J=6.88 Hz, 1H), 5.98 (d, J=7.13
Hz, 1H), 4.71 (d, J=7.00 Hz, 1H), 4.30 (br s, 1H), 3.93—4.16 (m, 4H), 3.83 (m, 2H), 3.36—
3.50 (m, 2H), 3.05 (s, 1H), LC/MS [M + H] = 655.1.
Example 22
Synthesis of 2-(((2R, 3S, 4R, 5R)(6-aminochloro-9H—purinyl)-3 yl-3 ,4-
dihydroxytetrahydrofuranyl)methoxy)(4-(2-methoxypyridin-3 -yl)benzyl)malonic acid
o N(Boc)2
0 0E! B(OH)2
<N \N N \
/ I |
E10 0 N
o NAG
Pd(dppf)C|2, K2C03
_ ~ . e,H20
I AC6 bAC
TFA,DCM NAG aq.LiOH,THF
—> —>
Example 22
Step 1:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy-5—(6-N,N’ —(bis-(terZ-butoxy-
carbonyl)amino)—2-chloro-9H—purinyl)ethynyltetrahydrofuran-Z-yl)—methoxy)—2-(4—
iodobenzyl)malonate (900 mg, 914.47 umol, 1 eq) and (2-methoxypy1idyl)boronic acid
(168 mg, 1.10 mmol, 1.2 eq) in dioxane (9 mL) 25 0C was added K2CO3 (379 mg, 2.74
—124—
mmol, 3 eq), Pd(dppf)C12 (67 mg, 9145 umol, 0.1 eq) and H20 (3 mL). The mixture was
degassed with N2 for a while and then heated to 80 0C for 16 h before it was diluted with
water (10 mL), and ted with ethyl acetate (2 x 10 mL). The combined organic layer
was dried by NazSO4, filtered and concentrated. The crude product was purified by Combi-
flash (silica gel, 10—50 % of EtOAc in petroleum ether) to give diethyl R, 3R, 4R, 5R)-
3,4-diacetoxy(6-MN’ -(bis-(Zert—butoxycarbonyl)amino)—2-chloro-9H—purinyl)—3-
ethynyltetrahydro-furanyl)-methoxy)-2—(4-(2-methoxypyridinyl)benzyl)malonate (l 17
mg, 13% yield) as a yellow gum.
Step 2:
To a solution of diethyl R, 3R, 4R, 4-diacetoxy(6-N,N’{bis-(tert-
butoxycarbonyl)amino)chloro-9H-purin—9-yl)-3—ethynyltetrahydrofuranyl)-methoxy)
(4-(2-methoxypyridinyl)benzyl)malonate (90 mg, 93.23 umol, 1 eq) in DCM (3 mL) was
added TFA (0.4 mL, 5.40 mmol, 58 eq). The solution was stirred at 20 °C for 2 h before it
was quenched with saturated aq. NaHCO3 (4 mL) and extracted with EtOAc (3 x 4 mL). The
combined organic layer was concentrated to give crude diethyl 2-(((2R, 3R, 4R, 5R)—3,4-
diacetoxy(6-aminochloro-9H-purinyl)ethynyltetrahydrofuranyl)methoxy)(4-
(2-methoxypyridiny1)benzy1)-malonate (42 mg) as a yellow gum.
Step 3:
To a solution of crude diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-aminochloro-
9H—purin-9—yl)—3-ethynyltetrahydrofuranyl)methoxy)(4-(2-methoxy-pyridin
yl)benzyl)malonate (42 mg, 54.89 umol, 1 eq) in THF (2.5 mL) was added 1M aq. LiOH (0.8
mL, 15 eq). The reaction mixture was stirred at 20 0C for 4 h before it was acidified to pH 6
with 1N aq. HCl and concentrated. The crude t was purified by preparative HPLC and
the fraction was dried by lyophilization to give the title compound (6 mg, 17% yield) as a
white solid.
1H NMR (400 MHz, CD30D) 5 ppm 8.10 (s, 1H), 8.01 (dd, J=4.94, 1.69 Hz, 1H), 7.48 (dd,
J=7.25, 1.63 Hz, 1H), 7.24 — 7.35 (m, 4H), 6.93 (dd, J=7.32, 5.07 Hz, 1H), 5.97 (d, J=7.50
Hz, 1H), 4.89 — 4.96 (m, 1H), 4.29 (br s, 1H), 4.05 (br d, J=5.00 Hz, 2H), 3.76 (s, 3H), 3.51
(br d, J=14.76 Hz, 1H), 3.42 (br d, J=14.51 Hz, 1H), 3.01 (s, 1H); LC/MS [M + H] = 625.1.
Example 23
Synthesis of 2-(((2R, 3S, 4R, (6-aminochloro-9H—purinyl)-3 -ethynyl-3 ,4-
dihydroxytetrahydrofuranyl)methoxy)—2-(3-(trifluoromethoxy)benzyl)malonic acid
0 NH2
0 OH N \
<’ ' i
Ho o N
o N CI
PX 23—7,..,
0 Ho‘ ’OH
Example 23
Proceeding as described in Example 1 above but substituting benzyl bromide with 1-
(bromomethyl)-4—(trifluoromethoxy)benzene provided the title compound as a white solid.
1H NMR (CD3OD, 300 MHz) 8 8.43 (s, 1H), 7.09—7.25 (m, 3H), 6.95—6.98 (d, J= 8.1 Hz,
1H), .04 (d, J: 7.32 Hz, 1H), 5.00—5.03 (d, J: 7.41 Hz, 1H), .37 (t, J: 3.33
Hz, 1H),4.05—4.15(m,2H),3.38—3.53 (q, J: 15 Hz, 2H), 2.99 (s, 1H); LC/MS [M + H] =
6020.
Example 24
Synthesis of 2—(((2R, 3S, 4R, 5R)—5-(6-amino-2—chloro—9H—purin—9-yl)—3 —ethynyl-3 ,4-
dihydroxytetrahydrofuranyl)methoxy)(thiophen-3 -ylmethyl)malonic acid
Example 24
Proceeding as described in Example 1 above but tuting benzyl bromide with 3—
(bromomethyl)thiophene provided the title compound as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.39 (s, 1H), 7.09—7.17 (m, 2H), 6.98—7.00 (d, J: 5.04.0 Hz,
1H), 6.01—6.04 (d, J= 7.47 Hz, 1H), 5.00—5.02 (d, J= 7.29 Hz, 1H), 4.32—4.34 (t, J= 2.76
Hz, 1H), 4.01—4.11 (m, 2H), 3.41—3.54 (q, J: 15 Hz, J: 9.03 Hz, 2H), 2.98 (s, 1H), LC/MS
[M + H] = 524.0.
-l26-
Example 25
Synthesis of 2-(((2R, 3S, 4R, 5R)(6-aminochloro-9H—purinyl)-3 -ethynyl-3 ,4-
dihydroxytetrahydrofuranyl)methoxy)—2-(propynyl)malonic acid
0 NH2
0 OH 0001,,N
Ho” :
Ho“ OOH
Example 25
ding as described in Example 1 above but substituting benzyl bromide with
propargyl bromide provided the title nd as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.96 (s, 1H), 6.07—6.09 (d, J= 7.53 Hz, 1H), 5.01—5.04 (d, J
= 7.53 Hz, 1H), 4.29—4.30 (m, 1H), 3.92—4.05 (m, 2H), 3.01—3.15 (m, 2H), 2.99 (s, 1H),
2.28—2.30 (t, J: 2.58 Hz, 1H); LC/MS [M + H] = 467.
Example 26
Synthesis of 2—(((2R, SS, 4R, (6-amino-2—chloro-9H—purinyl)-3 -ethynyl-3 ,4-
dihydroxytetrahydrofurany1)methoxy)malonic acid
0 o NH2 0 NH2
0M0E1 N 0 CE N - 0 OH N
</ :‘N FFADCM ML “323%” M
BO 0: N 41*“ N
o NAG —> E10 0: N NAc1—’ HO «fN
o 0: o
Aco bAc Acd bAc H5 bH
Example 26
Step 1:
A solution of diethyl 2-(((2R,3R,4R,5R)-3,4-diacetoxy(6-MN’ -(bis-(tert-butoxy-
carbonyl)amino)—2-chloro-9H—purinyl)ethynyltetrahydrofuran-Z-yl)methoxy)malonate
(200 mg, 0.26 mmol) in CH2C12 (1 mL) under argon here at 0 0C was added TFA (0.5
mL). The mixture was d for 5 minutes and allowed to warm up and stirred for l h.
Additional amount of TFA (0.4 mL) was added to the reaction mixture and it was stirred
further 1.5 h before it was concentrated. The residue was azeotroped with DCM (5 x 5 mL)
under reduced pressure to provide crude diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-
amino-Z-chloro-9H-purinyl)ethynyltetrahydro-furany1)methoxy)malonate which was
used in the next step without further purification.
Step 2:
To a solution of crude l 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-aminochloro-
in—9-yl)—3-ethynyltetrahydrofuran—2-yl)methoxy)malonate (026 mmol) from the
previous step in a mixture ofMeOH (8.5 mL) and water (1.5 mL) was added powdered
lithium hydroxide monohydrate (86 mg, 2.08 mmol). The resulting mixture was stirred for
16 h before the organic volatile was removed under reduced pressure. The residue was
diluted with additional water (11 mL) and ted with EtOAc (12 mL). The organic layer
was discarded. The aqueous phase was acidified to pH ~2.5 with 1N aq. HCl on and
extracted with EtOAc (3 x 12 mL). The combined organic layer was dried (NazSO4), filtered
and concentrated to provide the title compound (45.5 mg) as a light brown solid.
1H NMR (CD3OD, 300 MHz): 5 8.94 (s, 1H), 6.08 (d, J = 7.52 Hz, 1H), 5.05 (d, J = 7.52 Hz,
1H), 4.65 (s, 1H), 4.29 (t, J = 2.40 Hz, 1H), 4.06 (dd, J = 10.7, 2.5 Hz, 1H), 3.93 (dd, J =
.64, 2.50 Hz, 1H), 3.12 (s, 1H); LC/MS [M + H] = 428.
Synthesis of 2-(((2R, 3S, 4R, 5R)((1H-pyrazolyl)ethynyl)(6-aminochloro-9H-purin-
9-yl)-3 ,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
0 N(BOC)2 O N(BOC)2
OM03 IfiNH Woa
o /
o «811:1
N ED
—. 0
o (NIL/:1
: X 7’ Cl CI
3)ZCI2,Cu| /
.- ., TEA,THF / : . .
\ .
Aco ’OAc HN‘N Aco‘ ’OAc
O NH2 0 NH2
0 0E1 O OH
TFA DCM
, W (NfiNk
aq. L'OH THF QI , —, BO 0 N 0
O N/ HO «NnN
CI O N/ CI
/ /
_ _
’ — s
HN '9 ’ — s
HN '9
‘N AGO OAC ‘N HO OH
Example 27
Step 1:
To a mixture of 3-iodo- lH-pyrazole (407 mg, 2.1 mmol), PdC12(PPh3)2 (82 mg, 0.12
mmol), CuI (22 mg, 0.12 mmol), and Et3N (10 mL) in THF (10 mL) under argon atmosphere
was added diethyl 2-(((2R, 3R, 4R, 5R)—3,4-diacetoxy(6-N,N’ -(bis-(z‘erl—butoxycarbonyl)—
amino)chloro-9H-purinyl)ethynyltetrahydrofuranyl)methoxy)malonate (l g, 1.2
mmol). The resulting mixture was stirred at 60 0C overnight before it was allowed to cool to
-l28-
room temperature and the organic volatile was removed under reduced pressure. The
resulting crude residue was purified by flash silica gel column chromatography (60—100%
EtOAc in hexanes) to provide diethyl 2-(((2R,3R,4R,5R)—3-((lH—pyrazolyl)ethynyl)—3,4-
diacetoxy-S—(6-N,N’ -(bis-(terZ-butoxycarbonyl)amino)chloro-9H-purin—9-yl)tetrahydro—
furanyl)methoxy)malonate as a solid.
Step 2:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)—3-(( lH—pyrazol-3 -yl)ethynyl)-3,4-
diacetoxy-S—(6-N,N’—(bis-(terl—butoxycarbonyl)amino)chloro-9H—purin—9—yl)tetrahydro—
furanyl)methoxy)malonate (100 mg, 0.12 mmol) in a DCM (3 mL) was added TFA (1
mL). The resulting e was stirred at 25 °C for 4 h before it was concentrated to e
crude diethyl 2-(((2R, 3R, 4R, 5R)-3 -(( 1H-pyrazolyl)ethynyl)-3 ,4—diacetoxy(6—amino
chloro-9H—purinyl)tetrahydrofuranyl)methoxy)malonate which was used in the next
step without further purification.
Step 3:
To a solution of crude diethyl 2-(((2R, 3R, 4R, 5R)((lH—pyrazol-3—yl)ethynyl)-3,4-
oxy-S-(6-aminochloro-9H—purinyl)tetrahydrofuranyl)methoxy)malonate in a
e of THF (5 mL) and H20 (2 mL) was added LiOH'H2O (50 mg, 1.2 mmol). The
resulting e was stirred at 25 °C for 24 h before it was cooled to O 0C and acidified to
pH 6.5 with 1N aq. HCl. The reaction mixture was concentrated. The crude residue was
purified by preparative reversed-phase HPLC and dried by lyophilization to e the title
compound as a white solid.
1H NMR (CD3OD, 300 MHZ) 5 8.96 (s, 1H), 7.56-7.76 (m, 1H), 6.50-6.57 (m, 1H), 6.12—
6.14 (d, J: 7.14 Hz, 1H),5.13—5.15(d,./= 6.78 Hz, 1H), 4.63-4.70 (m, 1H), 4.38 (s, 1H),
399-4. 13 (m, 2H); LC/MS [M + H] = 495.
Examples 28 & 29
Synthesis of 2-(((2R, 3S, 4R, (6-aminochloro-9H—purinyl)—3-(( l -benzyl- lH-
pyrazol-3 -yl)ethynyl)-3 ,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
2-(((2R, 3S, 4R, 5R)-5—(6-amino—2-chloro-9H—pu1inyl)-3 -((1-benzyl-lH—pyrazol-5—
yl)ethynyl)-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
-l29-
o N(Boc)2 o N(Boc)2 N(Boc)z
3L?“ «“fN 052003,DMF >4“ </“ P”
$2.o N NACI BO 0 N
o o NAG + 38f?<No ’kcn
/ step1 / \
HNiN/ . : . éstepo4J TFA, DCM| .
~ a Q/ N‘N c o ,
AcO OAc N‘N A—co‘ OAc
step 2 lTFA, DCM
o NH2 0 NH2
5334:"El «“ 0 OEt N
</ :1
N IN: 50%?0 N
o o N Cl
©\/N~N/ | \ : . ,
N‘N Acd bAc
step:Taq.OACLiOH, THF step 5J0aq' LiOH, THF
0 NH2 0 NHZ
0%?“ «N ‘N
Ho 0 N «NM
o INACI IN:
©VN‘N//$2. .
31—7|
Hd '
’OH N‘N
Example 28 @ Example 29
Step 1 :
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)—3-((1H—pyrazolyl)ethynyl)-3,4-
diacetoxy-S-(6-N,N’-(bis-(terl-butoxycarbonyl)amino)chloro-9H-purinyl)tetrahydro-
2-yl)methoxy)malonate (100 mg, 0.12 mmol), in anhydrous DMF (2 mL) under argon
atmosphere at O 0C was added oven dried CszCO3 (78 mg, 024 . The mixture was
stirred at room ature for 20 minutes followed by addition of benzyl bromide (29 ul,
0.24 mmole). The resulting mixture was stired at room temperature for 2 h before it was
diluted with EtOAc (15 mL) and H20 (5 mL). The organic layer was separated, washed with
H20 (20 mL), brine, dried over NazSO4 and concentrated. The crude e was purified by
flash silica gel column chromatography (0—50% EtOAc in hexanes) to provide diethyl 2-
(((2R, 3R, 4R,5R)—3 ,4-diacetoxy-3 -((1 -benzyl- 1H-pyrazolyl)ethynyl)(6-N,N” -(bis-(lerl‘-
butoxycarbonyl)amino)—2-chloro-9H—purinyl)tetrahydrofuranyl)methoxy)-ma1onate and
l 2-(((2R, 3R, 4R, 5R)—3,4-diacetoxy-3 —((1 -benzyl- 1H-pyrazol—5 -yl)ethynyl)(6-N,N’ -
(bis-(tert—butoxycarbonyl)amino)—2-chloro-9H—purinyl)tetrahydro-furan
hoxy)malonate.
Steps 2 — 3:
Proceeding as descnbed in Example 27 above but substituting diethyl 2-
(((2R, 3R, 4R,5R)—3 -(( 1H-pyrazol-3 -yl)ethynyl)—3 ,4-diacetoxy(6-N,N’ -(bis-(lert—
-l30-
butoxycarbonyl)amino)—2-chloro-9H—purinyl)tetrahydrofuran-Z—yl)methoxy)malonate with
diethyl 2-(((2R, 3R, 4R, 5R)—3,4-diacetoxy-3 -((l l- 1H-pyrazol-3 -yl)ethynyl)(6-N,N’ -
(bi s-(tert—butoxycarbonyl)amino)—2-chloro—9H-purinyl)tetrahydrofuran-Z-yl)methoxy)—
malonate ed the title compound (Example 28) acid as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.95 (s, 1H), 7.685 (s, 1H), .38 (m, 5H), 6.50 (s, 1H),
6.10-6.13 (d, J: 7.05 Hz, 1H), 5.35 (s, 2H), 5.16—518 (d, J: 7.35 Hz, 1H), 4.68—4.76 (m,
1H), 4.38 (s, 1H), 3.96—4.16 (dd, J = 9.84 Hz, J =17 Hz, 2H), LC/MS [M + H] = 585.
Steps 4 — 5:
Proceeding as described in Example 27 above but substituting diethyl 2-
(((2R, 3R, 4R, 5R)—3 -(( 1H-pyrazol-3 -yl)ethynyl)—3 ,4-diacetoxy-5 -(6-N,N’ -(bi s-(lerZ-butoxycarbonyl
)amino)—2-chloro-9H—purinyl)tetrahydrofuran—2-yl)methoxy)malonate with
diethyl R, 3R, 4R, 5R)—3,4-diacetoxy-3 —((l -benzyl- 1H-pyrazol—5 -yl)ethynyl)-5—(6-N,N’ -
(bis-(terZ-butoxycarbonyl)amino)chloro—9H—purinyl)tetrahydrofuran-Z-yl)methoxy)—
malonate provided the title compound (Example 29) as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.88 (s, 1H), 7.53 (s, 1H), 7.23—7.35 (m, 5H), 6.59 (s, 1H),
6.10-6.13 (d, J: 6.09 Hz, 1H), 5.46 (s, 2H), 5.15—5.17 (d, J: 6.9 Hz, 1H), 43541.41 (m,
2H), 3.71—4.01 (dd, J= 10.71, J= 33, 2H); LC/MS [M + H] = 585.
Examples 30 & 31
Synthesis of yl(((2R, 3S, 4R, 5R)(5-chloro(isopropylamino)-3H—imidazo[4,5-
b]pyridinyl)ethynyl-3,4-dihydroxytetrahydrofuran-Z-yl)methoxy)malonic acid
2-benzyl—2-(((2R, 3S, 4R, 5R)-5 -(2-chloro(dimethylamino)-9H—purinyl)-3 -ethynyl-3 ,4-
dihydroxytetrahydrofuran-Z-yl)methoxy)malonic acid
-l3l-
o N 0 Cl
0 OEt <’ l 0 QB N
H N/ CI <’ 1
E10 0 EtO
O _ O N
O N/ Cl
BSA, TMSOTf Z X 7WD“ MeCN I X 7’
c -, .~ ,1
Acd bAc step 1 Acd bAc
i—PrNHz, TEA
Step 2 I
DMF, 75 °c
O \N/
O OEt N
</ Ii
+ BO 0 N
O N/ CI
—Ho“ °OH
jan'HNstep3 LiOH, THF Step4i aq. LiOH THF
—HO ”OH $740°0H
Example 30 Example 31
Step 1:
To a solution of l 2-benzy1-2—(((2R, 3R, 4,5-triacetoxy-3—ethyny1tetra-
hydrofuranyl)methoxy)malonate (500 mg, 0.91 mmol) in MeCN (6 mL) at 25 0C was
added 5,7-dichloro-1H-imidazo[4,5-b]pyridine (223 mg, 1.18 mmol) and followed by N,0-
bis(trimethy1silyl)acetamide (BSA) (535 uL, 2.19 mmol). The resulting suspension was
heated at 85 0C for 15 min as it became clear. The reaction mixture was allowed to cool to
nmmwmmmmmfiflmwdWaMMmufflMMHTQQnng8mmdflhme.Hm
mmmmmmmmumHMnmmmwaWS%flm3h%aflfimewmmgmmmdww
consumed. The reaction was ed with cold saturated aq. NaHCO3 solution and diluted
with EtOAc (15 mL). The organic layer was separated, washed with H20 (20 mL), brine,
dried over Na2SO4 and concentrated. The crude residue was purified by flash silica gel
column chromatography (O—50% EtOAc in hexanes) to provide diethyl 2-benzy1
(((2R,3R,4R,5R)—3,4-diacetoxy(5,7-dichloro-3H—imidazo[4,5-b]pyridin-3 -y1)—3-ethynyltetrahydrofuranyl
)methoxy)malonate as a foam.
Step 2:
To a sealed tube containing diethyl 2—benzyl(((2R, 3R, 4R, 5R)-3,4—diacetoxy(5,7-
ro-3H—imidazo[4,5-b]pyridinyl)ethynyltetrahydrofuranyl)methoxy)malonate
(80 mg, 0.12 mmol) in anhydrous DMF (1 mL) was added isopropyl amine (0.5 mL, 5.9
mmol) and Et3N (1 mL, 7.1 mmol). The reaction mixture was heated at 75 0C for 72 h before
it was allowed to cool and diluted with EtOAc (15 mL) and H20 (5 mL). The c layer
was separated, washed with H20 (20 mL), brine, dried over Na2SO4 and concentrated. The
residue was purified by flash silica gel column chromatography (0—50% EtOAc in hexanes)
to e l 2—benzyl—2-(((2R,3S,4R,5R)(5-chloro—7-(isopropylamino)-3H—imidazo-
[4,5-b]pyridin-3 -yl)ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonate and
diethyl 2-benzyl(((2R, 3S, 4R, 5R)—5-(5-chloro(dimethylamino)-3H—imidazo[4,5-b]—
pyridin-3 -yl)-3 -ethynyl-3 ,4-dihydroxytetrahydrofuranyl)methoxy)malonate as foam.
Step 3:
To a solution of diethyl 2-benzyl(((2R,3S,4R,5R)(5-chloro(isopropylamino)—
3H—imidazo[4,5-b]pyridinyl)—3 -ethynyl-3,4-dihydroxytetra-hydrofuranyl)methoxy)-
malonate (10 mg, 0.016 mmol) in a e of THF (3 mL) and H20 (1 mL) was added
LiOH-H2O (10 mg, 0.24 mmol). The resulting mixture was stirred at 25 °C for 24 h before it
was cooled to O 0C and acidified to pH 6.5 with 1N aq. HCl. The crude residue was purified
by preparative reversed-phase HPLC and dried by lyophilization to e 2-benzyl
(((2R, SS, 4R, 5R)(5 o—7-(isopropylamino)—3H—imidazo[4, 5-b]pyridin—3 -yl)—3 yl-
3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid as a white solid.
1H NMR (CD3OD, 300 MHz) 6 8.25 (s, 1H), 7.25—7.28 (m, 2H), 7.05 (m, 3H), 6.43 (s, 1H),
6.06—6.08 (d, J: 7.17 Hz, 1H), 4.95—4.98 (d, J: 705 Hz, 1H), 4.32 (s, 1H), 4.05—4.11 (m,
2H), 3.89—3.93 (m, 1H), 3.31—3.39 (m, 2H), 2.99 (s, 1H), 1.30—1.33 (m, 6H), LC/MS [M +
H] = 560.
Step 4:
To a solution of diethyl 2-benzyl(((2R,3,S', 4R,5R)(5-chloro-7—(dimethyl-amino)-
3H—imidazo[4,5-b]pyridin-3—yl)-3 -ethynyl-3,4-dihydroxytetrahydrofuran-2—yl)methoxy)-
malonate (21 mg, 0.035 mmol) in a mixture of THF (3 mL) and H20 (1 mL) was added
LiOH'H2O (30 mg, 0.71 mmol). The resulting mixture was stirred at 25 0C for 24 h before it
was cooled to O 0C and acidified to pH 6.5 with 1N aq. HCl. The reaction mixture was
concentrated. The crude residue was purified by preparative reversed-phase HPLC and dried
by lyophilization to provide the title compound as a white solid.
-l33-
1H NMR (CD3OD, 300 MHz) 5 8.68 (s, 1H), 7.21-7.24 (m, 2H), 6.99-7.03 (m, 3H), 6.49 (s,
1H), 6.15—6.17 (d, J: 7.08 Hz, 1H), 4.99—5.02 (d, .1: 7.17 Hz, 1H), 4.35—4.37 (t, .1: 3.12
Hz, 1H), 4.07-4.08 (m,2H), 3.36-3.50 (m, 8H), 2.99 (s, 1H); LC/MS [M + H] = 546.
Example 32
Synthesis of 2-(((2R, 3S, 4R, 5R)—5—(2-ch1oro((2-hydroxyethy1)amino)-9H-pu1iny1)
ethyny1-3 ,4-dihydroxytetrahydrofurany1)methoxy)—2—(thiophen-3 -y1methy1)ma1onic acid
0 0 O A020
0 CE 0 QB TFA 0 0E! 4_DMAp
3'(bromomethyl)thiophene DCM, 10% H20 pyridine
EtO 03:7 E10 0 —>E10 0
0 0
...0 CSgCOg
Q /
DMF,20°C \ Q3—7-0 / \ Q
.- -. )V , ., )T . .,
A06 0 8 A06 0 3 A06 OH
0' OH
0 0 HN’\/
N 0 CI
0 OEt (I /\/OH
1 A o OEt HzN 0 CE
N N \
fl N’ CI TEA,dioxane
—> <, <’ l 1
E10 0 —> /
0 BO 0 N \j:/ EtO o N
OAc BSA,TMSOTf O N 0 N C'
/ \ Q MeCN / / \ _
‘ \ _ .
S Acd l'OAc S 700$ i'OAc S Acd aOAc
0 HN/\/OH
0 0H N \
aq.LiOH,THF </ I i
—>HO 0 N
0 N’ Cl
/ \ _
3 H6 ”OH
Example32
Steps 1 — 3:
ding as described in Example 15 above but substituting allyl bromide with 3—
methy1)thiophene provided l 2-(thiopheny1methy1)(((2R, 3R, 4R)-3,4,5-
triacetoxyethynyltetrahydrofuranyl)methoxy)malonate as a solid.
Step 4:
To a solution of chloro-1H—imidazo[4,5-b]pyridine (238 mg, 1.26 mmol) in
MeCN (6 mL) at 25 °C was added N,O-bis(trimethy1si1y1)acetamide (B SA) (571 uL, 2.34
mmol). The ing suspension was heated at 85 0C for 15 min as it became clear. The
reaction mixture was allowed to cool to room temperature followed by addition of diethyl 2-
(thiophen-3 -y1methy1)(((2R, 3R, 4R)-3 ,4, 5 -triacetoxy-3 -ethyny1tetrahydrofurany1)-
methoxy)malonate (540 mg, 0.97 mmol) and TMSOTf (228 ul, 1.26 mmol) dropwise. The
reaction mixture was then d at 85 °C for 2.5 h as all of the starting material was
—134—
consumed. The reaction was quenched with cold saturated aq. NaHCO3 solution and diluted
with EtOAc (15 mL). The organic layer was separated, washed with H20 (20 mL), brine,
dried over Na2SO4 and concentrated. The crude e was purified by flash silica gel
column tography (O—50% EtOAc in hexanes) to provide diethyl 2-(((2R, 3R, 4R, 5R)-
3,4—diacetoxy(2,6-dichloro-9H—purinyl)—3-ethynyltetrahydrofuranyl)methoxy)-2—
(thiophenylmethyl)malonate as a foam.
Step 5:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy(2,6-dichloro-9H—purin
yl)ethynyltetrahydrofuranyl)methoxy)(thiophen-3—ylmethyl)malonate (100 mg,
0.146 mmol) in 1,4-dioxane (2 mL) was added TEA (20 uL, 0.146 mmol) followed by
ethanolamine (13 ul, 0.219 . The resulting mixture was stirred at 25 0C for 2 h before
it was diluted with EtOAc (15 mL) and H20 (5 mL). The organic layer was separated,
washed with H20 (20 mL), brine, dried over Na2SO4 and concentrated to provide crude
diethyl 2-(((2R, 3R, 4R, 5R)—3 ,4-diacetoxy(2-chloro((2-hydroxyethyl)amino)-9H—purin
yl)ethynyltetrahydrofuranyl)methoxy)(thiophenylmethyl)malonate which was
used in the next step without further purification.
Step 6:
To a solution of crude diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy(2-chloro—6-((2-
hydroxyethyl)amino)-9H—purinyl)ethynyltetrahydrofuranyl)methoxy)(thiophen
ylmethyl)malonate in a e of THF (4 mL) and H20 (1 mL) was added 2O (80
mg, 1.91 mmol). The resulting mixture was stirred at 25 °C for 24 h before it was cooled to 0
°C and acidified to pH 6.5 with 1N aq. HCl. The reaction mixture was concentrated. The
crude residue was purified by preparative reversed—phase HPLC and dried by lyophilization
to provide the title compound as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.32 (s, 1H), .16 (m, 2H), .99 (m, 1H), 6.00—
6.03 (d, J: 7.41 Hz, 1H), 4.99—5.02 (d, J: 7.38 Hz, 1H), 4.32—4.34 (t, J: 3.03 Hz, 1H),
400—4. 11 (m,2H), 3.65-3.79 (m, 4H), .53 (q, J= 15.42 Hz, J= 5.79 Hz, 2H), 2.98 (s,
1H); LC/MS [M + H] = 568.0.
Example 33
Synthesis of 2-(((2R, 3S, 4R, 5R)—5—(2-chloro—6-(isopropylamino)-9H-purin—9-yl)—3—ethynyl—
3 ,4-dihydroxytetrahydrofuranyl)methoxy)(thiophen-3 -ylmethyl)malonic acid
-l35-
<’ \”
HO O N
O NAG
/ \ _ S 7
8 —HO‘ ITOH
Proceeding as described in Example 32 above but substituting ethanolamine with i—
PrNH2 provided the title compound as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.28 (s, 1H), 7.08-7.16 (m, 2H), 6.97-6.99 (m, 1H), 5.99—
6.02 (d, J: 7.38 Hz, 1H), 5.00—5.02 (d, J: 735 Hz, 1H), 4.31-4.43 (m, 2H), 4.00-4.12
(m,2H), 3.40—3.53 (q, J= 15.63 Hz, J: 5.4 Hz, 2H), 2.98 (s, 1H), 1.27—1.32 (m, 6H), LC/MS
[M + H] = 566.0.
Example 34
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)(2-chloro((3-hydroxypropyl)amino)-9H—purin-
9-yl)ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
0 I o HNMOH O C
O 0E1 (NfN H2N\/\/OH
O OEt O OE'E
NAG (N N
fl I j: TEA,dioxane <’ I 1
EC 0 /
0 E10 0 N / E10 0 N
OAc BSA,TMSOTf o N 0 N
CI C'
Q MeCN _
~ ‘
AGO bAc 760“ bOAc H6 ”0H
aq. LiOH
MeOH, THF
0 HN/\/\OH
0 OH ac“N
HO 0: N
o NAG
—H(5: 30H
Step 1:
To a solution of 2,6-dichloro-9H—purine_(690 mg, 3.65 mmol) in dry CH3CN( 15 mL)
was added N,O-bis(trimethylsilyl)acetamide (0.28 mL, 112 mmol) Via syringe. The mixture
was heated to 95 °C under argon atmosphere for 5 minutes and then cooled to t. To
this mixture was added diethyl yl(((2R, 3R, 4R)-3,4,5-triacetoxy-3—ethynyltetra-
hydrofuranyl)methoxy)malonate (2 g, 3.65 mmol) and followed by TMSOTf (0.09 mL,
0.494 mmol). The resultin mixture was heated at 95 °C for 2.5 h before it was cooled to
ambient temperature and diluted with water (60 mL) and EtOAc (60 mL). The organic phase
-l36-
was washed successively with equal volumes of saturated NaHCO3 solution and brine. The
aqueous phase was further extracted with EtOAc (2 X 30 mL). The combined organic phase
was dried (MgSO4), filtered and concentrated. The crude residue was d by flash silica
gel column chromatography (5—60% EtOAc in hexane) to e diethyl 2-benzyl
(((2R, 3R, 4R, 5R)-3 cetoxy-5 -(2, 6-dichloro-9H—purinyl)tetrahydrofuran-2—yl)-
methoxy)malonate (1.61 g) as an off-white solid.
Step 2:
To a solution of diethyl 2-benzyl(((2R, 3R, 4R, 5R)-3,4-diacetoxy(2,6-dichloro-
9H—purinyl)tetrahydrofuranyl)methoxy)malonate (102 mg, 0.15 mmol) in dry dioxane
(1 mL) was added triethylamine (0.02 mL, 0.15 mmol) and 3-aminopropanol (16 mg, 0.212
mmol). The ing mixture was stirred for 1.5 h before it was diluted with water (15 mL)
and DCM (15 mL). and the organic phase was collected. The organic layer was washed with
brine (15 mL). The aqueous phase were further extracted with EtOAc (2 x 10 mL). The
combined organic layer was dried over MgSO4, filtered and concentrated to provide crude
diethyl 2-benzyl(((2R, 3R, 4R, 5R)-3 ,4-diacetoxy(2-chloro((3 -hydroxypropyl)amino)-
9H-purinyl)tetrahydrofuranyl)methoxy)malonate as a clear viscous oil.
Step 3:
To a solution of crude diethyl 2-benzyl(((2R, 3R, 4R, 5R)—3,4-diacetoxy(2-chloro-
6-((3 -hydroxypropyl)amino)-9H—purinyl)tetrahydrofuranyl)methoxy)malonate (0. 15
mmol) in H20 (0.2 mL), MeOH(1 mL) and THF (0.28 mL) was added ed LiOH
mono-hydrate (43 mg, 1.05 . The e was stirred for 4 h and then sonicated for
minutes. Additional LiOH mono—hydrate (7 mg) was added and sonication continued for
1 h before the organic volatile was removed under reduced pressure and the residue was
diluted with water (10 mL) and EtOAc (10 mL). The mixture was cooled at 0 °C and
acidified to pH ~3 with 1N aq. HCl. The organic phase was collected and the s phase
was further extracted with EtOAc (2 x 10 mL). The combined EtOAc phases were dried over
MgSO4, filtered and concentrated. The crude residue was purified by preparative reversed-
phase HPLC to e the title compound as a off-white solid.
1H NMR (CD3OD, 300 MHz) 5 8.19 (bs, 1H), 7.21—73 (m, 2H), 7.00—7.10 (m, 3H), 6.00 (d, J
= 7.36 Hz, 1H), 4.98 (d, J = 7.36 Hz, 1H), 4.33 (t, J = 3.18 Hz, 1H), 4.02—4.15 (m, 2H), 3.68
-l37-
(t, J = 6.18 Hz, 2H), 3.59—3.72 (m, 2H), 3.47 (d, J = 14.95 Hz, 1H), 3.38 (d, J =14.95 Hz,
1H), 2.99 (s, 1H), 1.84-1.95 (m, 2H); LC/MS [M + H] = 576.0.
Example 35
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)(2-chloro(((R)—2-hydroxypropyl)amino)-9H—
purinyl)ethyny1-3 ,4-dihydroxytetrahydrofuran-Z-yl)methoxy)malonic acid
Example 35
Proceeding as described in Example 34 above but substituting propanolamine with
(R)-l-aminopropanol and followed by ester hydrolysis with LiOH provided the title
compound as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.19 (bs, 1H), 7.22-7.30 (m, 2H), 7.02-7.10 (m, 3H), 6.01 (d,
J = 7.38 Hz, 1H), 4.98 (d, J = 7.38 Hz, 1H), 4.33 (t, J = 3.17 Hz, 1H), .13 (m, 3H),
.69 (m, 1H), 3.43 (qt, J = 14.64 Hz, 2H), 3.41-3.55 (m, 1H), 2.99 (s, 1H), 1.24 (d, J =
6.30 Hz, 3H); LC/MS [M + H] = 5760.
Example 36
Synthesis of 2-benzyl(((2R, 3S, 4R, (2-chloro-6—(((S)—2-hydroxypropyl)amino)—9H—
purinyl)-3—ethynyl-3 ,4-dihydroxytetrahydrofuran-Z-yl)methoxy)malonic acid
Example 36
Proceeding as described in Example 34 above but tuting propanolamine with
(SD-l—aminopropan-Z-ol and followed by ester hydrolysis with LiOH provided the title
compound as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.19 (bs, 1H), 7.23—7.29 (m, 2H), 7.03—7.10 (m, 3H), 6.00 (d,
J = 7.35 Hz, 1H), 4.96 (d, J = 7.35 Hz, 1H), 4.32 (t, J = 3.30 Hz, 1H), 3.98-4.13 (m, 3H),
.68 (m, 1H), 3.35-3.55(m, 3H), 2.99 (s, 1H), 1.25 (d, J = 6.30 Hz, 3H); LC/MS [M +
H] = 576.0.
Example 37
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)—5-(6-(bis(2-hydroxyethyl)amino)chloro-9H-
puriny1)—3-ethyny1-3 ,4-dihydroxytetrahydrofurany1)methoxy)malonic acid
0 \/\N/\/OH
0 OH N
HO O: N
0 «KC.
H6 bH
Example 37
Proceeding as bed in Example 34 above but substituting propanolamine with
diethanolamine and followed by ester hydrolysis with LiOH provided the title compound as a
white solid.
1H NMR , 300 MHz) 5 8.16 (s, 1H), 7.22-7.29 (m, 2H), 6.99-7.09 (m, 3H), 6.02 (d, J
= 7.33 Hz, 1H), 4.97 (d, J = 7.33 Hz, 1H), 4.00-4.37 (m, 2H), 4.29—4.34 (m, 2H), 4.03-4.13
(m, 3H), .91 (m, 4H), 3.46 (d, J = 14.92 Hz, 1H), 3.37 (d, J = 14.92 Hz, 1H), 2.98 (s,
1H); LC/MS [M + H] = 606.0.
Example 38
Synthesis of 2-benzy1(((2R, 3S, 4R, 5R)(2-chloro((2-methoxyethyl)amino)-9H-purin-
9-yl)—3-ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
0 HN/\/OMe
O OH N
HO 0 «11
: N
o N/ Cl
HO: ”OH
Example 38
Proceeding as described in Example 34 above but substituting propanolamine with 2-
methoxyethylamine and followed by ester hydrolysis with LiOH provided the title compound
as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.17 (bs, 1H), 7.22—7.30 (m, 2H), 7.01—7.09 (m, 3H), 6.01 (d,
J = 7.33 Hz, 1H), 4.98 (d, J = 7.33 Hz, 1H), 4.33 (t, J = 3.20 Hz, 1H),4.03-4.13 (m, 2H),
3.69-3.79 (m, 2H), 3.62 (t, J = 5.13 Hz, 2H), 3.47 (d, J = 14.89 Hz, 1H), 3.40 (s, 3H), 3.38 (d,
J = 14.89 Hz, 1H), 2.99 (s, 1H), LC/MS [M + H] = 576.0.
-l39-
Example 39
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)—5-(2-ch1oro((2-methoxyethyl)-(methy1)amino)—
9H-purinyl)—3-ethyny1-3,4-dihydroxytetrahydrofuran-Z-yl)methoxy)malonic acid
0 \N/\/OMe
0 OH /N
(N \N
HO 0:0 NA01
H6 ’OH
Example 39
Proceeding as described in e 34 above but substituting propanolamine with (2-
methoxyethyl)methylamine and followed by ester hydrolysis with LiOH provided the title
compound as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.18 (bs, 1H), 7.22—7.29 (m, 2H), 6.99-7.09 (m, 3H), 6.02 (d,
J = 721 Hz, 1H), 4.98 (d, J = 7.21 Hz, 1H), 4.32 (t, J = 3.41 Hz, 1H), 4.03—4.14 (m, 2H), 3.68
(t, J = 5.42 Hz, 2H), 3.34—3.49 (m, 7H), 3.36 (s, 3H), 2.99 (s, 1H); LC/MS [M + H] = 5900.
Example 40
Synthesis of 2-benzyl(((2R, SS, 4R, 5R)(2-chloro(((1—hydroxycyclobuty1)-
methy1)amino)-9H—purin—9-y1)—3—ethynyl—3,4-dihydroxytetrahydrofuran—Z-
hoxy)malonic acid
Example 40
Proceeding as described in Example 34 above but tuting olamine with 1-
(aminomethy1)cyclobutanol and followed by ester hydrolysis with LiOH provided the title
compound as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.18 (bs, 1H), 7.23—7.29 (m, 2H), 7.01—7.09 (m, 3H), 6.01 (d,
J = 7.36 Hz, 1H), 4.98 (d, J = 7.36 Hz, 1H), 4.32 (t, J = 3.21 Hz, 1H),4.03-4.11 (m, 2H),
3.73—3.79 (m, 2H), 3.36—3.50 (m, 2H), 2.99 (s, 1H),2.03-2.21 (m, 4H), 1.59—1.85 (m, 2H),
LC/MS [M + H] = 602.0.
Example 41
Synthesis of 2-benzyl(((2R, 3S, 4R, (2-chloro(3-hydroxyazetidiny1)-9H—purin
y1)-3 -ethyny1-3 ,4-dihydroxytetrahydrofurany1)methoxy)ma1onic acid
—140—
WO 46403
0 OH
/[EL/gN
HO <N
H6 bH
Example 41
ding as described in Example 34 above but substituting propanolamine with
azetidinol and followed by ester hydrolysis with LiOH provided the title compound as a
white solid.
1H NMR (CD3OD, 300 MHz) 5 8.29 (bs, 1H), 7.21—7.29 (m, 2H), 6.99-7.11 (m, 3H), 6.01 (d,
J = 7.33 Hz, 1H), 5.01 (d, J = 7.33 Hz, 1H), 4.57—4.82 (m, 3H), 4.33 (t, J = 3.39 Hz, 1H),
4.14—4.27 (m, 2H), 4.07 (qd, J = 4.04, 2.92 Hz, 2H), 3.30—3.50 (m, 2H), 2.98 (s, 1H), LC/MS
[M +H] = 574.0.
Example 42
Synthesis of yl(((2R, 3S, 4R, 5R)-5—(2-chloro(2-(hydroxymethyl)azetidin-l-yl)—9H—
purinyl)—3-ethynyl-3 ydroxytetrahydrofuran-Z-yl)methoxy)malonic acid
0 N
O OH N \
</ 1 N
HO 0:0 N NAG
HO“ "OH
Example 42
Proceeding as described in Example 34 above but substituting propanolamine with
azetidin-Z-ylmethanol and followed by ester hydrolysis with LiOH provided the title
compound as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.17-8.29 (m, 1H), 7.22—7.28 (m, 2H), 701—7. 12 (m, 3H),
.98—6.03 (m, 1H), 4.98 (d, J=7.30 Hz, 1H), 42741.45 (m, 3H), 4.00—4.13 (m, 3H), 3.83-
3.92 (m, 1H), 3.33—3.50 (m, 3H), 2.99 (s, 0.5H), 2.97 (s, 0.5H), 2.49—2.63 (m, 1H), .64
(m, 1H), LC/MS [M + H] = 588.0.
Example 43
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)—5-(2-chloro((1-(hydroxymethyl)-
cyclopropyl)amino)—9H—purinyl)—3-ethynyl-3,4—dihydroxytetrahydrofuran-Z-
yl)methoxy)malonic acid
—141—
Example 43
Proceeding as described in Example 34 above but substituting propanolamine with (1-
yclopropyl)methanol and followed by ester hydrolysis with LiOH provided the title
compound as a white solid.
1H NMR (CD3OD, 300 MHz) 6 8.18 (s, 1H), 7.22—7.32 (m, 2H), .11 (m, 3H), 6.01 (d,
J=7.36 Hz, 1H), 4.96 (d, J=7.36 Hz, 1H), 4.32 (t, J=3.24 Hz, 1H),4.02—4.14(m, 2H), 3.76
(bs, 2H), 3.46 (d, J=15.04 Hz, 1H), 3.38 (d, J=15.04 Hz, 1H), 2.99 (s, 1H), 0.88—1.03 (m,
4H); LC/MS [M + H] = 588.0.
Example 44
Synthesis of 2-benzyl—2-(((2R,3S,4R,5R)—5-(2-chloro—6-(((1-hydroxycyclopropyl)-
methyl)amino)-9H—purinyl)—3-ethyny1-3,4-dihydroxytetrahydrofuran-Z-
yl)methoxy)malonic acid
Example 44
ding as described in Example 34 above but substituting propanolamine with 1-
(aminomethyl)cyclopropanol and followed by ester hydrolysis with LiOH provided the title
compound as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.18 (s, 1H), 7.08—7.25 (m, 5H), 5.98—6.02 (d, J=7 Hz, 1H),
4.93—4.97 (m, 2H), 4.30 (bs, 1H), 3.98—4.10(m, 2H), 3.71 (bs, 2H), 3.39—3.51 (m, 2H), 3.00—
3.13 (s 1H), 0.71—0.80 (m, 4H); LC/MS [M + H] = 588.2.
Example 45
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)(2-chl oro((cyclobutylmethyl)amino)-9H-pu1in-
9-yl)ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
—142—
Proceeding as described in Example 34 above but substituting propanolamine with
cyclobutylmethanamine and followed by ester hydrolysis with LiOH provided the title
compound as a white solid.
1H NMR (CDsOD, 300 MHz) 5 8.19 (s, 1H), 7.24—7.27 (m, 2H), 7.05—7.07 (m, 3H), 5.98-
6.01 (d, J: 8 Hz, 1H), 4.93—4.95 (d, J: 7 Hz, 1H2), 4.31—4.33 (bs, 1H), .10 (m, 2H),
3.58 (s, 2H), 3.39—3.48 (m, 2H), 3.00 (s, 1H), 2.66—2.71 (m, 1H), 2.12—2.15 (m, 2H) 1.84—
1.97 (m, 4H); LC/MS [M + H] = 586.2.
Example 46
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)—5-(2-chloro(3-(hydroxymethyl)azetidinyl)-9H-
purin—9-yl)ethynyl—3,4-dihydroxytetrahydrofuran-Z-yl)methoxy)malonic acid
NNACI
Hcf bH
Example 46
Proceeding as described in Example 34 above but substituting propanolamine with
azetidinylmethanol and followed by ester hydrolysis with LiOH ed the title
compound as a white solid.
1H NMR , 300 MHz) 5 8.09 (s, 1H), 7.05—7.25 (m, 5H), 6.00-6.02 (d, J: 7Hz, 1H),
4.93-4.97 (m, 1H), 4.33 (bs, 1H), 3.96-4.11 (m, 2H), 3.78 (bs, 2H), 3.36—3.40 (m, 6H), 2.99
(bs, 2H); LC/MS [M + H] = 588.2.
Example 47
sis of 2-benzyl-2—(((2R, 3S, 4R, 5R)—5-(2-chloro(3-hydroxy-3 -methy1azetidinyl)-
9H-purinyl)—3 -ethynyl-3 ,4-dihydroxytetrahydrofuran-Z-yl)methoxy)malonic acid
—143—
N \
<N/ N
o: O 'N/Am
—HO‘: 'l’OH
Example 47
Proceeding as described in Example 34 above but substituting olamine with 3-
azetidinol and followed by ester hydrolysis with LiOH provided the title compound
as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.30 (s, 1H), 5 (m, 5H), .03 (d, J: 7H2, 1H),
4.98-5.01 (m, 1H), 4.33 (bs, 4H), 4.01—4.09 (m, 2H), 3.73 (bs, 1H), 3.35—3.47 (m, 2H), 2.98 (s,
1H), 1.57 (s, 3H); LC/MS [M + H] = 5882.
Example 48
Synthesis of 2-benzyl(((2R, 3S, 4R,5R)—5-(2-chloro((3 -hydroxycyclobutyl)—
(methyl)amino)—9H-purinyl)ethynyl-3,4-dihydroxytetrahydrofuran-Z-
yl)methoxy)malonic acid
Example 48
Proceeding as described in Example 34 above but substituting propanolamine with 3-
(methylamino)cyclobutanol and followed by ester hydrolysis with LiOH provided the title
compound as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.26 (s, 1H), 6.96-7.28 (m, 5H), 6.02-6.04 (d, J: 7H2, 1H),
.27 (bs, 1H), 4.98-5.02 (m, 1H), 4.33 (bs,2H), 3.95—4.15(m, 3H),3.36—3.51 (m, 4H), 2,99
(s, 1H), .69 (m, 2H), 2.22—2.25 (m, 2H); LC/MS [M + H] = 602.2.
Examples 49 & 50
Synthesis of 2—(((2R, 3S, 4R, 5R)(6-amino-2—ch1oro-9H—purinyl)-3 -ethyny1-3 ,4-
dihydroxytetrahydrofuran-Z-yl)methoxy)-3 -ethoxyoxo-2—(3-(trifluoromethy1)-
benzyl)propanoic acid
—144—
2-(((2R, 3S, 4R, 5R)-5 -(6-aminochloro—9H—purinyl)-3 -ethynyl-3 ,4-
dihydroxytetrahydrofuran-Z—yl)methoxy)—2-(3-(trifluoromethyl)benzyl)malonic acid
TFA, DCM
EtO o
S 7 Cszcog, DMF
Acd bAc
O NH2 0 2 O 2
0 0E1 0 DE N 0 OH N
(IN \N aq.LiOH,THF
I </ l ‘1 </ l
—> +
EtO o: N N/ HO O N N :1": HO O
o o N/ o N/
Cl on CI
_Aco“' ”om Ho‘ ’OH Hcs ”OH
CF3 CF3 CF3
e 49 Example 50
Proceeding as described in e 8 above but substituting furan with fluoromethyl
)benzene provided the title compounds both as white solid by preparative reversed-
phase HPLC purification.
2-(((2R, 3S, 4R, 5R)—5-(6-aminochloro-9H—purinyl)-3 -ethynyl-3 ,4-dihydroxytetrahydrofuranyl
)methoxy)—3-ethoxyoxo(3 uoromethyl)—benzyl)propanoic acid: 1H NMR
(CD3OD, 300 MHz) 5 8.33 (bs, 1H), 7.51—7.54 (d, J=8 Hz, 2H), 7.38-7.40 (d, J=6 Hz, 1H),
7.21—7.26 (t, J=7 Hz, 1H), 6.00—6.04 (m, 1H), .02 (dt, J=4.7, 52 Hz, 1H), 4.36 (bs,
1H), 4.02—4.22 (m, 4H), 3.45—3.58 (m, 2H), 3.02—3.12 (d, J=29 Hz, 1H), 1.18—1.24 (m, 3H),
LC/MS [M + H] = 614.2.
2-(((2R, 3S, 4R, 5R)—5-(6-aminochloro-9H—purinyl)-3 —ethynyl-3 ,4-dihydroxytetrahydro-
furanyl)methoxy)(3-(trifluoromethyl)benzyl)malonic acid: 1H NMR (CD3OD, 300
MHz) 5 8.30 (s, 1H) 7.52—7.54 (d, J=9 Hz, 2H), 7.37—7.39 (d, J = 7 Hz, 1H), 7.23—7.25
, (t,
J=7 Hz, 1H), 6.01-6.03 (d, J=7 Hz, 1H), 4.97—5.00 (d, J=7 Hz, 1H), 4.37 (bs, 1H), 4.12—4.14
(m, 2H), 3.44—3.57 (m, 2H), 3.01 (s, 1H), LC/MS [M + H] = 586.2.
Example 51
Synthesis of 2—(((2R, 3S, 4R, 5R)(6-amino-2—chloro-9H—purinyl)—3 -ethynyl-3 ,4-
dihydroxytetrahydrofuran-Z-yl)methoxy)(3-chlorobenzyl)malonic acid
—145—
O NH2
0 OH N
HO O: N
O N/ CI
—H(§ "’OH
Example 51
ding as described in Example 8 above but substituting furan with 3-chloro-
benzene ed the title compound as a white solid by ative reversed-phase HPLC
purification.
1H NMR (CD3OD, 300 MHz) 8 8.42 (s, 1H), 7.27 (bs, 1H), 7.14-7.15 (d, J: 6 Hz, 1H),
7.02—7.06 (m, 2H), .05 (d, J: 8 Hz, 1H), 5.03—5.06 (d, J: 7 Hz, 1H), 4.35—4.39 (m,
2H), 3.39—3.49 (m, 2H), 3.01 (s, 1H), 2.48—2.54 (t, J = 8 Hz, 1H) 2.22—2.32 (m, 1H); LC/MS
[M +H] = 552.1.
Example 52
Synthesis of R, 3S, 4R, 5R)—5-(6-amino-2—chloro—9H—purin—9-yl)—3 —ethynyl-3 ,4-
dihydroxytetrahydrofuranyl)methoxy)—2-(3 -methoxybenzyl)malonic acid
0 NH2
0 OH N \
<’ l N
HO 0:0 N NAG
H6 ’OH
Example 52
Proceeding as described in Example 8 above but substituting furan with 3-methoxy-
benzene provided the title compound as a white solid by preparative reversed-phase HPLC
purification.
1H NMR (CD3OD, 300 MHz) 6 8.40 (s, 1H), 6.96-7.02 (t, J : 8 Hz, 1H), 6.82 (bs, 2H), 6.59-
6.62 (m, 1H), 6.02-6.04 (d, J: 7 Hz, 1H), 5.01—5.04 (d, J: 8 Hz, 1H), 4.35—4.39 (m, 2H),
3.54 (s, 3H), 3.45—3.50 (m, 1H), 2.97 (s, 1H), 2.48-2.54 (t, J : 8 Hz, 1H) 2.22-2.32 (m, 1H),
LC/MS [M + H] = 548.1.
Example 53
Synthesis of 2-([1, 1'-biphenyl]ylmethyl)—2-(((2R,3S,4R,5R)(6-aminochloro-9H—
purinyl)-3—ethynyl—3 ,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
Example 53
Proceeding as described in Example 8 above but substituting furan with 3-biphenyl
provided the title compound as a white solid by preparative reversed-phase HPLC
ation.
1H NMR (CD3OD, 300 MHz) 8 8.23 (s, 1H), .43 (m, 9H), 5.99—6.02 (d, J: 7 Hz, 1H),
4.96—4.98 (d, J: 7 Hz, 1H), 4.35 (s, 1H), .15 (m, 2H), 3.41—3.57 (m, 2H), 3.04 (s,
1H): LC/MS [M + H] = 594.2.
Example 54
Synthesis of 2-(((2R, SS, 4R, 5R)(6—aminochloro-9H—purinyl)-3 -ethynyl-3 ,4-
dihydroxytetrahydrofuran-Z—yl)methoxy)-2—((2'—carboxy-[1,l'-biphenyl]-4—yl)methyl)malonic
Example 54
Proceeding as described in Example 8 above but substituting furan with 3- methyl
[1,1’-biphenyl]carboxylate provided the title compound as a White solid by preparative
reversed-phase HPLC purification.
1H NMR (CD3OD, 300 MHz) 6 8.27 (s, 1H), 7.71-7.73 (d, J: 7 Hz, 1H), 7.29-7.48 (m, 4H),
7.14-7.16 (d, J: 8 Hz, 1H), 7.08—7.10(d,J= 8 Hz, 2H), 5.99-6.01 (d, J: 8 Hz, 1H), 4.88—
4.91 (m, 1H), 4.30 (bs, 1H), 4.03—4.12 (m, 2H), 3.39-3.57 (m, 2H), 2.99 (s, 1H); LC/MS [M
+ H] = 63 8.2.
Example 55
Synthesis of 2-(((2R, 3S, 4R, 5R)(6—aminochloro—9H-purinyl)ethyl-3,4-
dihydroxytetrahydrofuran-Z-y1)methoxy)malonic acid
—147—
O N(Boc)2 0 N(Boc)z
oWOEt O QB N
Pd/C, H2, EtOAc Q </ f): TFA, DCM
EC (NfN
0: N NA —> EtO O N
0 CI : O N
, c|
Acd i’OAc A06 bAc
o NH2 0 NH2
0>2—CE (NIKKI 0 0H N
aq.NaOH,THF Q (/ l
ED 0: N NACI —> HO 0: N :NK
o o N/ Cl
Aw“ 'OAc Ho‘ ’OH
Example 55
Ddiethyl 2-(((2R, 3R, 4S, 5R)—5—(N6,N6-bis-Bocchloro-9H—pu1in-9—y1)—3 -((lert—
butoxycarbonyl)oxy)—4-fluorotetrahydrofurany1)methoxy)ma1onate (100 mg, 0.13 mmol)
was dissolved in EtOAc (2 mL). The solution was purged three times with Argon gas and
followed by careful addition of ium on carbon (20 mg, 10 wt%). The resulting slurry
was purged three times with Argon gas and then placed under H2 (1 atm in a balloon). The
reaction was held for 70 h at t temperature. The suspension was filtered through
diatomaceous earth, washed with EtOAc (3 X 2 mL). The filtrate was trated to an oil
which was then dissolved in DCM (1 mL) and ed by on of TFA (100 uL). The
resulting solution was held overnight before it was concentrated. The pale yellow oil residue
was dissolved in THF (1 mL) and cooled at 0 °C. To this reaction mixture was added 4M
NaOH (100 uL) and the reaction was allowed to warm to ambient temperature over 14 h
before it was concentrated. The crude residue was purified by preparative reversed-phase
HPLC to provide the title compound as a white solid.
1H NMR (CD3OD, 300 MHz) 6 8.90 (s, 1H), 6.09—6.11 (d, J: 7 Hz, 1H), 4.69—4.72 (d, J: 8
Hz, 1H), 4.64 (bs, 1H), 4.19 (s, 1H), 3.83 (bs, 3H), 1.88—1.95 (m, 3H), 1.06—1.11 (t, J: 7 Hz,
3H); LC/MS [M + H] = 432.2.
Example 56
Synthesis of R,3S, 4R, 5R)(6—aminoch1oro—9H—purinyl)ethy1-3,4-
dihydroxytetrahydrofuranyl)methoxy)—2-benzylmalonic acid
o N “”2
0 QB Pd/C,H2 0 CE (’N l ,l 0
tOAc N 0]
BO 0 —> EtO <N
% Etc 0 O
OAc BSA, TMSOTf
Q MeCN
_ '
Acd bAc Acd ISOAc
aq.LiOH
MeOH,THF
O NH2
0 OH N
HO O ddN
O N/ CI
H6 "0H
Example 56
Step 1:
A mixture of diethyl 2-benzyl(((2R,3R,4R)-3,4,5-triacetoxyethynyltetrahydro-
furan—2-yl)methoxy)malonate (1.0 mmol, 549 mg) and palladium on carbon (100 mg, 10
wt%) in EtOH (5 mL) and EtOAc (5 mL) under an atmosphere of H2 was stirred for 24 h
before it was filtered through diatomaceous earth, rinsed with EtOAc (3 X 5 mL). The filtrate
was concentrated and purified via flash silica gel column chromatography to provide diethyl
2-benzyl(((2R, 3R, 4R)-3 ,4, 5 -triacetoxy-3 -ethyltetrahydrofuranyl)methoxy)malonate.
Steps 2 — 3:
Proceeding as described in Example 7 above but substituting diethyl 2-(pyridin
ylmethy1)(((2R, 3R, 4R)-3 ,4, 5 -tri acetoxy-3 —ethyny1tetrahydrofuran—2-yl)methoxy)malonate
with diethyl 2-benzy1(((2R, 3R, 4R)—3 ,4, 5-triacetoxy-3 -ethy1tetrahydrofuranyl)methoxy)-
te and followed by ester ysis provided the title compound as a white solid via
preparative reversed-phase HPLC purification.
1H NMR (CD3OD, 300 MHz) 5 8.46 (s, 1H), 7.18-7.20 (m, 2H), 7.04—7.09 (m, 3H), 6.01-6.04
(d, J 2 8 Hz, 1H), 4.63—4.66 (d, J: 8 Hz, 1H), 4.21 (bs, 1H), 3.76—3.96 (m, 2H), 3.39—3.52
(m, 2H), 1.76-1.83 (m, 2H), 0.98-1.03 (t, J: 7 Hz, 3H), LC/MS [M + H] = 522.2
Example 57
sis of R, 3S, 4R, 5R)—5-(6-amino-2—chloro—9H—purinyl)-3,4-dihydroxy
vinyltetrahydrofuran-Z-yl)methoxy)benzylmalonic acid
—149—
o \
0 QB Lindlar catalyst H2 0 (N l i O
EtOH EtOAc N
EtO o '—> (N
0 BO
0 [N10
Ajwom BSA. TMSOTf
\ MeCN
~ .
Acd bAc
aq. LiOH
MeOH THF
Ho HNl/Nki<’
Ho‘ ’OH
Example 57
Step 1:
A mixture of diethyl 2-benzyl(((2R,3R,4R)-3,4,5-triacetoxyethynyltetra-
hydrofuran-Z—yl)methoxy)malonate (525 mg, 0.96 mmol) and Lindlar catalyst , 5
wt%) in EtOH (5 mL) and EtOAc (5 mL) under an atmosphere of Hz was stirred for 24 h
before it was d through diatomaceous earth, rinsed with EtOAc (3 X 5 mL). The filtrate
was concentrated and d via flash silica gel column tography to e diethyl
2-benzyl(((2R, 3R, 4R)-3 ,4, 5 -triacetoxy-3 -viny1tetrahydrofuran-Z-yl)methoxy)malonate.
Steps 2 — 3:
Proceeding as described in Example 7 above but substituting diethyl 2-(pyridin
ylmethyl)—2-(((2R, 3R, 4R)-3 ,4, 5 -tri acetoxy-3 -ethynyltetrahydrofuran-Z-yl)methoxy)malonate
with diethyl 2-benzyl(((2R, 3R, 4R)—3,4,5—triacetoxyvinyltetrahydrofuranyl)methoxy)-
malonate and followed by ester hydrolysis provided the title compound as a white solid via
preparative reversed—phase HPLC purification.
1H NMR (CD3OD, 300 MHz) 5 8.44 (s, 1H), 7.21—7.22 (m, 2H), 7.06-7.11 (m, 3H), 6.14—
6.23 (m, 1H), 6.08-6.10 (d, J= 8 Hz, 1H), 5.55—5.61 (m, 1H), 5.25—5.29 (m, 1H), 4.81 (s,
1H), 4.14 (bs, 1H), 3.91—3.94 (m, 1H), 3.62-3.65 (d, J: 9 Hz, 1H), 3.50—3.55 (d, J: 15 Hz,
1H), 3.39 (s, 1H); LC/MS [M + H] = 520.1.
Example 58
Synthesis of yl(((2R, 3S, 4R, 5R)—5-(5-chloro-3H—imidazo[4,5-b]pyridin—3-yl)-3—
ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
O OE‘ (”ND 0 OH
0 OEt N \
</ \ /N
H CI l H,THF. (
EC 0 —> —> l/
$0“ / HO O N
‘0 O N 0 N
BSA,TMSOTf o N Cl C]
\ DCE _
. ,
AGO bAC R _Aco‘: L’OAc H6 ’OH
R = H, TMS Example 58
Step 1:
To a solution of an anomeric mixture of diethyl 2-benzyl-2—(((2R, 3R, 4R)-3,4,5-
triacetoxyethynyltetrahydrofuranyl)methoxy)malonate (175 mg, 0.319 mmol) in dry
dichloroethane (3.5 mL) was added 5—chloro—3H-imidazo[4,5-b]pyridine (65 mg, 0.422
mmol) and followed by addition bis(trimethylsilyl)acetamide (BSA) (0.28 mL, 1.12
mmol) via syringe. The mixture was heated at 95 °C under argon atmosphere for 1 h before it
was cooled to ambient temperature and followed by addition of TMSOTf (0.09 mL, 0.494
mmol) via syringe. The resulting mixture was heated at 95 0C for 5 h before it was allowed
to cool and diluted with water (30 mL) and extracted with EtOAc (30 mL). The organic
phase was washed successively with equal volumes of saturated NaHCO3 solution and brine.
The aqueous phases was r extracted with EtOAc (2 x 30 mL). The combined organic
phase was dried (MgSO4), filtered and concentrated. The crude residue was purification by
preparative TLC (55% EtOAc in hexanes) to provide less polar diethyl yl—2-
(((2R, 3R, 4R,5R)—3,4-diacetoxy(5-chloro—3H—imidazo[4,5-b]py1idinyl)((trimethyl—
silyl)ethynyl)tetrahydrofuranyl)methoxy)malonate (44 mg) as a viscous oil and the desired
diethyl 2-benzyl(((2R, 3R, 4R, 5R)—3 ,4-diacetoxy(5-chloro-3H—imidazo[4, 5-b]pyridin—3 -
yl)ethynyltetrahydrofuranyl)methoxy)malonate (22 mg) as a viscous oil.
Step 2:
To a solution of l yl(((2R, 3R, 4R, 4-diacetoxy(5-chloro-3H-
imidazo[4,5—b]pyridinyl)ethynyltetrahydrofuranyl)methoxy)malonate (22 mg, 0.034
mmol) in THF (0.6 mL) was added a solution of 1N aq. LiOH (0.24 mL). Additional 1N aq.
LiOH (0.58 mL) was applied over a period of 2 days with a combination of periodically
sonication and stirring. The reaction mixture was concentrated and diluted with water (10
mL) and EtOAc (10 mL), The reaction mixture was cooled at 0 °C and acidified to pH ~3
with 1N aq. HCl. The layers were separated and the aq. layer was r extracted with
EtOAc (2 x 10 mL). The combined organic layer was dried over MgSO4, filtered and
trated. The crude residue was purified by ative reversed-phase HPLC to
provide the title compound as a off-white solid.
1H NMR (CD3OD, 300 MHz): 5 8.63 (bs, 1H), 8.01 (d, J: 8.14 Hz, 1H), 7.34 (d, J: 8.14
Hz, 1H), 7.29-7.23 (m, 2H), 7.07—6.99 (m, 3H), 6.21 (d, J= 7.33 Hz, 1H), 5.04 (d, J= 7.33
Hz, 1H), 4.34 (t, J: 3.02 Hz, 1H), 4.14—4.03 (m, 2H), 3.48 (d, J: 12.53 Hz, 1H), 3.37 (d, J:
12.53 Hz, 1H), 2.99 (s, 1H); LC/MS [M + H] = 5020.
Example 59
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)—5-(6-(benzylamino)—2-chloro-9H—purinyl)—3-
ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
“380%.“;OK MOMCI “fig—7,? TBAF THF
MOMO MOMO cozAll )J‘cozEt
RhZOAc4
ijz'fl A020, AcOH QCLOZB BnBr
OAC H so2 4 O
COzEt
<— .0 CS2003
cog/«u 002A" m~ 002A”*0
: : : :
é I"O)(‘—
AcO OAc
MOMO MOMO
(IN ‘N
| BnNH2
N N/ COzEt DIPEA COZEl
H dioxane NI—
BSA,TMSOTf 002A" ”A 002A" (Dy—N
MeCN - -
AcO OAc AcO OAc NY\N
aq LiOH
COZH Np THF
Step 1:
A suspension of sodium hydride (60%, mineral dispersion; 1.91 g, 47.7 mmoL) in
anhydrous THF (150 mL) was cooled to 0 OC and treated with a second solution of
(3aR, 5R, 6R, 6aR)(((lerl—butyldimethylsilyl)oxy)methyl)—6-ethynyl-2,2-dimethyltetrahydro-
furo[2,3-d][l,3]dioxolol (10g, 30.4mmoL) in THF (50 mL) over 15 s. After stirring
mins at 0 °C, the mixture was warmed to room temperature and stirred for an additional
1.5 h. The mixture was then cooled back to 0 OC and treated with MOMCl (6.81mL, 80.7
mmoL, 2.6 eq) was added dropwise. Once the addition was complete, the cooling bath was
removed and stirring was continued for 2 h at room temperature. The on was quenched
by the slow addition of saturated aqueous ammonium chloride (50 mL), washed with water
and extracted with ethyl acetate (100 mL). The organic phase was dried over sodium sulfate,
filtered, and concentrated. The crude product was purified via silica gel chromatography
(30% ethyl acetate in s) to afford utyl-(((3aR, 5R, 6R, 6aR)ethynyl(methoxy-
methoxy)—2,2-dimethyltetrahydrofuro[2,3 3]dioxol-5—yl)methoxy)dimethylsilane (9.95
g, 88% yield) as a white solid.
Step 2:
A solution of the above alcohol (9.8g, 26.3mmoL) in anhydrous THF (100mL) was
cooled to 0 OC and treated with 1N solution of tetrabutylammonium fluoride in THF (3 7mL,
36.8mmoL, 1.4 eq) over 15 minutes. After the addition is complete, the reaction was warmed
to room temperature and stirred for 3h. When the reaction was te (3h), the les
were concentrated ing a viscous residual oil which was dissolved in dichloromethane
(5mL), loaded directly onto a silica gel column (~300cc) and d via silica gel
chromatography, eluting with hexanes to 50% Ethyl acetate in hexanes to afford
((3aR, 5R, 6R, 6aR)ethynyl(methoxymethoxy)-2,2-dimethyltetrahydrofuro[2,3 -d][1,3]-
dioxolyl)methanol (6.18g, 91% yield) as a white solid.
Step 3:
A solution of the above alcohol (175 mg, 0.678 mmoL) in anhydrous benzene (8 mL)
and l 3-(propenyl) 2-diazomalonate (188 mg, 0.949 mmoL) was treated with
rhodium(II) acetate (5.8 mg, 0.013 mmoL, 0.02 eq) and warmed to 60-65 0C for 2 h. Once
complete, the solution is concentrated, dissolved in dichloromethane (1.5 mL) and loaded
directly onto a silica gel column (~100cc) and purified via silica gel chromatography, eluting
with (0-50% ethyl acetate in hexanes) to afford 1-ethyl 3-propenyl 2-
(((3Q‘R, 5R, 6R, 6aR)—6-ethynyl(methoxymethoxy)-2,2-dimethyltetrahydrofuro[2,3 -d] [1 ,3]-
yl)methoxy)malonate (252 mg, 87%) (mixture of isomers) as a pale-yellow oil.
Step 4:
While under nitrogen, a solution of malonate from the previous step (250 mg, 0.583
mmol) and benzyl e (0.42 mL, 3.5 mmol, 6 eq) in anhydrous DMF (8 mL) was treated
with and cesium carbonate (760 mg, 2.33 mmol) and stirred at room temperature for 4 h.
Once complete, the reaction was filtered through a celite pad, washed with water and
-l53-
extracted with ethyl acetate. The ed organic layers were dried over sodium sulfate,
filtered, and concentrated. The residual oil was dissolved in dichloromethane (2 mL), loaded
onto a silica gel column (~100cc) eluting with 30% ethyl acetate in hexanes to afford l-ethyl
3 -propen—1-yl 2-benzyl(((3aR, 5R, 6R, 6aR)ethynyl—6-(methoxymethoxy)-2,2-
dimethyltetrahydrofuro[2,3-a’][1,3]dioxolyl)methoxy)malonate (261 mg, 86%) (mixture of
isomers) as a pale yellow oil.
Step 5:
While under nitrogen, a water cooled (14-17 °C) solution of the acetonide from the
last step (500 mg, 0.964 mmoL) in acetic acid (3.9 mL) was treated with acetic anhydride
(0.965 mL, 10.3 mmoL, 10.7 eq) and trated sulfuric acid (410 uL, 0.326mmoL, 0.34
eq). The resulting solution was stirred for 4 h, diluted with water and extracted with ethyl
acetate. The combined organic solution washed with sodium bicarbonate (aqueous,
saturated; 100 mL), dried (Na2S04), filtered, and concentrated in vacuo. The al oil was
dissolved in dichloromethane (2 mL), and purified on a Biotage flash chromatography
system, eluted with hexanes to 50% ethyl acetate in hexanes. A diastereomeric mixture of 1-
ethyl 3 -propenyl 2-benzyl(((2R, 3R, 4R)-3 ,4, 5 -triacetoxy-3 yltetrahydrofuran
yl)methoxy)-malonate (420 mg, 8%) able s via silica gel chromatography, 40G
silica gel ) was isolated as a clear oil.
Step 6:
A suspension of 2,6—dichloroadenine (143 mg, 0.76 mmol, 1.01 eq) and MO-
bis(trimethy1silyl)acetamide (0.24 mL, 0.97 mmol, 1.29 eq) in anhydrous acetonitrile (5 mL)
was treated with a second solution of l-ethyl 3-((E)—prop-1—enyl) 2-benzyl(((2R, 3R, 4R)-
3,4,5-triacetoxyethynyltetrahydrofuranyl)-methoxy)malonate (143 mg, 0.75 mmol) in
ous acetonitrile (15 mL), followed by dropwise addition of trimethylsilyl
trifluoromethanesulfonate (0.18 mL, 1.0 mmol, 1.33 eq). After the addition was complete,
the reaction was warmed to 50 °C for 18h, then cooled to room temperature; (Reaction
begins a pale-yellow color and after 4h turns to a transparent amber). Once complete,
saturated aqueous sodium bicarbonate was added, and the mixture was stirred for 10 minutes.
The crude product was then extracted with ethyl acetate (3x3 0mL) and the combined organic
layer is dried (Na2SO4), filtered, and concentrated. The residue was dissolved in
romethane and purified on a Biotage flash chromatography , eluted with hexanes
to 50% ethyl acetate in hexanes to give l-ethyl 3-propenyl yl(((2R, 3R, 4R,5R)-
—154—
3,4-diacetoxy—5-(2,6—dichloro—9H-purinyl)—3-ethynyltetrahydrofuran-Z—
hoxy)malonate (as a mixture of isomers) as a white solid (400 mg, 77% yield).
Step 7:
A solution of l-ethyl 3-prop-l-en-l—yl 2-benzyl(((2R, 3R, 4R, 5R)—3,4-diacetoxy
(2,6-dichloro-9H—purinyl)—3-ethynyltetrahydrofuran-Z-yl)methoxy)-malonate (80 mg,
0.116 mmoL) in anhydrous dioxane (2 mL) was cooled to 0 0C was treated with DIPEA (30
uL, 0.174 mmoL, 1.5 eq) and benzylamine (13 uL, 0.116 mmoL, 1 eq). Once the addition
was complete, the solution was warmed to room temperature with continued stirring
overnight (18H). The mixture was diluted with ethyl acetate (50 mL) and washed with water
(20mL). The organic layer was dried (Na2SO4), filtered, and concentrated. The crude
product was purified via Biotage flash chromatography, g with 50% ethyl acetate in
hexanes to give l-ethyl 3-propen-l-yl 2-benzyl—2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6—
(benzylamino)chloro-9H—purinyl)—3-ethynyltetrahydrofuranyl)methoxy)malonate (as
a mixture ofisomers, ~l : 1) as a white solid (75mg, 85% yield).
Step 8:
A solution of l enyl yl(((2R, 3R, 4R, 5R)-3,4-diacetoxy—5-
(6-(benzylamino)chloro-9H—purinyl)-3 -ethynyltetrahydrofuran-Z-yl)methoxy)malonate
from the last step (70 mg, 0.092 mmoL) in THF (1 mL) was treated with a LiOH solution (31
mg, 1.35 mmoL, 15 eq; in 1 mL water) and stirred ght. The resulting solution was
ed with 2N HCl to pH 3 and the resulting suspension was stirred for 10 min., then
filtered, washed with cold water and dried. The title compound was isolated as a white solid
(50 mg, 89% yield).
1H NMR (400 MHz, CDCl3/CD3OD = 5:1) 6 7.98 (s. 1H), 7.25-6.84 (m, 10H), 5.85 (d, J =
6.4 Hz, 1H), 4.63 (s, 2H), 4.54 (d, J = 6.4 Hz, 1H), 4.17 (t, J = 3.2 Hz, 1H), 3.88 (qd, J = 10.3,
3.3 Hz, 2H), 3.36-3.16 (m, 2H), 2.49 (s, 1H). HPLC: 9.97 min, 97.0%. ESI-MS (m/Z): [M]+
calcd for ClN508, 608.15, found 608.1.
Example 60
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)(2-chloro((tetrahydro-ZH-pyranyl)amino)-
9H-purinyl)—3 -ethynyl-3 ,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
Example 60
The title compound was prepared in a manner ous to that set forth in Example
59, except tetrahydro-2H—pyranamine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CDCl3/CD3OD = 5:1) 6 8.09 (s, 1H), 7.18-7.12 (m, 2H), 7.01 (dd, J =
12.1, 7.2 Hz, 3H), 5.90 (d, J = 6.3 Hz, 1H), 4.57 (d, J = 6.3 Hz, 1H), 4.25 (t, J = 3.1 Hz, 2H),
4.00-3.89 (m, 4H), 3.51 (td, J = 11.6, 2.2 Hz, 2H), 3.42-3.330 (m, 2H), 2.52 (s, 1H), 1.94 (d, J
= 13.0 Hz, 2H), 1.57 (td, J = 11.2, 3.5 Hz, 2H). ESI—MS (m/z): [M]+ calcd for C27H28C1N509,
602.16, found 602.5.
Example 61
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)(2-chloro((2-(diethylamino)ethyl)—amino)—9H—
purinyl)ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)—malonic acid
Ph COZH _N
\+ H
o N’— N\/\N/\
HOZC 0y \N
/ / i '_ N\
HO 6H :8
Example 61
The title compound was prepared in a manner ous to that set forth in Example
59, except N1,Nl -diethylethane-1,2-diamine was used in place of benzylamine in step 7.
1HNMR (400 MHz, DMSO-66): 9.01 (s, 1H), 8.75 (s, 1H), 8.49 (s, 1H), 7.23—7.03 (m, 5H),
6.16 (s, 1H), 5.96 (d, J = 7.0 Hz, 1H), 5.84 (d, J = 6.9 Hz, 1H), 4.59 (t, J = 7.1 Hz, 1H), 4.13
(dd, J = 6.7, 2.7 Hz, 1H), .55 (m, 4H), 3.53 (s, 1H), 330—3. 15 (m, 6H), 3.06-2.97 (m,
2H), 126-1. 12 (m, 6H). ESI-MS (m/z): [M]+ calcd for C28H33C1N608, 617.20, found 6175.
Example 62
sis of 2-benzyl(((2R, 35, 4R,5R)—5-(2-chloro-6—(((R)-l—phenylethyl)amino)-9H—
purinyl)—3-ethynyl-3 ,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
1 L N\ N
/H6 6H \gl
Example 62
The title compound was prepared in a manner analogous to that set forth in e
59, except (R)-l-phenylethan-l-amine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CDCl3/CD3OD = 5:1) 5 8.25 (s, 1H), .27 (m, 4H), 7.23-6.94 (m,
6H), 5.91 (dd, J = 6.2, 1.7 Hz, 1H), 5.46 (d, J = 8.0 Hz, 1H), 4.58 (d, J = 6.2 Hz, 1H), 4.25 (t,
J = 2.4 Hz, 1H), 3.98-3.83 (m, 2H), 3.32 (dd, J = 6.3, 1.7 Hz, 2H), 2.48 (d, J = 1.7 Hz, 1H),
1.59 (dd, J = 6.9, 1.7 Hz, 3H). ESI—MS (m/z): [M]+ calcd for C30H28C1N508, , found
6221.
Example 63
Synthesis of 2-benzyl(((2R,3S, 4R,5R)(2-chloro(((S)phenylethyl)amino)-9H-purin-
9-yl)—3-ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
Example 63
The title compound was prepared in a manner analogous to that set forth in Example
59, except (S)—l-phenylethan-l-amine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CDCl3/CD3OD = 5: 1) 6 8.11 (s, 1H), 7.40-7.28 (m, 4H), 7.23-6.93 (m,
6H), 5.90 (d, J = 5.8 Hz, 1H), 5.45 (s, 1H), 4.52 (d, J = 5.8 Hz, 1H), 4.35—4.22 (m, 1H), 3.99
(t, J = 2.4 Hz, 2H), 3.42—3.25 (m, 2H), 2.50 (s, 1H), 1.58 (d, J = 6.9 Hz, 3H). ESI-MS (m/z):
[M]+ calcd for C30H28C1N508, 622.16; found 622.2.
Example 64
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)(2-chloro((tetrahydrofuranyl)-amino)-9H—
purinyl)ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)-malonic acid
-l57-
Ph 2 _N
\fi\ H
0 N’— N
/ : '_ N\
/Hc') (3H \8
Example 64
The title compound was prepared in a manner ous to that set forth in e
59, except tetrahydrofuran-3 -amine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CDC13/CD3OD = 5:1) 5 8.10 (s, 1H), 7.19-6.92 (m, 5H), 5.90 (d, J = 6.3
Hz, 1H), 4.72 (s, 1H), 4.58 (d, J = 6.3 Hz, 1H) 4.25 (t, J = 3.1 Hz, 1H), 3.94 (tp, J = 7.0, 4.0,
3.3 Hz, 3H), 3.70 (dt, J = 9.4, 3.6 Hz, 2H), 3.43—3.24 (m, 2H), 2.52 (s, 1H), 2.29 (dq, J = 13.2,
7.6 Hz, 1H), 1.93 (s, 1H). ESI-MS (m/z): [M]+ calcd for C26H26C1N509, 588.14, found 5883.
Example 65
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)—5-(2-chloro((S)hydroxypyrrolidinyl)-9H—
purinyl)—3-ethynyl-3 ,4-dihydroxytetrahydrofuran-Z-yl)methoxy)malonic acid
Ph COZH _N
H\ o NI— no OH
/ : L N\
116 6H Y
Example 65
The title nd was prepared in a manner analogous to that set forth in Example
59, except (S)—pyrrolidin-3 -01 was used in place of benzylamine in step 7.
1H NMR (400 MHz, CDCl3/CD3OD = 5:1) 6 8.10 (s, 1H), 7.22-6.92 (m, 5H), 5.92 (d, J =
.4 Hz, 1H), 4.55-4.48 (m, 2H), 4.29 (t, J = 3.7 Hz, 1H), 4.25-3.85 (m, 4H), 3.80-3.65 (m,
2H), 3.35—3.24 (m, 2H), 2.51 (s, 1H), 2.08—1.98 (m, 2H). ESI-MS (m/z): [M]+ calcd for
C26H26C1N509, 588.14; found 588.2.
Example 66
Synthesis of 2-benzyl(((2R, SS, 4R, 5R)(2-chloro(ethyl(methyl)amino)-9H-purinyl)—
3 yl-3 ,4-dihydroxytetrahydrofuran-Z-yl)methoxy)malonic acid
Ph COzH
—N \
\+0 0 N’— N\/
HOZC 3—7! /
/ : '_ N\
/Hc'> ()H Y
Example 66
The title compound was prepared in a manner analogous to that set forth in Example
59, except N—methylethanamine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CDC13/CD3OD = 5:1) 5 8.05 (s, 1H), 7.24—7.02 (m, 5H), 5.92 (d, J = 4.8
HZ, 1H), 4.46 (dd, J = 4.8, 1.3 HZ, 1H), 4.32 (dd, J = 4.9, 3.2 HZ, 1H), 4.05 (dd, J = 8.5, 4.0
Hz, 2H), 3.44—3.30 (m, 2H), 3.10-2.85 (m, 7H), 2.53 (s, 1H), 1.22 (t, J = 7.1 Hz, 3H). ESI-MS
(m/z): [M]+ calcd for C25H26C1N508, ; found 560.5.
Example 67
Synthesis of 2-benzyl(((2R, 3S, 4R, (2-chloro((2-fluorobenzyl)amino)-9H—purin
yl)-3 -ethynyl-3 ,4-dihydroxytetrahydrofuran-Z-yl)methoxy)ma1onic acid
Ph 2
\+ N,——N H El 1
O N
HOZC 031’ \N F
: '. N\
/H(3 6H \gl
Example 67
The title compound was prepared in a manner analogous to that set forth in Example
59, except (2-fluorophenyl)methanamine was used in place of amine in step 7.
1H NMR (400 MHZ, CDCl3/CD3OD = 5:1) 5 8.29 (s, 1H), 7.47-7.36 (In, 1H), 7.26-6.94 (m,
8H), 5.94 (d, J = 6.2 Hz, 1H), 4.82-4.76 (m, 2H), 4.60 (d, J = 6.2 Hz, 1H),4.35-4.23 (m, 1H),
3.98-3.84 (m, 2H), 3.44—3.30 (m, 2H), 2.46 (s, 1H). ESI-MS (m/z): [M]+ calcd for
C29H25ClFNsOs, 626.14, found 626.7.
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)(2-chloro((4-fluorobenzyl)amino)—9H-purin
yl)-3 -ethynyl-3 ,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
Example 68
The title nd was prepared in a manner analogous to that set forth in Example
59, except (4-fluorophenyl)methanamine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CDCl3/CD3OD = 5:1) 5 8.49 (s, 1H), 7.37 (dd, J = 8.4, 5.3 Hz, 2H),
7.24-6.89 (m, 7H), 5.97 (d, J = 6.3 Hz, 1H), 4.72 (s, 2H), 4.63 (d, J = 6.3 Hz, 1H), 47-428
(m, 1H), 4.06-3.87 (m, 2H), 3.46-3.26 (m, 2H), 2.54 (s, 1H). ESI-MS (m/z): [M]+ calcd for
C29H25ClFN508, 626.14, found 626.4.
Example 69
Synthesis of 2-benzyl—2-(((2R, 3S, 4R, 5R)—5-(2-chloro(((R)—2,3 -dihydro- 1H—inden— l -
yl)amino)-9H—purinyl)—3 -ethynyl-3 ydroxytetrahydrofuranyl)methoxy)-malonic
Ph 2 _N
H\ H
o N,— N,,,
/ .' L N\
’16 OH \(
Example69
The title compound was prepared in a manner analogous to that set forth in Example
59, except (R)-2,3-dihydro-lH-inden-l-amine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CDCl3/CD3OD = 5: 1) 5 8.30 (s, 1H), 7.29-6.97 (m, 9H), 5.95 (d, J = 6.2
Hz, 1H), 5.81 (t, J = 7.1 Hz, 1H), 4.59 (d, J = 6.3 Hz, 1H), 4.25 (d, J = 3.1 Hz, 1H), 3.94—3.73
(m, 2H), 3.40—3.31 (m, 2H), 3.07 (ddd, J = 14.0, 8.7, 4.8 Hz, 1H), 2.89 (dt, J = 158,77 Hz,
1H), .58 (m, 1H), 2.45 (s, 1H), 2.00 (dd, J = 13.6, 7.1 Hz, 1H). ESI-MS (m/z): [M]+
calcd for C31H28C1N508, 634.16; found 634.8.
Example 70
sis of 2-benzyl(((2R, 3S, 4R, 5R)(2-chloro(phenethylamino)-9H—purinyl)—3 -
ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
-l60-
Ph COZH
\+ — H
o N’— N
/ : '_ N\
/HO OH Y
Example70
The title compound was prepared in a manner ous to that set forth in Example
59, except 2-phenylethan-l-amine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CDC13/CD3OD = 5:1) 5 8.14 (s, 1H), 7.26-6.91 (m, 10H), 5.91 (d, J =
6.2 Hz, 1H), 4.57 (d, J = 6.2 HZ, 1H), 4.27 (t, J = 3.2 HZ, 1H), 3.96 (t, J = 4.0 HZ, 2H), 3.78
(m, 2H), 3.45—3.29 (m, 2H), 2.93 (t, J = 7.3 Hz,2H), 2.52 (s, 1H). ESI-MS (m/Z): [M]+ calcd
for C30H28C1N508, 622.16; found 622.5.
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)—5-(2-chloro(methylamino)-9H—purinyl)
ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
Ph 2 _N H
O NI— N\
/ .' L N\
/H6 6H Y
Example 71
The title nd was prepared in a manner analogous to that set forth in Example
59, except methylamine was used in place of benzylamine in step 7.
1HWR (400 MHz, CD3OD) 5 8.18 (s, 1H), 7.29—7.20 (m, 2H), 7.04 (dd, J = 5.1, 1.9 Hz,
3H), 5.99 (d, J = 7.4 Hz, 1H), 4.99 (d, J=7 Hz, 1H), 4.30 (t, J = 3.3 Hz, 11-4.01 (m,
2H), 3.49—3.34 (m, 2H), 3.06 (s, 3H), 2.98 (s, 1H). ESI-MS (m/Z): [M]+ calcd for
C23H22ClN508, 532.12, found 532.1.
Example 72
Synthesis of 2-benzyl-2—(((2R, 3S, 4R, 5R)—5 -(2-chloro-6—(((S)-2,3 -dihydro- 1H-inden- l —
yl)amino)—9H—purinyl)-3 -ethynyl-3 ,4-dihydroxytetrahydrofuranyl)methoxy)-malonic
-l6l-
Ph 2 _N
\+ H
o N’— N
H020 017’ \N
/ : '_ N\
/Ho 61-1 \gl
Example 72
The title compound was ed in a manner analogous to that set forth in Example
59, except (S)—2,3-dihydro-1H-inden-l-amine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 5 8.14 (s, 41-7.13 (m, 6H), 7.04 (t, J = 3.5 Hz, 3H), 6.01
(d, J = 7.4 Hz, 1H), 5.88-5.76 (m, 1H), 4.99 (d, J = 7.4 Hz, 1H), 4.32 (t, J = 3.3 Hz, 1H), 4.06
(dd, J = 5.5, 3.3 Hz, 2H), 3.53—3.34 (m, 2H), 3.13—3.05 (m, 1H), 3.00 (s, 1H), 2.99-2.87 (m,
1H), 2.67 (dd, J = 12.5, 4.2 Hz, 1H), 2.02 (dd, J = 12.8, 7.7 Hz, 1H). ESI-MS (m/z): [M]+
calcd for C31H28C1N508, 634.16, found 634.5.
Example 73
Synthesis of 2-benzy1(((2R, 35, 4R,5R)(2-chloro(ethylamino)-9H—purinyl)—3-
l-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
Ph 2
\7Lo H
o N’——N N\/
HOZC y \N
HO OH NY
Example73
The title compound was prepared in a manner analogous to that set forth in Example
59, except ethylamine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 6 8.16 (s, 1H), 740—7. 19 (m, 2H), 7.04 (dd, J = 5.1, 1.9 Hz,
3H), 5.98 (d, J = 7.4 Hz, 1H), 4.97 (d, J = 7.4 Hz, 1H), 430 (T, J = 3.3 Hz, 1H), 4.14-3.98
(m, 2H), 3.57 (d, J = 7.8 Hz, 2H), 3.49—3.33 (m, 2H), 2.98 (s, 1H), 1.28 (t, J = 7.2 Hz, 3H).
ESI-MS (m/z): [M]+ calcd for C24H24ClN508, 546.13; found 546.].
Example 74
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)(6-((S)—sec-butylamino)chloro-9H—purinyl)ethynyl-3 ,4-dihydroxytetrahydrofuran-Z-yl)methoxy)malonic acid
-l62-
Ph COZH
\+ —
O N,—
H020 017’ N\ \N “M? /:'_
/HOCHE
Example 74
The title compound was prepared in a manner analogous to that set forth in Example
59, except (S)—butanamine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 5 8.13 (s, 1H), 7.32—7.15 (m, 2H), 7.14-6.98 (m, 3H), 5.98 (d, J
= 7.4 Hz, 1H), 4.97 (d, J = 7.4 Hz, 1H), 4.31 (t, J = 3.2 Hz, 1H), 4.24 (s, 1H), 4.14-3.97 (m,
2H), .33 (m, 2H), 2.99 (s, 1H), 1.63 (q, J = 7.2 Hz, 2H), 1.27 (d, J = 6.5 Hz, 3H),
O.97(t, J = 7.4 Hz, 3H). ESI-MS (m/z): [M]+ calcd for C26H28C1N508, 574.16; found 574.1.
Synthesis of 2-benzyl(((2R,3 S,4R,5R)-5—(2-chloro((cyclopropylmethyl)—
1)amino)-9H-purinyl)-3—ethynyl-3,4-dihydroxytetrahydrofuran
yl)methoxy)malonic acid
PMCOZH
H020l7!qufi
HO OH
Example 75
The title compound was prepared in a manner analogous to that set forth in Example
59, except 1-cyclopropyl-N—methylmethanamine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 6 8.15 (s, 1H), 736-7. 18 (m, 2H), 7.03 (dd, J = 5.2, 2.0 Hz,
3H), 6.00 (d, J = 7.3 Hz, 1H), 4.97 (d, J = 7.3 Hz, 1H), 4.30 (dd, J = 4.1, 2.8 Hz, 1H), 4.07
(qd, J = 10.2, 3.5 Hz, 2H), 3.52—3.31 (m, 7H), 2.98 (s, 1H), 1.20—1.12 (m, 1H), 0.54 (dd, J =
8.2, 1.8 Hz, 2H), 0.45—030 (m, 2H). ESI-MS (m/z): [M]+ calcd for C27H28C1N508, 586.16;
found 586.9
Example 76
sis of 2-benzy1(((2R, SS, 4R,5R)(6-((carboxymethyl)amino)chloro-9H-purin
yl)-3 -ethynyl-3 ,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
-l63-
HOZC \NVC02H
HO OH
Example 76
The title compound was prepared in a manner analogous to that set forth in Example
59, except 2-amino-N,N—dimethylacetamide was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 5 8.21 (s, 1H), 7.38-7.14 (m, 2H), 7.12-6.98 (m, 3H), 6.11 (d, J
= 7.4 Hz, 1H), 4.96 (d, J = 7.3 Hz, 1H), 4.30 (q, J = 4.7, 4.0 Hz, 2H), 4.09-4.02 (m, 2H),
3.54-3.33 (m, 2H), 2.97 (s, 1H). ESI—MS (m/z): [M]' calcd for C24H22C1N5010, 574.11; found
5741.
Example 77
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)—5-(2-chloro((2-chlorobenzyl)amino)-9H-purin
yl)-3 -ethynyl-3 ,4—dihydroxytetrahydrofuranyl)methoxy)ma1onic acid
Ph 2 _N
Ho?031 H
o N’— NV
\N 6;.
/ . N\
/HO OH Y
Example77
The title compound was prepared in a manner ous to that set forth in Example
59, except (2-chlorophenyl)—methanamine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 5 8.17 (s, 1H), 7.43 (m, 2H), 7.28 (m, 3H), 7.22 (m, 1H), 7.00
(m, 3H), 5.99 (d, J: 7.4Hz, 1H), 4.98 (d, J: 7.4Hz, 1H), 4.82 (m, 2H), 4.30 (s, 1H), 4.05 (s,
2H), 3.42 (m, 2H), 2.98 (s, 1H). LC-MS: m/z = 597 H); m/z = 292 ose
fragment).
Example 78
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)(2-chloro((pyridinylmethyl)amino)—9H—
purin—9-yl)ethynyl—3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
HO2Cy«W0
/HO ;OH
Example 78
The title compound was prepared in a manner ous to that set forth in Example
59, except pyridinylmethanamine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 5 9.08 (bs, 1H), 8.73 (d, J: 5.7Hz, 2H), 8.51 (s, 1H), 7.68 (d, J
= 5.6Hz, 2H), 7.22 (m, 2H), 7.06 (m, 3H), 5.82 (d, J: 7.7Hz, 1H), 4.93 (d, J: 6.9Hz, 1H),
4.87 (d, J: 7.6Hz, 1H), 4.20 (m, 1H), 4.03 (m, 2H), 3.86 (m, 2H), 3.62 (s, 1H), 3.27 (m, 2H).
HPLC: Room temperature = 5.74 min, 97.7%. LC-MS: m/z = 610 (M+); m/z = 261 (M-
ribose fragment).
Synthesis of 2-benzyl-2—(((2R, 3S, 4R, (2-chloro-6—morpholino-9H—purin—9-yl)—3—
ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
Ph COzH /=N (\
33%ijwa: ‘ N\N
H0 6H x
Example 79
The title compound was prepared in a manner analogous to that set forth in Example
59, except morpholine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 6 8.20 (s, 1H), 7.22 (m, 2H), 7.01 (m, 3H), 6.00 (d, J= 7.6Hz,
1H), 4.99 (d, J: 7.6Hz, 1H), 4.30 (m, 1H), 4.22 (m, 4H), 4.04 (m, 2H), 3.78 (m, 4H), 3.47
(m, 2H), 2.99 (s, 1H). HPLC: 8.16 min, 98.2%. LC-MS: m/z = 588 (M+), 544 (M-COzH),
m/z = 240 (M-ribose fragment).
Example 80
Synthesis of 2-(((2R, 3S, 4R, 5R)-5—(6-(azepan- l -yl)—2-chloro-9H-purin-9—yl)-3 -ethynyl-3,4-
dihydroxytetrahydrofuranyl)methoxy)—2-benzylmalonic acid
Example 80
The title nd was prepared in a manner analogous to that set forth in Example
59, except azepane was used in place of benzylamine in step 7.
-l65-
1H NMR (400 MHz, CD3OD) 8 8.16 (s, 1H), 7.22 (m, 2H), 7.00 (m, 3H), 5.99 (d, J: 7.6Hz,
1H), 4.98 (d, J: 7.6Hz, 1H), 4.29 (m, 3H), 4.07 (m, 2H), 3.85 (m, 2H), 3.40 (m, 2H), 2.97 (s,
1H), 1.85 (m, 4H), 1.59 (m, 4H). I-IPLC: 9.67min, 98.1%. LC-MS: m/z = 600 (M+), m/z =
556 (M-COzH), m/z = 252 (M-ribose fragment).
Example 81
Synthesis of yl(((2R, 3S, 4R, 5R)—5—(2-chloro(cyclobutyl(methyl)amino)—9H-purin-
9-yl)ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
Ph 2
\7k /=
0 N
HQC X)\W NC)
/ _' L N\
”M0 0H \(
Example 81
The title compound was prepared in a manner analogous to that set forth in Example
59, except N—methylcyclobutanamine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 5 8.21 (s, 1H), 7.21 (dd, J = 7.0, 2.6 Hz, 2H), 6.99 (m, 3H),
.99 (d, J: 7.3 Hz, 1H), 5.74 (br s, 1H), 4.96 (d, J: 7.2 Hz, 1H), 4.28 (dd, J: 4.1, 2.8 Hz,
1H), 4.06 (dd, J: 10.2, 4.2 Hz, 1H), 4.01 (dd, J: 10.2, 2.9 Hz, 1H), 3.45 — 3.31 (m, 5H),
2.96 (s, 1H), 2.35 (q, J = 10.0 Hz, 2H), 2.23 (m, 2H), 1.87 — 1.63 (m, 2H); HPLC: 9.45 min,
98.9%. LC-MS: m/z = 587 (M+H), 543 (M-COzH), m/z = 238 (M-ribose nt).
Synthesis of 2-benzy1(((2R, 3S, 4R, 5R)(2-chloro(isopropyl(methyl)amino)-9H—purin-
9-yl)ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
Ph 2 \
O “F_N “r
/ : '_ N\
’10 6H \(
Example 82
The title compound was prepared in a manner analogous to that set forth in Example
59, except N—methylpropanamine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 6 8.17 (s, 1H), 7.21 (dd, J: 7.3, 2.2 Hz, 2H), 7.03 — 6.94 (m,
3H), 5.98 (d, J: 7.3 Hz, 1H), 4.97 (d, J: 7.3 Hz, 1H), 4.28 (dd, J: 4.0, 2.8 Hz, 1H), 4.04
(qd, J: 10.2, 3.5 Hz, 2H), 3.45 — 3.31 (m, 6H), 2.96 (s, 1H), 1.25 (d, J: 6.8 Hz, 6H), HPLC:
9.08 min, 99.9%. LC-MS: m/z = 575 (M+H), 531 (M-COzH), m/z = 226 (M-ribose
Example 83
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)—5-(2-chloro(cyclopropylamino)-9H—purinyl)—
3 -ethynyl-3 ,4-dihydroxytetrahydrofurany1)methoxy)malonic acid
Ph 2
l——N \+ H
0 N
H020 017mm \V
/ _' '_ N\
/Hc‘> 6H \8
Example 83
The title compound was prepared in a manner analogous to that set forth in Example
59, except cyclopropanamine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 5 8.14 (s, 1H), 7.23 (dd, J: 6.7, 2.8 Hz, 2H), 7.01 (m, 3H),
.97 (d, J: 7.4 Hz, 1H), 4.95 (d, J: 7.4 Hz, 1H), 4.28 (t, J: 3.3 Hz, 1H), 4.10 — 3.97 (m,
2H), 3.49 — 3.30 (m, 2H), 2.99 (m, 1H), 2.96 (s, 1H), 0.92 — 0.78 (m, 2H), 0.66 — 0.54 (m,
2H); HPLC: 7.83 min, 99.1%. LC-MS: m/z = 559 (M+H).
Example 84
Synthesis of 2-benzyl(((2R, 3S, 4R, (2-chloro((pyridin-3 -ylmethyl)amino)—9H—
purinyl)—3-ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)ma1onic acid
Example 84
The title compound was ed in a manner analogous to that set forth in Example
59, except pyridinylmethanamine was used in place of benzylamine in step 7.
1H1\H\4R (400 MHz, CD3OD) 5 8.87 (s, 1H), 8.70 (d, J: 5.6 Hz, 1H), 8.56 (d, J: 8.1 Hz,
1H), 8.22 (s, 1H), 7.97 (dd, J: 8.1, 5.7 Hz, 1H), 7.21 (dd, J: 6.5, 3.0 Hz, 2H), 7.07 — 6.90
(m, 3H), 5.97 (d, J: 7.4 Hz, 1H), 4.96 (d, J: 7.4 Hz, 1H), 4.92 (m, 2H), 4.29 (t, J: 3.4 Hz,
-l67-
1H), 4.04 (qd, J = 10.2, 3.4 Hz, 2H), 3.38 (m, 2H), 2.97 (s, 1H); HPLC: 5.82 min, 99.9%.
LC-MS: m/z = 261 (M-ribose fragment).
Example 85
Synthesis of 2-benzyl(((2R, SS, 4R, (2-chl oro((3-fluorobenzy1)amino)—9H-purin
yl)-3 -ethynyl-3 ,4-dihydroxytetrahydrofuranyl)methoxy)ma1onic acid
F’h\7LOCOzH o NWHQF
H020 y /\
é 5 '
HO 6H NYN
The title compound was prepared in a manner analogous to that set forth in Example
59, except (3 -fluorophenyl)methanamine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 5 8.19 (s, 1H), 7.32 (td, J: 8.0, 5.9 Hz, 1H), 7.24 — 7.16 (m,
3H), 7.12 (dd, J: 9.8, 2.3 Hz, 1H), 7.06 — 6.78 (m, 4H), 5.98 (d, J: 7.3 Hz, 1H), 4.94 (d, J:
7.3 Hz, 1H), 4.74 (m, 2H), 4.29 (t, J: 3.3 Hz, 1H), 4.03 (qd, .1: 10.3, 3.5 Hz, 2H), 3.47 —
3.26 (m, 2H), 2.97 (s, 1H); HPLC: 9.04 min, 99.5%. LC-MS: m/z = 627 (M+H), 583 (M-
COzH), m/z = 278 (M-ribose fragment).
Example 86
Synthesis of 2-benzyl(((2R, SS, 4R, 5R)—5-(2-chloro((3-chlorobenzy1)amino)-9H-purin
yl)-3 yl-3 ,4-dihydroxytetrahydrofuranyl)methoxy)ma1onic acid
Ph 2 _N l S
O N,— N CI
é .—‘ a
HO OH NY
Example 86
The title compound was prepared in a manner analogous to that set forth in Example
59, except (3 -chlorophenyl)methanamine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 5 8.18 (s, 1H), 7.40 (s, 1H), 7.34 — 7.05 (m, 5H), 6.98 (m, 3H),
.97 (d, J: 7.4 Hz, 1H), 4.95 (d, J: 7.4 Hz, 1H), 4.72 (m, 2H), 4.29 (t, J: 3.3 Hz, 1H), 4.09
-l68-
WO 46403
— 3.87 (m, 2H), 3.46 — 3.31 (m, 2H), 2.97 (s, 1H); HPLC: 9.45 min, 98.3%. LC-MS: m/z
643 (M+H), 598 (M-COzH), m/z = 294 (M-ribose fragment).
Example 87
Synthesis of 2-benzyl(((2R, 3S, 4R, (2-chloro((4-chlorobenzyl)amino)-9H-purin
y1)-3 -ethyny1-3 ,4-dihydroxytetrahydrofuranyl)methoxy)ma1onic acid
Ph 2 —N H
O N’— N\/©/
O /
H020 \
HO OH NYN
Example87
The title compound was prepared in a manner ous to that set forth in Example
59, except (4-ch1oropheny1)methanamine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 5 8.17 (s, 1H), 7.36 (d, J: 8.6 Hz, 2H), 7.31 (d, J: 8.5 Hz,
1H), 7.21 (dd, J: 6.8, 2.8 Hz, 2H), 7.02 — 6.96 (m, 3H), 5.97 (d, J: 7.3 Hz, 1H), 4.94 (d, J:
7.3 Hz, 1H), 4.71 (m, 2H), 4.29 (t, J: 3.3 Hz, 1H), 4.03 (qd, J: 10.2, 3.4 Hz, 2H), 3.46 —
3.30 (m, 2H), 2.96 (s, 1H), HPLC: 9.50 min, 98.7%. LC-MS: m/z = 643 (M+H), 598 (M-
COzH), m/z = 294 (M-ribose fragment).
Example 88
Synthesis of 2-(((2R, 3S, 4R, 5R)—5—(6-(azetidinyl)chloro-9H—purinyl)—3-ethyny1-3,4-
dihydroxytetrahydrofuran-Z—yl)methoxy)—2—benzylmalonic acid
Ph 2
W o N’——N [D
: '_ N\
/Ho 6H :2
Example 88
The title compound was prepared in a manner analogous to that set forth in Example
59, except azetidine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 8 8.25 (s, 1H), 7.24 — 7.08 (m, 2H), 7.10 — 6.85 (m, 3H), 5.97
(d, J: 7.4 Hz, 1H), 4.98 (d, J: 7.3 Hz, 1H), 4.43 (m, 4H), 4.29 (dd, J: 41,28 Hz, 1H),
4.07 (dd, .1: 10.2, 4.2 Hz, 1H), 4.00 (dd, J: 10.2, 2.9 Hz, 1H), 3.42 (d, J: 15.0 Hz, 1H),
-l69-
3.34 (d, J: 12.3 Hz, 2H), 2.95 (s, 1H), 2.51 (q, J: 7.7 Hz, 2H); HPLC: 7.58 min, 99.5%.
LC-MS: m/z = 558 (M+H), 554 (M-COzH), m/z = 210 (M-ribose fragment).
Example 89
Synthesis of 2-benzy1(((2R, 3S, 4R, 5R)(2-chloro(dimethylamino)-9H-purinyl)
ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
Ph COZH _N
\+ o N]— I\\I\
é i ‘
_ N \
HO OH Y
The title compound was prepared in a manner analogous to that set forth in Example
59, except dimethylamine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 6 8.17 (s, 1H), 7.22 (dd, J= 7.5, 2.0 Hz, 2H), 7.05 — 6.89 (m,
3H), 5.98 (d, J: 7.2 Hz, 1H), 4.96 (d, J: 7.3 Hz, 1H), 4.28 (dd, J: 4.0, 2.9 Hz, 1H), 4.04
(qd, J: 10.2, 3.5 Hz, 2H), 3.55 — 3.31 (m, 8H), 2.95 (s, 1H); HPLC: 8.16 min, 999%. LC-
MS: m/z = 546 (M+H), 502 (M-COzH), m/z = 198 (M-ribose fragment).
Example 90
sis of 2-benzyl(((2R, 3S, 4R, 5R)(2-chloro(pyrrolidinyl)—9H—purinyl)—3-
ethynyl-3,4-dihydroxytetrahydrofuran—2-y1)methoxy)malonic acid
Ph 002H
Example 90
The title compound was prepared in a manner analogous to that set forth in Example
59, except pyrrolidine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 5 8.21 (s, 1H), 7.21 (dd, J = 7.3, 2.3 Hz, 2H), 7.03 — 6.76 (m,
3H), 5.98 (d, J: 7.3 Hz, 1H), 4.98 (d, J: 7.3 Hz, 1H), 4.29 (dd, J: 4.2, 2.8 Hz, 1H), 4.15 —
3.86 (m, 4H), 3.66 (m, 2H), 3.41 (d, J: 15.0 Hz, 1H), 3.34 (d, J: 15.0 Hz, 1H), 2.95 (s, 1H),
2.02 (m, 4H), HPLC: 8.42 min, 95.6%. LC-MS: m/z = 573 (M+H), 529 H), m/z =
224 (M-ribose fragment).
-l70-
Example 91
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)—5-(2-chloro(cyclopentylamino)-9H-purinyl)—3-
ethynyl-3,4-dihydroxytetrahydrofurany1)methoxy)malonic acid
Ph 2 _N
\+ H
o N’— NO
é s '—.
HO OH NY
Example 91
The title nd was prepared in a manner analogous to that set forth in Example
59, except cyclopentanamine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 5 8.09 (s, 1H), 7.23 (dd, J = 6.7, 2.9 Hz, 2H), 7.01 (m, 3H),
.96 (d, J: 7.4 Hz, 1H), 4.94 (d, J: 7.4 Hz, 1H), 4.47 (m, 1H), 4.28 (t, J: 3.3 Hz, 1H), 4.04
(m, 2H), 3.43 (d, J: 14.9 Hz, 1H), 3.34 (d, J: 14.9 Hz, 1H), 2.96 (s, 1H), 2.19 — 1.98 (m,
2H), 1.78 (m, 2H), 1.72 — 1.64 (m, 2H), 1.62 — 1.52 (m, 2H), HPLC: 9.06 min, 989%. LC-
MS: m/z = 587 (M+H), 543 (M-COzH), m/z = 238 (M-n'bose fragment),
Synthesis of 2-benzyl(((2R, SS, 4R, 5R)(2-chloro-6—((cyclopropylmethyl)amino)—9H—
purinyl)—3—ethynyl-3 ,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
The title compound was prepared in a manner analogous to that set forth in Example
59, except cyclopropylmethanamine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 6 8.14 (s, 1H), 7.18 (d, J: 6.9 Hz, 2H), 7.12 — 6.68 (m, 3H),
.92 (d, J: 6.1Hz, 1H), 4.58 (d, J: 6.1 Hz, 1H), 4.28 (t, J: 3.2 Hz, 1H), 3.98(qd,J=10.3,
3.2 Hz, 2H), 3.50 — 3.04 (m, 4H), 2.55 (s, 1H), 1.08 (m, 1H), 0.52 (m, 2H), 0.26 (m, 2H);
HPLC: 8.52 min, 97.7%. LC-MS: m/z = 572 (M+H), 528 (M-COzH), m/z = 224 (M-ribose
fragment).
Example 93
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)(2-chloro(isopropylamino)—9H-puriny1)—3 -
1-3,4-dihydroxytetrahydrofurany1)methoxy)malonic acid
Ph COZH F” H
/ L N\ / i
HO 6H \8
Example 93
The title compound was prepared in a manner analogous to that set forth in Example
59, except propan-Z-amine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 5 8.05 (s, 1H), 7.23 — 7.12 (m, 2H), 7.09 — 6.78 (m, 3H), 5.91
(d, J: 6.2 Hz, 1H), 4.59 (d, J: 6.2 Hz, 1H), 4.37 (m, 1H), 4.28 (m, 1H), 3.42 (d, J: 14.8
Hz, 1H), 3.35 — 3.22 (m, 3H), 2.56 (s, 1H), 1.24 (d, J: 6.5 Hz, 6H); HPLC: 8.39 min, 98.9%.
LC-MS: m/z = 560 (M+H), 516 (M-COzH), m/z = 212 (M-ribose fragment).
Example 94
sis of y1(((2R, 3S, 4R,5R)—5—(2-ch1oro((2—hydroxymethylpropyl)amino)-
9H-puriny1)—3 -ethynyl-3 ,4-dihydroxytetrahydrofurany1)methoxy)malonic acid
Example 94
The title compound was prepared in a manner analogous to that set forth in Example
59, except 1-aminomethylpropanol was used in place of benzylamine in step 7.
1H-NMR (400 MHz, CD3OD) 5 8.16 (s, 1H) .22 (m, 2H) 7.03-7.01 (m, 3H) 5.97 (d,
J:7.4Hz, 1H) 4.95 (d, J:7.4Hz, 1H) 4.28 (t, J:3.2Hz, 1H) 4.05—4.03 (m, 2H) 3.72-3.69 (m,
2H)3.48-3.31 (m, 2H) 2.97 (s, 1H) 1.24 (s, 6H). ESI—MS (m/z): [M]' calcd for C26H28C1N509
589.98, found 588.4.
Example 95
Synthesis of2-benzy1(((2R,3S,4R,5R)(2-chloro(((S)hydroxypropan-2—y1)amino)-
9H-purinyl)—3-ethynyl-3,4-dihydroxytetrahydrofuran-Z-yl)methoxy)malonic acid
-l72-
Ph cozH _N
H\ o N,—
HOZC Ojj’ H1..(\OH
/ 5 ‘2
Example 95
The title compound was prepared in a manner analogous to that set forth in Example
59, except (S)—2-aminopropanol was used in place of amine in step 7.
1H—NMR (400 MHz, CD3OD) 5 8.18 (s, 1H) 7.24—2.22 (m, 2H) 7.03—7.01 (m, 3H) 5.97 (d,
J:7.4Hz, 1H) 4.93 (d, J:7.4Hz, 1H) .35 (m, 1H) 4.32-4.26 (m, 1H) 4.04 (d, J=3.2Hz,
2H) 3.62-3.60 (m, 2H) 3.48-3.32 (m, 2H) 2.96 (s, 1H) 1.29 (d, J=6.7Hz, 3H) ESI-MS (m/z):
[M]' calcd for C25H26CleO9 575.96; found 574.2.
Example 96
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)—5-(2-chloro(diethylamino)—9H—purinyl)—3-
ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
Ph 002”
9\ O N\/
O /
H020 \N
é 3 a
HO OH “7
Example 96
The title compound was prepared in a manner analogous to that set forth in Example
59, except lamine was used in place of benzylamine in step 7.
1H-NMR (400 MHz, CD3OD) 5 8.15 (s, 1H) 7.23-7.20 (m, 2H) .98 (m, 3H) 5.98 (d,
J:7.3Hz, 1H) 4.97 (d, J:7.3Hz, 1H) 4.29 (m, 1H) 4.15-3.83 (m, 6H) 3.43-3.33 (m, 2H) 2.96
(s, 1H) 1.24 (t, J:7.0Hz, 6H). ESI-MS (m/z): [M]' calcd for C26H28C1N589 573.98; found
5723.
Example 97
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)—5-(2-chloro((2-hydroxyethyl)amino)-9H-purin
yl)ethynyl-3,4-dihydroxytetrahydrofuran-2—yl)methoxy)ma1onic acid
-l73-
WO 46403
Ph COZH _N
\+ H
o N’— N\/\OH
N\ N é _: '_
HO OH 4
Example 97
The title compound was prepared in a manner analogous to that set forth in e
59, except 2-aminoethan-l-ol was used in place of benzylamine in step 7.
1H—NMR (400 MHz, CD3OD) 5 8.20 (s, 1H) 7.24—7.22 (m, 2H) 7.04—7.02 (m, 3H) 5.97 (d,
J=7.4Hz, 1H) 4.91 (d, J=7.3Hz, 1H) 4.29 (t, J=3.4Hz, 1H)) 4.06-3.98 (m, 2H) 3.76-3.73 (m,
2H) 3.66-3.63 (m, 2H) 3.43—3.33 (m, 2H) 2.96 (s, 1H). ESI—MS (m/z): [M]' calcd for
C24H24C1N509 561.93; found 560.2.
Example 98
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)-5—(2-chloro(((R)— l -hydroxypropan-2—yl)amino)-
9H-purinyl)—3 -ethynyl-3 ,4-dihydroxytetrahydrofurany1)methoxy)malonic acid
Ph 2 —N
\4\ H
o N,—
HOZC 03—7; N.(\0H
: ‘. N\
/H5 (3H Y
Example 98
The title compound was prepared in a manner analogous to that set forth in Example
59, except (R)—2-aminopropan-l-ol was used in place of benzylamine in step 7.
1H—NMR (400 MHz, CD3OD) 5 8.12 (s, 1H) .22 (m, 2H) 7.03—7.01 (m, 3H) 5.96 (d,
J:7.4Hz, 1H) 4.95 (d, J:7.4Hz, 1H) 4.42—4.32 (m, 1H) 4.28 (t, J:3.3Hz, 1H) 4.08-4.00 (m,
2H) 3.66-3.58 (m, 2H) 3.45—3.33 (m, 2H) 2.97 (s, 1H) 1.27 (d, z, 3H) . ESI—MS (m/z):
[M]' calcd for C25H26C1N509 ; found 574.2
Example 99
Synthesis of 2—benzyl—2-(((2R, 3S, 4R, 5R)-5—(2-ch1oro—6-(cyclopropyl(2-hydroxyethyl)amino)-
9H-purinyl)-3 -ethynyl-3 ,4-dihydroxytetrahydrofuran-Z-yl)methoxy)malonic acid
—174—
HOZCmWNfOH
/H0 6H
The title compound was prepared in a manner analogous to that set forth in Example
59, except 2—(cyclopropylamino)ethan-l-ol was used in place of benzylamine in step 7.
1H—NMR (400 MHz, CD3OD) 5 8.23 (s, 1H) 7.24—7.22 (m, 2H) 7.04—7.01 (m, 3H) 6.02 (d,
J:7.4Hz, 1H) 4.96 (d, J:7.3Hz, 1H) 4.30-4.28 (m, 1H) 4.10—4.04 (m, 4H) 3.78 (t, J=5.9Hz,
2H) 3.44—3.32 (m, 3-3.19 (m, 1H) 2.96 (s, 1H) 1.01—0.97 (m, 2H) .74 (m, 2H).
e 100
Synthesis of 2-benzyl(((2R, 3S,4R,5R)—5-(2-chloro((R)-3 -hydroxypyrrolidinyl)—9H—
purinyl)ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
H02031’Who—0H
/HO 6H
Example 100
The title compound was prepared in a manner analogous to that set forth in Example
59, except (R)-pyrrolidinol was used in place of benzylamine in step 7.
1H NMR (400 MHZ, CD3OD) 8 8.24 (s, 1H), 7.23 (d, J = 7.2 Hz, 2H), 7.06-6.96 (m, 3H),
6.01 (d, J = 7.3 Hz, 1H), 5.01 (s, 1H), 4.56 (d, J = 26.1 Hz, 1H), 4.33-4.31 (m, 1H), 4.20 (d, J
= 12.5 Hz, 1H), 4.10-4.00 (m, 3H), 3.78 (m, 2H), 3.50-3.35 (m, 2H), 2.97 (s, 1H), 2.14-2.05
(m, 2H).
Example 101
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)(2-chloro((S)(hydroxymethyl)—pyrrolidin- l -
yl)-9H-purinyl)ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
COZH l/OH
H020y
/HO 6H
Example 101
-l75-
The title compound was prepared in a manner analogous to that set forth in Example
59, except (S-pyrrolidinylmethanol was used in place of benzylamine in step 7.
1H NMR (400 MHz, DMSO-d6) 6 8.37 (s, 1H), 8.34 (s, 1H), 7.15 (m, 2H), 7.01 (m, 3H),
6.16 (br s, 1H), 5.96 (br s, 1H), 5.81 (d, J: 7.5 Hz, 1H), 4.82 (d, J: 7.4 Hz, 1H), 4.18 — 4.08
(m, 1H), 3.94 (m, 2H), 3.71 (m, 2H), 3.50 (m, 2H), 3.20 (s, 4H), 3.13 (s, 1H), 2.33 (m, 1H),
2.04 (m, 1H), 1.98 — 1.89 (m, 1H), 177 (m, 1H), 1.65 (m, 1H), HPLC: 7.22 min, 97.7%.
Example 102
sis of 2-benzyl(((2R, 3S, 4R, 5R)—5—(2-chloro((R)—3 -(hydroxymethyl)-pyrrolidin- l -
yl)-9H-purinyl)-3 -ethynyl-3 ,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
COzH 0
H02011’N040”
Example 102
The title compound was prepared in a manner analogous to that set forth in Example
59, except (R)-pyrrolidinylmethanol was used in place of amine in step 7.
1H NMR (400 MHz, 6) 6 8.37 (s, 1H), 8.34 (s, 1H), 7.21 — 7.11 (m, 2H), 7.01 (m,
3H), 6.16 (br s, 1H), 5.96 (br s, 1H), 5.81 (d, J: 7.5 Hz, 1H), 4.82 (d, J: 7.5 Hz, 1H), 4.44
(m, 1H), 4.25 — 4.07 (m, 3H), 3.95 (m, 2H), 3.87 — 3.64 (m, 3H), 3.51 (m, 2H), 3.20 (s, 1H),
2.37 — 2.27 (m, 1H), 2.04 (m, 1H), 1.98 — 1.86 (m, 1H), 1.76 (m, 1H), 1.66 (m, 1H), HPLC:
Rt = 7.20 min, 970%.
Example 103
Synthesis of 2-benzyl(((2R,3S,4R,5R)(2-chloro((R)(hydroxymethyl)-pyrrolidin-l-
yl)—9H-purinyl)—3-ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
HOZCg7!
/H0 614
Example 103
The title compound was prepared in a manner analogous to that set forth in Example
59, except (R)-pyrrolidinylmethanol was used in place of benzylamine in step 7.
-l76-
1H NMR (400 MHz, CD3OD) 5 8.21 (s, 1H), 7.28 — 7.16 (m, 2H), 7.08 — 6.87 (m, 3H), 5.99
(d, J= 7.3 Hz, 1H), 4.97 (d, J: 7.3 Hz, 1H), 4.41 (m, 1H), 4.28 (m, 1H), 4.12 — 3.93 (m,
4H), 3.72 (m, 2H), 3.42 (d, J: 15.0 Hz, 1H), 3.33 (d, J: 15.0 Hz, 2H), 2.96 (s, 1H), 2.05 (m,
4H); HPLC: 7.73 min, 98.2%; ESI-MS: m/z = 254 (M-ribose fragment).
Example 104
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)-5—(2-chloro((S)(hydroxymethyl)—pyrrolidin
y1)-9H-puriny1)ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
Example 104
The title compound was prepared in a manner ous to that set forth in Example
59, except (S)—pyrrolidinylmethanol was used in place of amine in step 7.
1H NMR (400 MHz, CD3OD) 5 8.22 (s, 1H), 7.22 (m, 2H), 7.07 — 6.88 (m, 3H), 5.99 (d, J:
7.3 Hz, 1H), 4.98 (d, J: 7.3 Hz, 1H), 4.44 (m, 1H), 4.29 (dd, J: 4.0, 2.9 Hz, 1H), 4.07 (m,
2H), 4.05 (qd, J: 10.2, 3.5 Hz, 2H), 3.77 (dd, J: 11.0, 4.2 Hz, 1H), 3.66 (dd, J: 11.1, 6.5
Hz, 1H), 3.42 (d, J: 15.1 Hz, 1H), 3.33 (d, J=15.1Hz, 1H), 2.95 (s, 1H), 2.07 (m, 4H),
HPLC: 7.77 min, 99.3%; ESI—MS: m/z = 642 (M+ACN).
Example 105
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)—5-(2-chloro(cyclopropyl(methyl)amino)—9H—
puriny1)ethyny1-3 ,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
Ph COZH
#\ I:
O N
HOZC Ojj’NW \V
- — N
Example 105
The title compound was prepared in a manner analogous to that set forth in e
59, except N—methylcyclopropanamine was used in place of benzylamine in step 7.
1H NMR (400 MHz, CD3OD) 5 8.36 (s, 1H), 7.26 — 7.12 (m, 2H), 7.02 (m, 3H), 6.03 (d, J =
7.3 Hz, 1H), 4.97 (d, .1: 7.3 Hz, 1H), 4.30 (dd, .1: 3.9, 2.8 Hz, 1H), 4.19 — 3.97 (m, 2H),
3.57 — 3.29 (m, 5H), 3.21 (m, 1H), 2.96 (s, 1H), 1.05 — 0.85 (m, 2H), 0.83 — 0.62 (m, 2H);
HPLC: Rt = 8.41 min, 98.6%, ESI-MS: m/z = 224 (M-ribose fragment).
Example 106
Synthesis of 2-benzyl(((2R, SS, 4R, 5R)(2-chloro-6—((cyclopropylmethyl)amino)—9H—
purinyl)-3 -ethynyl-3 ,4-dihydroxytetrahydrofuranyl)methoxy)—3 -(methylamino)
oxopropanoic acid
0 o o NH 0 NH 0
BnBr Ph AczO Ph
O MeOM / 0gN 0 0 AcOH
HO S '7'0,, H O S 7'0..
C52003 O .. 0_SO 70
X —2>N2 DMF MeOZC S 7'0 H2804 MeOZC
: OMe : :
O : .,, X—p : .,, K—>
O O
MOMO Rh2(OAc)4 MOMC‘) MOMO AcO 0A0
benzene
26—dichloroadenine
BSA TMSOTf MeCM
I |
NH 0 NH O
h\ I:N
“If aq. LiOH Ph\ 0 NI:N Hf DIPEA Wk
d'o ane NI:N
Hogs0031’wa .iMeozc m m ; Meozc 033’ W0
: '_ N\ / N\
/HO OH /Ac6 bAc Y “2N\/A AcO OAc YN
Cl C
Example 106
Step 1:
A stirred solution of [(3aR, 5R, 6R, 6aR)—6-ethynyl(methoxymethoxy)-2,2-dimethyl-
tetrahydro-2H—furo[2,3-d][1,3]dioxol—5-yl]methanol (480 mg, 1.87 mmol) and methyl 2-
diazo(methylcarbamoyl)acetate (440 mg, 2.8 mmol, prepared ing to literature:
European l ofOrganic Chemistry, 2014 (24), 5302-5311) in anhydrous benzene (20
mL) under en was treated with rhodium tetraacetate (16 mg, 0.04 mmol) and heated to
60 °C for 4 h. The resulting mixture was cooled to room temperature and concentrated. The
resulting oil was ved in romethane, loaded onto a silica gel column eluting with
-100% ethyl acetate in hexane to afford methyl 2-{[(3aR, 5R, 6R, -ethynyl
(methoxymethoxy)—2,2-dimethyl-tetrahydro—2H-furo[2, 3 -d][1,3]dioxolyl]methoxy }
(methylcarbamoyl)acetate (455 mg, 63% yield) as a diastereomeric pair.
Step 2:
A solution of methyl 2-{[(3aR, 5R, 6R, 6aR)ethynyl(methoxymethoxy)-2,2-
dimethyl-tetrahydro-2H—furo[2,3-d][1,3]dioxolyl]methoxy}(methylcarbamoyl)acetate
(450 mg, 116 mmol) and benzyl bromide (0.97 mL, 8.13 mmol) in anhydrous DMF (4 mL)
was treated with cesium carbonate (757 mg, 2.32 mmol). The reaction mixture was stirred at
room temperature overnight. The reaction was quenched with water (10 mL), diluted with
diethyl ether (70 mL) and washed with saturated aqueous sodium chloride (50 mL) twice.
The organic layer was dried with NaSO4 and concentrated to give a yellow oil. The residue
was purified by silica gel column and eluted with 10- 70% ethyl acetate in hexane to afford a
diastereomeric mixture methyl 2-benzyl(((3aR,5R, 6R, 6aR)—6-ethynyl-6—(methoxy-
methoxy)-2,2-dimethyltetrahydrofuro[2, 3 -d] [ l , 3 ]dioxol-5—yl)methoxy)-3 —(methylamino)-3 -
(mwmmmmeGanflméwWDwadwmflfi.
Step 3:
While under nitrogen, an ice cooled stirred solution of methyl yl
(((3aR, 5R, 6R, 6aR)—6-ethynyl(methoxymethoxy)—2,2-dimethyltetrahydrofuro[2,3 -d] [ l ,3 ]-
dioxolyl)methoxy)(methylamino)oxopropanoate (500 mg, 1.05 mmol) in acetic acid
(4 mL) was treated with acetic anhydride (1 mL, 11.15 mmol) and trated sulfuric acid
(0.02, 0.35 mmol). The reaction solution was slowly warmed to room ature. After 4
hours, reaction was diluted with water and extracted with ethyl acetate (80 mL each). The
organic solution was washed with saturated sodium bicarbonate (100 mL), dried over NazSO4
mflcmwmfifififlflemmmmoflwwdbwhafinmdemwmmemmWMfiwbyflwh
tography to e (3R, 4R, 5R)(((2-benzylmethoxy(methylamino)-l,3-
dioxopropanyl)oxy)methyl)ethynyltetrahydrofuran-2,3,4-triyl tate as an
anomer/diastereomeric mixture.
Step 4:
A suspension of 2-6—dichloroadenine (48 mg, 0.25 mmol) and N,O—bis(trimethylsilyl)-
acetamide (0.08 mL, 0.32 mmol) in anhydrous acetonitrile (7 mL) was treated with a second
solution of (3R, 4R, 5R)—5-(((2—benzyl— l -methoxy-3—(methylamino)—l,3-dioxopropan—2-
yl)oxy)methyl)ethynyltetrahydrofuran-2,3,4-triyl triacetate (130 mg, 0.25 mmol) in
ous acetonitrile (10mL), followed by se addition of trimethylsilyl trifluoro-
methanesulfonate (0.06 mL, 0.33 mmol). Once the on was complete, the reaction was
heated to 50 0C for 18h, cooled to room temperature and quenched with saturated sodium
bicarbonate solution (80 mL). After stirring for a 5 minutes the solution was thracted with
ethyl acetate (3x80mL), dried over NazSO4 and concentrated. The residue was dissolved in
dichloromethane and purified by flash chromatography to provide (2R, 3R, 4R, (((2-
benzyl- l -methoxy(methylamino)— l ,3 -dioxopropanyl)oxy)methyl)(2,6-dichloro-9H—
-l79-
purin—9-yl)—3-ethynyltetrahydrofuran—3,4-diyl diacetate (135 mg, 83% yield) as a foamy solid
(diastereomer pair).
Step 5:
While under nitrogen, a solution of (2R, 3R, 4R, 5R)(((2-benzyl-1—methoxy
(methylamino)-1, 3 -dioxopropan-2—yl)oxy)methyl)—5-(2,6-dichloro—9H—purinyl)—3 -ethynyltetrahydrofuran-3
,4-diyl diacetate (70 mg, 0.11 mmol) in e (2 mL) was cooled to 0 °C
and treated with diisopropylethylamine (0.03 mL, 0.16 mmol) and cyclopropylamine (0.01
mL, 0. 13 mmol), and warmed to room temperature with stirring overnight. The reaction
mixture was diluted with ethyl acetate (80 mL), washed with water (50 mL) and saturated
aqueous sodium chloride (50 mL). The organic layer was dried over NazSO4 then filtered and
concentrated. The residue was dissolved in dichloromethane and purified by flash column
chromatography to afford (2R, 3R, —2-(((2-benzylmethoxy(methylamino)-1,3—
dioxopropan—2-yl)oxy)methyl)(2—chloro—6-((cyclopropylmethyl)amino)—9H—purinyl)—3-
ethynyltetrahydrofuran-3,4-diyl diacetate (70 mg, 95% yield) as an off-white solid
(diastereomeric pair).
Step 6:
To solution of (2R, 3R, 4R, 5R)(((2-benzylmethoxy-3 -(methylamino)-1,3-dioxo-
propanyl)oxy)methyl)(2-chloro((cyclopropylmethyl)amino)-9H—purinyl)
ethynyltetrahydrofuran-3,4-diyl diacetate (70 mg, 0.10 mmol) in THF (1 mL) was treated
with LiOH (24 mg, 1.02 mmol) in water (1 mL) and stirred at room temperature overnight.
Reaction pH was ed to 4-5 using cold 2 N HCl. Upon itation, the suspension was
stirred for another 10 min. The solid was collected, washed with cold water and dried to
provide 2-benzyl(((2R, 3S, 4R, 5R)(2-chloro—6-((cyclopropylmethyl)amino)-9H—purin
yl)-3—ethynyl—3,4-dihydroxytetrahydro-furan—2-yl)methoxy)—3-(methylamino)oxopro-
panoic acid (45 mg, 75% yield) as an ite solid (diastereomeric pair).
1H NMR (400 MHz, CDCla/CD3OD = 5:1) 5 8.01 (s, 0.45H), 7.48 (s, 0.55H), 7.22—7.03 (m,
5H), 5.86 (dd, J = 4.7, 3.0 Hz, 1H), 4.43 (dd, J = 8.5, 4.6 Hz, 1H), 4.31-4.06 (m, 2H), 3.84-
3.72 (m, 1H),3.45-3.21 (m, 4H), 2.62 (d, J = 40.9 Hz, 1H), 2.46 (d, J = 8.1 Hz, 3H), 1.05 (dq,
J = 8.0, 3.7 Hz, 1H), 0.51 (ddd, J = 8.1, 4.0, 1.6 Hz, 2H), 0.31-0.18 (m, 2H). ESI-MS (m/z):
[M]+ calcd for C27H29C1N6O7, 585.18, found 585.9.
Example 107
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)—5-(6-(benzylamino)—2-chloro—9H—purinyl)—3-
l-3,4-dihydroxytetrahydrofuranyl)methoxy)—3-(methylamino)—3-oxopropanoic acid
H I:N “Q
/N o
0:1 WN O
é .' L
HO OH NYN
Example 107
The title compound was ed in a manner analogous to that set forth in Example
106, except benzylamine was used in place of cyclopropylamine in step 5.
1H NMR (400 MHz, CDCl3/CD3OD = 5:1) 6 8.03 (s, 0.46H), 7.52 (d, J: 2.7Hz, 0.54H),
7.42—7.04 (m, 10H), 5.89 (t, J: 4.3 Hz, 1H), 4.73 (m, 2H), 4.44 (dd, J: 6.0, 4.5 Hz, 1H),
4.33—4.15 (m, 2H), 3.79 (dd, J: 10.6, 4.5 Hz, 1H), 3.45—3.27 (m, 2H), 2.62 (d, J: 36.6 Hz,
1H), 2.48 (d, J: 13.2 Hz, 3H). ESI-MS (m/Z): [M]+ calcd for C30H29C1N6O7, 621.18, found
621.4.
Example 108
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)(2-chloro((2-chlorobenzyl)amino)-9H—purin
y1)-3 -ethynyl-3 ,4-dihydroxytetrahydrofurany1)methoxy)—3 -ethoxy-3 -oxopropanoic acid
\/O O N
/ - -
- N\
/ - \(
Example108
The title compounds is prepared in a manner analogous to that set forth in Example
59, except only 5 equivalents of m hydroxide are used in step 8.
1H NMR (400 MHz, CD3OD) 5 8.16 (s, 1H), 7.42 (m, 2H), 7.26 (m, 2H), 7.21 (m, 2H), 6.99
(m, 3H), 5.97 (d, J: 7.6Hz, 1H), 4.96 (d, J: 7.6Hz, 1H), 4.82 (m, 2H), 4.28 (m, 1H), 4.03
(m, 2H), 3.75 (m, 2H), 3.38 (m, 2H), 3.22 (m, 2H), 2.97 (s, 1H) 1.29 (t, J: 7.6Hz, 3H).
HPLC: 9.43 min, 96.2%. LC-MS: m/z = 642, 597 (M-COzH), m/z = 292 (M-ribose
fragment).
Example 109
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)—5-(2-chloro((pyridinylmethyl)amino)—9H—
purinyl)-3 -ethynyl-3 ,4-dihydroxytetrahydrofuranyl)methoxy)-3 -ethoxy-3 -oxopropanoic
Example 109
The title compounds is prepared in a manner analogous to that set forth in e
59, except only 5 equivalents of lithium hydroxide are used in step 8. Compound was
isolated as ~2:1 mixture of diastereomers.
1H NMR (400 MHz, DMSO-d6) of major isomer: 5 8.73 (d, J: 5.9Hz, 2H), 8.15 (s, ,
7.98 (d, J: 5.9Hz, 2H), 7.23 (m, 2H), 7.06 (m, 3H), 6.00 (m, 1H), 5.00 (m, 2H), 4.10 (m,
4H), 3.39 (m, 2H), 3.12 (s, 0.80H), 1.17 (m, 3H). 1H NMR (DMSO-d6) of minor isomer: 5
8.73 (d, J: 5.9Hz, 2H), 8.31 (s, 0.32H), 7.98 (d, J: 5.9Hz, 2H), 7.23 (m, 2H), 7.06 (m, 3H),
6.00 (m, 1H), 5.00 (m, 2H), 4.10 (m, 4H), 3.39 (m, 2H), 3.01 (s, 0.41H), 1.17 (m, 3H).
HPLC: 6.25 min, 94.8%. LC-MS: m/z = 638 (M+), 594 (M-COzH), m/z = 259 (M-ribose
fragment).
Example 110
Synthesis of 2-(((2R, 3S, 4R, 5R)—5—(2-chloro(isopropy1amino)—9H-purinyl)—3-ethynyl-
3 ,4-dihydroxytetrahydrofuranyl)methoxy)((5—methylisoxazol-3 -yl)methyl)malonic acid
/=N H
o N
HO C O /
/Ho 6H Y
Example 110
The title compound was ed in a manner analogous to that set forth in Example
59, except 3-(bromomethy1)methy1isoxazole was used in place of benzyl bromide in step 4
and propanamine is used in place of benzylamine in step 7.
-l82-
1H-NMR (400 MHz, CD3OD) 5 8.46 (s, 1H) 5.99 (d, J:7.6Hz, 1H) 5.95 (s, 1H) 5.07 (d,
J:7.6Hz, 1H) 4.41—4.38 (m, 1H) 4.31—4.29 (m, 1H) 4.07—4.05 (m, 1H) 3.99-3.88 (m, 1H)
3.50-3.38 (m, 2H) 2.95 (s, 1H) 2.05 (s, 3H) 1.27 (d, J:6.5Hz, 6H). ESI-MS (m/z): [M]+ calcd
for C23H25C1N609 564.93; found 5661
Example 1 1 1
Synthesis of 2-(((2R,3S,4R,5R)—5-(2-chloro((4-fluorobenzyl)amino)-9H—purinyl)
ethynyl-3,4—dihydroxytetrahydrofuranyl)methoxy)((5-methylisoxazol
yl)methyl)malonic acid
//N\ F
COZH _N Hg
0 N/_ N
HOZC 03—7, /\
é 5 '-
HO 6H N7“
Example 111
The title nd was prepared in a manner analogous to that set forth in Example
59, except 3-(bromomethyl)methylisoxazole was used in place of benzyl bromide in step 4
and (4-fluorophenyl)methanamine is used in place of benzylamine in step 7.
1H-NMR (400 MHZ, CD3OD) 6 8.62-8.58 (br s, 1H) 7.41-7.38 (m, 2H) 7.07-7.01 (m, 2H)
6.01 (d, J=7.4Hz, 1H) 5.96 (s, 1H) 5,09 (d, z, 1H) 4.82-4.71 (m, 2H) 4.31-4.29 (m,
1H) 4.06 (dd, J=10.0,3.8Hz, 1H) 3.97 (dd, J=10.1,3.1Hz, 1H) .32 (m, 2H) 3.18 (s, 3H)
2.96 (s, 1H).
Example 112
sis of 2-(benzo[d]thiazolylmethyl)—2-(((2R,3S, 4R, 5R)(2-chloro—6-((4-
fluorobenzyl)amino)—9H—purin—9-yl)—3—ethynyl-3,4-dihydroxytetrahydrofuran—Z-
yl)methoxy)malonic acid
S,N F
K 0 NF Mg
H020 op! /\
é 5 '—
HO oH NYN
Example 112
The title compound was prepared in a manner analogous to that set forth in Example
59, except 2-(bromomethyl)benzo[d]thiazole is used in place of benzyl bromide in step 4 and
rophenyl)methanamine was used in place of benzylamine in step 7.
1H-NMR (400 MHz, CD3OD) 6 857-854 (br s, 1H) .70 (m, 2H) 7.45-7.41 (m, 2H)
7.23—7.20 (m, 1H) 7.12-7.16 (m, 1H) 7.09—7.04 (m, 2H) 5.94 (d, J:7.3Hz, 1H) 5.15 (d,
J:7.1Hz, 1H) 4.77—4.72 (m, 2H) 4.35—4.32 (m, 1H) 4.20 (dd, J:10.1,2.7Hz, 1H)4111 (dd,
J:10.1,3.1Hz, 1H) 3.99-3.86 (m, 2H) 2.77 (s, 1H).
Example 113
Synthesis of 2-(((2R, SS, 4R, 5R)(6-aminochloro-9H—purinyl)-3 yl-3 ,4-
dihydroxytetrahydrofuran-Z-yl)methoxy)-3 -oxo-3 -(pyrrolidin— l -yl)propanoic acid
Example 113
The title compound was prepared in an analogous manner to e 59 except ethyl
2-diazooxo(pyrrolidinyl)propanoate was used instead of l-ethyl 3-(prop-l-en-l-yl)
2-diazomalonate in Step 3 and ammonia is used in place of benzylamine in Step 7. The
product is ed as a 55/45mixture of diastereomers.
Major diastereomer 1H-NMR (400 MHz, CD3OD) d 8.80 (s, 1H) 5.99 (d, J=7.4Hz, 1H) 5.05
(d, J=7.4Hz, 1H) 4.88 (s, 1H) 4.28-4.26 (m, 1H) 4.13 (dd, J=10.7,2.5Hz, 1H) 4.00 (dd,
, 3.9Hz, 1H) 3.66-3.39 (m, 4H) 3.17 (s, 1H) 1.89-1.79 (m, 4H). Minor diasteomer 1H-
NMR (400 MHz, CD3OD) 6 8.89 (s, 1H) 6.03 (d, J=7.4Hz, 1H) 5.05 (d, J=7.4Hz, 1H) 4.86
(s, 1H) 4.28-4.26 (m, 1H) 3.90-3.86 (m, 2H) 3.66-3.39 (m, 4H) 3.16 (s, 1H) 1.89-1.79 (m,
4H). ESI—MS (m/z): [M]' calcd for C19H21C1N607 480.86; found 479.1
Example 1 14
Synthesis of 2-(((2R, SS, 4R,5R)—5-(2—chloro—6-(cyclopentylamino)—9H—purin—9-yl)—3 —ethynyl-
3 ydroxytetrahydrofuran-Z-yl)methoxy)oxo-3 -(pyrrolidin- l -yl)propanoic acid
Example 114
The title compound was prepared in an analogous manner to Example 59 except ethyl
2-diazooxo(pyrrolidin—1-yl)propanoate was used instead of l-ethyl 3—(propenyl)
2-diazomalonate in Step 3 and cyclopentanamine is used in place of benzylamine in Step 7.
The product is isolated as a 55/45 mixture of diastereomers.
Major diastereomer.1H NMR (400 MHz, CD3OD) d 8.72 (s, 1H) 5.96 (d, J=7.4Hz, 1H) 5.04
(d, z, 1H) 4.87 (s, 1H) 4.52-4.48 (m, 1H) 4.28-4.25 (m, 1H) 4.14 (d, J=10.5Hz, 1H)
4.01 (dd, J=10.6,5.2Hz, 1H) .36 (m, 4H) 3.17 (s, 1H) 2.10-2.04 (m, 2H) 1.84—1.77 (m,
6H) 1.69-1.58 (m, 4H) Minor reomer IHNMR (400 MHz, CD3OD) 5 8.64 (s, 1H)
6.00 (d, J=7.4Hz, 1H) 5.01 (d, J=7.4Hz, 1H) 4.85 (s, 1H) 4.52-4.48 (m, 1H) 4.28—4.25 (m,
1H) 3.92-3.86 (m, 2H) .36 (m, 4H) 3.16 (s, 1H) 2.10—2.04 (m, 2H) 1.84-1.77 (m, 6H)
.58 (m, 4H) (.ESI-MS (m/z): [M]' calcd for C24H29C1N607 548.98; found 547.3.
e 1 15
Synthesis of 3-amino(((2R, 3S, 4R, 5R)—5—(2-chloro(cyclopentylamino)-9H-purinyl)—3-
ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)-3 -oxopropanoic acid
TBDPSO N \ N BSAMTMSOV TBDPSO ONWC' TBAF, AcOH eC THF
_ . + </ |
/ : : N A
AcO OAc N 0'
H Aco 0Ac A126 OAc N191“
H2NOJHKlkOEtOlNl=NRr12(OAc)4
COZH c0251 c0251
HN2 $0 ONWHfi1 NH4QH,THF\Oz aq.LIOH,THFHN2 $0/ O-NWMO HNm)\2
- « \
<15 OH AcO 0A1: Aco 0A1: N:(N
Example 115
Step 1:
While under nitrogen, a suspension of 2,6-dichloroadenine (2.91 g, 15.4 mmoL, 1.01
eq) and N,0-bis(trimethylsilyl)acetamide (4.87 mL, 19.6 mmoL, 1.29 eq) in anhydrous
acetonitrile (90 mL). Next, a solution of (2R, 3R, 4R, 5R)-2,4-bis(acetyloxy){[(terl—
butyldiphenylsilyl)oxy]methyl}-4—ethynyloxolan—3-y1 acetate (8.2 g, 15.22 mmoL) in
anhydrous acetonitrile (10 mL) was added, followed by dropwise addition of trimethylsilyl
WO 46403
trifluoromethanesulfonate (3.67 mL, 20.3 mmoL, 1.33 eq). The reaction was warmed to 50
0C for 18h, then cooled to room temperature. (Reaction begins a pale-yellow color and after
4hmmsmaUmwmmnmmm)SummwammmswmmanmmmeOmLqume
and the mixture was stirred for ten minutes. The resulting mixture was extracted with ethyl
acetate (3 x 100 mL) and the combined organic layer was dried (Na2S04), filtered, and
trated. The residue was dissolved in dichloromethane /ethyl acetate (~3 mL, 1:1),
loaded onto a silica gel column (~300 cc), and eluted with 0-30% ethyl acetate in s to
provide (2R, 3R, 4R, 5R)—2-(((lerZ-butyldiphenylsilyl)oxy)methyl)-5—(2,6-dichloro-9H-purin—9-
yl)ethynyltetrahydrofuran-3,4-diyl diacetate (8.2 g, 81%) as a white solid.
Step 2:
A solution of (2R, 3R, 4R, 5R)—2-(((ZerZ-butyldiphenylsilyl)oxy)methyl)(2,6-dichloro-
9H-purinyl)—3-ethynyltetrahydrofuran-3,4-diyl diacetate (1.6 g, 2.4 mmoL) in anhydrous
THF (25 mL) was cooled to 0 oC and treated with acetic acid (0.192 mL, 3.36 mmoL, 1.4 eq)
a 1 N solution of tetrabutylammonium fluoride in THF (3.36 mL, 3.36 mmoL, 1.4 eq). After
the addition was complete, the reaction was warmed to room temperature with stirring for 3h.
TmnwamnmmmmummmmEmedapmfikdfiaflmhammmCMmmmgmmw(0w
50% ethyl acetate in hexanes to afford (2R, 3R, 4R, 5R)(2,6-dichloro-9H-purinyl)
ammllmwmmmaMWHMMMdMM6AdMdemM0%g8&QMaWMEmmr
Step 3:
While under nitrogen, a solution of ((2R, 3R, 4R, 5R)—5-(2,6-dichloro-9H—purinyl)
ethynyl(hydroxymethyl)tetrahydrofuran-3,4-diyl diacetate (172 mg, 0.40 mmol) and ethyl
3-(aminooxy)diazooxopropanoate (160 mg, 1.02 mmoL, 2.5 eq) in anhydrous toluene
(3 mL) was treated with m (II) acetate dimer (5 mg, 0.011 mmoL, 2.8 mol%) and
wmmaho&WCfix5h.flwrwamnwwcmwmmMaLmflpwfikdfiaflwhummm
chromatography (25-75% ethyl acetate in romethane) to afford (2R, 3R, 4R, 5R)(((1-
aminoethoxy-1,3-dioxopropan—2-yl)oxy)methyl)(2,6-dichloro-9H—purinyl)
ethynyltetrahydrofuran-3,4-diyl diacetate (101 mg, 45% in ~85: 15 mixture of diastereomers)
Mawmhmgws
Step 4:
While under nitrogen, a solution of (2R, 3R, 4R, 5R)—2-(((1-aminoethoxy-1,3-dioxo-
propanyl)oxy)methyl)-5—(2,6-dichloro-9H—purin—9-yl)-3—ethynyltetrahydrofuran—3,4-diyl
diacetate (157mg, 0.28mmol) in dioxane (2.5 mL) was d with diisopropylethyl-amine
-l86-
(0.100 mL, 061 mmoL, 2.2 eq) and cyclopentylamine (0.065 mL, 0.066mmoL, 2.33 eq).
After stirring at room ature for 18 h, the mixture was diluted with ethyl acetate (20
mL), washed with water (10 mL), dried (NazSO4), filtered, and concentrated to provide crude
(2R, 3R, 4R, 5R)(((1 -amino-3 -ethoxy- l ,3 propanyl)oxy)methyl)—5-(2-chloro
(cyclopentylamino)—9H—purinyl)—3 -ethynyltetrahydrofuran-3 l diacetate.
Step 5:
The ing residue from the previous step was stirred in ammonium hydroxide and
ethanol (1:1/vzv, 10 mL) at room temperature overnight. The mixture was concentrated,
dissolved in THF (2.5 mL) and treated with lithium hydroxide (23 mg, 0.96 mmoL, 3.4 eq)
dissolved in water (2.5 mL). The mixture was stirred at room temperature with onal
gentle heating for ~3h, then neutralized with 1N HCl to pH~6 and concentrated in vacuo. The
crude product was dissolved in water and purified by reverse phase HPLC and dried by
lyophilization to provide the title compound (52 mg, 37% for 3 steps) as a voluminous white
solid.
1H NMR (400 MHz, D20) of major isomer: 5 8.30 (s, 1H), 5.81 (m, 1H), 4.88 (d, J: 6.6Hz,
1H), 4.80 (d, J: 6.8Hz, 1H), 4.24 (m, 2H), 4.20 (bs, 1H), 3.83 (m, 2H), 3.01 (s, 1H), 1.85 (m,
2H), 1.49 (m, 6H). 1H NMR (400 MHz, D20) of minor isomer: 8 8.39 (s, 1H), 5.81 (m, 1H),
4.88 (d, J: 6.6Hz, 1H), 4.80 (d, J: 6.8Hz, 1H), 4.24 (m, 2H), 4.20 (bs, 1H), 3.83 (m, 2H),
2.99 (s, 1H), 1.85 (m, 2H), 1.49 (m, 6H). HPLC: Rt = 7.08 min, 93.0%. ESI-MS for
C20H23C1N607 calcd. , found 493.2 (M-); ESI—MS for C10H11ClN5 calcd. 236.07, found
2360 (M-ribose fragment).
Example 116
Synthesis of 2-(((2R, 3S, 4R,5R)—5-(2—chloro—6-(cyclopentylamino)—9H—purinyl)—3-ethynyl-
3,4-dihydroxytetrahydrofuranyl)methoxy)malonamide
Example 116
The title compound was prepared as a second product from step 5 in the synthesis of
e 115. It was isolated as a voluminous white solid (8.5 mg, 6%).
-l87-
1H NMR (400 MHz, DMSO—ds): 8.57 (s, 0.5H), 8.31 (s, 1H), 7.73 (s, 1H), 7.38 (m, 1.5H),
7.21 (m, 1.5H), 7.05 (m, 0.5H), 6.87 (m, 0.5H), 6.20 (m, 1H), 6.02 (d, J: 7.0Hz, 1H), 5.79
(d, J= 7.8Hz, 1H), 5.02 (s, 1H), 4.73 (s, 1H), 4.39 (m, 1H), 4.18 (m, 1H), 3.79 (m, 1H), 3.68
(s, 1H), 1.85 (m, 2H), 1.49 (m, 6H). HPLC: Rt = 6.64 min, 97.1%. ESI-MS for
C1N7O6 calcd. 493.15, found 492.3 (M-); ESI—MS for C10H11C1N5 calcd. 236.1, found
236.1 (M-ribose fragment).
Example 117
Synthesis of 2-(((2R, 3S, 4R, 5R)(2—chloro—6-(methylamino)-9H—purin-9—yl)ethynyl-3,4-
dihydroxytetrahydrofuranyl)methoxy)malonic acid
Example 117
The title compound was prepared in a manner analogous to that set forth in Example
59, except methylamine was used in place of benzylamine in step 7 and step 4 is eliminated.
1H NMR (400 MHz, CD3OD) 5 8.88 (s, 1H), 6.05 (d, J: 7.6Hz, 1H), 5.03 (d, J: 7.6Hz, 1H),
4.62 (s, 1H), 4.26 (m, 1H), 4.04 (m, 1H), 3.90 (m, 1H), 3.11 (s, 1H), 3.07 (s, 3H). HPLC: Rt =
.92 min, 97.9%. ESI-MS for C16H16ClN508 calcd. 441.07, found 442.5 (NH); ESI—MS for
N5 calcd. 182.02, found 184.2 (M-ribose fragment).
Example 118
Synthesis of 2-(((2R, 3S, 4R, 5R)(6-(benzylamino)chloro-9H—purinyl)-3 -ethynyl-3,4-
dihydroxytetrahydrofuran-Z-yl)methoxy)malonic acid
— H
HO 0 NI— N
O N
; L N\
/H6 6H \8
Example 18
The title compound was ed in a manner analogous to that set forth in Example
59, except step 4 was eliminated.
1H NMR (400 MHz, CD30D) 5 8.87 (s, 1H), 7.39 (m, 2H), 7.33 (m, 2H), 7.26 (m, 1H), 6.06
(d, J: 7.6Hz, 1H), 5.02 (d, J: 7.6Hz, 1H), 4.76 (m, 2H), 4.62 (s, 1H), 4.26 (s, 1H), 4.03 (m,
1H), 3.90 (m, 1H), 3.10 (s, 1H). HPLC: Rt = 7.83 min, 98.2%. ESI-MS for C22H20CleOs
calcd. 517.10 found 516.7 (M-), ESI-MS for C12H9C1N5 calcd. 258.05, found 258 (M-ribose
fragment).
Example 119
Synthesis of 2-(((2R, 3S, 4R, 5R)(2-chloromorpholino-9H—purinyl)-3 -ethynyl-3 ,4-
dihydroxytetrahydrofuran—2-yl)methoxy)—2-(phenylsulfonyl)acetic acid
Example 119
The title compound was prepared in an analogous manner to e 59 except ethyl
2-diazo(phenylsulfonyl)acetate was used instead of l-ethyl penyl) 2-
alonate in Step 3, morpholine was used in place of benzylamine in Step 7 and Step 4 is
eliminated.
1H NMR (400 MHz, DMSO—ds) of major : 5 8.40 (s, 1H), 7.83 (m, 2H), 7.66 (m, 2H),
7.53 (m, 1H), 5.83 (m, 1H), 5.50 (d, J: 7.8Hz, 1H), 4.80 (d, J: 7.8Hz, 1H), 4.16 (m, 4H),
3.98 (m, 1H), 3.76 (m, 4H), 3.63 (s, 1H). 1H NMR (400 MHZ, DMSO-ds) of minor isomer: 6
8.41 (s, 1H), 7.83 (m, 2H), 7.66 (m, 2H), 7.53 (m, 1H), 5.83 (m, 1H), 5.50 (d, J: 7.8Hz, 1H),
4.66 (d, J: 7.8Hz, 1H), 4.16 (m, 4H), 3.98 (m, 1H), 3.76 (m, 4H), 3.61 (s, 1H). HPLC: Rt =
7.83 (minor), 8.18 min (major), 99.6% (40:60). ESI-MS for C26H26C1N509 calcd. 587.14,
found 588 (M+), ESI-MS for C24H24C1N509S calcd. 593.10, found 592 (M-); ESI-MS for
C23H23C1N507S calcd. 548.10, found 548 (M-COzH), ESI-MS for C9H9C1N50 calcd. 238.05,
found 240 (M-ribose fragment).
Example 120
Synthesis of 2-(((2R, 3S, 4R, 5R)—5-(2-chloro(cyc1opentylamino)—9H—purinyl)—3-ethynyl-
3 ,4-dihydroxytetrahydrofurany1)methoxy)(methylsulfonyl)acetic acid
Example 120
The title compound was prepared in an analogous manner to Example 59 except ethyl
2-diazo(methylsulfonyl)acetatewas used instead of 1-ethyl 3-(propenyl) 2-
diazomalonate in Step 3, cyclopentanamineis used in place of benzylamine in Step 7 and Step
4 is eliminated.
1H NMR (400 MHz, DMSO—ds) of major isomer: 6 8.47 (s, 1H), 5.85 (m, 1H), 5.36 (m, 1H),
.01 (m, 1H), 4.86 (d, J = 8.0Hz, 1H), 4.42 (m, 2H), 4.33 (m, 1H), 4.25 (m, 2H), 4.14 (m, 1H),
4.00 (m, 1H), 3.37 (s, 1H), 3.05 (s, 3H), 1.97 (m, 2H), 1.72 (m, 2H), 1.57 (m, 4H). 1H NMR
(400 MHz, DMSO-ds) of minor isomer: 5 8.39 (s, 1H), 5.33 (m, 1H), 5.36 (m, 1H), 4.68 (d, J
= 8.0Hz, 1H), 4.42 (m, 2H), 4.33 (m, 1H), 4.25 (m, 2H), 4.14 (m, 1H), 4.00 (m, 1H), 3.37 (s,
1H), 3.05 (s, 3H), 1.97 (m, 2H), 1.72 (m, 2H), 1.57 (m, 4H). HPLC: Rt = 8.02 min, 98.4%.
ESI-MS for C20H24C1NsOsS calcd. 529.10, found 530 (M+), ESI-MS for C10H11C1N5 calcd.
236.07, found 238 ose fragment).
Examples 121 & 122
Synthesis of 2-(((2R, 3S, 4R, 5R)(6-aminocarbamoyl-9H-purinyl)ethyny1-3,4-
dihydroxytetrahydrofuranyl)methoxy)benzyl-3—ethoxy—3 -oxopropanoic acid
R, 3S, 4R, 5R)—5-(6-aminocarbamoyl-9H-purinyl)-3 -ethynyl-3,4—
dihydroxytetrahydrofuranyl)methoxy)—2-benzylmalonic acid
o N(BOC)2 o NH2
O 08 (N 0 QB
l NaCN DBACO (,N \N
EC 0 N
o NACI DMSO EtO o N
o NACN
_ \ / 60(3 16h _
—Ac05 bOAc —AcO¢ LOAC
iaq. LiOH, THF
O NH2
0 OH <91“N HO 0AJN
o N/JWI/NHZ’“ <N811::
o N/Sl/NHZ
0 lg
H6 ’OH
e 122 Example 121
Step 1:
To a solution of diethyl 2-benzyl(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-(N,N ’-
bis(tert—butoxycarbonyl)amino)—2—chloro—9H—purinyl)—3-ethynyltetrahydrofuran
yl)methoxy)malonate (1.00 g, 1.17 mmol, 1 eq) in DMSO (10 mL) and H20 (2 mL) was
added 1,4-diazabicyclo[2.2.2]octane (128 uL, 1.17 mmol, 1 eq) and NaCN (114.20 mg, 2.33
mmol, 2 eq). The solution was stirred at 60 °C for 3 h bfore it was diluted with water (15
mL) and ted with ethyl acetate (3 X 15 mL). The combined organic layer was washed
with water (50 mL), brine (50 mL), dried by NazSO4, and filtered and concentrated. The
crude residue was purified by Combi-flash (silica gel, 30—70% EtOAc in petroleum ether) to
give diethyl 2-benzyl(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-(N,N ’-bis(tert-butoxycarbonyl)-
amino)—2-cyano-9H—purinyl)—3-ethynyltetrahydrofuranyl)methoxy)malonate (312 mg,
40% yield) as a yellow gum.
Step 2:
To a solution of diethyl 2-benzyl-2—(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-(N,N ’-
bis(1erl—butoxycarbonyl)amino)—2-cyano-9H—purin—9-yl)-3—ethynyltetrahydrofuran—2-
yl)methoxy)malonate (50 mg, 75.23 umol, 1 eq) in DCM (1.7 mL) was added TFA (0.3 mL)
at 0 °C. The solution was stirred at 20 °C for 1 h before it was d with saturated aq.
NaHCO3 to adjust the pH to 9. The mixture was extracted with ethyl acetate (3 x 3 mL). The
organic was concentrated to give crude diethyl 2-(((2R, 3S, 4R, 5R)(6-aminocyano-9H—
purinyl)—3 -ethynyl-3 ,4-dihydroxytetra-hydrofuranyl)methoxy)—2-benzylmalonate (45
mg) as a yellow gum.
Step 3:
To a solution of crude diethyl 2-(((2R, 3S, 4R, 5R)(6-aminocyano-9H-purinyl)—
3-ethynyl-3,4-dihydroxytetra-hydrofuran—2-yl)methoxy)—2—benzyl—malonate (65 mg, 115.14
umol, 1 eq) in MeCN (2 mL) was added 7,8,9-hexahydro-2H—pyrimido[1,2-a]-
dine (TBD) (1 M aq., 461 uL, 4 eq). The reaction mixture was stirred at 20 0C for 18 h
before it was trated. The crude residue was purified by preparative HPLC and the
fractions were dried by lization to give 2-(((2R, 3S, 4R, 5R)(6-aminocarbamoyl-
9H-purinyl)ethynyl-3,4—dihydroxytetrahydrofuran-2—yl)methoxy)benzyl-3—ethoxy—3-
oxopropanoic acid (Example 121) (4.1 mg, 5% yield) as a white solid and 2-(((2R,3S,4R,5R)—
-(6-aminocarbamoyl-9H-purinyl)ethyny1-3,4-dihydroxytetrahydrofuran
yl)methoxy)benzylmalonic acid (Example 122) (2.2 mg, 3% yield) as a white solid.
-l9l-
Example 121; 1H NMR (400 MHz, CD3OD) 5 ppm 8.19~8.39 (m, 1H) 7.26 (br d, J=5.88 Hz,
2H) 7.03 — 7.12 (m, 3H) 6.20 (dd, J=9.69, 7.19 Hz, 1H) 4.91 — 4.97 (m, 1H) 4.29 (br s, 1H)
3.98 — 4.24 (m, 4H) 3.41 — 3.53 (m, 1H) 3,31 — 3.40 (m, 1H) .08 (m, 1H) 1.18 (q, J=7.25
Hz, 3H), LC/MS [M + H] = 555.1.
Example 122: 1H NMR (400 MHz, CD3OD) 6 ppm 8.504 (s, 1H) 7.16 — 7.28 (m, 2H) 7.07
(br s, 3H) 6.20 (d, J=5.88 Hz, 1H) 4.92 — 4.99 (m, 1H) 4,37 (br s, 1H) 3.97 (br d, J=3.63 Hz,
2H) 3.32 — 3.48 (m, 2H) 3.01 (s, 1H), LC/MS [M + H] = 527.0.
Example 123
Synthesis of (1 , 35, 4R, 5R)(6-aminochloro-9H-purinyl)-3 -ethyny1-3 ,4-
dihydroxytetrahydrofurany1)methoxy)methoxyoxoethy1)phosphonic acid
0 O
N(BOC)2 BCOMe o N(Boc)2 o NH2
M90 OMe
N N N
\ q 10m.
(1‘ \N
</ l 1 N2 M604: [ TMSBr,MeCN \N
//'\ H04]:Q\4?~0Me (ii I A
HO :20,” / M80 0 Ho 0
N X07! N 3' X07! N
c1 Rh2(OAc)4,toluene 0'
—AcO: i"0Ac A95 iOAO A95 iOAC
iaq. NaOH, THF
0 NH2
,N .N
H04,”8.29011. < l A
HO O : O 'N N Cl
H6 “OH
Example123
Step 1:
A mixture of (2R,3R,4R,5R)—5-(6-(N,N’-bis(lerl—butoxycarbonyl)amino)-2—chloro—
9H-puriny1)—3-ethyny1(hydroxymethyl)tetrahydrofuran-3,4-diyl diacetate (565 mg,
0.926 mmol, 10 eq) and methyl 2-diazo-2—(dimethoxyphosphoryl)acetate (247 mg, 1.20
mmol, 1.3 eq) was azeotroped twice with toluene and the resulting oil was solved in
toluene (5.7 mL). The reaction solution was d at ambient temperature under argon
atmosphere and fitted with a jacketed reflux ser. Rhodium(II) acetate (0.185 mmol, 82
mg, 0.2 eq) was added and the reaction heated at 75°C for 9 h before it was cooled to room
temperature. The reaction mixture was concentrated and the resulting oil was purified by
flash silica gel column chromatography to provide (2R, 3R, 4R, 5R)—5 -(6-(N,N’ -bis(terz‘-butoxy-
-l92-
carbonyl)acetamido)—2-chloro-9H-purinyl)((1—(dimethoxyphosphoryl)—2-methoxy-2—
oxoethoxy)methyl)-3 yltetrahydrofuran-3 l diacetate.
Steps 2—3:
Deprotection of the product from the previous step was performed according to the
procedure described for step 4 in Example 121. Aq. NaOH solution was used instead of
KOEt that lead to the carboxylic acid. The title compound was isolated as a white solid from
preparative reversed-phase HPLC.
1H NMR (CD3OD, 300 MHz) 5 8.08 (s, 1H), 6.06 (bs, 1H), 5.06—5.08 (d, J: 5 Hz, 1H), 4,28
(s, 1H), 3.90—4.10 (m, 2H), 3.79 (s, 3H), 3.98 (bs, 2H), 3.13 (s, 1H); LC/MS [M + H] =
478.2.
Example 124
sis of (l-(((2R,3S,4R,5R)(2-chloromorpholino-9H—purinyl)ethynyl-3,4-
dihydroxytetrahydrofuranyl)methoxy)ethoxy—2-oxoethyl)phosphonic acid
r) o o 00 00
% \OEtp",OEt
1 N2 Etc—“FfjOEt
HO </NN N10 TMSBr MeCN N/kc EtO HOSE—fjoa [hr/Am
:0: 'N Rh2(OAc)4. toluene
Acd I'OAc :Acd bAc :Acd bAc
(l-(((2R, 3S, 4R, 5R)—5-(2-chloromorpholino-9H—purin-9—yl)-3 -ethynyl-3,4-dihydroxytetrahydrofuran
methoxy)—2-ethoxyoxoethyl)phosphonic acid is prepared in a
manner analogous to that set forth in Example 59, except ethyl 2-diazo(diethoxyphos-
phory1)acetate in place of 2-diazomalonate in step 3, morpholine is used in place of
benzylamine in step 7 and step 4 is eliminated. Compound was isolated as a 1:1 mixture of
diastereomers.
1H NMR (400 MHz, DMSO-ds) of major isomer: 6 8.59 (s, 1H), 5.90 (m, 1H) 5.00 (d, J:
7.0Hz, 1H), 4.25 (m, 2H), 4.05 (m, 4H), 3.99 (m, 1H), 3.83 (m, 1H), 3.75 (m, 4H), 3.01 (s,
-l93-
1H) 1.05 (t, J: 7.1Hz, 3H). 1H NMR (400 MHz, DMSO-ds) of minor isomer: 5 8.48 (s,
1H), 5.88 (m, 1H), 4.94 (d, J: 6.9Hz, 1H), 4.25 (m, 2H), 4.05 (m, 4H), 3.99 (m, 1H), 3.83
(m, 1H), 3.75 (m, 4H), 3.01 (s, 1H), 0.99 (t, J= 7.1Hz, 3H). HPLC: minor isomer = 6.63 min;
major isomer = 6.65 min, 98.6%. LC-MS: m/z = 562 (M+); m/z = 240 ose fragment).
e 125
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)-3—ethynyl-3 ,4-dihydroxy(5-(trifluoromethy1)—3H—
imidazo[4,5-b]pyridin-3—y1)tetrahydrofurany1)methoxy)malonic acid
«N O O
O 0E1 I1l 0 CE 0 0“ N
, N
u N CF, </ ,\ aqLiOH <’ l\
BO 0 —> 8HO ,
/ 0 N $010 E10 0 N
O 0 N
BSA.TMSOTf N CF3 THF 01:3
\ MeCN _
_ .
AC6 me 120‘: EOAC H6 "OH
Example 1 12
Proceeding as described in Example 15 above but substituting 6-amino
chloroadenine with 5-(trifluoromethy1)-3H—imidazo[4,5-b]pyridine provided the title
compound as a White solid.
1H NMR (CD3OD, 300 MHz) 5 8.82 (bs, 1H), 8.23 (d, J=8 Hz, 1H), 7.78 (d, J=8 Hz, 1H),
7.29—7.26 (m, 2H), 7.03—7.00 (m, 3H), 6.32 (d, J=7 Hz, 1H), 5.10 (d, J=7 Hz, 1H), 4.37—4.36
(m, 1H), 4.08 (d, J=3 Hz, 2H), 3.42 (dd, J=15, 28 Hz, 2H), 2.98 (s, 1H); LC/MS [M + H] =
5352.
Example 126
Synthesis of 2—(((2R, 3S, 4R, 5R)—5-(6-amino-2—ch1oro—9H-purin—9-y1)—3 —ethyny1—3 ,4-
dihydroxytetrahydrofurany1)methoxy)—2-(thiazoly1methy1)malonic acid
0 O N
\N o NH2
0 OEt s \ 0 CE (/ 1 A o oH
\=N N
'HCI H N’ \
CI </ . 1
E10 0 —> EC 0
0 0 ”0 O N /
GAO C52003,DMF OAc o N
\ 1.BSA,TMSOTf C.
Q \
. _ SVN . . MecN S\N _
Aco‘ ’OAc Aco‘ ’OAC IOH,THF v —HO‘: _OH
Example 126
ding as described in Example 15 above but substituting allyl bromide with 4—
(chloromethy1)thiazole provided the title compound as a white solid.
—194—
1H NMR (CD3OD, 300 MHz) 5 8.76 (bs, 1H), 8.57 (bs, 1H), 7.36 (bs, 1H), 6.00 (d, J=7 Hz,
1H), .95 (m, 1H), 4.35 (bs, 1H), 4.08—4.04 (m, 2H), 3.66—3.64 (m, 2H), 2.98 (s, 1H);
LC/MS [M + H] = 524.9.
Example 127
Synthesis of 2-(((2R, SS, 4R, 5R)—5-(2-acetylamino—9H-purinyl)ethynyl-3,4-
dihydroxytetrahydrofuran-2—yl)methoxy)—2—benzylmalonic acid
N(Boc)2
NH2 )”)3 N(Boc)2
8f” Boo 0,4-DMAP2
N NAG «Nf: Pd(PPh3)2C|2
3°C «gfi
H DMF
—AcO ’o
«BSA TMSOTflMeCN
NH2 NH2 0 NH2
OEt N
NW4—aq. LiOH THF N1 \
1Naq. HCI (I l N
EtO :CNJLéf‘— E10 0 N NW
_ EtO
—HO ’0OH —AcO Acd ”OAc
Example127
Step 1:
To a suspension of 6—amino—2-chloroadenine (3.0 g, 17.69 mmol, 1 eq) in DCM (60
mL) was added 4-DMAP (2.16 g, 17.69 mmol, 1 eq), TEA (21.48 g, 212.30 mmol, 29.55 mL,
12 eq) and (Boc)20 (30.89 g, 141.53 mmol, 8 eq). The sion was stirred at 20°C for 18
h before it was diluted with saturated aq. NH4C1 (100 mL), and extracted with ethyl acetate (2
x 100 mL). The combined organic layer was washed with brine (200 mL), dried by ,
filtered and concentrated. The crude residuewas purified by Combi-fiash (silica gel, 0—20%
EtOAc in petroleum ether) to give tert-butyl 6-(N,N’ -bis(terZ-butoxycarbonyl)amino)
chloro-9H-purinecarboxylate (904 mg, 11% yield) as a yellow gum.
Step 2:
To a solution of tert—butyl 6—(N,N’ -bis(tert-butoxycarbonyl)amino)—2—chloro—9H-
purinecarboxylate (900 mg, 1.92 mmol, 1 eq) in DMF (12 mL) was added Pd(PPh3)2C12
(134.43 mg, 191.52 umol, 0.1 eq) and tributyl(1-ethoxyvinyl)stannane (832 uL, 2.46 mmol,
1.29 eq) under N2 atmosphere. The sion was stirred at 95 °C for 3 h before it was
diluted with saturated aq. KF solution (8 mL) and stirred at 20 °C for 1 h. The mixture was
extracted with ethyl acetate (2 x 8 mL). The ed organic layer was washed with water
(20 mL), brine (15 mL), dried by Na2S04, filtered and concentrated. The crude residue was
-l95-
d by flash (silica gel, 30—70% EtOAc in petroleum ether) to give tert—butyl N—
(Zert—butoxycarbonyl)amino -(2-(1-ethoxyvinyl)—9H—puriny1)carbamate (256 mg, 33%
yield) as a white solid.
Step 3:
To a solution of the product from the last step (60 mg, 109.38 umol, 1 eq) and diethyl
2-benzyl(((2R, 3R, 4R)-3 ,4, 5 -triacetoxy-3 —ethynyltetrahydrofuranyl)methoxy)—ma1onate
(53.22 mg, 131.26 umol, 1.2 eq) in MeCN (1 mL) was added BSA (65 uL, 262.52 umol, 2.4
eq). The solution was stirred at 65 °C for 0.5 h before it was cooled to 25 OC and followed by
addition of TMSOTf (24 uL, 131.26 umol, 1.2 eq). The ing solution was stirred at 65
°C for 1 h before it was diluted with ted aq. NaHCO3 (5 mL) and extracted with EtOAc
(2 x 5 mL). The combined organic layer was trated. The crude residue was purified
by preparative TLC (EtOAc) to give diethyl 2-benzyl(((2R, 3R, 4R, 5R)—3,4-diacetoxy(6-
amino(1-ethoxyvinyl)—9H—purin—9-y1)-3—ethynyltetrahydrofuran—2-y1)-methoxy)malonate
(42 mg, 55% yield) as a colorless gum.
Step 4:
To a solution of diethyl 2-benzyl(((2R, 3R, 4R, 4-diacetoxy(6-amino(1-
ethoxyvinyl)-9H-purinyl)ethynyltetrahydrofuranyl)methoxy)-malonate (40 mg,
57.66 umol, 1 eq) in THF (1.5 mL) was added 1M aq. HCl aq. (0.5 mL, 867 eq). The
mixture was stirred at 20 °C for 21 before it was d with saturated aq. NaHCO3 (5 mL)
and the mixture was extracted with ethyl acetate (3 x 5 mL). The combined organic layer
was dried by Na2S04, filtered and concentrated to provide crude diethyl 2-benzyl
(((2R, 3R, 4R, 5R)—3 ,4—diacetoxy-5 -(2—acetyl—6-amino—9H—purinyl)—3 -ethynyltetrahydrofuranyl
)methoxy)malonate (40 mg) as a light yellow gum.
Step 5:
To a solution of crude diethyl 2-benzyl(((2R, 3R, 4R, 5R)-3,4-diacetoxy(2-acetyl-
6-amino-9H—purin—9-y1)-3—ethynyltetrahydrofuran—2-yl)methoxy)malonate (30 mg, 45.07
umol, 1 eq) in THF (4 mL) was added 1M aq. LiOH aq. (901 uL, 20 eq). The mixture was
stirred at 20 0C for 6 before it was acidified with 1N aq. HCl to pH 6 and concentrated. The
crude residue was purified by preparative HPLC and the fraction was dried by lyophilization
to give the title compound (1.4 mg, 6% yield) as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.43 (bs, 1H), 7.14—6.98 (m, 5H), 6.06 (d, J=6.4 Hz, 1H),
4.89 (d, J=6.8 Hz, 1H), 4.26 (m, 1H), 3.94—3.91 (m, 2H), 3.30—3.21 (m, 2H), 2.91 (s, 1H),
2.61 (s, 3H); LC/MS [M + H] = 5260.
e 128
Synthesis of R, 3S, 4R, 5R)(6-aminochloro-9H—purinyl)—3 -ethynyl-3 ,4-
dihydroxytetrahydrofuran-Z—yl)methoxy)-2—(thiophen-Z-ylmethyl)malonic acid
0 O N
0 CE: \\ o OEt (I 1A
S N N CI
BO 0 —>
ho“ EtO o
o 0
052003. DMF OAc 1. BSA, TMSOTf
i Q
, . \ S ‘ . MeCN
Acd bAc Acd bAc 2- aq. LIOH, THF
Example 128
Proceeding as described in Example 15 above but substituting allyl bromide with 2-
(bromomethyl)thiophene provided the title compound as a White solid.
1H NMR (CD3OD, 300 MHz) 5 8.37 (bs, 1H), 7.10 (d, J=5 Hz, 1H), 6.93—6.72 (m, 2H), 6.00
(d, J=7.2 Hz, 1H), 4.98 (d, J=7.6 Hz, 1H), 4.23 (bs, 1H), 4.06 (bs, 2H), 3.62—3.58 (m, 2H),
2.94 (s, 1H); LC/MS [M + H] = 5239.
Example 129
Synthesis of 2-(((2R, 3S, 4R,5R)—5-(2-chloro(cyclopentylamino)—9H—purinyl)—3-ethynyl-
3,4-dihydroxytetrahydrofuran-Z-yl)methoxy)-2—(phenylsulfonyl)acetic acid
QI0 OH N
0 NF N
05° 0 /
_ _
/H<‘5 5H NYN
e 129
The title compound was prepared in an analogous manner to Example 59 except ethyl
2-diazo(phenylsulfonyl)acetate was used instead of l-ethyl 3-(propen—1-yl) 2—diazo
malonate in Step 3, cyclopentanamine is used in place of benzylamine in Step 7 and Step 4 is
eliminated.
LC/MS [M + H] = 592.0.
-l97-
Example 130
Synthesis of 2-(((2R, 3S, 4R, 5R)(2-chloro—6-(methylamino)-9H—purinyl)-3 -ethynyl-3,4-
dihydroxytetrahydrofuran-Z—yl)methoxy)—2—(4-(l-ethyloxo—1,2-dihydropyridin-3 -
zyl)malonic acid
O O
O N
q «~15 WN A—>N Br
0 QB
0 N
o N
BO O ::03' N CI K2C03,DMF o _S 7
Acd 9OAC /\N
Example 130
Proceeding as described in Example 20 above but substituting diethyl 2-
(((2R, 3R, 4R, 5R)—3 ,4—diacetoxy-5 -(6—N,N’ -(bi s-(lert—butoxycarbonyl)amino)chloro-9H—
purinyl)—3-ethynyltetrahydrofuran-Z-yl)methoxy)malonate with diethyl 2-(((2R, 3R, 4R,5R)-
3,4-diacetoxy(6-((lert-butoxycarbonyl)(methyl)amino)chloro-9H-purinyl)ethynyl-
tetrahydrofuran-Z-yl)methoxy)malonate provided the title compound as a white solid.
1H NMR (400 MHz, CD3OD) 5 ppm 8.04 (s, 1H), 7.58 (dd, J=6.7, 1.9 Hz, 1H), 7.27—7.38
(m, 5H), 6.35 (t, J=6.9 Hz, 1H), 5.95 (d, J=7.8 Hz, 1H), 4.77 (d, J=7.8 Hz, 1H), 4.28 (t, J=2.6
Hz, 1H), 3.96—4.13 (m, 4H), 3.38—3.57 (m, 2H), 3.05 (s, 1H,) 2.99 (m, 3H), 1.32 (t, J=7.3 Hz,
3H); LC/MS [M + H] = 653.1.
Example 131
Synthesis of R, 3S, 4R, 5R)—5—(6-chloro-3 -methyl- azolo[3 ,4-b]pyridin- l -yl)-3 -
ethynyl-3 ,4-dihydroxytetrahydrofuran-Z-yl)methoxy)(4-(2-oxotetrahydropyrimidin- 1 (2H)-
yl)benzyl)malonic acid
-l98-
0“ t-B OK OH 0 Cl
OH o=N/—\_c| JLNDA Tin:
—>“N ANjig SOCIZ, DCM )L /E>A
—> HN N
H N2 DCM THF ”b k»
0 CE
‘0 O
aq. TFA DCM o E10
C52003 DMF
o ‘—o
)LN ‘. ., \. K‘—
AcO )LN AcO 0
HNk) :Oj/jcz:EooHOH HNQ
4-DMAP
pyridine
O O
OOinom'iin g1,Cl O OH
aq. LiOH N/ \
_>THF HO 0 \N /
0 N Cl
DBU TMSOTf
0 MeCN
. . .
HNLN AcO¢ ’OAc WbN A00 HNLN H6 "0H
K) Example 131
Step 1:
To a solution of (4-aminophenyl)methanol (27.65 g, 224.44 mmol, 1 eq) in a mixture
of anhydrous DCM (100 mL) and anhydrous THF (50 mL) maintained at 25 °C was added 1-
chloro-3 -isocyanatopropane (26.83 g, 224.44 mmol, 1 eq) se. The reaction e
became slightly exothermic and turned yellow as a precipitate was formed within 15 minutes.
The mixture was stirred for 1.5 h before hexanes (50 mL) was added. The mixture was
stirred for additional 15 min before the solid product was collected by filtration, rinsing with
a mixture ofDCM and hexanes (5:1 = vzv). Upon drying ed 1-(3-chloropropyl)(4-
(hydroxymethyl)phenyl)urea (38.45 g) as a light yellow solid. .
Step 2:
To a solution of 1-(3-chloropropyl)—3-(4-(hydroxymethyl)phenyl)urea (30.00 g, 123.6
mmol, 1.0 eq) in THF (300 mL) at 25 °C was added a solution of 1M t-BuOK in THF (247.2
mL, 247.2 mmol, 20 eq) dropwise while stirring vigorously with a mechanical stirrer. The
resulting heterogeneous mixture was stirred at 25 °C for 6 h before it was cooled to 0 °C and
acidified to pH 5—6 with 2N aq. HCl. The organic volatile was then removed under d
pressure. The crude solid was taken up in MeOH (75 mL) and concentrated. The resulting
solid mixture was rinsed with a solution of 7% MeOH in DCM (220 mL) under gentle
heating and the solid was d off. The solid was rinsed again with 7% MeOH in DCM
(150 mL) and filtered. The combined rinse was concentrated to give the desired crude 1-(4-
(hydroxymethyl)phenyl)tetrahydropyrimidin-2(1H)-one as a yellowish solid (27.68 g).
W0 20191246403
Step 3:
Tbawwmmmdkmw14¢mewmwwmmmflMmemmmmmmflU0
one (15.00 g, 72.74 mmol, 1 eq) in DCM (250 mL) was added a solution of thionyl chloride
(1061 mL, 145.48 mmol, 2 eq) at 25 0C under a N2 atmosphere. The mixture was stirred at
0C for 8 h before it was diluted with EtOAc (250 mL) and stirred for 30 min. The solid
was collected by filtration, rinsed with EtOAc and dried to provide crude chloro—
methyl)phenyl)tetrahydropyrimidin-2(lhO—one (15.00 g).
Step 4:
To a solution of diethyl 2-(((3aR, 5R, 6R, -acetoxy-2,2-dimethyl(prop-l-yn-l-
yl)tetrahydrofuro[2,3-d][1,3]dioxolyl)methoxy)malonate (7.04 g, 16.99 mmol, 1 eq) in
DMF (70 mL) was added CS2CO3 (11.07 g, 33.98 mmol, 2 eq) and crude 1-(4-(chloro-
methyl)phenyl)tetrahydropyrimidin-2(1H)—one (5.09 g, 25.49 mmol, 1.5 eq) at 20 CC. The
mixture was stirred at 20 °C for 5 h before it was diluted with H20 (300 mL) and extracted
‘MmEKMcOxlmnm)Tmcmmmwogmmwwnwmw%deMflmm%%OmU,
mmmwaNm&MJMMwmwammewiTMcmwpmwawupmfiaflwflwhmma
gel column chromatography % e in DCM) to provide diethyl 2-
(((3aR, 5R, 6R, 6aR)acetoxyethynyl-2,2-dimethyltetrahydrofuro[2,3 -d][1,3]dioxol-5 -
yl)methoxy)—2-(4-(2-oxotetrahydropyrimidin-l(2H)-yl)benzyl)malonate (9.62 g, 94% yield)
as a solid.
Step 5:
To a solution of diethyl 2-(((3aR,5R, 6R, 6aR)acetoxy-6—ethynyl-2,2-dimethyl-
ydrofuro[2, 3 -d] [ l ,3 ] dioxol-5 -yl)methoxy)(4-(2-oxotetrahydropyrimidin-1(2110-
yl)benzyl)malonate (17.31 g, 28.72 mmol, 1 eq) in DCM (90 mL) was added H20 (18
mL) and TFA (90 mL, 1.22 mol, 42 eq) at 0 °C. The reaction mixture was stirred at 20—25°C
mefiwwcmwwnmwumhnmmwdmwwm.mefidwwwamflmmflwMI
DCM (2 x50 mL) under reduced pressure to provide the crude product diethyl 2-
(((2R, 3S, 4R)—3 -acetoxy-3 -ethynyl-4, 5 -dihydroxytetrahydrofuran-2—yl)methoxy)—2—(4-(2-
oxotetrahydropyrimidin-1(2H)-yl)benzyl)malonate which was used in the next step without
funherpunficafion.
Step 6:
To a solution of crude diethyl 2-(((2R,3S,4R)—3-acetoxyethynyl-4,5-dihydroxy-
tetrahydrofuranyl)methoxy)—2-(4-(2-oxotetrahydropyrimidin- l (2]10-yl)benzy1)malonate
(17.23 g, crude) in DCM (170 mL) was added 4-DMAP (374 mg, 3.06 mmol, 0.1 eq), A020
nL,18377rnnufl,6eq)andpyrkhne(l9781nL,245021nnufl,8eq)at0°C1 The
reaction mixture was stirred at 20—25°C for 16 h before it was concentrated under reduced
pressure. The residue was solved in EtOAc (200 mL), washed with 1N aq. HCl (150
mL), 10% aq. CquO4 (150 mL), saturated aq. NaHCO3 (150 mL) and brine (150 mL), dried
over NazSO4, filtered and concentrated to provide crude diethyl 2-(4-(2-oxotetrahydro-
pyrimidin-1(2110-yl)benzyl)(((2R, 3R, 4R)-3 ,4, 5 -triacetoxy-3 -ethynyltetrahydrofuran
yl)methoxy)malonate (19.24 g) as a foam which was d onto the next step without
fufiherpufificafion.
Step 7:
mnfionofmudedmflmd2(4424mowndwdmmwmnMHPKZHnybmuyDQ-
(((2R,3R,4R)-3,4,5—triacetoxyethynyltetrahydrofuranyl)methoxy)malonate (450 mg,
0.70 mmol, 1 eq) and 6-chloromethyl-lH-pyrazolo[3,4-b]pyridine (128 mg, 0.77 mmol,
1.1 eq) in MeCN (4 mL) was added DBU (315 uL, 2.09 mmol, 3.0 eq) at 0 oC. The solution
was stirred at 0 0C for 5 min and followed by addition of a solution of TMSOTf (566 uL,
3Bnme45apmhkCNCMMQdmmMW.flwsdenwmsmmdMOOCfiHOShmm
then stirred at 70 °C for 16 h before it was allowed to cool to 25 °C and adjusted the pH to 9
meMmmwanMHOI.memmmwwemmaahmmemflawmwa40mL)Tm
combined c layer was dried with NazSO4, filtered and concentrated. The crude residue
which was purified by Combi-fiash on silica gel (0—10%MeOH in DCM) to give diethyl 2-
(((2R, 3R, 4R, 5R)—3 ,4-diacetoxy(6-chloro-3 -methyl- 1H-pyrazolo[3 ,4-b]pyridin- l -yl)-3 -
ethynyltetrahydrofuranyl)methoxy)—2-(4—(2-oxotetrahydropyrimidin-1(2110-yl)benzyl)—
mammeESmg49%ymM)%aydbwgmn
Step 8:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-chloro—3-methyl-1H-
pyrazolo[3 ,4-b]pyridin-1—yl)-3 -ethynyltetrahydrofuran-2—yl)methoxy)(4-(2-oxotetrahydro-
pyrimidin-l(2]10-yl)benzyl)malonate (296 mg, 392 umol, 1 eq) in THF (6 mL) was added aq.
LKHlsdufion(2hL‘196nflg10eq) ThesdufionumssfinedatSOoClbr2hbefineflm
organic volatile was removed under reduced pressure. To the water layer was added 1N HCl
to adjust the pH to 5—6. The mixture was concentrated to give crude product which was
purified by preparative HPLC (Column: YMC-Actus Triart C18 150*30mm*5um; mobile
phase: [water %FA)—ACN]; B%: %, 10min). The product was isolated by
WO 46403
lyophilization to give 2-(((2R,3S,4R,5R)(6—chloro—3-methyl-1H—pyrazolo[3,4-b]pyridin—l—
yl)ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)(4-(2-oxotetrahydropyrimidin-
l(2H)-yl)benzyl)malonic acid (32 mg) as a white solid..
1H NMR (400 MHz, DMSO-d6) 5 ppm 8.27 (d, J=8.28 Hz, 1H), 7.31 (d, J=8.28 Hz, 1H),
6.97 (d, J=8.53 Hz, 2H), 6.81 (d, J=8.53 Hz, 2H), 6.49 (s, 1H), 6.20 (s, 1H), 6.13 (d, J=7.53
Hz, 1H), 5.97 (s, 1H), 4.98 (d, J=7.53 Hz, 1H), 4,13 (dd, J=8.4l, 2.64 Hz, 1H), 3.93—3.99 (m,
1H), 3.84—3.9l(m, 1H), 3.64 (s, 1H), 3.42—3.52 (t, J=5.60 Hz, 2H), 3.17—3.23 (m, 2H), 3.05—
3.16 (m, 2H), 2.45 (s, 3H), 1.90 (m, 2H); LC/MS [M + H] = 614.3.
Example 132
Synthesis of 2-(((2R, 3S, 4R, 5R)—5-(2-chlorooxo- lH-purin-9(6hO-yl)-3 yl-3 ,4-
dihydroxytetrahydrofuran-2—yl)methoxy)-2—(4-(2-oxotetrahydropyrimidin— 1 (2H)-
yl)benzyl)malonic acid
0 CI 0 O
O O OH N
\N aq. LiOH </ i NH
HO O N
O NA
OAc CIHNLN Cl
BSA TMSOTfo
MeCN O
. . . .
'4ij AcO AOc(5 ’OAc Ho‘ ’OH
K) Example 132
Step 1:
To a solution of 2,6—dichloro-9H—purine (3 79.97 mg, 2.01 mmol) in MeCN (5
mL) was added BSA (956 uL, 3.87 mmol) at 25°C. The reaction mixture was stirred at 65°C
for 0.5 h and then cooled back to 25°C. To this mixture was added diethyl 2-(4-(2—oxotetra-
hydropyrimidin-1(2110-yl)benzyl)(((2R, 3R, 4R)-3 ,4, 5 -triacetoxy-3 yltetrahydrofuran-
2-yl)methoxy)malonate (1 g) in MeCN (5 mL) and TMSOTf (419 uL, 2.32 mmol) at 25 °C
and further stirred at 65 0C for 5 h. The on mixture was allowed to cool to 25 0C before
it was quenched with saturated aq. NaHCO3 (10 mL) and extracted with EtOAc (3 x 5 mL).
The combined organic layer was washed brine (10 mL), dried over anhydrous NazSO4,
filtered and trated. The crude reisude was purified by flash silica gel column
chromatography (0—10% MeOH in DCM) to provide diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy
(2,6-dichloro-9H-purinyl)—3-ethynyltetrahydrofuranyl)methoxy)—2-(4-(2-
oxotetrahydropyrimidin-l(2H)-yl)benzyl)malonate (365 mg) as a foam.
Step 2:
WO 46403
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy-5—(2,6-dichloro-9H—purin—9-
yl)-3 -ethynyltetrahydrofuranyl)methoxy)(4-(2-oxotetrahydropyrimidin-1(2110-
yl)benzyl)malonate (180 mg) in THF (2 mL) was added LiOH'HzO (97.39 mg, 2.32 mmol, 10
eq) in H20 (1 mL) at 25°C. The reaction mixture was stirred at 40°C for 2 h before the
organic volatile was removed under reduced pressure. The aqueous phase was acidified to
pH 5—6 with 1N aq. HCl and concentrated under d re. The crude residue was
purified by preparative HPLC (column: YMC-Actus Triart C18 150*30mm*5um, mobile
phase: [water (0.225%FA)-ACN]; B%: 13%—33%, 10min) and dried by lyophilization to
provide 2-(((2R, 3S, 4R, 5R)(2-chlorooxo— 1H—purin-9(6ID-yl)—3 -ethynyl-3 ,4-dihydroxy-
tetrahydrofuran-Z-yl)methoxy)(4-(2-oxotetrahydropyrimidin-1(2H)-y1)benzyl)malonic
acid (15 mg) as a white solid.
1H NMR (400 MHz, CD3OD) 6 ppm 8.62 (s, 1H), 7.24 (d, J=8.31 Hz, 2H), 7.03 (d, J=8.31
Hz, 2H), 6.32 (d, J=6.48 Hz, 1H), 4.61 (d, J=6.48 Hz, 1H), 4.28—4.34 (m, 1H), 3.92—4.04 (m,
2H), 3.55—3.66 (m, 2H), 3.33—3.40 (m, 4H), 3.02 (s, 1H), 1.99—2.06 (m, 2H); LC/MS [M +
H] = 617.2.
Example 133
Synthesis of 2—(((2R,3S, 4R,5R)ethynyl-3,4-dihydroxy(5-methyl-2,4-dioxo-3,4-
dihydropyrimidin-l(2110-yl)tetrahydrofuran—2-yl)methoxy)—2-(4-(2—oxotetrahydropyrimidin-
1(2110-yl)benzyl)malonic acid
0 0 o o o
0 GE o OE! >—< 0 OH >—<
\ )=o / NH aq. LiOH / NH
NH THF
BO 0 E10 0 N
0 0 o _> HO 0
OAc —< N—<
BSA,TMSOTf o o
o MeCN o o
. _ . _ ,
)LN Aco‘ ’OAc )LN Aco‘ ’OAC )LN Ho‘ ”OH
HNU HN\\) HNk)
e 133
Step 1:
To the mixture of 5—methylpyrimidine-2,4(lH,3I-D—dione (100 mg, 792.94 umol, 1
eq) in MeCN (2 mL) was added BSA (490 uL, 1.98 mmol, 2.5 eq). The mixture was stirred
at 85°C for 0.5 h. The mixture was cooled to 0°C and followed by addition of a solution
of diethyl 2-oxotetra-hydropyrimidin— 1 (2]10-yl)benzyl)—2-(((2R, 3R, 4R)-3,4,5-triace-
toxyethynyltetrahydrofuranyl)methoxy)malonate (385 mg) in MeCN (2 mL) and
TMSOTf (430 uL, 2.38 mmol, 3.0 eq) was added dropwise. The e was stirred at 65°C
under N2 atmosphere for 5 h before it was allowed to cool to 25 °C and quenched with
saturated aq. NaHCO3 (10 mL). The mixture was extracted with EtOAc (3 x 5 mL). The
organic layers were combined, dried over Na2S04, filtered and concentrated in vacuo. The
crude compound was purified by silica gel column chromatography (0—5% MeOH in DCM)
to provide diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxyethynyl(5-methyl-2,4-dioxo-3,4-
dihydropyrimidin-l(2110-yl)tetrahydrofuran—2-yl)methoxy)—2-(4-(2—oxotetrahydropyrimidin-
1(2H)-yl)benzyl)malonate (208 mg, 37% yield) as a solid.
Step 2:
To a on of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxyethynyl(5-methyl-2,4-
dioxo-3,4-dihydropyrimidin-1(2H)-y1)tetrahydrofuran-Z-yl)methoxy)(4-(2-oxotetrahydro-
pyrimidin-1(2hO-yl)benzyl)malonate (200 mg, 280.62 umol, 1 eq) in THF (2 mL) was added
LiOH'HzO (58.88 mg, 1.40 mmol, 5 eq) in H20 (1 mL) at 20-25°C. The reaction mixture
was stirred at 40°C for 1 h before the organic volatile was removed under reduced pressure.
The aqueous phase was acidified to pH is 5—6 with 1N aq. HCl and concentrated under
reduced pressure, The crude residue was purified by preparative HPLC (column: YMC-
Actus Triart C18 150*30mm*5um; mobile phase: [water (0.225%FA)—ACN], B%: 13%-
33%, 10min) and then followed by lyophilization to provide 2-(((2R,SS,4R,5R)-3 yl-
3 ydroxy-5 -(5-methyl-2,4-dioxo-3 ,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran
yl)methoxy)(4—(2-oxotetrahydropyrimidin-1(2H)-yl)benzyl)malonic acid (49 mg) as a
white solid.
1H NMR (400 MHz, CD3OD) 6 ppm 7.83 (d, J=0.75 Hz, 1H), 7.33 (d, J=8.28 Hz, 2H), 7.11
(d, J=8.28 Hz, 2H), 6.06 (d, J=7.78 Hz, 1H), 4.44 (d, J=7.78 Hz, 1H), 4.16 (t, J=2.26 Hz,
1H), 3.92—4.05 (m, 2H), 3.47—3.65 (m, 3H), .41 (m, 3H), 2.98 (s, 1H), 2.04 (m, 2H),
1.62 (s, 3H); LC/MS [M + H] = 5731.
Example 134
Synthesis of 2-(((2R, 3S, —5-(2,4-dioxo-3 ,4-dihydropyrimidin- 1 (2]10-yl)-3 -ethynyl-3 ,4-
oxytetrahydrofuranyl)methoxy)(4-(2-oxotetrahydropyrimidin-1(2H)-
yl)benzyl)malonic acid
—204—
WO 46403
o o o
0 0a 0 OH
aq. LiOH / NH
BO 0
0 o _. HO 0
GAO N—<
BSA TMSOTfO o
\ \
o MeCN o
, , , _
)LN Acd ’oAc )LN HO ’OH
HNK) HN\J
Example 134
Proceeding as described in Example 133 above but substituting thymine with uracil
provided the title compound as a white solid.
1H NMR (400 MHz, CD3OD) 5 ppm 7.91 (d, J=80 Hz, 1H), 7.31 (d, J=8.4 Hz, 2H), 7.15 (d,
J=8.4 Hz, 2H), 6.01 (d, J=7.5 Hz, 1H), 5.20 (d, J=8.0 Hz, 1H), 4.36 (d, J=7.5 Hz, 1H), 4.17
(t, J=2.4 Hz, 1H), 3.99 (dd, J=18.8, 2.5 Hz, 2H), 3.55—3.66 (m, 2H), 3.44—3.52 (m, 1H),
3.33—3.38 (m, 3H), 3.01 (s, 1H), 1.99 = 559.1.
— 2.10 (m, 2H), LC/MS [M + H]
Example 135
Synthesis of R, 3S, 4R, 5R)(4-aminooxopy1imidin-l (2H)-yl)-3 -ethynyl-3 ,4-
oxytetrahydrofuranyl)methoxy)(4-(2-oxotetrahydropyrimidin-1 (2110-
yl)benzyl)malonic acid
\_:)H=o 0 NH2
0 OH ,—<
aq.Li0H / \N
o N—<: _> HO 0
GAO N—<
BSA TMSOTf o
MeCN 0
_ ,
)LN ACO HNbN A00 HNXN Ho‘ OH
\J Example 135
Proceeding as described in Example 133 above but substituting thymine with ne
provided the title compound as a white solid.
1H NMR (400 MHz, DMSO-dp) 5 ppm 7.92—8.05 (m, 1H), 7.76—7.92 (br s, 1H), 7.45—7.62 (s,
1H), 7.03—7.19 (m, 4H), 6.55 (s, 1H), 5.91—5.99 (m, 1H), 5.87 (d, J=6.80 Hz, 1H ), 5.80 (d,
J=6.00 Hz,1H), 5.57 (d, J=7.20 Hz, 1H), 4.13 (t, J=6.80 Hz, 1H), 4.02—4.08 (m, 1H), 3.68—
3.82 (m, 2H), 3.50—3.57 (m, 2H), 3.22 (s, 1H), 3.19—3.22 (m, 3H), 1.82—1.99 (m, 2H), LC/MS
[M + H] = 558.3.
WO 46403
Example 136
Synthesis of 2-(((2R, 3S, 4R, 5R)(2-ch1oro—6-((cyc1opropylmethyl)amino)-9H-purinyl)
ethyny1-3 ,4-dihydroxytetrahydrofuran-Z-yl)methoxy)(4-(2-oxotetrahydropyrimidin-1(2H)-
yl)benzyl)malonic acid
0 N \ N O NH O NH
0 QB </ | A 0 GE N 0 OH N
N N/ \
CI N aq. LiOH \
H </ I </
THF l
BO 0 EC 0 N HO 0 N
O O A —> 0
OAc N N9k
BSA, TMSOTf c1 Cl
\ \ \
0 MeCN O O
. . . . . .
)LN Aco‘ ’OAc )LN Aco‘ ’OAc LN Ho‘ ’OH
HNK) HNK) HN\J
Example 136
Proceeding as descnbed in Example 133 above but substituting thymine with 2-
chloro-N—(cyclopropylmethyl)-9H—purinamine ed the title compound as a white
solid.
1H NMR (400 MHz, CD30D) 6 ppm 8.22 (s, 1H), 7.28 (br d, J=8.03 Hz, 2H), 7.03 (d,
J=8.28 Hz, 2H), 5.97 (d, J=7.28 Hz, 1H), 4.72—4.77 (m, 1H), 4.28 (s, 1H), 3.95—4.05 (m,
2H), 3.34—3.52 (m, 8H), 3.05 (s, 1H), .02 (m, 2H), 1.11—1.20 (m, 1H), 0.51—0.59 (m,
2H), 0.34 (q, J=4.85 Hz, 2H), LC/MS [M + H] = 670.1.
Example 137
Synthesis of 2-(((2R, 3S, 4R, 5R)(2-ch1oro—6-(methy1amino)-9H—puriny1)ethyny1-3,4-
dihydroxytetrahydrofuran-Z-yl)methoxy)(4-(3 -(2-hydroxyethy1)
oxotetrahydropyrimidin- 1 (2]10-y1)benzy1)malonic acid
OH OTBDPS 0TBDPS OTBDPS
1. NaH,THF — Aczo DMAP _
2. TBDPSCI, NaH 03 \ / ne.DCM \/ TBAF
O —>O > O >
>—NH Oy— O
DMF >—N 2. NaBH >—N THF
HN\_/—C| War =/—N\_) Ho:/_N\—N) y”
c| BOW
SOCI2DMF$60 1. TFA, H20
DCM 2. Acgo, Py
052003 DMF
AcO\/\N\\)
HN/ o HN/
(IN O OH
I /N \N
N A < I A
HNC' LIOH HooONNCl
BSA, TMSOTf THF 0 :L:.,
MeCN )LN H5 'OH
Hoka)
Examp|e137
Step 1:
To a solution of compound 1-(3-chloropropy1)(4-(hydroxymethyl)pheny1)urea (5 g,
.60 mmol, 1 eq) in THF (100 mL) at 0°C was added NaH (9.89 g, 247.22 mmol, 60% in
mineral oil, 12 eq). The reaction mixture was stirred at 25°C for 1.5 h before it was then
added TBDPSCl (6.80 g, 24.72 mmol, 1.2 eq) and stirred further for additional 1.5 h. To the
reaction mixture was then added allyl bromide (9.97 g, 82.41 mmol, 4 eq) and stirred further
for 16 h. To the reaction mixture was added H20 (50 mL) and the resulting mixture was
extracted with EtOAc (3 x 100 mL). The combined organic layer was washed with brine
(100 mL), dried over Na2S04, d and concentrated. The crude residue was purified by
silica gel column chromatography and eluted with EtOAc in eum ether (0—30%) to
provide l(4-(((z‘ert—butyldiphenylsilyl)oxy)methyl)phenyl)tetrahydropyrimidin-
2(1H)-one (6 g, 60% yield) as an oil.
Step 2:
To a on of compound 1-allyl(4-(((terl-butyldiphenylsilyl)oxy)methy1)-
phenyl)tetrahydropyrimidin-2(MED-one (6 g, 12.38 mmol, 1 eq) in a mixture of MeOH (60
mL) and DCM (30 mL) at -78 °C, ozone (15 psi) was introduced until the blue color of the
solution persisted for 20 minutes. The excess of ozone was removed by bubbling nitrogen
gas for 10 minutes. To this reaction mixture was added NaBH4 (937 mg, 24.76 mmol, 2 eq)
and the mixture was allowed to reach 0 oC and stirred for 15 h at 25°C. The mixture was
poured into 1N aq. HCl (50 mL) and extracted with EtOAc (2 x 100 mL). The combined
organic layer was washed with water (100 mL) and brine (100 mL), dried (Na2S04), filtered
and concentrated to give crude 1-(4-(((lert—butyldiphenylsilyl)oxy)methyl)phenyl)—3-(2-
hydroxyethyl)tetrahydropyrimidin-2(1H)-one (6.6 g) as an oil which was used directly in the
nextstep.
Step 3:
Toasdufionofmude1{4(«kwbbugddnfiwnybflyDoxyflnmhprhmndy3{2-
hydroxyethyl)tetrahydropyrimidin—2(IIfl-one (12.38 mmol, 1 eq) in DCM (40 mL) and
pyridine (3.00 mL, 3714 mmol, 3 eq) at 25°C was added AC2O (2.32 mL, 24.76 mmol, 2 eq)
and 4-DMAP (151 mg, 1.24 mmol, 0.1 eq). The mixture was stirred for 2 h before it was
qmehWhEOfiMfl)TMmMmmmwmmmdmmBQMGxflMi)Tm
combined c layer was washed with water (2 x 30 mL), brine (30 mL), dried over
NazSO4, filtered and concentrated to provide the crude 2—(3-(4-(((tert-butyldiphenylsilyl)-
thyl)phenyl)—2-oxotetrahydropyrimidin-1(2110-yl)ethyl acetate which was used in the
next step directly.
Step 4:
Toasdufionofmude243{4(«kvpbuqdmphmndmhdkmyflnmhybphmndy2-
oxotetrahydropyrimidin-1(2H)-yl)ethyl acetate (6.57 g, 12.38 mmol, 1 eq) in THF (40 mL)
was added 1 M TBAF solution in THF (18.57 mL, 1.5 eq) at 0°C. The mixture was stirred at
°C for 1 h before H20 (100 mL) was added. The reaction mixture was ted with
EtOAc (4 x 100 mL). The combined organic layer was washed with brine (50 mL), dried
over Na2S04, filtered and concentrated. The water phase was further extracted with CHzClz
(4 x 100 mL). The combined organic layer was washed with brine (50 mL), dried over
NMKMfiMmMmmemmwmmmwmmmmwmtCmmmwhwwmmwfimwe
product and further purified on silica gel column chromatography (40—100% EtOAc in
petroleum ether) to provide 2-(3 -(4—(hydroxymethyl)phenyl)oxotetrahydropyrimidin-
-yl)ethyl acetate (3.14 g) as as a white soild.
Step 5:
To a mixture of 2-(3-(4-(hydroxymethyl)phenyl)oxotetrahydropyrimidin-l(2H)-
yl acetate (1.28 g, 438 mmol, 1 eq) and DMF (3.37 uL, 43.79 umol, 0.01 eq) in DCM
(25 mL) at 0°C was added SOClz (5 mL, 68.92 mmol, 15.74 eq). The mixture was d at
50°C for 2 h before it was concentrated to give crude 2-(3—(4-(chloromethyl)phenyl)oxo—
tetrahydropyrimidin—1(2I-D-yl)ethyl acetate (1.51g) which was used in the next step without
fufiherpunficafion.
Step 6:
To a solution of crude 2-(3 -(4-(chloromethyl)phenyl)oxotetrahydropyrimidin-
l(2H)-yl)ethyl e (1.51 g, 4.38 mmol, 1 eq) and of diethyl 2-(((3aR,5R, 6R, 6aR)—6-
acetoxy-2,2—dimethyl(propyn—1-yl)tetrahydrofuro[2,3 —d][1,3]dioxol—5-yl)methoxy)-
malonate (1.91 g, 4.60 mmol, 1.05 eq) in DMF (8 mL) was added CszCO3 (4.28 g, 13.14
mmol, 3 eq) . The mixture was stirred at 25°C for 16 h before it was diluted with H20 (40
mL) and extracted with EtOAc (3 x 30 mL). The combined organic layer was washed with
saturated aq. NH4C1 (2 x 15 mL), water (2 x 15 mL), brine (15 mL), dried over Na2S04,
fidemmamwmmWiTMnmmwwmpmfiwbywbmnfimmflgmflwmmmwgd
% EtOAc in eum ether) to provide diethyl 2-(((3aR, 5R, 6R, 6aR)—6-acetoxy
ethynyl-2,2-dimethyltetrahydrofuro[2,3 -d][1,3]dioxol-5 thoxy)(4—(3 -(2-acetoxyethyl
)oxotetrahydropyrimidin-1(2hO-yl)benzyl)malonate (2.20 g, 68% yield) as a yellow
Step 7:
To a solution of diethyl 2-(((3aR, 5R, 6R, 6aR)acetoxyethynyl-2,2-dimethyl-
tetrahydrofuro[2,3-d][1,3]dioxolyl)methoxy)(4-(3 -(2-acetoxyethyl)oxotetrahydro—
pyrimidin—l(2H)—yl)benzyl)malonate (2.20 g, 3.19 mmol, 1 eq) in DCM (7.5 mL) was added
TFA (7.5 mL, 101,30 mmol, 32 eq) and H20 (1.5 mL). The mixture was stirred at 25°C for
16 h before it was diluted with water (20 mL), Then the pH of the mixture was adjusted to 7—
8mmNfimOmwdTMMMmRMewwammwwmmflfihMxmmD/Mmme
organic phase was washed with brine (10 mL), dried over anhydrous NazSO4, filtered and
concentrated to provide crude diethyl 2-(((2R,3S,4R)—3-acetoxyethynyl-4,5-dihydroxy-
tetrahydrofuranyl)methoxy)(4-(3 -(2-acetoxyethyl)oxotetrahydropyrimidin-1(2110-
fl»muflhmkmfie@lg)waydbwgmn
To a solution of the above crude product (2.1 g, 3.19 mmol, 1 eq) in DCM (15 mL)
was added AC2O (1.79 mL, 19.14 mmol, 6 eq), ne (2.06 mL, 25.52 mmol, 8 eq) and 4-
DMAP (3 8.97 mg, 319.00 umol, 0.1 eq). The mixture was stirred at 25°C for 2 h before it
was diluted with EtOAc (100 mL), sequentially washed with 1N aq. HCl (2 x 30 mL). The
organic layer was washed with water (20 mL), saturated aq. NaHCO3 solution (2 x 20 mL),
water (20 mL), and brine (10 mL). The organic layer was dried over MgSO4 and
concentrated to provide crude diethyl 2-(4-(3—(2-acetoxyethyl)oxotetrahydropyrimidin-
l(2H)-yl)benzyl)(((2R, 3R, 4R)-3 ,4, 5 -triacetoxy-3 -ethynyltetrahydrofuranyl)methoxy)-
te (2.3 g) as a yellow foam.
Step 8:
To a solution of 2-chloro-N—methyl-9H-purinamine (151.59 mg, 825.68 umol, 1.1
eq) in MeCN (3 mL) was added BSA (408.19 uL, 1.65 mmol, 2.2 eq). The mixture was
stirred at 65°C for 0.5 h before it was cooled to 0 °C and followed by addition of l 2-(4-
(3 -(2—acetoxyethyl)—2—oxotetrahydropyrimidin-1(2H)-yl)benzyl)-2—(((2R,3R,4R)-3 ,4, 5 -
triacetoxyethynyltetrahydrofuranyl)methoxy)malonate (550 mg, crude) in MeCN (3
InL)andTh4SOTf(4069luL,225nnnd,3eq) Thenfixnnevmssfinedat65°Cfor3h
before it was allowed to cool to 25 °C and quenched with saturated aq. NaHCO3 (20 mL).
The reaction mixture was extracted with EtOAc (4 x 20 mL). The combined c layer
was washed with water (10 mL), brine (10 mL), dried over Na2S04, filtered and concentrated.
The crude residue was purified by flash column chromatography on silica gel (30 — 70%
EtOAc in petroleum ether) first and then further purified by preparative TLC (7% MeOH in
DCM) to e diethyl 2-(4-(3 -(2-acetoxyethyl)oxotetrahydropyrimidin-1(2H)-
yl)benzyl)(((2R, 3R, 4R, 5R)-3 ,4-diacetoxy(2-chloro(methylamino)-9H-purinyl)-3 -
ethynyltetrahydrofuranyl)methoxy)malonate (180 mg, 22% yield) as a foam.
Step 9:
To a solution of diethyl 2-(4—(3 -(2-acetoxyethyl)oxotetrahydropyrimidin-1(2I-D-
yl)benzyl)(((2R, 3R, 4R, 5R)-3 ,4-diacetoxy(2-chloro—6-(methylamino)—9H—purinyl)—3 -
ethynyltetrahydrofuranyl)methoxy)malonate (180 mg, 210.21 umol, 1 eq) in THF (1 mL)
was added saturated aq. LiOH solution (1.5 mL). The e was stirred at 50°C for 2 h
Whmflwogmmvdmk“mnmwwdmmflmmwwpmwmerMeflhfmemmmmww
ed to 2—3 with 6N aq. HCl solution and then concentrated. The crude residue was
purified by preparative HPLC (column: YMC-Actus ODS—AQ 150*30 5u; mobile phase:
[water (O.225%FA)—ACN], B%: %,15min) to provide 2-(((2R,3S,4R,5R)—5-(2-chloro-
6-(methylamino)—9H—purinyl)—3-ethyny1-3,4-dihydroxytetrahydrofuranyl)methoxy)
(4-(3—(2-hydroxyethyl)oxotetrahydropyrimidin-1(2]10-yl)benzyl)malonic acid (71.8 mg,
W%ymMflmaWMRmmd
1H NMR (400 MHz, CD3OD) 5 ppm 8.14 (s, 1H), 7.27 (d, J=8.0 Hz, 2H), 6.98 (d, J=8.0 Hz,
2H), 5.96 (d, J=7.5 Hz, 1H), 4.76 (d, J=7.4 Hz, 1H), 4.26 (br s, 1H), 4.04 (s, 2H), 3.66 (t,
J=5.6 Hz, 2H), 3.36—3.55 (m, 8H), 3.05 (m, 4H), 1.96—2.04 (m, 2H); LC/MS [M + H] =
6741.
Example 138
Synthesis of 2-(((2R, 3S, 4R, 5R)(2—chloro—6-((cyc1opropylmethyl)amino)—9H-purinyl)
ethynyl-3 ,4-dihydroxytetrahydrofurany1)methoxy)(4-(3 -(2-hydroxyethyl)
oxotetrahydropyrimidin— 1 (21-D—y1)benzy1)mal onic acid
0 N We\ N EH 0
o OEt </ | X 0 0E: N o
N N/ CI </ / \N aq LiOH
H THF
EC 0 EtO o N / 6/?NH
\ \
0 MeCN o
p . A ,
)‘N Acd bAc LN Acd bAc )‘N
AcO\/\N AcO\/\N HO\/\N
Example 138
Proceeding as described in Example 137 above but substituting 2-chloro-N—methyl-
9H-purinamine with 2-chloro-N—(cyclopropylmethyl)-9H—purin—6-amine provided the title
nd as a white solid.
1H NMR (400 MHz, CD3OD) 8 ppm 8.09 (s, 1H), 7.28 (d, J=8.3 Hz, 2H), 7.01 (d, J=8.3 Hz,
2H), 5.96 (d, J=7.5 Hz, 1H), 4.74 (d, J=7.3 Hz, 1H), 4.26 (t, J=2.8 Hz, 1H), 4.04 (d, J=2.3
Hz, 2H), 3,62—369 (m, 2H), .54 (m, 4H), 3.34—3.42 (m, 6H), 3.06 (s, 1H) 1.97—205
(m, 2H), 1.09—1.21 (m, 1H), .61 (m, 2H), 0.34 (q, J=4.8 Hz, 2H); LC/MS [M + H] =
Example 139
Synthesis of 2-(((2R, 3S, 4R, 5R)(2-chl oro(isopropylamino)-9H-purinyl)ethyny1-
3,4-dihydroxytetrahydrofuran-Z-y1)methoxy)—2-(4-(3 -(2—hydroxyethy1)—2-
oxotetrahydropyrimidin- 1(2H)—yl)benzyl)malonic acid
NK/km 0 0
I N//LNHN o o
aq LiOH
THF <N/ILNHN
QBSA TMSOTfO QMeCN g)’*0
Acobe ~20be )LN
HO\/\N\\) Example 139
Proceeding as bed in Example 137 above but substituting 2-chloro-N—methyl—
9H-purinamine with 2-chloro-N—isopropyl-9H-purinamine provided the title compound
as a white solid.
1H NMR (400 MHz, CD30D) 5 ppm 8.08 (s, 1H), 7.29 (d, J=8.3 Hz, 2H), 7.02 (d, J=8.3 Hz,
2H), 5.95 (d, J=7.5 Hz, 1H), 4.73 (d, J=7.5 Hz, 1H), 4.39 (br s, 1H), 4.26 (t, J=2.5 Hz, 1H),
4.04 (d, J=2.0 Hz, 2H), 3.66 (t, J=5.8 Hz, 2H), 3.37—3.52 (m, 9H), 1.97—2.04 (m, 2H), 1.30 (d,
J=6.3 Hz, 6H), LC/MS [M + H] = 702.1.
Example 140
Synthesis of R, 3S, 4R, 5R)—5—(2-chloro(isopropylamino)-9H—purinyl)—3-ethynyl-
3 ,4-dihydroxytetrahydrofuranyl)methoxy)(4-(2-oxotetrahydropyrimidin-1(21-D-
yl)benzyl)malonic acid
O N \ 0 0
0 CE: {/N ll 0 0
N/C NN/ILNH aq. LiOH
THF NN//LNH
O MeCN
_ . .
)‘N ACOc (11%“ Acd NXN Hd
HN\\) HU HNK) Example 140
Proceeding as described in Example 133 above but substituting thymine with 2-
chloro-N—isopropyl-9H-purinamine ed the title compound as a white solid.
1H NMR (400 MHz, CD30D) 8 ppm 8.16 (s, 1H) 7.32 (d, J=8.44 Hz, 2H) 7.08 (br d, J=8.31
Hz, 2H) 5.99 (d, J=7.46 Hz, 1H) 4.81 (d, J=7.46 Hz, 1H) 4.41 (br s, 1H) 4.26 - 4.31 (m, 1H)
3.97 — 4.12 (m, 2H) 3.40 - 3.57 (m, 4H), 3.33 - 3.37 (m, 2H), 3.03 (s, 1H), 1.99 (m, 2H), 1.31
(m, 6H), LC/MS [M + H] = 658.3.
Example 141
Synthesis of 2-(((2R, 3S, 4R, 5R)(2-chloro—6-(methylamino)-9H—purinyl)-3 -ethynyl-3,4-
dihydroxytetrahydrofuran-2—yl)methoxy)(4-(2-oxotetrahydropyrimidin—1(2H)—
yl)benzyl)malonic acid
WO 46403
\ \
O N 0 NH 0
\N NH
0 DE (/N |J\ 0 CB N o
N/ CI </ I \N aq. LiOH
E10 0 N
o /
0 MeCN
_ _ ‘
HN)\\N Acd HNXN Acd bAc HNLN
K) k) K) Example 141
Proceeding as described in Example 133 above but substituting thymine with 2-
chloro-N-methyl-9H-purinamine provided the title compound as a white solid.
1H NMR (400 MHz, CD30D) 5 ppm 8.20 (s, 1H), 7.27 (d, J=8.13 Hz, 2H), 7.00 (d, J=8.00
Hz, 2H), 5.97 (d, J=7.38 Hz, 1H), 4.80 (d, J=7.38 Hz, 1H), 4.27 (s, 1H), 4.04 (m, 2H), 3.37 -
3.50 (m, 4H), 3.31 (d, J=1.13 Hz, 3H), 3.06 (s, 2H) 3.04 (s, 1H), 1.90 - 2.00 (m, 2H), LC/MS
[M + H] = 630.2.
Example 142
Synthesis of 2—(((2R, 3S, 4R, 5R)—5-(6-amino-2—chloro—9H-purin—9-yl)—3 —ethynyl-3 ,4-
dihydroxytetrahydrofuranyl)methoxy)—2-(thiazolylmethyl)malonic acid
OWOEt (I: iNim 0
BO 0
0 NH2
OAc 052003 DMF OAc 1 BSA TMSOTf
/ MeCN
Ac0¢ yOAc 2. aq. LiOH, THF
Example 142
Proceeding as described in Example 15 above but substituting allyl e with 2-
(bromomethyl)thiazole provided the title compound as a white solid.
1H NMR (400 MHz, CD30D) 5 ppm 8.56 (s, 1H), 7.56 (d, J=3.4 Hz, 1H), 7.33 (d, J=3.4 Hz,
1H), 6.00 (d, J=5.6 Hz, 1H), 4.68 — 4.73 (m, 1H), 4.38 (dd, J=6.3, 3.4 Hz, 1H), 3.98 — 4.07 (m,
2H), 3.85 (s, 2H), 3.00 (s, 1H); LC/MS [M + H] = 524.9.
Example 143
sis of 2—(((2R, SS, 4R, 5R)(6-amino-2—chloro-9H-purinyl)—3 -ethynyl-3 ,4-
dihydroxytetrahydrofuran—2-yl)methoxy)—2-(thiazol-S-ylmethyl)malonic acid
0 S O
O NH2
0 OEt ( 0 GE:
/ (HN/ IN:k 0 OH N
N CI </ l \i
EtO o —>
0 /
OAc CSZCO3,DMF EStO HO O N
OAc 1.,BSA TMSOTf o N CI
\ MeCN
"I 2. aq. LiOH THF <\N\ .-
A00 OAC :Ho‘ 5,
Example143
Proceeding as described in Example 15 above but substituting allyl bromide with 5—
(chloromethyl)thiazole provided the title compound as a white solid.
1H NMR (400 MHz, CD3OD) 5 ppm 8.75 (s, 1H), 8.47 (s, 1H), 7.72 (s, 1H), 6.03 (d, J=7.3 Hz,
1H), 4.97 (d, J=7.3 Hz, 1H), 4.36 (dd, J=4.3, 3.0 Hz, 1H), 4.12 - 4.18 (m, 1H), 4.04 - 4.10 (m,
1H), 3.63 = 524.9.
— 3.79 (m, 2H), 3.00 (s, 1H), LC/MS [M + H]
Example 144
Synthesis of 2-(((2R, SS, 4R, 5R)(6—amino-2—chloro—9H-puriny1)—3 -ethynyl-3 ,4-
dihydroxytetrahydrofuranyl)methooxy)(4—(pyrrolidinyl)benzyl)malonic acid
CHLOE; En ch03
E10 0 K2C03 E0
:0 K—>co2 3 0U' DMF
A—CO )<.DMA 80°c HOE A—cO Ow;3<—> A—cO 04%
O NH2
0 QB N \ N
TFA H20 A620 </ I A
O” —> OAC Eto o N
o N/ CI
Pyndlne BSA TMSOTf
A—cO 0
A—co‘ MeCN
Ac EtO — X 7!
_ 5 ‘4,
AcO OAc
O NHz
O OH N
aq.L|OH. </ 1‘“
HO 0 N A
o N Cl
HO OH
Exam ple 144
Step 1:
To a on of diethyl 2-(((3aR, 5R, 6R, 6aR)acetoxyethynyl-2,2-dimethyltetra-
hydrofuro[2,3-d][1,3]dioxolyl)methoxy)malonate (10.0 g, 24.13 mmol, 1 eq) in DMF (100
mL) was added CszCO3 (23.59 g, 72.39 mmol, 3 eq) and 1—(bromomethyl)—4-iodo—benzene
(10.75 g, 36.20 mmol, 1.5 eq). The suspension was stirred at 20°C for 1 h before it was
diluted with water (200 mL). The resulting mixture was extracted with EtOAc (4 x 50 mL).
The combined organic layer was washed with water (2 x 200 mL), brine (200 mL), dried over
anhydrous NazSO4, filtered and concentrated. The crude residue was d by flash
column tography on silica gel (5— 20% of EtOAc in petroleum ether) to provide
diethyl 2-(((3aR, 5R, 6R, -acetoxyethynyl-2, 2-dimethyltetrahydrofuro[2, 3 -d][1,3]-
dioxolyl)methoxy)(4-iodobenzyl)malonate (11.83 g, 74% yield) as a white solid as a
white solid.
Step 2:
—214—
To a solution of diethyl 2-(((3aR,5R, 6R, 6aR)—6-acetoxyethynyl—2,2-dimethyltetra—
hydrofuro[2,3-d][1,3]dioxolyl)methoxy)(4-iodobenzyl)malonate (2.00 g, 3.17 mmol, 1
eq) in DMA (22 mL) was added K2CO3 (1.32 g, 9.52 mmol, 3 eq), CuI (120.84 mg, 634.50
umol, 0.2 eq) and proline (438.30 mg, 3.81 mmol, 1.2 eq). The green suspension was stirred
at 80°C under N2 atmosphere for 16 h before it was allowed to cool and poured into water (40
mL) and 2N aq. LiOH (1 mL). The mixture was extracted with ethyl acetate (2 X 30 mL).
The resulting aq. layer was ed to pH 5 with 1N aq. HCl solution and then ted
with ethyl acetate (2 x 40 mL). The combined organic layer was washed with water (80 mL),
brine (80 mL), dried over NazSO4, d and concentrated to give crude (S)(4-(2-
, 5R, 6R, 6aR)acetoxyethynyl-2,2-dimethyltetrahydrofuro[2,3 -d][1,3]dioxol-5 -
yl)methoxy)ethoxy(ethoxycarbonyl)oxopropyl)phenyl)pyrrolidinecarboxylic acid
(390 mg) as a yellow gum.
Step 3:
To a solution of crude (4-(2-(((3aR, 5R, 6R, 6aR)—6-acetoxyethynyl-2,2-
dimethyltetrahydrofuro[2, 3 —d][1,3]dioxol-5—yl)methoxy)—3—ethoxy—2-(ethoxycarbonyl)-3 -
oxopropyl)phenyl)pyrrolidinecarboxylic acid (420 mg, 680.01 umol, 1 eq) in DMF (5 mL)
was added K2CO3 (282 mg, 2.04 mmol, 3 eq) and EtI (81.58 uL, 1.02 mmol, 1.5 eq). The
mixture was stirred at 20°C for 0.5 h before it was diluted with water (10 mL), and extracted
with ethyl acetate (2 x10 mL). The ed organic layer was washed with water (20 mL),
brine (20 mL), dried over NazSO4, and filtered and concentrated to give crude diethyl 2-
(((3aR, 5R, 6R, 6aR)—6-acetoxyethynyl-2,2-dimethyltetrahydrofuro[2,3 -d][1,3]dioxol-5 -
yl)methoxy)—2-(4-((S)(ethoxycarbonyl)pyrrolidinyl)benzyl)malonate (330 mg) as a
yellow foam.
Step 4:
To a solution of crude diethyl aR, 5R, 6R, 6aR)—6-acetoxyethynyl-2,2-
dimethyltetrahydrofuro[2, 3 —d][1,3]dioxol—5-yl)methoxy)—2-(4-((S)(ethoxycarbonyl)pyro-
lidin—1-yl)benzyl)malonate (330 mg, crude) in DCM (4 mL) was added H20 (0.8 mL) and
TFA (4 mL) at 0°C. The solution was stirred at 20°C for 4.5 h before it was quenched with
saturated aq. NaHCO3 to adjust the pH to 9. The mixture was extracted with ethyl acetate (2
x 8 mL). The combined organic layer was washed with brine (20 mL), dried over NazSO4,
filtered and concentrated to crude diethyl 2—(((2R,3S,4R)acetoxyethynyl-4,5-dihydroxy-
tetrahydrofuranyl)methoxy)—2-(4—((S)—2—(ethoxycarbonyl)pyrrolidinyl)benzyl)malonate
(285 mg) as a yellow foam.
Step 5:
To a solution of crude diethyl R,3S,4R)—3-acetoxyethynyl-4,5-dihydroxytetra-
hydrofuran—2-yl)methoxy)—2-(4-((S)—2-(ethoxycarbonyl)pyrrolidin- l -yl)benzyl)malonate (28 5
mg) in pyridine (4 mL) was added 4—DMAP (172 mg, 1.41 mmol, 3 eq) and AczO (352.60
uL, 3.76 mmol, 8 eq). The solution was stirred at 20°C for 16 h before it was diluted with
water (10 mL), and extracted with ethyl e (3 x 10 mL). The combined organic layer
was washed with brine (20 mL), dried by Na2SO4, filtered and concentrated. The crude
residue was purified by flash column chromatography on silica gel (20-50% of ethyl acetate
in petrol ether) to give diethyl 2-(4-((S)(ethoxycarbonyl)pyro-lidinyl)benzyl)—2-
(((2R,3R,4R)-3,4,5—triacetoxyethynyltetrahydrofuranyl)methoxy)-malonate (220 mg,
51% yield for four steps) as a yellow gum.
Step 6:
To a suspension of diethyl (S)—2-(ethoxycarbonyl)pyrrolidin-l—yl)benzyl)
(((2R, 3R, 4R)-3,4,5-triacetoxyethynyltetrahydrofuranyl)methoxy)malonate (50 mg,
72.50 umol, 1 eq) and 6-chloropurine (15 mg, 86.99 umol, 1.2 eq) in MeCN (1 mL) was
added BSA (44.80 uL, 181.24 umol, 2.5 eq). The suspension was stirred at 65°C for 0.5 h
before it was cooled down to 0°C and followed by addition of TMSOTf (32.75 uL, 181.24
umol, 2.5 eq). The mixture was stirred at 65°C for 1 h before it was poured into saturated aq.
NaHCO3 (3 mL). The reaction mixture was extracted with ethyl acetate (3 x 3 mL). The
combined organic layer was trated. The crude e was purified by preparative
TLC (petroleum ether : EtOAc=2: 1) to give diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-
amino—2-chloro-9H—purin-9—yl)ethynyltetrahydrofuran-2—yl)methoxy)-2—(4-((S)—2—(ethoxy-
carbonyl)pyrrolidinyl)benzyl)malonate (33 mg, 57% yield) as a yellow gum.
Step 7:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy-5—(6-aminochloro-9H—
purinyl)—3-ethynyltetrahydrofuranyl)methoxy)(4—((S)—2-(ethoxycarbonyl)pyrrolidin-
1-yl)benzyl)malonate (28 mg, 35.03 umol, 1 eq) in THF (2 mL) was added 1M aq. LiOH
(701 uL, 20 eq). The mixture was stirred at 20°C for 4.5 h before the organic volatile was
removed under reduced pressure. The aq. layer was acidified to pH 6 with 1N aq. HCl
on before it was concentrated. The crude residue was purified by preparative HPLC
-2l6-
(Column: YMC-Triart Prep C18 150*40mm*7um; mobile phase: [water %FA)—ACN];
B%: 15%-35%, 10 min.) and dried by lyophilization to provide 2-(((2R,3S, 4R,5R)—5-(6-
aminochloro-9H—purinyl)ethynyl—3,4-dihydroxytetrahydrofuran—2-y1)methoxy)(4-
(pyrrolidin-l-y1)benzy1)malonic acid (2.6 mg) as a white solid.
1H NMR (400 MHz, CD3OD) 8 ppm 8.21 (s, 1H), 7.05 (d, J=8.53 Hz, 2H), 6.26 (d, J=8.53
Hz, 2H), 5.98 (d, J=7.53 Hz, 1H), 4.92 - 5.02 (m, 1H), 4.29 - 4.33 (m, 1H), 4.09 (dd,
6, 238 Hz, 1H), 3.97 (dd, J=10.04, 3.01 Hz, 1H), 3.38 (d, J=14.56 Hz, 1H), 3.23 (d,
J=14.56 Hz, 1H), 3.02 =
- 3.09 (m, 4H), 3.00(s, 1H), 1.89 - 1.97 (m, 4H), LC/MS [M + H]
5871.
e 145
Synthesis of 2-(((2R,3S,4R,5R)(6-amino(ethylthio)-9H-purinyl)ethyny1-3,4-
oxytetrahydrofuranyl)methoxy)benzylmalonic acid
0 NBocz o NBOCQ NH2
0 OEt N 0E1
1 id NaSEt <’N 1N1 TFA
BO 0:0,N N
N EtO000::IiOfNN
DMF20°C 0—:HNO' s/\ 0—0» [Niw
Ac(§ 6A0 A60 1OAc "
AcO 0A0
O NH2
0 OH N
aq.LiOH,THF (’ l
—> HO 0 N
o MAS“
Hci~ 6H
Example 145
Step 1:
To a mixture of diethyl 2-benzyl(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-(bis-(z‘ert—
butoxycarbonyl)amino)—2-chloro-9H-puriny1)ethynyltetrahydrofuran—2-yl)methoxy)—
malonate (300 mg, 349.53 umol, 1 eq) in DMF (3 mL) was added NaSEt (88.20 mg, 1.05
mmol, 3 eq). The mixture was stirred at 20°C for 20 h before it was partitioned between
water (15 mL) and EtOAc (15mL). The aqueous phase was extracted with EtOAc (2 X 10
mL). The combined organic layer was washed with brine (10 mL), dried over anhydrous
NazSO4, and filtered and concentrated under reduced pressure to to provide crude diethyl 2-
benzyl(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-amino(ethylthio)-9H—purinyl)-3 -ethynyl-
tetrahydrofuranyl)methoxy)malonate (310 mg) as an oil which was used for next step
without further purification.
Step 2:
To a mixture of crude diethyl 2-benzy1(((2R, 3R, 4R, 5R)—3,4-diacetoxy-5—(6-amino-
2-(ethylthio)-9H—purinyl)ethynyltetrahydrofuranyl)methoxy)malonate (310 mg) in
DCM (3 mL) was added TFA (1.5 mL, 2026 mmol). The mixture was stirred at 20°C for 2 h
before it was neutralized to pH 7~ 8 with saturated aq. NaHCO3. The reaction mixture was
extracted with EtOAc (3 x 20 mL). The combined extract was washed with brine (15 mL),
dried over ous NazSO4, filtered and concentrated under reduced pressure to provide
crude diethyl y1(((2R, 3R, 4R, 5R)—3,4-diacetoxy(6-amino(ethylthio)-9H—purin-
9-yl)—3-ethynyltetrahydrofuran-Z-yl)methoxy)malonate as a foam.
Step 3:
To a mixture of crude diethyl 2-benzy1(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-amino-
2-(ethylthio)-9H—purinyl)ethynyltetrahydrofuranyl)methoxy)malonate (280 mg,
crude) in THF (3 mL) was added saturated aq. LiOH (3 mL). The e was stirred at
55°C for 1 h before it was cooled to room temperature. The reaction mixture was extracted
with EtOAc (3 x 8 mL). The aqueous phase was adjusted to pH 2-3 with 2M aq. HCl before
it was extracted with EtOAc (4 x lOmL), dried over anhydrous NazSO4, filtered and
concentrated. The crude product was purified by preparative HPLC (column: YMC-Triart
Prep C18 150*40mm*7um;mobile phase: [water(0.225%FA)-ACN]; B%: 23%-43%,11 min)
and dried by lyophilization to give 2-(((2R, 3S, 4R, 5R)(6—amino(ethylthio)-9H-purin
yl)ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)benzylmalonic acid (4.4 mg) as
a white powder.
1H NMR (400 MHz, 6) 5 ppm 12.59 — 1432 (m, 2H), 8.30 (s, 1H), 7.33 (s, 2H),
.21 (m, 5H), 6.15 (s, 1H), 6.00 (d, J=6.78 Hz, 1H), 5.82 (d, J=7.53 Hz, 1H), 5.01 (s,
1H), 4.14 (dd, J=6.40, 2.64 Hz, 1H), 3.99 (d, J=13.05 Hz, 1H), 3.83 (s, 1H), 3.58 (s, 1H),
3.17 — 3.18 (m, 2H), 2.99 — 3.13 (m, 2H), 1.31 (t, J=7.28 Hz, 3H); LC/MS [M + H] = 5440.
Example 146
Synthesis of R, 3S, 4R, 5R)—5-(6-amino-2—chloro-9H—purinyl)—3-ethyny1-3,4-
dihydroxytetrahydrofuranyl)methoxy)(4-(1 -(2-methoxyethyl)oxo-l ,2-
dihydropyridiny1)benzy1)malonic acid
0 N(Boc)2
Br / \/\Cl Br HO o CBr4 12:12:113
—> —>
HN \ K2003.acetone /0\/\N \ Pd(dppf)CI2 K2C03
\ \ ofN \
dioxane H20 /
\ 1<2coa DMF
N(Boc)2 0 NH: 0 ”Hz
O (NyrgNlNA
—k 0 c1 aq. LiOH
; —>
A06 'OAc
Example 148
Proceeding as ed in Example 11 above but substituting chloro(methoxy)—
methane with 1-chloromethoxyethane provided the title compound as a white solid.
1H NMR (400 MHz, DMSO-d6) 5 ppm 8.41 (s, 1H), 7.80 (s, 2H), 7.60 (dd, J=6.78, 2.01 Hz,
1H), 7.46 (dd, , 2.01 Hz, 1H), 7.35 (d, J=8.28 Hz, 2H), 7.21 (d, J=8.28 Hz, 2H), 7.19 —
7.24 (m, 1H), 6.26 — 6.31 (m, 1H), 5.82 (d, J=7.78 Hz, 1 H,) 4.86 (d, J=7.78 Hz, 1H), 4.17 (d,
J=1.76 Hz, 1H), 4.10 (t, J=5.14 Hz, 2H), 4.02 (dd, J=10.29, 4.77 Hz, 1H), 3.78 — 3.85 (m,
1H), 3.54 = 669.0.
— 3.64 (m, 3H), 3.29 (d, J=2.01 Hz, 2H), 3.24 (s, 3H), LC/MS [M + H]
Example 147
Synthesis of 2-(((2R, SS, 4R, 5R)-5—(2-chloro—6-(methylamino)-9H—purinyl)ethynyl-3,4-
dihydroxytetrahydrofuran—Z-yl)methoxy)-2—(4-(2-oxo-1,2—dihydropyridin—3 -
yl)benzyl)malonic acid
0 o 0 0 NH
0E1 o OEt (,N pl 0 OEt
N N’ </N l
TFA/DCM/HZO A0204DMAP H c1
E10 0 N NAG
:3—70 EtO E10 0
o o o
.. .0 pyridine OAc BSA, TMSOTf
.,I )v :3—7:.,I MeCN 5 a,
Aco‘ 0 Aco‘ 0A0
1 AcO OAc
HO HQ \ ,Boc
\ Boc E‘OH
O N N’ \
Boc20, TEA O OH \ TFA
DMAP,DCM <:, l N10 —. //'\ —> EtO
o N
Pd(dppf)CIzK2003 c1 DOM
HO 0 :0: 'N
Z dioxane, H20. _ O
aq. LiOH, THF
Example 147
Step 1:
To a solution of diethyl 2-(((3aR, 5R, 6R, 6aR)—6-acetoxyethynyl—2,2-dimethyltetra—
hydrofuro[2,3-d][1,3]dioxolyl)methoxy)—2-(4-iodobenzyl)malonate (2.0 g, 3.17 mmol, 1
eq) in DCM (15 mL) was added H20 (3 mL) and TFA (15 mL) at 0°C. The on was
stirred at 25°C for 16 h before it was quenched with saturated aq. NaHCO3 (150 mL). The
mmmmwwmmmwMthwmwmwQXMmmm.Nmamhmdmgmdwmww
washed with brine (200 mL), dried over Na2SO4, filtered and concentrated to give crude
diethyl 2-(((2R, 3S, 4R)-3 -ethynyl-3 ,4, 5 -trihydroxytetrahydrofuranyl)methoxy)—2-(4-
iodobenzyl)malonate (1.74 g) as a yellow foam.
Step 2:
To a solution of diethyl 2-(((2R,3S,4R)ethyny1-3,4,5-trihydroxytetrahydrofuran
hoxy)—2-(4-iodobenzyl)malonate (1.74 g, 3.17 mmol, 1 eq) in pyridine (20 mL) was
added 4-DMAP (1.16 g, 9.52 mmol, 3 eq) and AczO (2.38 mL, 2539 mmol, 8 eq). The
solution was d at 25°C for 3 h before it was diluted with water (60 mL) and extracted
with ethyl acetate (2 X 60 mL). The combined organic layer was washed with water (100
mL), brine (100 mL), dried over Na2S04, filtered and concentrated. The crude residue was
purified by flash column chromatography on silica gel (10 — 50% of ethyl e in
petroleum ether) to give diethyl 2-(4-iodobenzy1)(((2R, 3R, 4R)-3,4,5-triacetoxyethynyl-
tademmmnameaMmedmmfiU85g8&6flddfinhwwEm)maydbwfimm.
Step 3:
To a solution of diethyl 2-(4—iodobenzyl)-2—(((2R, 3R, 4,5-triacetoxyethynyl-
tetrahydrofuranyl)methoxy)malonate (1.00 g, 1.48 mmol, 1 eq) in MeCN (12 mL) was
added 2-chloro-N—methyl-9H—purin—6-amine (327 mg, 1.78 mmol, 1.2 eq) and BSA (916 uL,
3.71 mmol, 2.5 eq). The suspension was stirred at 65°C for 0.5 h before it was cooled down
to 0°C and followed by addition of TMSOTf (804 uL, 4.45 mmol, 3 eq). The resulting
mixture was stirred at 65°C for 1.5 h before it was d with saturated aq. NaHCO3 (10
mDmflwmmmmmaWM%mu2xMmDNMMmmmwmymdme%W%Md
with brine (25 mL), dried over NazSO4, filtered and concentrated, The crude residue was
purified by flash column chromatography on silica gel (10 — 50%ethyl acetate in petroleum
ether) to give diethyl 2-(((2R, 3R, 4R, 5R)—3,4—diacetoxy(2—chloro—6-(methylamino)-9H—
purinyl)—3-ethynyltetrahydrofuranyl)methoxy)(4-iodobenzyl)malonate (595 mg, 50%
ymw)%aydbwsdm.
Step 4:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy-5—(2-chloro(methyl-
amino)—9H—purinyl)—3-ethynyltetrahydrofuranyl)methoxy)(4-iodobenzyl)malonate
(592 mg, 741.88 umol, 1 eq) in DCM (8 mL) was added 4—DMAP (18 mg, 148.38 umol, 0.2
eq), TEA (413 uL, 2.97 mmol, 4 eq) and (Boc)20 (324 mg, 1.48 mmol, 2 eq). The solution
was d at 20°C for 2 h before it was diluted with ted aq. NH4C1 (20 mL) and
extracted with ethyl acetate (2 X 20 mL). The combined organic layer was washed with brine
(40 mL), dried over NazSO4, filtered and concentrated. The crude was purified by flash
column chromatography on silica gel (15 — 50% of ethyl acetate in petroleum ether) to give
diethyl 2-(((2R, 3R, 4R, 5R)—3 ,4-diacetoxy(6-((lert—butoxycarbonyl)(methyl)amino)
chloro-9H-purinyl)ethynyltetrahydrofuranyl)methoxy)—2-(4-iodobenzyl)malonate
(560 mg, 84% yield) as a foam.
Step 5:
To a mixture of diethyl 2-(((2R, 3R, 4R, 4-diacetoxy-5—(6-((terl—butoxycarbonyl)-
(methyl)amino)chloro-9H—purinyl)ethynyltetrahydrofuranyl)methoxy)—2-(4-
iodobenzyl)malonate (660 mg, 734.89 umol, 1 eq) and roxypyridin—3-yl)boronic acid
(204.18 mg, 1.47 mmol, 2 eq) in dioxane (6 mL) and H20 (2 mL) was added Pd(dppf)C12
(53.77 mg, 73.49 umol, 0.] eq) and K2CO3 (304.70 mg, 2.20 mmol, 3 eq). The yellow
mixture was degassed with N2 gas for 10 min before the mixture was stirred at 70°C for 2.5 h
The mixture was diluted with water (5 mL) and extracted with ethyl e (3 x 5 mL). The
ed organic layer was dried over NazSO4, filtered and concentrated. The crude was
purified by flash column chromatography on silica gel (50 — 100% of ethyl acetate in
petroleum ether) to give diethyl 2-(((2R, 3R, 4R, 5R)—3,4-diacetoxy(6-((terl—butoxycarbonyl
)(methyl)amino)—2-chloro-9H—purinyl)—3 -ethynyltetrahydrofuranyl)methoxy)-
2-(4—(2—oxo—l,2-dihydropyridinyl)benzyl)malonate (146 mg) as a foam.
Step 6:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)—3,4-diacetoxy(6-((tert—butoxycarbonyl)-
(methyl)amino)chloro-9H-purin—9-yl)-3—ethynyltetrahydrofuranyl)methoxy)—2-(4-(2—
oxo-1,2-dihydropyridinyl)benzyl)malonate (145 mg, 167.58 umol, 1 eq) in DCM (6 mL)
was added TFA (1.5 mL, 20.26 mmol, 121 eq). The solution was stirred at 25°C for 1 h
before it was neutralized with ted aq. NaHCO3 solution. The mixture was extracted
with ethyl acetate (3 x 12 mL). The combined organic layer was washed with bline (30 mL),
dried over Na2S04, filtered and concentrated. The crude was purified by preparative TLC
-22l-
(ethyl acetate) to give diethyl R, 3R, 4R, 5R)-3,4—diacetoxy(2—chloro—6-(methylamino)—
9H—purinyl)—3-ethynyltetrahydrofuranyl)methoxy)(4-(2-oxo-1,2-dihydropyridin
yl)benzyl)malonate (110 mg) as a solid.
Step 7:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)—3,4-diacetoxy—5-(2-chloro(methyl-
amino)-9H—purinyl)—3 -ethynyltetrahydrofuran-2—yl)methoxy)-2—(4-(2-oxo-1,2-dihydro—
nyl)benzyl)malonate (105 mg, 137.23 umol, 1 eq) in THF (4.5 mL) was added aq.
LiOH solution (1 M, 1.5 mL, 11 eq). The mixture was stirred at 25°C for 4 h before the
organic volatile was removed under reduced pressure. The aq. layer was acidfied to pH 6
with 1N aq. HCl solution and concentrated. The crude residue was purified by preparative
HPLC (Column: iart Prep C18 150*40mm*7um, mobile phase: [water (0.225%FA)-
ACN]; B%: 20%-40%, 10min) and dried by lization to give 2-(((2R,3S,4R,5R)(2-
chloro(methylamino)—9H—purinyl)-3 -ethynyl—3,4-dihydroxytetrahydrofuranyl)-
methoxy)—2-(4-(2-oxo-1,2-dihydropyridin-3 -yl)benzyl)malonic acid (6.6 mg) as a white solid.
1H NMR (400 MHz, DMSO-d6) 5 ppm 8.44 (s, 1H), 8.23 (d, J=3.75 Hz, 1H), 7.48 (d, J=6.63
Hz, 1H), 7.39 (d, J=7.00 Hz, 2H), 7.34 (d, J=5.63 Hz, 1H), 7.13 - 7.22 (m, 2H), 6.15 - 6.29
(m, 2H), 6.00 (d, J=6.75 Hz, 1H), 5.82 (d, J=7.38 Hz, 1H), 4.71 — 4.89 (m, 1H), 4.16 (dd,
J=4.94, 2.56 Hz, 1H), 3.86 — 4.05 (m, 1H), 3.53 — 3.83 (m, 1H), 3.51 (s, 1H), 3.48 — 3.30 (m,
5H overlapped under water peark), 2.90 (d, J=4.38 Hz, 3H), LC/MS [M + H] = 624.9.
e 148
Synthesis of 2-(((2R, SS, 4R, 5R)-5—(2-chloro—6-(methylamino)-9H—purinyl)ethynyl-3,4-
dihydroxytetrahydrofuran—2-yl)methoxy)—2-(4-(3—methyl—2-oxotetrahydropyrimidin-1(2I10-
yl)benzyl)malonic acid
WO 46403 2019/038245
orsops OTBDF’S OH on o
o 051
NaH,Me|,DMF TBAF,THF som DMF
o —,o —.o +»0 + EtO o
hm hm 2“ [mM y“ :L) O
Acd ’0
052C03, DMF
BSA, TMSOTf, MeCN
Example 148
Step 1:
To a solution of 1-(4—(((tert—butyldiphenylsilyl)oxy)methyl)phenyl)tetrahydro-
pyrimidin-2(1]10-one (7.33 g, 16.48 mmol, 1 eq) in DMF at 0 °C was added NaH (725 mg,
6WMnmmammLB13mdedeQ.memmmW%mhmdfifl5mmamHNMWwby
wmmdeHflm1mmflfi92mmdflew.memmmmmwmwufimmfimmO—
°C over 16 h before it was diluted with H20 (100 mL) and extracted with EtOAc (3 X 50
mL). The combined organic layer was washed with brine (100 mL), dried over NazSO4,
filtered and concentrated. The crude was purified by flash column chromatography on silica
gel (0—50% EtOAc in petroleum ether) to provide 1—(4-(((terl—butyldiphenylsilyl)oxy)—
methyl)phenyl)methyltetrahydropyrimidin-2(1H)—one (3.68 g, 48% yield) as a colourless
Step 2:
To a solution of 1-(4-(((tert-butyldiphenylsily1)oxy)methyl)phenyl)-3 -methyltetra-
hydropyrimidin-2(1110-one (3.68 g, 8.02 mmol, 1 eq) in THF (35 mL) was added TBAF in
THF (1.5 M, 10.70 mL, 2 eq) at 0°C. The reaction mixture was stirred at 25°C for 1.5 h
before it was diluted with H20 (20 mL) and extracted with EtOAc (3 x 50 mL). The
combined c layer was washed with brine (50 mL), dried over Na2S04, filtered and
cmwmmdflwmmwwwfiwMflMmmmMMmMgwmmflkmdwflé
MeOH in DCM) to provide 1-(4-(hydroxymethyl)phenyl)-3 -methyltetrahydropyrimidin-
2(1H)—one (1.06 g, 60% yield) as a yellow solid.
Step 3:
To a on of hydroxymethyl)phenyl)methyltetrahydropy1imidin—2(1H)—
one (1.06 g, 4.81 mmol, 1 eq) in DCM (10 mL) and DMF (0.1 mL) was added SOC12 (698
uL, 9.62 mmol, 2 eq) at C. The reaction mixture was stirred for 0.5 h and additional
amount of SOClz (419uL, 5.77 mmol, 1.2 eq) was added. The resulting mixture was stirred
at 40°C for 1 h before it was trated. The residue was azeotroped with DCM (3 X 10
mL) under reduced pressure to provide crude chloromethyl)phenyl)-3 -methyltetra-
hydropyrimidin-2(lhO-one which was used in the next step without further purification.
Step 4:
To a solution of diethyl 2-(((3aR, 5R, 6R, 6aR)acetoxyethynyl-2,2-dimethyltetra-
hydrofuro[2,3-d][1,3]dioxoly1)methoxy)malonate (1.78 g, 4.30 mmol, 1 eq) in DMF (20
mL) was added CszCO3 (4.21 g, 12.91 mmol, 3 eq) at 25°C. The reaction mixture was stirred
for 0.5 h and followed by addition of crude 1-(4-(chloromethyl)phenyl)methyltetrahydro-
pyrimidin-2(1]10-one (1.13 g). The reaction mixture was stirred at 25°C for 16 h before it
was d with H20 (50 mL) and extracted with EtOAc (3 x 20 mL). The combined
organic layer was washed with brine (30 mL), dried over Na2S04, filtered and
concentrated. The crude was purified by column tography on silica gel (0—10% of
MeOH in DCM) to provide diethyl 2-(((3aR, 5R, 6R, 6aR)acetoxyethynyl-2,2-dimethyl-
tetrahydrofuro[2, 3 -d][1,3]dioxol-5 -yl)methoxy)(4-(3 -methyloxotetrahydropyrimidin-
1(2H)-y1)benzyl)malonate (2.63 g, 78% yield) as a brown foam.
Step 5:
To a solution of diethyl 2-(((3aR,5R, 6R, 6aR)acetoxy-6—ethynyl-2,2-dimethyltetra-
hydrofuro[2,3 -d][1,3]dioxol—5 -yl)methoxy)—2-(4-(3—methyl—2-oxotetrahydropyrimidin- 1 (2110-
yl)benzyl)malonate (2.62 g, 4.25 mmol, 1 eq) in DCM (25 mL) at 0°C was added TFA (25
mL, 337.65 mmol, 79 eq) and H20 (25 mL, 138.77 mmol, 33 eq). The reaction mixture was
d at 20-25°C for 16 h before it was concentrated under reduced pressure. The residue
was azeotroped with DCM (3 x 20 mL) under reduced pressure to provide crude diethyl 2-
(((2R,3S, 4R)—3-acetoxyethynyl-4,5-dihydroxytetrahydrofuran-2—yl)methoxy)-2—(4-(3-
methyloxotetrahydropyrimidin-1(2fD-yl)benzyl)malonate (2.57 g) as a syrup which was
used in the next step without further purification.
Step 6:
To a solution of crude diethyl 2-(((2R,3S,4R)—3-acetoxyethyny1-4,5-dihydroxytetra-
hydrofuranyl)methoxy)(4-(3 -methyloxotetrahydropyrimidin-1(2H)-yl)benzyl)-
—224—
malonate (2.57 g) in DCM (25 mL) at 20-25°C was added A020 (2.39 mL, 25.50 mmol, 6
eq), 4-DMAP (51.92 mg, 425.00 umol, 0.1 eq) and pyridine (2.74 mL, 3400 mmol, 8 eq) .
The reaction mixture was stirred at 25°C for 16 h before it was concentrated under reduced
pressure. The residue was re-dissolved in EtOAc (50 mL), washed with 1N aq. HCl (40
mL), 10% aq.Cu2SO4 (40 mL), saturated aq. NaHCO3 (40 mL) and brine (40 mL), dried over
Na2SO4, filtered and concentrated to provide crude diethyl 2-(4-(3—methyl—2-oxotetrahydro-
din- 1 (2]10-yl)benzyl)(((2R, 3R, 4R)-3 ,4, 5 -triacetoxy-3 -ethynyltetrahydrofuran
yl)methoxy)malonate (262 g, 53% yield for two steps) which was used in the next step
without further purification.
Step 7:
To a solution of 2-chloro-N—methyl—9H—purinamine (181 mg, 983.86 umol, 1.3 eq)
in MeCN (2.5 mL) under N2 atmosphere was added BSA (468 uL, 1.89 mmol, 2.5 eq) at 20-
°C. The reaction mixture was stirred at 65°C for 0.5 h before it was cooled to 25°C. To
this mixture was added crude diethyl 2-(4—(3 -methyloxotetrahydropyrimidin-1(21-D-
yl)benzyl)-2—(((2R, 3R, 4R)-3 ,4, 5 -triacetoxy-3 -ethynyltetrahydrofuranyl)methoxy)malonate
(500 mg, 756.81 umol, 1 eq) in MeCN (2.5 mL) and TMSOTf (205 uL, 1.14 mmol, 1.5
eq) and stirred at 65°C for 5 h before it was quenched with saturated aq. NaHCO3 (10 mL).
The mixture was then ted with EtOAc (3 x 10 mL). The ed organic layer was
washed with brine (20 mL), dried over anhydrous Na2SO4, filtered, and concentrated. The
crude was purified by flash column chromatography on silica gel column (0—10% MeOH in
DCM) to provide diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy(2-chloro(methylamino)-9H—
purin—9-yl)-3—ethynyltetrahydrofuranyl)methoxy)(4-(3 -methyloxotetrahydropyrimidin-1
(2hO-yl)benzyl)malonate (530 mg, 60% yield) as a foam.
Step 8:
To a solution of l 2-(((2R, 3R, 4R, 4-diacetoxy(2-chloro(methyl-
amino)-9H—purinyl)—3—ethynyltetrahydrofuranyl)methoxy)(4-(3 —methyloxotetra-
hydropyrimidin-l(2110-yl)benzyl)malonate (540 mg, 688.59 umol, 1 eq) in THF (6 mL) was
added 2O (288.96 mg, 6.89 mmol, 10 eq) in H20 (3 mL) at 25°C. The reaction
mixture was stirred at 40°C for 2 h before the organic volatile was removed under reduced
pressure. The aq. phase was acidified to pH 2 — 3 with 1N aq. HCl solution and then
ThamhwwpmmwbymwmmwflflflflammmYMOAmmBMHCB
mm*5um, mobile phase: [water (0.225%FA)-ACN], B%: 23%-43%, 10min) and
dried by lization to provide 2—(((2R, 3S, 4R, (2-chloro-6—(methylamino)—9H-purin-
9-yl)—3-ethynyl-3,4-dihydroxytetrahydrofurany1)methoxy)—2-(4-(3 -methyloxotetra-
hydropyrimidin-1(2H)-yl)benzyl)malonic acid (776 mg, 17% yield) as a white solid.
1H NMR (400 MHz, DMSO-dd) 5 ppm 1300—1393 (S, 2H), 8.37 (s, 1H), 8.23 (d, J=5.01 Hz,
1H), 7.11 (d, J=8.31 Hz, 2H), 6.90 (d, J=8.19 Hz, 2H), 6.15 (s, 1H), 5.98 (s, 1H), 5.81 (d,
J=7.58 Hz, 1H), 4.82 (s, 1H), 4.15 (dd, J=4.34, 3.00 Hz, 1H), 3.96 (m, 1H), 3.78 (m, 1H),
3.53 (s, 1H), 3.43—3.52 (m, 2H), 3.23 (m, 2H), 3.20—3.10 (m, 4H pped with solvent
water peak), 2.91 (m, 2H), 2.81 (s, 3H), 1.95 (m, 2H), LC/MS [M + H] = 644.1.
Example 149
Synthesis of 2—(((2R, 3S, 4R, 5R)(6-amino-2—chloro-9H—purinyl)—3-ethynyl-3,4-
oxytetrahydrofuranyl)methoxy)—2-(4-(3-methyloxotetrahydropyrimidin- l (2110-
yl)benzyl)malonic acid
Example 149
Proceeding as described in Example 148 above but substituting 2—chloro-N—methyl-
9H-purinamine with 2-chloro-9H—purinamine provided the title compound as a white
solid.
1H NMR (400 MHz, CD3OD) 5 ppm 8.21 (s, 1H), 7.26 (m, J=8.28 Hz, 2H), 6.96 (m, J=8.28
Hz, 2H), 5.97 (d, J=7.53 Hz, 1H), 4.70-4.83 (m, 1H), 4.27 (t, J=2.76 Hz, 1H), 3.99—4.07 (m,
2H), 3.32—3.52 (m, 6H), 3.05 (s, 1H), 2.87 (s, 3H), 2.00 (quin, J=5.83 Hz, 2H), LC/MS [M +
H] = 630.2.
Example 150
Synthesis of 2-(((2R, 3S, 4R, 5R)(2-chloro((cyclopropylmethyl)amino)-9H-purinyl)
ethynyl-3,4-dihydroxytetrahydrofuran-Z—yl)methoxy)-2—(4-(3 -methyl-2—
oxotetrahydropyrimidin- l (2]10-yl)benzyl)malonic acid
K, Y Y
0 O NH 0 NH
0 DE GE! 0 0H
,N:L/LN N \ N
' N10 I A
E10 0 </NN
I :;ONlm HO 0 (/N
O <HI N/Kc' LiOH o N CI
o : BSA,TMSOTf,MeCN o : S /
\NLN p.
Aco‘ OAC AcO )LN Ho‘ ’OH
\ \
Example 150
Proceeding as described in Example 148 above but substituting 2-chloro-N—methyl—
9H-purinamine with ro-N-(cyc1opropylmethy1)-9H-purinamine provided the title
compound as a white solid.
1H NMR (400 MHz, CDsOD) 5 ppm 8.12 (s, 1H), 7.27 (d, J=8.28 Hz, 2H), 7.00 (d, J=7.68 Hz,
2H), 5.96 (d, J=7.53 Hz, 1H), 4.70 (d, J=7.53 Hz, 1H), 4.26 (t, J=2.89 Hz, 1H), 4.03 (br s, 2H),
3.33—3.54 (m, 8H), 3.05 (s, 1H), 2.88 (s, 3H), 1.97—2.04 (m, 2H), 1.11-1.20 (m, 1H), 0.53—0.59
(m, 2H), 0.34 (m, 2H); LC/MS [M + H] = 684.3.
e 151
Synthesis of 2-(((2R, 3S, 4R, (2-chloro—6-(isopropylamino)-9H-purin—9-yl)—3—ethynyl—
hydroxytetrahydrofuran-2—y1)methoxy)(4-(3 -methy1oxotetrahydropyrimidin-
1(2H)—yl)benzyl)malonic acid
4f“N \
n NACI
BSA TMSOTf MeCN 3L
Example 151
Proceeding as described in Example 148 above but substituting 2—chloro-N-methyl-
9H-purinamine with 2-chloro-N-isopropyl-9H-purinamine provided the title compound
as a white solid.
1H NMR (400 MHz, CD3OD) 5 ppm 8.08 (s, 1H), 7.28 (d, J=8.28 Hz, 2H), 7.00 (d, J=8.53 Hz,
2H), 5.95 (d, J=7.53 Hz, 1H), 4.66—4.80 (m, 1H), 4.32-4.48 (m, 1H), 4.25 (t, J=2.89 Hz, 1H),
4.00-4.08 (m, 2H), 3.34—3.53 (m, 6H), 3.05 (s, 1H), 2.88 (s, 3H), 1.94-2.06 (m, 2H), 1.24—1.35
(m, 6H); LC/MS [M + H] = 672.1.
Example 152
Synthesis of 2-(((2R, 3S, 4R, 5R)(6-aminoch1oro-9H—purinyl)-3 -ethyny1-3 ,4-
dihydroxytetrahydrofuran-Z-yl)methoxy)—2-(4—(2-oxo-3 -propyltetrahydropyrimidin-1(2H)-
y1)benzyl)malonic acid
o NH2 0 NH2 0 NH2
0 CE \ OEt 0 OH
< N
l 10¢”? ( [\N
EtO O:L
0 H ZOE—ll ;mNO LiOH HO O N
O N C
O BSA TMSOTf MeCN o : S 2
)LN Aco‘ 0A0 AcO )LN H0 'OH
\/‘N\\) \PNb )
Example 152
Proceeding as descnbed in Example 148 above but substituting MeI and 2—chloro—N—
methyl-9H—purinamine with l-bromopropane and 2-chloro-9H—purinamine provided the
title compound as a white solid.
1H NMR (400 MHz, CD3OD) 6 ppm 8.15 (s, 1H), 7.28 (d, J=8.4 Hz, 2H), 6.99 (d, J=8.4 Hz,
2H), 5.97 (d, J=7.5 Hz, 1H), 4.75 (d, J=7.6 Hz, 1H), 4.27 (s, 1H), 3.99 — 4.11 (m, 2H), 3.46 —
3.54 (m, 2H), 3.35 — 3.44 (m, 4H), 3.16 — 3.27 (m, 2H), 3.05 (s, 1H), 1.97 — 2.03 (m, 2H), 1.50
— 1.58 (m, 2H), 0.88 (t, J=7.4 Hz, 3H); LC/MS [M + H] = 658.1.
e 153
Synthesis of 2-(((2R,3S,4R,5R)(2-chloro(isopropylamino)—9H—puriny1)ethynyl-
3 ,4-dihydroxytetrahydrofuran—Z-y1)methoxy)—2-(4-(1—(2-hydroxyethyl)oxo-1,2-
dihydropyridiny1)benzy1)malonic acid
0 o HN/k
o HN/k
OQOE‘ 1.TFA,H20,DCM OQOE' OQOEt /N Br
2, A020, ne J\ < l A
EtO +
:L., )fO DCM EtO (“1:10
:3—7,O H Cl O
0 0 EtO O N
GAO O N Cl
BSA,TMSOTf,MeCN : S / TBDpsofN \
\ 0 A05 bAc Acd ’OAC \
HN/k HN’k J KZCOSDMF
To a solution of diethyl aR, 5R, 6R, 6aR)—6-acetoxyethynyl—2,2-dimethyltetra—
hydrofuro[2,3-d][1,3]dioxolyl)methoxy)malonate (4.13 g, 9.97 mmol, 1 eq) in DCM (40
mL) at 20 °C was added TFA (40 mL, 540.24 mmol, 54 eq) and H20 (4 mL, 222.03 mmol,
22 eq). The mixture was stirred at 20 0C for 15 h before it was ed by ted aq.
NaHCO3 (200 mL) and extracted with EtOAc (5 X 50 mL). The combined organic layer was
washed brine (200 mL), dried over anhydrous NazSO4, filtered and concentrated to give
crude diethyl 2-(((2R, 3S, 4R)—3 -acetoxy-3 -ethynyl-4, 5 -dihydroxytetrahydrofuranyl)-
methoxy)malonate (4.14 g) as a light yellow syrup which was used in the next step directly.
To a solution of the above crude product (4.14 g, 12.46 mmol, 1 eq) in pyridine (40
mL) was added AczO (9.33 mL, 99.67 mmol, 8 eq) and 4-DMAP (3.81 g, 31.15 mmol, 2.5
eq). The e was stirred at 20 °C for 16 h before it was quenched by water (150 mL) and
the resulting solution was extracted with EtOAc (4 x 50 mL). The combined organic layer
was washed with 0.5 N aq. HCl (120 mL) and water (2 x 100 mL), brine (100 mL), dried
owmdemmbhfiOgmwmdmdamwmmmdTmemmhmflmwwwpmmmflwflwh
column chromatography on silica gel (30—50% EtOAc in petroleum ether) to provide diethyl
2-(((2R, 3R, 4R)-3,4,5-triacetoxyethynyltetrahydrofuranyl)methoxy)malonate (2.60 g) as
a syrup.
Step 2:
To a on of diethyl 2-(((2R, 3R, 4R)-3,4,5-triacetoxy-3—ethynyltetrahydrofuran—2-
yl)methoxy)malonate (1.2 g, 2.62 mmol, 1 eq) and 2-chloro-N-isopropyl-9H—purinamine
(665 mg, 3.14 mmol, 1.2 eq) in MeCN (15 mL) was added BSA (1.62 mL, 6.54 mmol, 25
eq). The suspension was stirred at 65°C for 0.5 h before it was cooled down to 0°C. To this
solution was added TMSOTf (1.45 g, 6.54 mmol, 1.18 mL, 2.5 eq). Then the mixture was
d at 65°C for 2.5 h before it was quenched by ted aq. NaHCO3 (50 mL) and the
rammguwmmW%@MdemmeAu4xmnm)TMcmmmwogmmmems
MMMWmmemMfimJMmMMwmmmmlHmwwmmwmmflwmm
column chromatography on silica gel (30 — 50% of EtOAc in petroleum ether) to provide
diethyl 2-(((2R, 3R, 4R, 5R)—3,4-diacetoxy(2-chloro(isopropylamino)—9H-purinyl)—3 -
ethynyltetrahydrofuranyl)methoxy)malonate (814 mg, 51% yield).
Step 3:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy-5—(2-chloro(isopropyl—
amino)-9H—purinyl)—3-ethynyltetrahydrofuranyl)methoxy)malonate (120 mg, 197 umol,
WO 46403
1 eq) in DMF (1 mL) was added K2C03 (81.56 mg, 590.15 umol, 3 eq) and 3-(4-(bromo-
methyl)phenyl)(2-((ZerZ-butyldiphenylsilyl)oxy)ethyl)pyridin-2(MED-one (161 mg, 295
umdjjem.memmmW%smmdm20%Hmd5hbfidefiw&dmmmuthmmUO
mL) and extracted with EtOAc (4 x 5 mL). The combined organic layer was washed with
water (2 x 30 mL), dried over anhydrous NazSO4, filtered and concentrated. The residue was
purified by flash column chromatography on silica gel (30 — 60% of EtOAc in petroleum
ether) to provide diethyl 2-(4-(1-(2—((l‘erl—butyldiphenylsilyl)oxy)ethyl)oxo-l,2-dihydro-
n-3 -yl)benzyl)—2-(((2R, 3R, 4R, 5R)-3 ,4—diacetoxy(2—chloro—6-(isopropyl-amino)-9H—
purinyl)—3-ethynyltetrahydrofuranyl)methoxy)malonate (154 mg) as a colorless oil.
Step 4:
To a solution of diethyl 2-(4-(1-(2-((ZerZ-butyldiphenylsilyl)oxy)ethyl)oxo-1,2-
dihydropyridin-3 -yl)benzyl)(((2R, 3R, 4R,5R)-3 ,4-diacetoxy-5 -(2-chloro(i yl—
amino)-9H—purinyl)—3-ethynyltetrahydrofuran-2—yl)methoxy)malonate (150 mg, 139 umol,
1 eq) in THF (1 mL) was added TBAF (1 M, 209 uL, 1.5 eq) and AcOH (5.98 uL, 104.59
umol, 0.75 eq) at 0 OC. The mixture was stirred at 20 0C for 16 h before it was d with
water (5 mL) and the resulting solution was extracted with EtOAc (3 x 5 mL). The combined
mymdwflwumRMWflmmmwflwfimeflwmflwmmmmdTmemmms
purified by preparative TLC (petroleum ether: EtOAc = 1:4) to provide diethyl 2-
(((2R, 3R, 4R, 5R)-3 ,4-diacetoxy-5 —(2-chloro(i ylamino)—9H—purinyl)-3 -ethynyl-
tetrahydrofuranyl)methoxy)(4—(1-(2-hydroxyethyl)-2—oxo-1,2-dihydropyridin-3 -
yl)benzyl)malonate (51 mg, 32% yield) as a white solid.
Step 5:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy(2-chloro(isopropyl-
amino)—9H—purin-9—yl)—3 -ethynyltetrahydrofuran-2—yl)methoxy)-2—(4—(1-(2—hydroxyethyl)—2—
oxo-1,2-dihydropyridinyl)benzyl)malonate (50 mg, 60 umol, 1 eq) in THF (0.5 mL) was
added sat.LiOH.aq (2.51 mg, 60 umol, 0.5 mL, 1 eq). The mixture was stirred at 20 °C for
2.5 h before the organic volatile was removed under reduced pressure. The ing aq.
solution was acidified to pH 2 with 2 N aq. HCl solution and concentrated. The residue was
further purification by preparative HPLC n: YMC-Triart Prep C18 150*40mm*7um;
mobile phase: [water (0.225%FA)—ACN]; B%: 28%-48%, 10min) to e 2-
(((2R,3S,4R,5R)(2—chloro—6-(isopropylamino)-9H—pu1in—9-yl)-3—ethynyl—3,4-dihydroxy—
WO 46403
tetrahydrofuranyl)methoxy)—2-(4—(1-(2-hydroxyethyl)-2—oxo-1,2—dihydropyn' din—3 -
yl)benzyl)malonic acid (10.8 mg, 26% yield) as a white solid.
1H NMR (400 MHz, CD3OD) 5 ppm 8.08 (s, 1H), 7.55 (dd, J=6.7, 1.9 Hz, 1H), 7.21 — 7.42 (m,
5H), 6.34 (t, J=6.8 Hz, 1H), 5.95 (d, J=7.3 Hz, 1H), 4.74 (d, J=7.3 Hz, 1H), 4.24 - 4.39 (m,
2H), 4.00 — 4.14 (m, 4H), 3.76 — 3.87 (m, 2H), 3.40 — 3.54 (m, 2H), 3.06 (s, 1H), 1.24 (dd, J=6.4,
2.9 Hz, 6H); LC/MS [M + H] = 697.0.
Examples 154 & 155
Synthesis of 2—(((2R, SS, 4R, (6-amino-2—chloro-9H—purinyl)—3 -ethynyl-3 ,4-
dihydroxytetrahydrofuran—2-yl)methoxy)—2-(4-(4-methyloxopiperazin—1-yl)benzyl)malonic
2—(((2R, 3S, 4R, 5R)-5 -(6—amino-2—chloro—9H—purinyl)—3 -ethynyl-3 ,4—
dihydroxytetrahydrofuranyl)methoxy)—2-(4-((2-
((carboxymethyl)(methyl)amino)ethyl)amino)benzyl)malonic acid
2‘\ @014 0
TFA' DCM O 0
J HCHO SOCIZ. DMF —> 8k,“ N E10 0
N +
Boc’ CULCSZCOS NJ DCM
DMF’d'°Xa”e HNJ
NaBchN 2LNNJ
Boc’ MeOH /NJ — XOTIO
0)<
032005,, DMFJ
O NH2 NH2 0 O
o 0E1 </N (,qu OE! 0 0E!
[\N 1) TFA, H20, DCM
BO 0 N A H N’J‘CI o EC 0
o N CI o ‘— o
S I‘MOAC 2) AcZO, 4—DMAP ‘5 7"‘0
— —
. pyridine‘DCM O
. J ,, )<
005 0A3 0
N A06 ’OAc N Acd N Aco‘
/ /N\) /N\)
aq.LiOH
NH: NH;
OH </“ 11 OH </”
/ ‘1
0:9,” /
N 01 + :30,” N CI
— :
'a O 5 '9
HO OH )\ HO OH
Example 154 N Example 155
To a mixture of tert-butyl 3-oxopiperazinecarboxylate (8.7 g, 43.45 mmol, 1.2 eq)
and (4-iodophenyl) methanol (8.5 g, 36.32 mmol, 1 eq) in DMF (10 mL) and e (90
mL) was added CuI (1.03 g, 5.43 mmol, 0.15 eq) , 2-(hydr0xymethyl)methyl-propane—1,3-
diol (653 mg, 5.43 mmol, 0.15 eq) and CszCO3 (35.39 g, 108.62 mmol, 3 eq). The mixture
was stirred at 110 °C under N2 atmosphere for 14 hours before it was cooled. The inorganic
solid was filtered off and the filtrate was concentrated in vacuo. The residue was diluted with
water (50 mL) and extracted with ethyl e (3 x 50 mL). The combined organic layer was
washed with brine (50 mL), dried by Na2S04, filtered and concentrated. The crude residue
was purified by flash silica gel chromatography (0 — 10% of EtOAc in petroleum ether) to
provide lert—butyl 4—(4-(hydroxymethyl)phenyl)—3-oxopiperazine-1—carboxylate (6.1 g, 55%
ymMflmaWMESdm.
Step 2:
To a solution of lert—butyl 4-(4-(hydroxymethy1)phenyl)—3-oxopiperazine
carboxylate (2 g, 6.53 mmol, 1 eq) in DCM (10 mL) was added TFA (5.00 mL, 67.53 mmol,
.34 eq) at 0 oC. The mixture was stirred at 25 °C for 3 h before it was concentrated. The
residue was diluted with water (20 mL) and extracted with a mixture ofDCM and MeOH
(50: 1=v:v, 2 x 20 mL). The ed organic layer was concentrated to provide crude 1—(4-
(hydroxymethyl)phenyl)piperazinone (2.45 g) as a ess oil.
Step 3:
To a solution of crude 1-(4-(hydroxymethyl)phenyl)piperazinone (2.45 g, 11.88
mmol, 1 eq) in MeOH (15 mL) was added HCHO (720 uL, 26.12 mmol, 22 eq), AcOH (5
mL, 87.42 mmol, 7.4 eq). The mixture was stirred at 25 0C under N2 atmosphere for 15 h
before NaBH3CN (2.05 g, 32.65 mmol, 2.75 eq) was added and the resulting mixture was
stirred for 2 h. The reaction mixture was concentrated in vacuo. The residue was purified by
flash column chromatography on silica gel (10 — 40% ofMeOH in EtOAc) to give 1-(4-
(hydroxymethyl)phenyl)—4-methylpiperazin—2-one (1.23 g) as a colorless oil.
Step 4:
To a solution of 1-(4—(hydroxymethyl)phenyl)—4-methylpiperazin-2—one (1.23 g, 5.58
mmol, 1 eq) in DCM (2 mL) was added DMF (0.2 mL) and SOC12 (810 uL, 11.17 mmol, 2
eq). The e was d at 25 °C for 30 min to give white sion before it was
concentrated under reduced pressure to give crude 1-(4-(chloromethyl)phenyl)methyl-
piperazinone (1.27 g, 95% yield) as a white solid which was used in the next step directly.
Step 5:
To a solution of diethyl 2-(((3aR, 5R, 6R, 6aR)acetoxy-6—ethynyl-2,2-dimethyltetra-
hydrofuro[2,3—d][1,3]dioxol—5-yl)methoxy)malonate (1.4 g, 3.38 mmol, 1 eq) in DMF (15
mL) was added CszCO3 (3.30 g, 10.14 mmol, 3 eq) and crude 1-(4-(chloromethyl)-phenyl)—4-
methylpiperazinone (1.21 g, 5.07 mmol, 1.5 eq). The mixture was stirred at 25 °C for 1 h
mmmfiwwfiMmdmdeWMEWMCM%MMwiTMcmwnmmwwwpmmwby
flash column chromatography on silica gel (O—50% MeOH in EtOAc) to give diethyl 2-
(((3aR, 5R, 6R, 6aR)acetoxyethynyl-2,2-dimethyltetrahydrofuro[2, 3 -d][1,3]dioxol-5 -
yl)methoxy)(4-(4-methyloxopiperazin- l -y1)benzyl)malonate (1.02 g).
Step 6:
To a solution of diethyl 2-(((3aR,5R, 6R, 6aR)acetoxy-6—ethynyl-2,2-dimethyltetra-
uro[2,3—d][1,3]dioxol—5-yl)methoxy)—2-(4-(4—methyl—2-oxopiperazin—1-yl)benzyl)-
malonate (1.02 g, 1.65 mmol, 1 eq) in DCM (5 mL) and water (1 mL, 55.51 mmol, 34 eq)
was added TFA (4.99 mL, 6736 mmol, 41 eq). The mixture was stirred at 25 °C for 20 h
before it was concentrated to give crude diethyl R,3S, 4R)ethynyl-3,4,5-trihydroxy-
tetrahydrofuran-2—yl)methoxy)—2-(4-(4-methyl-2—oxopiperazin-1—yl)benzyl)malonate (1.13 g)
as an oil.
To a solution of diethyl 2-[[(2R,3S,4R)—3-ethynyl-3,4,5-trihydroxy-tetrahydrofuran
yl]methoxy]—2-[[4-(4—methyl—2-oxo—piperazinyl)phenyl]methyl]propanedioate (1. 13 g,
2.11 mmol, 1 eq) in DCM (10 mL) was added 4-DMAP (25.78 mg, 211.00 umol, 0.1 eq)
pyridine (1.07 mL, 13.2 mmol, 6.3 eq) and AC2O (927 uL, 9.9 mmol, 4.7 eq). The mixture
was stirred at 25 °C for 16 h before it was concentrated. The residue was diluted with EtOAc
(20 mL) and 1N aq. HCl (10 mL). The organic layer was separated and the aqueous layer
was extracted with EtOAc (4 x 20 mL). The combined organic layer was washed with water
(50 mL), brine (50 mL) and dried over anhydrous , filtered and concentrated to
provide crude l 2-(4-(4-methyloxopiperazinyl)benzyl)—2-(((2R,3R,4R)—3,4,5-
triacetoxyethynyltetrahydrofuranyl)methoxy)malonate (674 mg) as an syrup.
Step 7:
To a solution of 2-chloro-9H-purinamine (76 mg, 450.46 umol, 1.2
eq) in dichloroethane (3 mL) was added BSA (204 uL, 825.84 umol, 2.2 eq). The mixture
was stirred at 65°C for 0.5 h before it was cooled to 0°C and crude diethyl 2-(4-(4—methyl—2-
oxopiperazin- l nzyl)—2-(((2R, 3R, 4R)-3 ,4, 5 -triacetoxy-3 -ethynyltetrahydrofuran
yl)methoxy)malonate (248 mg, 375.38 umol, 1 eq) in dichloroethane (1 mL) and TMSOTf
(102 uL, 563.07 umol, 1.5 eq) was added. The mixture was stirred at 65°C for 2 h under N2
atmosphere before it was quenched with ted aq. NaHC03 (15 mL) and extracted with
EtOAc (4 x 20 mL). The combined organic layer was dried over anhydrous Na2S04, flltered
and concentrated. The residue was purified by flash column tography on silica gel (0
— 30% ofMeOH in EtOAc) to provide diethyl 2-(((2R, 3R, 4R, 4-diacetoxy(6-amino-
2—chloro-9H—purin—9-yl)—3-ethynyltetrahydrofuran-2—yl)methoxy)—2—(4-(4-methyloxo—
piperazinyl)benzyl)malonate (62 mg) as a white solid.
Step 8:
To a solution of diethyl R, 3R, 4R, 5R)-3,4-diacetoxy-5—(6-aminochloro-9H—
purinyl)—3 yltetrahydrofuranyl)methoxy)-2—(4-(4-methyloxopiperazin
yl)benzyl)malonate (171 mg, 222.02 umol, 1 eq) in THF (2 mL) was added aq, LiOH (5.32
mg, 222.02 umol, 2 mL, 1 eq). The mixture was stirred at 25 0C for 2.5 h before it was
acidified to pH 2 — 3 with 2N aq. HCl. The mixture was concentrated under d
pressure. The crude residue was further purified by preparative HPLC to provide 2-
(((2R, 3S, 4R, 5R)-5 —(6-amino-2—chloro—9H—purin-9—yl)—3 -ethynyl-3 ,4-dihydroxy-tetrahydro—
furanyl)methoxy)-2—(4-(4-methyloxopiperazinyl)benzyl)-malonic acid (3.3 mg) as an
off-white solid and 2—(((2R, 3S, 4R, 5R)(6-aminochloro—9H—purinyl)ethynyl-3,4-
dihydroxytetrahydrofuran-2—yl)methoxy)-2—(4-((2-((carboxymethyl)(methyl)amino)ethyl)—
amino)benzyl)malonic acid (3.7 mg) as a white solid.
2-(((2R, 3S, 4R, 5R)(6-aminochloro-9H—purinyl)-3 -ethynyl-3 ,4-dihydroxytetrahydro-
furan-2—yl)methoxy)(4—(4-methyloxopiperazin-l-yl)benzyl)malonic acid: 1H NMR
(400 MHz, CD3OD) 5 ppm 8.35 (s, 1H), 7.35 (d, J=8.3 Hz, 2H), 6.97 (d, J=8.5 Hz, 2H), 5.95
(d, J=5.5 Hz, 1H), 4,70 - 4.79 (m, 1H), 4.33 (dd, J=9.0, 3.3 Hz, 1H), 3.96 - 4.14 (m, 2H),
3.54 — 3.66 (m, 2H), 3.49 (s, 2H), 3.35 (s, 1H), 3.21 (s, 2H), 2.83 (t, J=5.4 Hz, 2H), 2.32 -
2.48 (m, 3H), 1.89 (s, 3H), LC/MS [M + H] = 630.2.
2-(((2R, 3S, 4R, 5R)(6-amino-2—c hloro-9H-purinyl)-3 -ethynyl-3 ,4-dihydroxytetrahydro-
furan-2—yl)methoxy)(4-((2-((carboxymethyl)(methyl)amino)ethyl)amino)benzyl)malonic
acid: 1H NMR (400 MHz, CD3OD) 8 ppm 8.56 (s, 1H), 7.03 (d, J=8.5 Hz, 2H), 6.49 (d,
J=8.3 Hz, 2H), 6.01 (d, J=6.0 Hz, 1H), 4.70 (d, J=6.0 Hz, 1H), 4.34 (br d, J=4.3 Hz, 1H),
3.94 (dd, J=9.7, 6.9 Hz, 1H), 3.83 (dd, J=9.9, 2.4 Hz, 1H), 3.59 (s, 2H), 3.34 - 3.42 (m, 2H),
3.22 - 3.27 (m, 2H), 3.20 (s, 2H), 3.04 (s, 1H), 2.83 (s, 3H); LC/MS [M + H] = 649.3.
—234—
Example 156
Synthesis of 2-(((2R, 3S, 4R, 5R)—5-(5 -ch1oro((2,4-dimethoxybenzy1)amino)-3H-
imidazo[4,5-b]pyridin-3 -y1)—3-ethyny1-3,4—dihydroxytetrahydrofuran-2—yl)methoxy)—2—(4-(2-
oxotetrahydropyrimidin- 1 (2]10—y1)benzy1)malonic acid
NN:. Qmfi o ~H
0 CE N
OAc —>NO <’ Ii
\c‘ TMSOTf BSA DIEA NMP E10 0 N /
0 o N CI
HNXN MeCN
' 130°C
AcO —ACO OAC
microwave O
K) )LN 5 a,
HO OH
aq. LiOH, THF
HNLN ~*
HO "0H
K) Example 156
Step 1:
To a mixture of chloro-3H-imidazo[4,5-b]pyridine (317 mg, 1.69 mmol, 1 eq) in
MeCN (6 mL) was added BSA (1.04 mL, 4.22 mmol, 2.5 eq). The mixture was stirred at 65
0C under N2 atmosphere for 0.5 h before it was cooled to 0°C. To the mixture was added
diethyl 2-oxotetrahydropy1imidin-1 (2]10-y1)benzy1)-2—(((2R, 3R, 4R)-3 ,4, 5-triacetoxy—3 -
ethynyltetrahydrofuranyl)methoxy)ma1onate (1.20 g, 1.85 mmol, 1.1 eq) and TMSOTf
(913.99 uL, 5.06 mmol, 3 eq). The mixture was stirred at 65 °C under N2 atmosphere for 6 h
before it was quenched with NaHCO3 (15 mL). The reaction mixture was extracted with
EtOAc (3 X 15 mL). The combined organic layer was washed with brine (2 x 5 mL), dried
over Na2S04, filtered and concentrated under reduced pressure. The crude residue was
purified by flash column chromatography on silica gel (0 — 100% of EtOAc in petroleum
ether) to provide diethyl 2-(((2R, 3R, 4R, 5R)—3,4-diacetoxy(5,7-dichloro—3H-imidazo[4,5-
b]pyridiny1)ethyny1tetrahydrofurany1)methoxy)(4-(2-oxotetrahydropyrimidin—
1(2H)—y1)benzy1)malonate (752 mg) as a foam.
Step 2:
To a mixture of diethyl R, 3R, 4R, 5R)-3,4-diacetoxy(5,7-dichloro-3H—
imidazo[4,5—b]pyridiny1)—3-ethynyltetrahydrofuranyl)methoxy)—2-(4-(2-
oxotetrahydropyrimidin-1(2H)-y1)benzy1)malonate (752 mg, 970.82 umol, 1 eq) and 2,4-
dimethoxybenzylamine (292 uL, 1.94 mmol, 2 eq) and DIEA (507 uL, 2.91 mmol, 3 eq) were
taken up into a microwave tube in NMP (4 mL). The sealed tube was irradiated in a
microwave reactor at 130°C for 2 h before it was diluted with H20 (10 mL) and extracted
with EtOAc (3 x 15 mL). The combined organic layer was washed with brine (10 mL), dried
over Na2SO4, filtered and concentrated under reduced pressure. The crude residue was
purified by flash column chromatography on silica gel (0 — 100% of EtOAc in petroleum) to
provide diethyl 2-(((2R, 3S, 4R, 5R)-5—(5-chloro((2,4-dimethoxybenzyl)amino)-3H—imidazo-
[4,5—b]pyridin-3 -ethynyl-3,4—dihydroxytetrahydrofuranyl)methoxy)(4-(2-oxotetra-
hydropyrimidin-1(2H)-yl)benzyl)malonate (249 mg, 26% yield) as a foam.
Step 3:
To a mixture of diethyl 2-(((2R,3S,4R,5R)(5-chloro((2,4-dimethoxybenzyl)-
amino)-3H—imidazo[4,5-b]pyridinyl)ethynyl-3,4-dihydroxytetrahydrofuranyl)-
methoxy)—2—(4-(2-oxotetrahydropyrimidin—1(2H)-yl)benzyl)malonate (239 mg, 291.01 umol,
1 eq) in THF (4 mL) and H20 (3 mL) was added LiOH (69.69 mg, 2.91 mmol, 10 eq). The
mixture was stirred at 25 °C for 20 h before it was ed to pH 6-7 with 2N aqueous HCl
and concentrated under reduced pressure. The crude residue was purified by preparative
HPLC (column: Phenomenex Gemini-NX 150*30mm*5um, mobile phase: [water
(0.1%TFA)-ACN]; B%: 25%-65%, 10 min) and dried by lyophilization to provide 2-
(((2R, 3S, 4R, 5R)(5 -chloro((2,4-dimethoxybenzyl)amino)—3H—imidazo[4, 5-b]pyridin-3 -
yl)—3-ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)(4-(2-oxotetrahydropyrimidin-
1(2hO-yl)benzyl)malonic acid (9.5 mg) as a white solid.
1H NMR (400 MHz, CD3OD) 5 ppm 8.23 (s, 1H), 7.27 (d, J=8.44 Hz, 2H), 7.21 (d, J=8.31
Hz, 1H), 7.00 (d, J=8.44 Hz, 2H), 6.58 (d, J=2.32 Hz, 1H), 6.46 — 6.51 (m, 2H), 6.04 (d,
J=7.34 Hz, 1H), 4.73 (d, J=7.34 Hz, 1H), 4.43 (s, 2H), 4.27 (t, J=3.06 Hz, 1H), 4.01 (d,
J=2.93 Hz, 2H), 3.87 (s, 3H), 3.78 (s, 3H), 3.37 — 3.47 (m, 2H), 3.31 — 3.37 (m, 2H), 3.22 (t,
J=5.87 Hz, 2H), 3.03 (s, 1H), 1.78-1.85 (m, 2H); LC/MS [M + H] = 765.1.
e 157
Synthesis of 2-(((2R,3S,4R,5R)—5-(7-aminochloro-3H—imidazo[4,5-b]pyridinyl)
1-3 ydroxytetrahydrofuranyl)methoxy)(4-(2-oxotetrahydropyrimidin-1(2H)-
yl)benzyl)malonic acid
NH o NH2
0 OH N OH
<, \ TFA, DCM
l <,Nle/ic
HO o N N’ (:1
O —0: 00'—
Example 157
To a mixture of 2-(((2R, 3S, 4R, 5R)—5-(5-chloro((2,4-dimethoxybenzyl)amino)-3H—
imidazo[4,5-b]pyridinyl)ethynyl-3,4—dihydroxytetrahydrofuran-2—yl)methoxy)-2—(4-(2-
oxotetrahydropyrimidin-l(2]10-yl)benzyl)malonic acid (160 mg, 209.11 umol, 1 eq) in DCM
(3 mL) was added TFA (1 mL, 13.51 mmol, 64.59 eq). The mixture was stirred at 25 °C for
2 h before it was concentrated. The residue was d by preparative HPLC n:
YMC-Actus Triart C18 150*30mm*5um; mobile phase: [water (0.225%FA)-ACN], B%:
%—40%, 10 min) and dried by lyophilization to provide 2—(((2R, 35, 4R, (7—amino-5—
chloro-3H—imidazo[4,5-b]pyridinyl)ethynyl-3,4-dihydroxytetrahydrofuranyl)-
methoxy)(4-(2-oxotetrahydropyrimidin-l(2H)-yl)benzyl)malonic acid (5.4 mg) as a white
solid.
1H NMR (400 MHz, CD3OD) 5 ppm 8.34 (s, 1H), 7.28 (d, J=8.31 Hz, 2H), 7.02 (d, J=8.44
Hz, 2H), 6.49 (s, 1H), 6.07 (d, J=7.21 Hz, 1H), 4.78 (d, J=7.21 Hz, 1H), 4.30 (t, J=3.18 Hz,
1H), 3.93-4.08 (m, 2H), 3.45 — 3.54 (m, 2H), 3.35—3.49 (m, 4H), 3.04 (s, 1H), 1.94—2.00 (m,
2H); LC/MS [M + H] = 615.1.
Example 158
Synthesis of 2-((lH—pyrazol-S-yl)methyl)(((2R,3S, 4R, 5R)(6—aminochloro—9H—purin-
9-yl)ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
0 N(BOC)2 film 0 N(BOC)2 O NH2
0QCE (/NN m5“’ O OEt N 1.TFA DCM O OH N
N \ v \
1 “11¢ </ l i 2, aq. LiOH, THF (’ l i
EC 0 / /
X07N E10 0 N HO 0 N
K2C03,DMF
N CI o N
, c.
\ ‘
,N\ 2 :10); — \ \ ,NH :2
~. ., . ., . .,
A06 ’0“ N B00Ac5 bAc N H5 ’OH
Example 158 Cal-210
Proceeding as described in Example 1 above but substituting benzyl bromide with
tert-butyl 5-(bromomethyl)- lH—pyrazole-l-carboxylate provided the title compound as a
white solid.
1H NMR (400 MHz, CD3OD) 5 ppm 8.46 (s, 1H), 7.32 (s, 1H), 6.17 (s, 1H), 6.02 (d, J=7.13
Hz, 1H), 4.83 (s, 1H), 4.34 (s, 1H), 3.98 — 4.11 (m, 2H), 3.43 — 3.54 (m, 2H), 2.95 (s, 1H);
LC/MS [M + H] = 508.1.
Example 159
Synthesis of 2-benzyl(((2R, 3S, 4R, 5R)—5-(2-chloro( 1 -tosyl- 1H-pyrazolyl)—9H-purin-
3-ethyny1-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid
7%?,Bo o 0
/ /
0 CI 0 o
0 OEt <1: N 0 aq. LiOH THF 0 OH N
Nim ‘N
1 3)4, 082003 </ 1
,N :0;O </N —’ E10 0 :0 fiN—TSE ,N IN: HO O
dioxane,H20 NAG
: O: ,N
Aco‘ 'bAc AcO ’O HO ’OH
Example 159
Step 1:
To a mixture of diethyl 2-benzyl(((2R, 3R, 4R, 5R)-3,4-diacetoxy(2,6-dichloro-
9H-purinyl)ethynyltetrahydrofuranyl)methoxy)malonate (1.3 g, 1.92 mmol, 1 eq)
and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)tosyl-1H-pyrazole (669 mg, 1.92
mmol, 1 eq)1n dioxane (10 mL) and H20 (3 mL) under a N2 atmosphere was added
Pd(PPh3)4 (222 mg, 192 umol, 0.1 eq) and CszCO3 (1.88 g, 5.76 mmol, 3 eq). The mixture
was stirred at 100 °C for 3 h before it was filtered and the filtrate was concentrated under
reduced pressure, The crude residue was purified by flash silica gel column chromatography
(0 — 50% ofEtOAc in petroleum ether) to provide diethyl 2-benzyl(((2R, 3R, 4R, 5R)-3,4-
diacetoxy(2-chloro(1-tosyl-1H-pyrazolyl)-9H-purinyl)ethyny1tetrahydrofuran-
ethoxy)malonate (170 mg) as a foam.
Step 2:
To a solution diethyl 2-benzyl(((2R, 3R, 4R, 5R)-3,4-diacetoxy-5—(2-chloro(1-
tosyl-1H-pyrazolyl)-9H—purin-9—yl)—3 -ethynyltetrahydrofuranyl)methoxy)malonate (50
mg, 58 umol, 1 eq) in THF (1 mL) was added 1M aq. LiOH (1 mL, 18 eq). The e was
stirred at 25 0C for 14 h before it was d with EtOAc (10 mL) and water (10 mL). The
aqueous phase was adjusted to pH 2-3with 2M aq. HCl solution and extracted with EtOAc (2
x 40 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced
pressure. The crude e was purified by preparative HPLC (column: YMC-Triart Prep
C18 150*40mm*7um, mobile phase: [water (O.225%FA)-AC], B%: 40%-60%,10 min) to
provide 2-benzyl-2—(((2R, 3S, 4R, (2-chloro-6—( l —tosyl— 1H-pyrazolyl)—9H-purin-9—yl)—
3-ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)malonic acid (2.0 mg) as a white
solid.
1H NMR (400 MHz, CD3OD) 5 ppm 8.98 (s, 1H), 8.69 (s, 2H) 7.47 (d, J=8.25 Hz, 2H), 7.30
(d, J=6.88 Hz, 2H), 7.07 — 7.19 (m, 4H), 6.92 (d, J=8.00 Hz, 2H), 6.24 (d, J=7.63 Hz, 1H),
.85 (d, J=7.63 Hz, 1H), 4.35 (t, J=2.56 Hz, 1H), 4.03 — 4.09 (m, 1H), 3.90 (d, J=10.63 Hz,
1H), 3.40 = 723.2.
— 3.50 (m, 1H), 2.92 (s, 1H), 2.05 (s, 3H); LC/MS [M + H]
Example 160
Synthesis of 2-(((2R, SS, 4R, 5R)(2-chloro—6-(methylamino)-9H-purinyl)-3 -ethynyl-3,4-
dihydroxytetrahydrofuran-Z-yl)methoxy)(4—(2-oxo- l l— l ,2-dihydropyridin-3 —
yl)benzyl)malonic acid
\ ,Boc
O N
\ ,Boc
o N > 0 OEt
N Br N
0 ~
. do <’ 1
</ l N \ / NAC] N
Eto o :ZO: ,N N/ CI KCO2 3. DMF O ::
: bAc Acd
. —,
Aco‘ ’OAc \/\N
Example 160
Proceeding as described in Example 19 above but substituting diethyl 2—
(((2R, 3R, 4R, 5R)—3 ,4-diacetoxy-5 -(6-N,N’ -(bi s-(lert—butoxycarbony1)amino)chloro-9H—
purinyl)—3-ethynyltetrahydrofuranyl)methoxy)malonate with diethyl 2-(((2R,3R,4R,5R)—
3,4-diacetoxy(6-((lerl—butoxycarbonyl)(methyl)amino)chloro—9H—purinyl)ethynyl-
tetrahydrofuran-Z-yl)methoxy)malonate provided the title compound as a white solid.
1H NMR (400 MHz, DMSO-d6) 8 ppm 8.44 (s, 1H), 8.25 (d, J=4.3 Hz, 1H), 7.68 (dd, J=6.7,
1.8 Hz, 1H), 7.29 — 7.51 (m, 3H), 7.18 (d, J=7.5 Hz, 2H), 6.28 (t, J=6.8 Hz, 1H), 6.21 (s, 1H),
6.01 (d, J=6.8 Hz, 1H), 5.83 (d, J=7.3 Hz, 1H), 4.82 (s, 1H), 4.17 (dd, J=5.1, 2.6 Hz, 1H),
3.96 (s, 1H), 3.89 (t, J=7.3 Hz, 2H), 3.79 (s, 1H), 3.58 (s, 1H), 3.25 (s, 1H), 2.90 (d, J=4.5
Hz, 3H), 1.67 (sxt, J=7.3 Hz, 2H), 0.88 (t, J=7.4 Hz, 3H), LC/MS [M + H] = 667.1.
Example 161
Synthesis of 2-(((2R, 3S, 4R, 5R)(6-amino—2-(1-hydroxyethyl)-9H-purinyl)-3 -ethynyl-3,4-
dihydroxytetrahydrofuran—2-yl)methoxy)benzylmalonic acid
NIK/lfil/0 l'\\l/laeBOH—|::> f/KKLiOH /
I ’ OO—E—Tajrhplefi;
Step 1:
To a solution of diethyl yl(((2R, 3R, 4R, 5R)—3,4-diacetoxy—5-(2-acetyl
amino-9H—purinyl)ethynyltetrahydrofuranyl)methoxy)malonate (48 mg, 72.11 umol,
1 eq) in MeOH (2 mL) at 0°C was added NaBH4 (4.09 mg, 108.17 umol, 1.5 eq). The
solution was stirred at 0°C for 1 h. Additional NaBH4 (4.1 mg) was added to the reaction
mixture and it was stirred at 0°C for 0.5 h before it was diluted with water (6 mL) and
extracted with ethyl acetate (3 X 6 mL). The combined organic layer was dried by ,
filtered and concentrated. The crude residue was purified by preparative TLC (ethyl acetate)
to give diethyl yl(((2R, 3R, 4R, 5R)—3,4-diacetoxy(6-amino(1-hydroxyethyl)—
9H-purinyl)—3-ethynyltetrahydrofuranyl)methoxy)malonate (20 mg) as a syrup.
Step 2:
To a solution of l 2-benzyl(((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-amino(1-
hydroxyethyl)-9H-purinyl)—3 -ethynyltetrahydrofuran-2—yl)methoxy)malonate (16 mg,
23.96 umol, 1 eq) in THF (2 mL) was added 1M aq. LiOH (0.5 mL, 21 eq). The mixture was
stirred at 20°C for 3 h before it was acidifed to pH 5 with 1N aq. HCl solution. The mixture
was extracted with ethyl acetate (5 x 3 mL). The combined organic layer was concentrated.
The crude residue was purified by preparative HPLC (Column: YMC-Triart Prep C18
150*40mm*7um, mobile phase: [water (0.225%FA)-ACN], B%: 13%-33%, 10min) and
dried by lyophilization to give 2-(((2R, 3S, 4R, 5R)(6-amino(1-hydroxyethyl)—9H—purin
yl)-3—ethynyl—3,4-dihydroxytetrahydrofuran—2-yl)methoxy)—2-benzylmalonic acid (4.0 mg) as
a white solid.
1H NMR (400 MHz, CD3OD) 5 ppm 8.49 (d, J=8.88 Hz, 1H), 7.18 — 7.25 (m, 2H), 7.07 — 7.14
(m, 3H), 6.09 (dd, J=9.82, 6.94 Hz, 1H), 4.76 — 4.84 (m, 2H), 4.29 — 4.36 (m, 1H), 3.89 — 4.03
—240—
(m, 2H), 3.32 — 3.45 (m, 1H), 3.24 — 3.28 (m, 1H), 3.02 (d, J=10.13 Hz, 1H), 1.52 (d, J=6.50
Hz, 3H); LC/MS [M + H] = 528.1.
e 162
Synthesis of 2-(((2R, 3S, 4R, 5R)(6-aminochloro-9H-purinyl)-3 -ethynyl-3 ,4-
dihydroxytetrahydrofuranyl)methoxy)(4-(l-methyloxo-1,2-dihydropyridin-3 —
yl)benzyl)malonic acid
0 NBoc2 \ O
N Br
</ l
O /J\
:10: IN N CI K2003,DMF
Acd~ $OAc \N
Example 162
Proceeding as described in Example 19 above but substituting 3-(4-(bromomethyl)—
)-l —propylpyridin-2(1H)—one with 3-(4-(bromomethyl)phenyl)- l -methylpyridin-2(1H)—
one provided the title compound as a white solid.
1H NMR (400 MHz, CD3OD) 5 ppm 8.12 (s, 1H), 7.55—7.53 (m, 1H), 7.38—7.28 (m, 5H),
6.33 (t, J=6.8 Hz, 1H), 5.94 (d, J=7.6 Hz, 1H), 4.75 (d, J=7.6 Hz, 1H), 4.27—4.26 (m, 1H),
4.09—4.01 (m, 2H), 3.55 (s, 3H), 3.53—3.44 (m, 2H), 3.05 (s, 1H); LC/MS [M + H] = 625.0.
Example 163
Synthesis of 2-benzyl(((2R, 3S, 4R, (6-(3 -carboxypropyl)—2-chloro-9H—purinyl)-3 -
ethynyl-3,4-dihydroxytetrahydrofuran-Z-yl)methoxy)malonic acid
—241—
0 o
N CE OEt
< f;/ N Ban\A/[LOEt
\ N 0E1
TFA, DCM
N </N i
Cl —>N 0 X0)
Pd(Ph3P)4,THF N </ I +
N ,VOAC
o N NAG
o H Acd 110Ac
0$3333ch
o</ \N
' OOOEiBSA TMSOTf MeCN/ aq LiOH THF EOt O<N1NA :L/(Vtoa:N
—HO 1
bH —ACO 1’
Example 163
Step 1:
To a on of 2,6—dichloro(tetrahydro—2H—pyranyl)-9H-purine (4.00 g, 14.65
mmol, 1 eq) and Pd(Ph3P)4 (1.69 g, 1.46 mmol, 01 eq) in THF (30 mL) under N2
atmosphere at 0 °C was added a solution of 0.5 M oxyoxobutyl)zinc(II) bromide
(7323 mL, 36.61 mmol, 2.5 eq) se. The mixture was stirred from 0 — 25 0C over 16 h
before it was cooled to 0 °C and quenched with 0.5N aq. HCl solution. The reaction mixture
was extracted with EtOAc (3 x 100 mL). The combined organic extract was washed with
H20 (100 mL), brine (50 mL), dried over Na2SO4, filtered and concentrated. The crude
residue was purified by flash column chromatography on silica gel (10—75% EtOAc in
petroleum ether) to provide ethyl 4—(2-chloro(tetrahydro—2H-pyranyl)-9H-purin
yl)butanoate (2.83 g).
Step 2:
To a solution of thy] 4-(2-chloro-9—(tetrahydro-2H-pyranyl)-9H-purinyl)-
butanoate (1.50 g, 4.25 mmol) in DCM (15 mL) was added TFA (10 mL). The mixture was
stirred at 25 0C for 7 h before it was concentrated under reduced pressure. The residue was
re-taken up in H20 (50 mL) and neutralized to pH 7 with saturated aq. . The
resulting mixture was extracted with EtOAc (3 x 75 mL). The combined organic layer was
washed with brine, dried over , filtered and concentrated to provide ethyl 4-(2-chloro-
9H-purinyl)butanoate (1.05 g).
Steps 3 — 4:
Proceeding as described in e 5 above but substituting uracil with ethyl 4-(2—
chloro-9H-purinyl)butanoate provided the title compound as a white solid.
—242—
1H NMR (400 MHz, CD3OD) 5 ppm 8.74 (s, 1H), 7.27—7.24 (m, 2H), 7.09—7.08 (m, 3H),
6.09 (d, J=7.6 Hz, 1H), 5.05 (d, J=7.6 Hz, 1H), 4.31—4.14 (m, 1H), 4.10—4.06 (m, 2H), 3.18—
3.16 (m, 3H), 2.41 (t, J=7.2 Hz, 2H), 217—2. 15 (m, 2H), 1.22 (t, J=7.6 Hz, 2H); LC/MS [M +
H] = 589.1.
Examples 164 and 165
Synthesis of (R)—2-(((2R, 3S, 4R,5R)(6-aminochloro-9H-purin-9—yl)-3 -ethynyl-3 ,4-
dihydroxytetrahydrofuran—2-yl)methoxy)—3 -ethoxy-3 -oxo—2-(4-(2-oxotetrahydropyrimidin-
l(2H)-yl)benzyl)propanoic acid
(S)—2-(((2R, 3S, 4R, 5R)—5-(6-aminochloro-9H-purinyl)-3 -ethynyl-3,4-
dihydroxytetrahydrofuranyl)methoxy)-3 -ethoxy-3 -(4-(2-oxotetrahydropyrimi din-
l(2hO-yl)benzyl)propanoic acid
0 0 NH2 0 ”Hz
0 OE! (:INEICI 0 OEt O
/ (N \ >—OH
I i <N<N 'Nic E10 0 E10 0 N E10 0
0 o N/ 0‘ aqLiOH o
O BSA, TMSOTf O THF O
, -. ,1 _ ,1
’OAc
AcO MeCN OAc HO OH
Example 164
O NH2 0 NH2
0 OH
</ . :1
HO O N E10>I (N
0 N CI O
EL <.
”OH 3L
HNJ Example 9 ”NJ Example 165
Step 1:
To a suspension of 2-chloro—9H—purinamine (1.04 g, 6.15 mmol, 1.7 eq) in MeCN
(10 mL) at 25 0C was added N,O-bis(trimethylsilyl)acetamide (BSA) (3.1 mL, 0.0127 mol,
3.5 eq). The resulting suspension was heated at 85 0C for 30 min as it became clear. The
on mixture was allowed to cool to 25 oC followed by addition of a solution of diethyl 2-
(4-(2-oxotetrahydropyrimidin- l (2H)-yl)benzyl)—2-(((2R, 3R, 4R)-3 ,4, 5-triacetoxy-3 -
ethynyltetrahydrofuran-Z-yl)methoxy)malonate (2.34 g, 0.0036 mol, 1.0 eq) in MeCN (10
mL) and TMSOTf (1.12 mL, 0.00615 mol, 1.7 eq) dropwise. The reaction mixture was then
heated at 70—80 °C ght as all of the starting material was consumed. The reaction was
allowed to cool to 25 0C before it was diluted with MeCN (100 mL) and quenched with
saturated aq. NaHCO3 solution (150 mL). The ble was removed by filtration. The
—243 —
organic layer of the filtrate was separated, washed with H20 (50 mL), brine (50 mL), dried
over Na2S04 and concentrated. The crude e was purified by flash silica gel column
chromatography (0 — 5% MeOH in CH2C12) to provide diethyl 2-(((2R, 3R, 4R, 5R)-3,4-
diacetoxy-5—(6-aminochloro-9H—purin-9—yl)ethynyltetrahydrofuranyl)methoxy)(4-
(2-oxotetrahydropyrimidin-l(2H)-yl)benzyl)malonate (1.1 g, 40% yield) as a white solid.
Step 2:
To a solution of diethyl 2-(((2R, 3R, 4R, 5R)-3,4-diacetoxy-5—(6-aminochloro-9H—
purinyl)—3 -ethynyltetrahydrofuranyl)methoxy)(4—(2-oxotetrahydropyrimidin- 1 (2H)-
zyl)malonate (400 mg, 0.53 mmol, 1 eq) in THF (4 mL) and H20 (4 mL) at 0 0C was
added LiOH monohydrate (89 mg, 2.12 mmol, 4 eq). The resulting mixture was stirred at
room temperature overnight before the organic volatile was removed under reduced pressure.
The mixture was cooled to 0 0C and acidified to pH 6 with 1N aq. HCl solution and
concentrated under reduced pressure The crude residue was purified by preparative
ed-phase HPLC to provide a pair of diastereomers as a white solid: (R)
(((ZR, 3S, 4R, 5R)-5 -(6-aminochloro—9H—purin-9—yl)—3 yl-3 ,4-dihydroxytetrahydro—
2-yl)methoxy)—3-ethoxyoxo(4-(2-oxotetrahydropyrimidin-l(2110-yl)benzyl)-
propanoic acid and (S)(((2R, 3S, 4R, 5R)(6-aminochloro-9H-purinyl)-3 -ethynyl-3,4-
dihydroxytetrahydrofuran-2—yl)methoxy)-3—ethoxy—3—oxo-2—(4-(2-oxotetrahydropyrimidin—
l(2H)-yl)benzyl)propanoic acid which the stereo configuration was arbitrarily assigned. In
addition, Example 9 was also isolated as a white solid.
(R)(((2R, SS, 4R, 5R)-5 -(6-aminochloro-9H-purinyl)-3 -ethynyl-3 ydroxytetra-
hydrofuranyl)methoxy)-3 -ethoxy-3 -oxo—2-(4-(2—oxotetrahydropyrimidin-1(2H)-
yl)benzyl)propanoic acid: 1H NMR (300 MHz, CD3OD) 5 8.32 (s, 1H), 7.28 (d, J=8.1 Hz,
2H), 7.01 (d, J=8.1 Hz, 2H), 6.00 (d, J=7.5 Hz, 1H), 4.84 (d, J=7.5, 1H), 4.28—406 (m, 3H),
3.99—3.95 (m, 2H), 3.52—3.35 (m, 6H), 3.08 (s, 1H), 2.02—1.97 (m, 2H), 1.21 (t, J=7.1, 3H);
LC/MS [M + H] = 644.05.
(S)—2—(((2R, SS, 4R, 5R)—5 -(6-amino-2—chloro—9H—purinyl)—3 -ethynyl-3 ,4-dihydroxytetra—
hydrofuran—2-yl)methoxy)-3 -ethoxy-3 -oxo—2-(4-(2-oxotetrahydropyrimidin-1(2H)-
zyl)propanoic acid: 1H NMR (300 MHZ, CD3OD) 5 8.08 (s, 1H), 7.26—7.29 (d, J=6.8
Hz, 2H), .01 (d, J=7.23 Hz, 2H), 5.96—5.99 (d, J=7.14 Hz, 1H), 4.75—4.77 (d, J=7.5,
—244—
1H), 4.02—4.24 (m, 5H), 3.32—3.66 (m, 6H), 3.15 (s, 1H), 1.95—2.19 (m, 2H), 1.22—1.27 (m,
3H); LC/MS [M + H] = 644.05.
Examples 166 and 167
sis of (R)(((2R, SS, 4R,5R)(6-aminochloro-9H-purinyl)ethyny1-3,4-
dihydroxytetrahydrofuranyl)methoxy)-3 -oxotetrahydropyrimidin-1(2110-
yl)phenyl)propanoic acid
(((2R, SS, 4R,5R)—5-(6-aminochloro-9H—purinyl)-3 -ethynyl-3,4-
dihydroxytetrahydrofuranyl)methoxy)-3 -(4-(2-oxotetrahydropyrimidin-1(2110-
yl)phenyl)propanoic acid
0 NHZ o\_ NH2 0 NH2
0 GB N OH N OH N
</1‘” t
- H" </ P“ H...
1. aq. L-IOH, THF </ 1‘“
E10 0 N /
2. heating 0 N A O N A
O N | o N CI + O N CI
0 O O
. . . ,
)LN . .
Aco‘ ’OAc )LN Ho‘ ’OH )LN Ho‘ OH
HNK) HAL) Example 165 ML) Example 166
The crude product of Example 9 from the work up was dried in the vacuum oven at
60 °C for 2 days before it was purified by preparative HPLC to provide a pair of
diastereomers: (R)(((2R, SS, 4R, 5R)(6-aminochloro—9H-purinyl)-3 -ethynyl-3 ,4-
dihydroxytetrahydrofuranyl)methoxy)-3—(4-(2-oxotetrahydropyrimidin—1(2]10-yl)phenyl)-
propanoic acid and (S)(((2R, SS, 4R, 5R)(6-aminochloro-9H-purinyl)-3 -ethyny1-3,4-
oxytetrahydrofuran-2—yl)methoxy)-3—(4-(2-oxotetrahydropyrimidin—1(2]10-yl)phenyl)-
propanoic acid which the stereo configuration was arbitrarily assigned. Both were isolated as
white solids.
(((2R, SS, 4R, 5R)-5 -(6—amino-2—chloro—9H—purinyl)—3 -ethynyl-3 ,4—dihydroxytetra—
hydrofuranyl)methoxy)-3 -(4-(2-oxotetrahydropyrimidin- 1 (2]10-yl)phenyl)propanoic acid:
1H NMR (300 MHz, CD3OD) 5 8.38 (s, 1H), 7.22 (d, J=8.3 Hz, 2H), 7.04 (d, J=8.3 Hz, 2H),
.92 (d, J=7.3 Hz, 1H), 4.36—4.32 (m, 1H), 4.30 (d, J=7.3 Hz, 1H), 4.17 (t, J=2.3 Hz, 1H),
4.07—4.03 (m, 1H), 3.80—3.75 (rn, 1H), 3.54—3.49 (m, 2H), 3.33—3.31 (m, 2H), 3.25—3.19 (m,
1H), 3.12 (s, 1H), 3.09—3.02 (m, 1H), 2.02—1.97 (m, 2H); LC/MS [M + H] = 572.0.
(S)—2-(((2R, SS, 4R, 5R)—5 -(6-aminochloro—9H—purinyl)—3 -ethynyl-3 ,4-dihydroxytetra-
hydrofuran—2-yl)methoxy)(4-(2-oxotetrahydropyrimidin-1(2H)—yl)phenyl)propanoic acid:
1H NMR (300 MHz, CD3OD) 5 8.47 (s, 1H), 7.26 (d, J=8.2 Hz, 2H), 7.15 (d, J=8.3 Hz, 2H),
—245—
.97 (d, J=7.0 Hz, 1H), 4.97 (d, J=7.0 Hz, 1H), 4.31 (t, J=6.4 Hz, 1H), 4.20 (t, J=3.4 Hz, 1H),
3.91 (d, J=3.4 Hz, 1H), 3.65 (t, J=6.0 Hz, 2H), .33 (m, 2H), 3.23—3.17 (m, 2H), 3.08
(s, 1H), .01 (m, 1H),2.10—1.95(m,2H);LC/1V1S [M + H] = 572.0.
Example 168
sis of 2-benzy1(((2R, 3S, 4R, 5R)—5-(2-chloro(hydroxyamino)—9H—purinyl)—3-
ethyny1-3,4-dihydroxytetrahydrofurany1)methoxy)malonic acid
CI HN ,OH
O HN
N OEt N
</ \N \N
l X NHAOH, TEA </ l X 0 0H
O N / dioxane, H20 N / aq. LiOH, THF </N 1
: :0: N
, Cl —, 0 N CI —>
HO 0 N
o NAG
i’OAc AcO‘~ bAC :
2,
HO OH
Example 168
Step 1:
To a solution of diethyl 2-benzy1(((2R, 3S, 4R, 5R)(5-chloro(hydroxyamino)-
3H—imidazo[4,5-b]pyridinyl)-3 -ethyny1-3,4-dihydroxytetrahydrofuranyl)methoxy)-
malonate (98 mg, 0.144 mmol) in dioxane (2 mL) was added an s solution of
hydroxylamine (0.1 mL, 1.6 mmol, 16 M) and Et3N (35 uL, 0.16 mmol). The reaction
mixture was stirred for 2.5 h and then it was diluted with EtOAc (15 mL) and H20 (5 mL).
The organic layer was separated, washed with H20 (20 mL), brine (20 mL), dried over
Na2SO4 and concentrated to provide crude diethyl 2-benzyl(((2R, 3R, 4R, 5R)-3,4-diacetoxy-
-(2—chloro(hydroxyamino)-9H—purinyl)ethynyltetrahydrofuran—2-y1)methoxy)—
te (88 mg) as an off-solid which was used in the next step without further purification.
Step 2:
To a solution of crude diethyl 2-benzyl(((2R, 3R, 4R, 5R)-3,4-diacetoxy(2-chloro-
6-(hydroxyamino)-9H—purinyl)—3-ethynyltetrahydrofuranyl)methoxy)malonate (88 mg,
0.14 mmol) in a mixture of THF (0.2 mL), MeOH (0.62 mL) and H20 (0.15 mL) was added
LiOH'H2O (31 mg, 0.75 mmol). The resulting mixture was stirred at 25 0C for 5.5 h before
the organic volatile was removed under d pressure. The aq. layer was cooled to 0 0C
and acidified to pH 6.5 with 1N aq. HCl on before it was concentrated. The crude
residue was purified by preparative reversed-phase HPLC to provide 2-benzyl
(((2R, 3S, 4R, 5R)-5—(5 -chloro(hydroxyamino)—3H—imidazo[4, 5-b]pyridin-3 -y1)—3-ethynyl-
3,4-dihydroxytetrahydrofuran-Z-y1)methoxy)malonic acid (17 mg) as a reddish solid.
WO 46403 2019/038245
1H NMR (CD3OD, 300 MHz) 6 8.25 (s, 1H), 7.25—7.28 (m, 2H), 7.05 (m, 3H), 6.43 (s, 1H),
6.06—6.08 (d, J=7.17 Hz, 1H), 4.95—4.98 (d, J=7.05 Hz, 1H), 4.32 (s, 1H), 4.05—4.11 (m, 2H),
3.89—3.93 (m, 1H), .39 (m, 2H), 2.99 (s, 1H), 1.30—1.33 (m, 6H); LC/MS [M + H] =
5331.
Example 169
Synthesis of 2-(((2R, 3S, 4R, 5R)—5—(2-chloro(isopropylamino)—9H-purinyl)—3-ethynyl-
3,4—dihydroxytetrahydrofuranyl)methoxy)(thiazol—4—yl)-3—(thiophen—3-y1)propanoic
ifioEEACH:BU MeCN ISI”NMOEH£30kA.cO\ Q—Oéjx Km
‘N Rh2(OAC)4DCE _SO 7"0
HN’\ of CSZCO3DMF
«Ml/LN
H20,DCM N N/ACI s
2) A020, DMAP, Py TMSOTf, BSA
Example 169
Step 1:
To a solution of ethyl 2-(thiazolyl)acetate (2 g, 11.7 mmole) in CH3CN (15 mL) at
0 °C was added DBU (2.62 ml, 17.6 mmole) and 4-acetamidibenzene sulfonylazide (3.4 g,
14.1 mmole) in CH3CN (10 mL). The reaction mixture was stirred at room temperature for
1.5 h before it was concentrated under reduced pressure to dryness. The resulting crude was
purified by silica gel column chromatography (0—40% EtOAc in hexanes) to provide ethyl 2-
diazo(thiazolyl)acetate (2.0 g).
Step 2:
To a mixture of (3aR, 5R, 6R, 6aR)ethynyl(hydroxymethyl)—2,2-dimethyltetra-
hydrofuro[2,3-d][1,3]dioxolyl acetate (7 g, 27.32 mmol, 1 eq) in DCE (15 mL) was added
Rh(OAc)2 9 mg, 2.73 mmol, 0.1 eq) and ethyl 2-diazo(thiazolyl)acetate (6.46 g,
32.78 mmol, 1.2 eq) in DCE (15 mL) dropwise at 0°C. The mixture was stirred at 25 °C
under N2 atmosphere for 14 h before the insoluble was filtered and the filtrate was
concentrated under reduced pressure. The crude residue was purified by flash silica gel
—247—
WO 46403
column chromatography (0 — 50% of EtOAc in petroleum ether) to provide ethyl 2—
(((3aR, 5R, 6R, 6aR)—6-acetoxyethynyl-2,2-dimethyltetrahydrofuro[2, 3 3]dioxol-5 -
yl)methoxy)(thiazolyl)acetate (10.81 g, 93% yield) as an oil.
Step 3:
To a mixture of ethyl 2-(((3aR,5R,6R,6aR)acetoxyethynyl-2,2-dimethyltetra—
hydrofuro[2,3-d][1,3]dioxol—5-yl)methoxy)—2-(thiazolyl)acetate (2.69 g, 6.33 mmol, 1 eq)
in DMF (5 mL) was added CS2CO3 (6.18 g, 18.98 mmol, 3 eq). The mixture was stirred at 25
0C under N2 atmosphere for 0.5 h before 3-(bromomethyl)thiophene (2.8 g, 15.81 mmol, 25
eq) was added. The resulting mixture was d at 25°C for 14 h before the insoluble was
filtered and the filtrate was diluted with H20 (15 mL) and extracted with EtOAc (3 x 15 mL).
The combined organic layer was washed with saturated aq. NH4Cl (3 x 15 mL), dried over
Na2SO4, filtered and concentrated under reduced pressure. The crude residue was purified by
flash silica gel column chromatography (0 — 50% of EtOAc in petroleum) to provide ethyl 2-
(((3aR, 5R, 6R, 6aR)—6-acetoxyethynyl-2,2-dimethyltetrahydrofuro[2, 3 -d][1,3]dioxol-5 -
yl)methoxy)—2-(thiazolyl)—3-(thiophen-3—yl)propanoate (2.27 g, 69% yield) as an oil.
Step 4:
To a mixture of ethyl 2-(((3aR,5R,6R,6aR)acetoxyethynyl-2,2-dimethy1tetra-
hydrofuro[2,3 -d][1,3]dioxol-5 -yl)methoxy)(thiazolyl)-3 -(thiophen-3 -yl)propanoate
(2.27 g, 4.35 mmol, 1 eq) in DCM (5 mL) and H20 (0.5 mL) was added TFA (5 mL, 67.53
mmol, 15.5 eq). The mixture was stirred at 15 0C under N2 here for 14 h before it was
adjusted to 7-8 pH with saturated aq. NaHCO3 (50 mL) and concentrated under reduced
re. The residue was diluted with H20 (5 mL) and extracted with EtOAc (4 x 15 mL).
The ed organic layer was washed with brine (10 mL), dried over Na2SO4, filtered and
concentrated under reduced re to provide crude ethyl 2—[[(2R,SS,4R)—3—acetoxy
ethynyl-4,5-dihydroxy-tetrahydrofuranyl]methoxy]thiazol-4—yl(3—thienyl)propanoate
(1.82 g) as a syrup.
To a solution of ethyl 2-[[(2R,3S,4R)acetoxyethynyl-4,5-dihydroxy-tetrahydro-
2-yl]methoxy]thiazolyl(3-thienyl)propanoate (1.82 g, 3.78 mmol, 1 eq) in
pyridine (8 mL) under a N2 atmosphere at 0 °C was added 4-DMAP (1.39 g, 11.34 mmol, 3
eq) and AC2O (2.83 mL, 3024 mmol, 8 eq). The mixture was stirred at 15 0C for 15 before it
was diluted with H20 (20 mL) and extracted with EtOAc (3 x 15 mL). The combined
organic layer was washed with 10% CuSO4 solution (2 x 15 mL), dried over Na2SO4, filtered
WO 46403
and concentrated under reduced pressure to give crude (3R, 4R, 5R)—5-(((1-ethoxy-1—oxo
(thiazolyl)(thiophenyl)propanyl)oxy)methyl)ethynyltetrahydrofuran-2,3,4-triyl
triacetate (2.42 g) as a syrup.
Step 5:
To a mixture of 2-chloro-N—isopropyl-9H—purinamine (606.20 mg, 2.86 mmol, 1
eq) in DCE (20 mL) was added BSA (1.77 mL, 716 mmol, 2.5 eq). The mixture was stirred
at 85 0C under a N2 here for 0.5 h before it was allowed to cool to 0 oC and followed
by addition of crude (3R,4R,5R)—5-(((1-ethoxyoxo(thiazol-4—yl)—3-(thiophen—3-yl)—
propanyl)oxy)methyl)ethynyltetrahydrofuran-2,3,4-triyl triacetate (1.62 g, 2.86 mmol, 1
eq) and TMSOTf (1.55 mL, 8.59 mmol, 3 eq). The resulting mixture was stirred at 65 °C
under N2 for 14 h before it was ed with saturated aq. NaHCO3 (20 mL). The reaction
mixture was diluted with H20 (10 mL) and extracted with DCM (3 x 20mL). The combined
organic layer was washed with brine (3 x 15mL), dried over Na2SO4, filtered and
trated under reduced pressure. The crude residue was purified by flash silica gel
column chromatography (0 — 50% of EtOAc in petroleum ether) to provide (2R, 3R, 4R, 5R)—5-
(2-chloro-6—(isopropylamino)—9H—purinyl)—2-(((l-ethoxyoxo—2-(thiazolyl)-3 -(thio—
phenyl)propanyl)oxy)methyl)ethynyltetrahydrofuran-3,4-diyl ate (402 mg,
crude) as a syrup.
Step 6:
To a mixture of (2R, 3R, 4R, 5R)(2—chloro—6-(isopropylamino)-9H—purinyl)
((( 1 -ethoxyoxo(thiazolyl)—3 -(thiophen-3 -yl)propanyl)oxy)methyl)-3 -ethynyltetra-
hydrofuran-3,4-diyl ate (3 84 mg, crude) in THF (2 mL) and H20 (1 mL) was added
LiOH (128 mg, 5.35 mmol). The mixture was stirred at 50 0C for 6 h before it was diluted
with H20 (40 mL) and extracted with EtOAc (10 mL). The aqueous phase was acidified to
pH 2—3 with 2 N aqueous HCl until pH~2-3 and then trated under reduced pressure.
The crude residue was purified by preparative HPLC (column: YMC-Actus Triart C18
150*30mm*5um; mobile phase: [water(0.225%FA)—ACN]; B%: 40%-60%, 10 min) and
dried by lyophilization to provide a diastereomeric mixture (ca. 1:1) of 2-(((2R, 3S, 4R, 5R)
(2-chloro-6—(isopropylamino)—9H-purinyl)ethynyl-3,4-dihydroxytetrahydrofuran
yl)methoxy)(thiazolyl)(thiophenyl)propanoic acid (17.5 mg) as a white solid.
—249—
1H NMR (400 MHz, CD3OD) 5 ppm 8.92 — 9.01 (m, 1H), 8.04 — 8.28 (m, 1H), 7.60 — 7.71 (m,
1H), 7.10 — 7.15 (m, 1H), 6.98 — 7.06 (m, 1H), 6.77 — 6.94 (m, 1H), 5.90 — 6.02 (m, 1H), 4.91 —
.06 (m, 2H), 4.40 (br s, 1H), 4.19 — 4.32 (m, 1H), 3.89 — 3.99 (m, 1H), 3.65 — 3.87 (m, 3H),
2.89 — 3.02 (m, 1H), 1.25 = 605.2.
— 1.35 (m, 6H); LC/MS [M + H]
Examples 170 & 171
Synthesis of (S)(((2R, SS, 4R,5R)—5-(2-chloro(isopropylamino)-9H—purinyl)-3—
ethynyl-3,4-dihydroxytetrahydrofuran-2—yl)methoxy)—3-phenyl(thiazolyl)propanoic
(R)(((2R, 3S, 4R, 5R)-5 -(2-chloro(i sopropylamino)—9H—purinyl)-3 -ethynyl-3 ,4-
dihydroxytetrahydrofuran-Z-yl)methoxy)phenyl(thiazolyl)propanoic acid
EWOB HNk
\N N
O:31. k
O </ \N
.110 l A
u N c1
A06 0
TMSOTf, BSA
0&—OH
4 N N
SL “ <’ </ P“
\N o: N ’
o 0: N
o NAG
H6 'IOH ’OAC
Example 170 Example 171
Proceeding as described in Example 169 above but substituting 3-(bromomethyl)thiophene
with benzyl bromide provided a pair of reorneiic products which the stereo
configuration was assigned arbitrarily. Both products were purified by preparative HPLC
and isolated as white solids.
(S)—2-(((2R, 3S, 4R, 5R)—5 -(2-chloro—6-(i ylamino)-9H—purinyl)-3 -ethynyl-3 ,4-
dihydroxytetrahydrofuran-Z—yl)methoxy)-3—phenyl—2-(thiazolyl)propanoic: 1H N1VIR
, 300 MHz) 6 8.99 (s, 1H), 7.91 (s, 1H), 7.70 (s, 1H), 7.07-7.23 (m, 5H), 5.91-5.94
(d, J: 6.9 Hz, 1H), 4.87-4.90 (d, J: 7.0 Hz, 1H), 4.21-4.45 (m, 2H), .94 (m, 4H), 3.02
(s, 1H), 1.29-1.31 (d, J: 6.48 Hz, 6H); LC/MS [M + H] = 599.0.
WO 46403
(R)-2—(((2R, SS, 4R, 5R)—5 -(2—chloro-6—(i sopropylamino)-9H—purin-9—yl)-3 -ethynyl -3 ,4-
dihydroxytetrahydrofuranyl)methoxy)phenyl(thiazolyl)propanoic: 1H NMR
(CD3OD, 300 MHz) 8 8.97-8.98 (d, J= 1.83 Hz, 1H), 8.07 (s, 1H), 7.573—7579 (d, J= 1.86
Hz, 1H), .09 (m, 5H), 5.97-5.99 (d, J: 7.17 Hz, 1H), 4.98-5.00 (d, J: 7.23 Hz, 1H),
4.40-4.42 (m, 1H), 4.27-4.29 (t, J: 3.84 Hz, 1H), 3.93-3.97 (m, 2H), 3.59-3.81 4.31,
37.47 Hz, 2H), 2.95 (s, 1H), 129-133 (d, J: 6.39 Hz, 6H); LC/MS [M + H] = 5990.
Examples 172 & 173
Synthesis of (S)—2-(((2R,3S, 4R,5R)—5-(2-chloro((cyclopropylmethyl)amino)—9H—purin
yl)—3-ethynyl—3,4-dihydroxytetrahydrofuran-2—yl)methoxy)—3—phenyl—2-(thiazol
yl)propanoic acid
(R)(((2R, 3S, 4R, 5R)(2-chloro—6-((cyclopropylmethyl)amino)—9H—purinyl)—3 -ethynyl-
3,4-dihydroxytetrahydrofuranyl)rnethoxy)phenyl(thiazolyl)propanoic acid
H)“ ”OH
e 172 e 173
Proceeding as described in Examples 170 and 171 above but substituting 2-chloro—N—
isopropyl—9H-purinarnine with 2-chloro—N-(cyclopropylmethyl)—9H-purinamine
provided a pair of diastereomeric products which the stereo configuration was assigned
arbitrarily. Both products were purified by preparative HPLC and isolated as white solids.
(S)(((2R, 3S, 4R, 5R)—5 loro((cyclopropylmethyl)amino)—9H—purinyl)-3 -ethynyl-
3 ,4-dihydroxytetrahydrofuranyl)methoxy)-3 -phenyl(thiazolyl)propanoic acid:
1H NMR (CD3OD, 300 MHz) 6 .99 (d, J: 1.95 Hz, 1H), 7.93 (s, 1H), 7.69-7.70 (d, J:
1.86 Hz, 1H), 7.03-7.23 (m, 5H), 5.92-5.94 (d, J: 696 Hz, 1H), 4.87-4.89 (d, J: 7.11Hz,
1H), 4.19-4.22 (m, 1H), 3.59-3.94 (rn, 4H), 3.42-3.43 (m, 2H), 3.02 (s, 1H), 1.12-1.22 (m,
1H), 0.54-0.61 (m, 2H), 0.32-0.37 (m, 2H); LC/MS [M + H] = 611.0.
(R)(((2R, SS, 4R, 5R)(2-chloro((cyclopropylmethyl)amino)-9H-purinyl)-3 -ethynyl-
3 ,4-dihydroxytetrahydrofuranyl)methoxy)-3 -phenyl(thiazolyl)propanoic acid:
1H NMR (CD3OD, 300 MHz) 8 8.96-8.97 (d, J: 1.89 Hz, 1H), 8.07 (s, 1H), 7.55-7.56 (d, J:
2.07 Hz, 1H), 6.94-7.11 (m, 5H), 5.97-5.99 (d, J: 7.17 Hz, 1H), 4.98-5.00 (d, J: 7.29 Hz,
1H), .29 (t, J= 3.66 Hz, 1H), 3.94—3.95 (m, 2H), 3.59-3.80 (q, J= 14.64, 32.46 Hz,
2H), 3.39-3.50 (m, 2H), 2.96 (s, 1H), 1.13-1.23 (m, 1H), 0.55-0.62 (m, 2H), .38 (m,
2H); LC/MS [M + H] = 611.0.
Example 174
Synthesis of 2-(((2R, 3S, 4R, 5R)—5—(2-chloro(isopropylamino)-9H—puriny1)—3-ethyny1-
3,4-dihydroxytetrahydrofuran—2—y1)methoxy)—2—(thiazolyl)—3-(4-
(trifluoromethoxy)phenyl)propanoic acid
Example 174
Proceeding as bed in Example 169 above but substituting 3-(bromomethy1)thio-
phene with 1-(bromomethyl)(trifluoromethoxy)benzene provided the title compound as a
mixture of reomers (ca. 1:1) and isolated as a white solid.
1H NMR (400 MHz, CD3OD) 5 ppm 8.95 — 9.02 (m, 1H), 8.05 — 8.27 (m, 1H), 7.59 — 7.74 (m,
1H), 7.15 — 7.32 (m, 2H), 6.78 — 6.98 (m, 2H), 5.89 — 6.00 (m, 1H), 4.92 — 5.10 (m, 1H), 4.32 —
4.46 (m, 1H), 4.22 — 4.32 (m, 1H), 3.76 — 3.98 (m, 2H), 3.57 — 3.71 (m, 2H), 2.98 — 3.04 (m,
1H), 1.26 = 682.8.
— 1.32 (m, 6H); LC/MS [M + H]
Example 175
Synthesis of 2-(((2R, 3S, 4R, 5R)(6-aminoch1oro—9H—puriny1)—3-ethyny1-3,4-
dihydroxytetrahydrofuran-2—y1)methoxy)-3—(4-(2-oxotetrahydropyrimidin— 1 (2]10—y1)pheny1)-
2-(thiazolyl)propanoic acid
SWOB Br 1) TFA, H20, DCM, OEt
, C,
K 2) A620, 4-DMAP, pyridine
O XODMOAC \N
+ <’ I:
: N Cl
¢ 1, H
‘ bAc
OZN ACO
, BSA
</ \N
l (Boc)20 \N
NA <— l
o N
o ”at
E: 3, CI 4-DMAP,DMF Cl
H6 90800
OZN OZN
lFe, aq.NH4C|, EtOH NHBOC
NBocz \N
QB (NfN l
CIMN/ NACI
0: 0 ,N NAG DCM o
:6 30301: HNX”
C vC'
TFA,DCM
f”NI/kCII
Example 175
Step 1:
A mixture of 1-(bromomethyl)nitro-benzene (7.62 g, 35.26 mmol, 3 eq) and NaI
(352.31 mg, 2.35 mmol, 0.2 eq) in DMF (50 mL) was stirred at 15 0C for 30 min. Then this
mixture was added to a solution of ethyl aR, 5R, 6R, 6aR)—6-acetoxy-6—ethynyl-2,2-
dimethyltetrahydrofuro[2,3-d][1,3]dioxolyl)methoxy)—2-(thiazolyl)acetate (5 g, 11.75
mmol, 1 eq) and CS2CO3 (19.15 g, 58.76 mmol, 5 eq) in DMF (50 mL) at 15 °C was d
for 30 min. The resulting mixture was stirred for 8 h before it was quenched by water (200
mL). The mixture was extracted with EtOAc (4 x 30 mL). The combined organic layer was
washed with water (3 x 100 mL), dried over anhydrous NazSO4, filtered and concentrated.
The residue was d by flash column chromatography on silica gel (0 — 40% of EtOAc in
petroleum ether) to provide ethyl 2-(((3aR,5R, 6R, 6aR)—6-acetoxyethynyl-2,2-dimethyltetrahydrofuro
[2, 3 -c[][1,3]dioxol-5 —yl)methoxy)—3 -(4-nitrophenyl)(thiazolyl)propanoate
(4.89 g) as a syrup.
Step 2:
To a solution of ethyl 2-(((3aR, 5R, 6R, 6aR)acetoxyethynyl-2,2-dimethyltetra-
hydrofuro[2,3 -d][1,3]dioxolyl)methoxy)-3 -(4-nitrophenyl)—2-(thiazolyl)propanoate
(4.89 g, impure) in DCM (25 mL) and H20 (25 mL) was added TFA (25 mL 337.65 mmol).
The mixture was stirred at 30 °C for 23 h before it was diluted with water (100 mL) and the
resulting mixture was extracted with DCM (6 x 30 mL). The combined organic layer was
washed with saturated aq. NaHCO3 (2 x 100 mL), dried over anhydrous , filtered and
concentrated to provide crude ethyl 2-(((2R, 3S,4R)ethynyl-3,4,5-trihydroxytetrahydro-
furanyl)methoxy)—3-(4-nitrophenyl)—2-(thiazol-4—yl)propanoate (4.56 g) as a brown oil.
To a on of crude ethyl 2-(((2R,SS,4R)ethyny1-3,4,5-trihydroxytetrahydro-
furan—2-yl)methoxy)—3-(4-nitrophenyl)(thiazol-4—yl)propanoate (4.56 g) in DCM (50 mL)
was added 4-DMAP (232.86 mg, 1.91 mmol), pyridine (6.15 mL, 76.24 mmol) and AczO
(8.93 mL, 9530 mmol) dropwise. The mixture was stirred at 15 °C for 19 h before it was
quenched with water (100 mL) and the resulting mixture was extracted with DCM (4 x 30
mL). The combined organic layer was washed with water (3 x 100 mL), and dried over
anhydrous Na2S04, filtered and trated. The crude residue was purified by flash
column chromatography on silica gel (10—55% EtOAc in petroleum ether) to provide
(3R, 4R, 5R)-5 —(((1-ethoxy-3 —(4-nitrophenyl)—1-oxo—2—(thiazolyl)propan—2—yl)oxy)methyl)-
4-ethynyltetrahydrofuran-2,3,4-triyl triacetate (1.02 g) as a yellow oil.
Step 3:
To a solution of 2,6-dichloro-9H—purine (3 82.64 mg, 2.02 mmol) in MeCN (5
mL) was added BSA (1.04 mL, 4.22 mmol). The suspension was stirred at 65°C for 0.5 h as
it became clear. The resulting solution was cooled down to 0°C and followed by addition of
a solution of (3R, 4R, 5R)-5—(((1-ethoxy(4—nitrophenyl)—1-oxo(thiazolyl)propan-2—
yl)oxy)methyl)ethynyltetrahydrofuran-2,3,4-triyl tate (1.02 g) in MeCN (5 mL) and
TMSOTf (4.22 mmol, 762.15 uL). Then the mixture was stirred at 65°C for 1 h before it was
ed with saturated aq. NaHCO3 (40 mL) and the ing mixture was extracted EtOAc
(4 x 20 mL). The ed organic layer was dried over anhydrous NazSO4, d and
concentrated to provide crude (2R, 3R, 4R, 5R)(2,6-dichloro-9H-purinyl)(((1-ethoxy
(4-nitrophenyl)oxo(thiazolyl)propanyl)oxy)methyl)-3 -ethynyltetrahydrofuran—3 ,4-
diyl diacetate (1.71 g) as a yellow solid.
Step 4:
To a solution of crude (2R, 3R, 4R, 5R)(2,6-dichloro-9H-purinyl)—2-(((1-ethoxy
(4-nitrophenyl)oxo—2-(thiazol-4—yl)propan—2-yl)oxy)methyl)-3 -ethynyltetrahydrofuran—3 ,4-
diyl diacetate (1.0 g) in MeOH (20 mL) in a seal tube was added NH4.OH (28.04 mmol, 4.00
—254—
mL2T%cmmmmmmm.TMHmMMewmswkdmwsmmdmlMWCfixl5hbfiMefiww
allowed to cool and diluted with water (20 mL) and the resulting mixture was extracted with
EtOAc (3 x 10 mL). The ed c layer was dried over anhydrous Na2S04, filtered
and concentrated to give crude ethyl 2-(((2R,3S,4R,5R)(6-aminochloro-9H-purinyl)-
3-ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)-3 -(4-nitrophenyl)(thiazol
yl)propanoate (752 mg) as a yellow solid,
Step 5:
To a solution of crude ethyl 2—(((2R, SS, 4R, 5R)(6-amino—2—chloro—9H-purinyl)—3-
ethynyl-3,4—dihydroxytetrahydrofuranyl)methoxy)(4-nitrophenyl)(thiazolyl)-
propanoate (752 mg), 4-DMAP (58.33 mg, 477.44 umol) and Et3N (7.16 mmol, 996.81
uL) in DMF (8 mL) at 0 0C was added BoczO (1.04 g, 4.77 mmol). The mixture was stirred
M2OWHm2hbdMefiwmdmmflvmhwmeMni)wdmemammgmmmmums
emwmdmmeAdflxmnm)UwamMmdmymdwmwwmfidmammem
, filtered and trated to give crude ethyl 2-(((2R, 3R, 4R, 5R)(6-(bis-(z‘erl—
butoxycarbonyl)amino)chloro-9H—purinyl)((lert—butoxycarbonyl)oxy)ethynyl-3—
hydroxytetrahydrofuranyl)methoxy)-3 -(4-nitrophenyl)(thiazolyl)propanoate (91 1
Ing)asabnnvnsohd
Step 6:
To a solution of crude ethyl 2-(((2R,3R,4R,5R)(6-(bis-(tert—butoxycarbonyl)—
amino)—2-chloro-9H—purinyl)—4-((Zerl—butoxycarbonyl)oxy)ethynylhydroxytetrahydrofuranyl
)methoxy)(4-nitrophenyl)(thiazol-4—yl)propanoate (711 mg) in EtOH (7
mL) was added saturated aq. NH4C1 (764.21 umol, 7 mL) and iron (426.7? mg, 7.64 mmol).
The e was stirred at 50 0C for 2 h before it was filtered through a pad of Celite and the
filtrate was concentrated. Then the crude residue was taken up in water (20 mL) and the
resulting mixture was ted with EtOAc (3 x 15 mL). The combined organic layer was
dried over anhydrous NazSO4, filtered and concentrated to give crude ethyl 3-(4-amino-
)(((2R, 3R, 4R, 5R)(6-(bis-(lerl—butoxycarbonyl)amino)—2-chloro-9H—purinyl)
((tert—butoxycarbonyl)oxy)-3 -ethynyl-3 -hydroxytetrahydrofuranyl)methoxy)- 2-(thiazol
yl)propanoate (552 mg) as a brown solid.
Step 7:
To a solution of crude ethyl 3—(4-aminophenyl)(((2R, 3R, 4R, 5R)—5—(6-(bis—(Zert-
butoxycarbonyl)amino)chloro-9H-purinyl)((lerl—butoxycarbonyl)oxy)ethynyl
hydroxytetrahydrofuranyl)methoxy)— 2-(thiazol—4—yl)propanoate (552 mg) in DCM (5 mL)
was added 1-chloro-3 anato-propane (109.94 mg, 919.60 umol). The mixture was
stirred at 15 °C for 16 h before it was concentrated under reduce pressure. The crude residue
was purified by flash column chromatography on silica gel (20—100% EtOAc in petroleum
ether) to provide ethyl 2-(((2R, 3R, 4R, 5R)(6-(bis-(tert—butoxycarbonyl)amino)chloro—
9H-purinyl)((terZ-butoxycarbonyl)oxy)—3-ethynyl-3 -hydroxytetrahydrofuran—2-
yl)methoxy)(4-(3-(3-chloropropyl)ureido)phenyl)(thiazol-4—yl)propanoate (283 mg) as
an off—white solid.
Step 8:
To a solution of ethyl 2-(((2R, 3R, 4R, 5R)(6-(bis-(tert-butoxycarbonyl)amino)
chloro-9H—purinyl)((terl—butoxycarbonyl)oxy)ethynylhydroxytetrahydrofuran—2-
yl)methoxy)(4-(3-(3-chloropropyl)ureido)phenyl)(thiazolyl)propanoate (283 mg,
277.47 umol, 1 eq) in THF (3 mL) was added NaH (55.49 mg, 1.39 mmol, 60% in mineral
om5em.Tmnmmmewwmfimdm15%Hm5hbfidefiwmqmmdwdwflflb0(15
mL). To this mixture was added NaOH (166.48 mg, 4.16 mmol, 15 eq) and the resulting
mixture was d at 40 °C for 48 h before the organic volatile was removed under reduced
pressure. The aq. layer was acidified with 2N aq. HCl (1 mL) and concentrated under
reduced pressure to give crude 2-(((2R, 3S, 4R, 5R)(6-((terz‘-butoxycarbonyl)amino)
chloro-9H—purinyl)ethynyl-3,4-dihydroxytetrahydrofuran-2—yl)methoxy)-3 —(4-(2-
oxotetrahydropyrimidin-1(2110-yl)phenyl)(thiazolyl)propanoic acid (238 mg) as a
yellow solid.
Step 9:
A e of crude 2-(((2R, 3S, 4R, 5R)—5-(6-((z‘erZ-butoxycarbonyl)amino)chloro—
9H-pu1inyl)—3-ethynyl-3,4—dihydroxytetrahydrofuran-2—yl)methoxy)(4—(2-oxotetra-
hydropyrimidin-1(2IiO-yl)phenyl)(thiazolyl)propanoic acid (238 mg) in DCM (2 mL)
was added TFA (9.45 mmol, 0.7 mL). The mixture was stirred at 15 °C for 2 h before it was
concentrated under d pressure. The crude residue was purified by Preparative HPLC
([water (0.225%FA)-ACN]; B%: %, 10min) to provide a diastereomeric e (ca.
1 : 1) of 2-(((2R, 3S, 4R, 5R)-5—(6-aminochloro-9H—purin-9—yl)ethynyl-3,4-dihydroxytetra-
uran—2-yl)methoxy)-3 -(4-(2—oxotetrahydropyrimidin-1(2]10—yl)phenyl)—2-(thiazol
yl)propanoic acid (22.9 mg) as a white solid.
1H NMR (400 MHz, CD3OD) 5 ppm 9.01 (m, 1H), 7.98 — 8.32 (m, 1H), 7.59 — 7.83 (m, 1H),
6.91 — 7.34 (m, 4H), 5.88 — 6.07 (m, 1H), 4.72 — 4.96 (m, 1H), 4.13 — 4.32 (m, 1H), 3.60 — 4.00
(m, 4H), 3.43 — 3.56 (m, 2H), 3.35 — 3.42 (m, 2H), 2.96 — 3.14 (m, 1H), 1.89 — 2.08 (m, 2H);
LC/MS [M + H] = 655.3.
Example 176
Synthesis of 2-(((2R,3S,4R,5R)(2-ch1oro(isopropy1amino)—9H—puriny1)—3-ethyny1-
3 ,4-dihydroxytetrahydrofuran-Z-yl)methoxy)(4-(2-oxotetrahydropyrimidin— 1 (2110-
yl)phenyl)(thiazolyl)propanoic acid
0E1 N Fe, aq.NHAC|
<1 ' A EtOH
X0)! N 0' N
DIEA,MeCN X07! C'
AC6 bAC
NaH, NaOH
THF, H20
HNK) Example 176
Step 1:
A solution of crude (2R, 3R, 4R, 5R)—5-(2,6—dichloro—9H—puriny1)—2-(((1—ethoxy(4-
heny1)— 1 -(thiazolyl)propan-2—yl)oxy)methyl)—3 -ethynyltetrahydrofuran-3 ,4—
diyl diacetate (1.17 g) in MeCN (10 mL) was added -Z-amine (1.0 mL, 11.64 mmol)
and DIEA (0.9 mL). The mixture was stirred at 15 °C for 16 h before it was diluted with
water (30 mL) and the resulting mixture was extracted EtOAc (4 x 20 mL). The combined
organic layer was dried over anhydrous Na2SO4, filtered and concentrated to give crude
(2R, 3R, 4R, 5R)-5 -(2—chloro(isopropylamino)-9H-purinyl)(((1-ethoxy-3 -(4-
nitropheny1)oxo(thiazoly1)propan—2-y1)oxy)methyl)—3 -ethyny1tetrahydrofuran-3 ,4-
diyl diacetate (1.16 g) as a yellow solid.
Step 2:
To a solution of crude (2R, 3R, 4R, 5R)(2-chloro-6—(isopropylamino)—9H-purinyl)—
2-(((1-ethoxy-3 -(4-nitrophenyl)—1-oxo(thiazolyl)propany1)oxy)methyl)-3 -
WO 46403
ethynyltetrahydrofuran-3,4—diyl diacetate (1.16 g) in EtOH (5 mL) was added Fe powder
(856.75 mg, 15.34 mmol) and saturated aq. NH4Cl (1.53 mmol, 5 mL). The mixture was
stirred at 50 °C for 2 h before it was filtered through a pad of Celite and the filtrate was
concentrated to give crude (2R, 3R, 4R, 5R)(((3-(4-aminophenyl)—1-ethoxyoxo(thiazol-
4-yl)propanyl)oxy)methyl)—5-(2—chloro(isopropylamino)-9H—purin—9-yl)-3—
ethynyltetrahydrofuran-3,4—diyl diacetate (1.05 g) as a yellow solid.
Step 3:
To a solution of crude (2R, 3R, 4R, 5R)—2-(((3—(4-aminophenyl)—1-ethoxyoxo
(thiazolyl)propanyl)oxy)methyl)(2-chloro(isopropylamino)-9H—purinyl)
ethynyltetrahydrofuran-3,4-diyl diacetate (1.05 g) in DCM (10 mL) was added 1-chloro
isocyanato-propane (172.85 mg, 1.45 mmol). The mixture was stirred at 15 0C for 16 h
before it was quenched with water (20 mL) and the resulting mixture was extracted with
DCM (3 x 10 mL). The combined organic layer was dried over anhydrous Na2S04, filtered
and concentrated to give crude ethyl 2-(((2R,3S,4R,5R)(2-chloro(isopropylamino)-9H—
purin—9-yl)-3—ethynyl—3,4-dihydroxytetrahydrofuran—2-yl)methoxy)—3-(4-(3 —(3-chloropropyl)-
ureido)phenyl)(thiazolyl)propanoate (1.33 g) as a yellow solid.
Step 4:
To a solution of crude ethyl 2-(((2R, 3S, 4R, (2-chloro—6-(isopropylamino)—9H—
purinyl)—3-ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)(4—(3 -(3-chloropropyl)-
ureido)phenyl)(thiazol-4—yl)propanoate (1.23 g) in THF (12 mL) was added NaH (290.84
mg, 7.27 mmol, 60% in mineral oil). The mixture was stirred at 15 0C for 5 h before it was
ed with H20 (6 mL) and ed by addition ofNaOH (290.85 mg, 7.27 mmol). The
mixture was stirred at 15 °C for 16 h and then at 40 0C for 8 h. Additional NaOH (600 mg)
was added to e and the mixture was d at 40 °C for 4 h before it was quenched
with water (20 mL). The resulting solution was extracted with EtOAc (15 mL). The aq.
layer was acidified with 2N aq. HCl (15 mL) to produce a precipitate. The solid was
ted by filtration and purified by preparative HPLC (column: YMC-Actus Triart C18
150*30mm*5um; mobile phase: [water (0.225%FA)-ACN]; B%: 30%-50%, 10min) to
provide a diastereomeric mixture (ca. 1:1) of 2-(((2R, 3S, 4R, 5R)(2-chloro(isopropylamino
)-9H—purinyl)—3-ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)—3—(4-(2-
oxotetrahydropyrimidin-l(2H)-yl)phenyl)-2—(thiazol—4-yl)propanoic acid (245 mg) as a white
solid
1H NMR (400 MHz, CD3OD) 5 ppm 8.99 (d, J=1.6 Hz, 1H), 7.88 — 8.18 (m, 1H), 7.53 — 7.79
(m, 1H), 7.30 (d, J=8.3 Hz, 1H), 7.03 — 7.13 (m, 2H), 6.95 (d, J=8.4 Hz, 1H), 5.83 — 6.03 (m,
1H), 4.63 — 4.74 (m, 1H), 4.33—4.43 (m, 1H), 4.09 — 4.29 (m, 1H), 3.72 — 4.01 (m, 3H), 3.59 —
3.70 (m, 1H), 3.41 — 3.53 (m, 2H), 3.33-3.38 (m, 2H), 2.91 — 3.14 (m, 1H), 1.83 — 2.05 (m,
2H), 1.25 = 697.4.
— 1.35 (m, 6H), LC/MS [M + H]
Example 177
Synthesis of 2-(((2R, 3S, 4R, (6—chloro(isopropylamino)— 1H—pyrazolo[3,4-
d]pyrimidinyl)—3 yl-3 ,4—dihydroxytetrahydrofuranyl)methoxy)—3 -phenyl-2—
(thiazolyl)propanoic acid
0 CI
N/ GE
1 1 3 N/ \N
1 NHZ
n N (:1 o ‘N
o N/xKCI A
OAc DBU,TMSOTf _ S / DIEA,EtOH
MeCN A60“ °0Ac
HO: OH
e 177
Step 1:
To a on of 4,6—dichloro-1H—pyrazolo[3,4-d]pyrimidine (620 mg, 1.11 mmol, 1
eq) and (3R, 4R, 5R)(((1 -ethoxyoxo-3 -phenyl(thiazolyl)propan—2-yl)oxy)methyl)-
4-ethynyltetrahydrofuran-2,3,4-triyl triacetate (230.35 mg, 1.22 mmol, 1.1 eq) in MeCN (6.5
mL) under a N2 atmosphere at 0°C was added DBU (501 uL, 3.32 mmol, 3 eq). The mixture
was stirred at 0°C for 5 min and followed by addition of TMSOTf (900.93 uL, 4.99 mmol,
4.5 eq) dropwise. The mixture was stirred at 0°C for 30 min and then stirred at 65°C for 16 h
befoe it was quenched with saturated aq. NaHCO3 (10 mL) and extracted with EtOAc (3 x 6
mL). The combined organic phase was dried over anhydrous Na2804, filtered and
concentrated. The crude residue was d by flash column chromatography on silica gel
(10 — 40% of EtOAc in petroleum ether) to provide (2R, 3R, 4R, 5R)—5-(4,6—dichloro—1H—
pyrazolo[3 ,4—d]pyrimidin-1—yl)—2-(((1—ethoxy—1-oxo—3 -phenyl(thiazol-4—yl)propan
yl)oxy)methyl)ethynyltetrahydrofuran-3,4-diyl diacetate (220 mg) as a foam.
Step 2:
To (2R, 3R, 4R, (4,6-dichloro- 1H—pyrazolo[3 ,4-d]pyrimidin-1—yl)(((1-ethoxy-
l-oxo-3 -phenyl(thiazolyl)propanyl)oxy)methyl)—3 -ethynyltetrahydrofuran-3 ,4-diyl
diacetate (260 mg, 377.61 umol, 1 eq) in EtOH (2 mL) was added propan—2-amine (64.89 uL,
755.23 umol, 2 eq) and DIEA (131.55 uL, 755.23 umol, 2 eq). The mixture was d at
°C for 4 h before it was diluted with EtOAc (30 mL), washed with water (8 mL), brine (8
mL), dried over anhydrous Na2S04, d and concentrated. The crude residue was
purified by preparative TLC (EtOAc2petroleum ether = 2: 1) to give (2R,3R,4R,5R)(6-
(isopropylamino)—1H-pyrazolo[3 ,4-d]pyrimidinyl)(((1-ethoxyoxo-3 -
phenyl(thiazolyl)propanyl)oxy)methyl)ethynyltetrahydrofuran-3,4-diyl diacetate
(70 mg) as a foam,
Step 3:
To a solution of (2R, 3R, 4R,5R)(6—chloro—4-(isopropylamino)-1H—pyrazolo[3,4-
d]pyrimidinyl)(((1-ethoxyoxo-3 -phenyl(thiazolyl)propanyl)oxy)methyl)—3 -
ethynyltetrahydrofuran-3,4-diyl diacetate (70 mg, 98.43 umol, 1 eq) in THF (1 mL) was
mmwlflHHhOMJ3mQ.memmmwwsmmdm5WCfinMhbfimefiwu
concentrated to dryness. The crude residue was d by preparative HPLC (column:
YMC-Actus Triart C18 150*30mm*5um; mobile phase: [water (0.225%FA) - ACN]; B%:
43%-63%, 10 min) and dried by lyophilization to provide a diastereomeric mixture (ca. 1:1)
of 2—(((2R, 3S, 4R, 5R)—5-(6-chloro-4—(isopropylamino)-1H-pyrazolo[3 ,4-d]pyrimidinyl)—3 -
ethynyl-3,4-dihydroxytetrahydro-furanyl)methoxy)—3-phenyl(thiazolyl)propanoic
acid (15.7 mg) as a white solid.
1H NMR (400 MHz, CD30D) 5 ppm 8.76 — 9.10 (m, 1H), 7.93 — 8.08 (m, 1H), 7.40 — 7.65 (m,
1H), 6.89 — 7.08 (m, 4H), 6.80 — 6.88 (m, 1H), 6.11 — 6.20 (m, 1H), 5.14 — 5.28 (m, 1H), 4.38 —
4.50 (m, 1H), 4.29 - 4.37 (m, 1H), 3.93 - 4.11 (m, 1H), 3.78 - 3.86 (m, 1H), 3.47 — 3.63 (m,
2H), 2.97 = 598.7.
— 3.09 (m, 1H), 1.25 — 1.31 (m, 6H); LC/MS [M + H]
Example 178
Synthesis of 2-(((2R, 3S, 4R, 5R)(4-aminochloro- 1H-pyrazolo[3 ,4-d]pyrimidinyl)—3 -
ethynyl—3,4-dihydroxytetrahydrofuranyl)methoxy)—3-pheny1(thiazolyl)propanoic
0 CI 0 NH2 0 NH2
CE: QB OH
8 / \N 5 / \N s / \N
K N‘ l K \ N‘N ' A K N‘
0::O:,N NH OH H o THF NCIaq"O’L' H THF A
NCI 4'21 O
O 0:0,N Nc|
A66 "OAc A60“ "0A6 —HO‘: 'bH
Example178
Step 1:
To a solution of (2R, 3R, 4R,5R)—5-(4,6-dichloro-1H—pyrazolo[3,4-d]pyrimidinyl)—2-
thoxyoxophenyl(thiazolyl)propanyl)oxy)methyl)-3 -ethynyltetrahydro-
furan-3,4-diyl diacetate (100 mg, 145.24 umol, 1 eq) in THF (1 mL) was added NH4OH
(199.76 uL, 1.45 mmol, 10 eq). The mixture was stirred at 15°C for 14 h before it was
trated to s to provide crude (2R, 3R, 4R, 5R)(4-aminochloro-lH-pyrazolo-
[3 ,4—d]pyrimidinyl)—2-(((l-ethoxyoxo—3 -phenyl(thiazol-4—yl)propany1)oxy)-
methyl)ethynyltetrahydrofuran-3,4-diyl diacetate (120 mg) as a white solid.
Step 2:
To a solution of crude (2R, 3R, 4R, 5R)(4-aminochloro— 1H—pyrazolo[3,4-
d]pyrimidinyl)(((1-ethoxyoxo-3 -phenyl(thiazolyl)propany1)oxy)methyl)-3 -
ltetrahydrofuran-3,4-diyl diacetate (145.24 umol, 1 eq) in THF (4 mL) and H20 (2
mL) was added LiOH-H2O (60.94 mg, 1.45 mmol, 10 eq). The mixture was stirred at 50°C
for 16 h before it was concentrated to dryness. The crude residue was purified by preparative
HPLC (column: YMC-Actus Triart C18 150*30mm*5um;mobile phase: [water(0.225%FA)-
ACN]; B%: 28%-48%, 10min) and dried by lyophilization to e a diastereomeric
mixture (ca. 1:1) of 2-(((2R,3S,4R,5R)—5-(4-aminochloro- 1H—pyrazolo[3,4-d]pyrimidin
yl)ethynyl-3,4-dihydroxytetrahydrofuran-Z-y1)methoxy)-3 -phenyl(thiazolyl)-
propanoic acid (32.8 mg) as a white solid.
1H NMR (400 MHz, CD3OD) 5 ppm 8.87 — 9.01 (m, 1H), 7.91 — 8.06 (m, 1H), 7.47 — 7.67 (m,
1H), 7.01 — 7.06 (m, 2H), 6.93 - 7.00 (m, 2H), 6.84 - 6.90 (m, 1H), 6.12 — 6.20 (m, 1H), 5.14 -
.27 (m, 1H), 4.26 — 4.33 (m, 1H), 3.76 — 4.03 (m, 2H), 3.48 — 3.70 (m, 2H), 2.96 — 3.05 (m,
1H); LC/MS [M + H] = 557.0.
Example 179
Synthesis of 2-(((2R, 3S, 4R, 5R)(6-aminochloro-9H—purinyl)-3 -ethynyl-3 ,4-
dihydroxytetrahydrofuran-Z-yl)methoxy)(thiazolyl)acetic acid
MM» «M o Boc 2
/— N< ) o NH2
N \ N CE 5372—0 N OH
\ N
N \ N 1TFA DCM' s \
</ l '- \ N
N//’\ N |\N\ </
z l N/J\C| 2. aq .LOH,THF' \ </ 1
HO N H o N LN H o N
0 o o N//l\0|
w Rh2(OAc)4
\ e
— X 7’ X 7/
. :
Acd :OAc Acd :OAc HO: :OH
14 15 Example 179
Step 1:
To a solution of ,4R,5R)—5—((6-N,N’-bis-(tert—butoxycarbonyl)amino)chloro-
9H—purinyl)ethynyl-2—(hydroxymethyl)tetrahydrofuran-3,4-diyl diacetate (2 g, 3.28
mmol) in e (10 mL) was added ethyl 2-diazo—2-(thiazolyl)acetate (841 mg, 4.26
mmol) and Rh2(OAc)4 (145 mg, 0.328 mmol) under an argon atmosphere. The resulting
mixture was stirred at 70 °C for 2 h before it was allowed to cool to room temperature. The
c volatile was removed under reduced pressure. The resulting crude was purified by
silica gel column chromatography (O—40% EtOAc in hexanes) to provide (2R, 3R, 4R, 5R)
(6—(bis-(tert—butoxycarbonyl)amino)—2-chloro-9H—purin—9—yl)((2-ethoxyoxo—1-(thiazol-
4-yl)ethoxy)methyl)—3-ethynyltetrahydrofuran-3,4-diyl diacetate (1.78 g) as a syrup.
Step 2:
To a solution of (2R, 3R, 4R,5R)(6—(bis-(terZ-butoxycarbonyl)amino)chloro-9H—
9-yl)—2-((2-ethoxyoxo(thiazolyl)ethoxy)methyl)-3 -ethynyltetrahydrofuran—3 ,4-
diyl diacetate (310 mg) in DCM (3 mL) at 25 0C was added TFA (2 mL). The mixture was
stirred for 2 h before it was concentrated under reduced re to provide crude
(2R, 3R, 4R, 5R)-5 -(6-aminochloro-9H-purinyl)((2-ethoxyoxo(thiazol
yl)ethoxy)methyl)ethynyltetrahydrofuran-3,4-diyl diacetate.
To a solution of crude (2R, 3R, 4R, 5R)(6-aminochloro-9H-purinyl)—2-((2-
ethoxyoxo(thiazolyl)ethoxy)methyl)-3 -ethynyltetrahydrofuran-3 ,4-diyl diacetate in
THF (1 mL) and H20 (1 mL) at 0 °C was added LiOH monohydrate (100 mg). The resulting
mixture was stirred at 25 °C overnight before the organic volatile was removed under d
pressure. The mixture was cooled to O 0C before it was acidified to pH ~6 with 1N aq. HCl
solution and concentrated under reduced pressure. The crude residue was d by
preparative reversed-phase HPLC to provide a diastereomeric mixture (ca. 1:1) of 2-
(((2R, SS, 4R, 5R)-5 ino—2-chl oro—9H—pu1inyl)—3 yl-3 ,4—dihydroxytetrahydro—
furanyl)methoxy)(thiazolyl)acetic acid as a white solid.
1H NMR (CD3OD, 300 MHz) 5 .00 (m, 2H), 7.67-7.68 (m, 1H), 6.02—6.06 (m, 1H),
.28-5.32 (d, J=12.27 Hz, 1.5H), 5.14-5.16 (d, J=7.56 Hz, 0.5H), 4.24—4.28 (m, 1H), 3.69—
4.09 (m, 2H), 3.16 (s, 0.5H), 2.95 (s, 0.5H); LC/MS [M + H] = 467.0.
Examples 180 and 181
Synthesis of (S)—2—(((2R, 3S, 4R,5R)—5-(6—amino—2—chloro—9H—purinyl)—3-ethynyl-3,4—
dihydroxytetrahydrofuranyl)methoxy)phenyl(thiazolyl)propanoic acid
(R)(((2R, 3S, 4R,5R)—5-(6-aminochloro-9H-purinyl)-3 -ethynyl-3,4-
dihydroxytetrahydrofuranyl)methoxy)-3—phenyl(thiazolyl)propanoic acid
$3Diff/ACN(Boc)2 N(Boc)2 NH2
BnBr C52003 DMF S\N\ 3:7;er TFA CHZCIZ S\\N war:
AcO OAc AcO OAc AC6 OH
laqi LiOH, THF
0 NH2 NH2
\5—0H N N
\ < n 1 + </ u 1
N 0 if): ’N O
N C] : ::O ,N N/ 0|
—HO: “
OH f’OH
Example 180 Example 181
Proceeding as described in Example 169 above but substituting 3-(bromomethyl)thio-
phene and 2-chloro-N—isopropyl-9purinamine with benzyl e and 2-chloroadenine
provided a pair of diastereomeric products which the stereo configuration was assigned
arily. Both products were purified by preparative HPLC and isolated as white solids.
(S)—2-(((2R, 3S, 4R, 5R)—5 -(6-aminochloro-9H-purinyl)—3 -ethynyl-3 ,4-dihydroxytetra-
hydrofuran—2-yl)methoxy)—3-phenyl(thiazol-4—yl)propanoic acid: 1H NMR (CD3OD, 300
MHz) 6 895-896 (d, J: 2.01Hz, 1H), 8.34 (s, 1H), 7.54—7.55 (d, J: 2.01 Hz, 1H), 6.97—
7.12 (rn, 5H), 5.97—5.99 (d, J: 6.99 Hz, 1H), 4.97—4.99 (d, J: 7.08 Hz, 1H), 4.27-4.29 (t, J
= 4.23, 3.18 Hz, 1H), .99 (m, 2H), 3.62-379 (q, J: 14.82, 39.24 Hz, 2H), 2.97 (s, 1H);
LC/MS [M + H] = 557.0.
(R)—2-(((2R, 3S, 4R, 5R)-5 -(6—amino—2-chloro—9H—purinyl)-3 -ethynyl-3 ,4-dihydroxytetra—
uran-2—yl)methoxy)-3—phenyl—2-(thiazolyl)propanoic acid: 1H NMR (CD3OD, 300
MHz) 6 8.95-8.96 (m, 1H), 7.99 (s, 1H), 7.70—7.71 (d, J: 1.98 Hz, 1H), 7.05—7.25 (m, 5H),
.92—5.94 (d, J = 7.02 Hz, 1H), 4.85—4.87 (d, J = 7.29 Hz, 1H), 4.20—4.22 (q, J = 2.64 Hz,
1H), 3.58-3.90 (m, 4H), 3.02 (s, 1H), LC/MS [M + H] = 557.0.
Example 182
Synthesis of ((2R, 3S, 4R,5R)(6-amino—2-chloro—9H—puriny1)ethynyl-3,4—
dihydroxytetrahydrofuranyl)methoxy)—2-carboxy(thiazol—4-yl)ethyl)benzoic acid
83—24(— N(Boc)2B o N(Boc)2 NHZ
/\©/C02M€ o/—
sL\ [\N 1.TFA,CHZC|2
LN <’NN lNJ\C| “ l/xk 2.aq.LiOH,THF s\\ lNim
2g7 “
N 0'
C52003 DMF Q?”
AcO OAc ACO OAc HO OH
OMe OH
Example 182
Proceeding as described in Example 179 above but substituting BnBr with methyl 3-
(bromomethyl)benzoate ed the title compound as a mixture of diastereomers (ca. 1:1)
and isolated as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.99-9.01 (m, 1H), 8.33 (s, 0.5H), 8.14 (s, 0.5H), 7.66—7.88
(m, 3H), 7.45-7.48 (d, J: 729 Hz, 0.5H), 7.36—7.39 (d, J: 7.86 Hz, 0.5H), 7.17—7.22 (t, J:
7.56 Hz, 0.5H), 7.00—7.05 (d, J: 747 Hz, 0.5H), 5.99—6.01 (d, J: 7.29 Hz, 0.5H), 5.93—5.95
(d, J: 6.87 Hz, 0.5H), 5.00—5.03 (d, J: 738 Hz, 0.5H), 4.90—4.95 (d, J: 6.80 Hz, 0.5H),
.31 (m, 1H), 3.80—4.01 (m, 2H), 3.63—3.69 (m, 2H), 3.01 (s, 0.5H), 2.92 (s, 0.5H),
LC/MS [M + H] = 601.0.
Example 183
Synthesis of 2-(((2R, SS, 4R, (6—amino-2—chloro-9H-puriny1)—3 -ethyny1-3 ,4-
dihydroxytetrahydrofuran-Z—yl)methoxy)-2—(thiazolyl)—3-(3-
(trifluoromethoxy)phenyl)propanoic acid
N(Boc)2 o 0/— 2
SLN 'NJ\C| <N 2 a \ 01 LiOH THF W111
O 'N/kCI N
S 07‘N 052003 DMF NwNN
AcO OAc F300 ACO OAc F3CO HO OH
Example 183
Proceeding as bed in Example 179 above but substituting BnBr with 1-
(bromomethy1)(trifluoromethoxy)benzene provided the title compound as a mixture of
diastereomers (ca. 1:1) and ed as a white solid.
1H NMR (CD3OD, 300 MHz) 6 8.97-9.00 (m, 1H), 8.41 (s, 0.5H), 8.26 (s, 0.5H), 7.68-7.69
(d, J: 1.92 Hz, 0.5H), 7.62—7.63 (d, J: 1.83 Hz, 0.5H), 6.88—7.21 (m, 4H), 6.00—6.02 (d, J:
7.14 Hz, 0.5H), 5.94—5.96 (d, J: 6.78 Hz, 0.5H), 5.04—5.07 (d, J: 7.44 Hz, 0.5H), 4.91-4.94
(d, J: 6.87 Hz, 0.5H), 4.28-4.33 (m, 1H), 3.62-3.96 (m, 4H), 2.98 (s, 0.5H), 2.96 (s, 0.5H);
LC/MS [M + H] = 641.0.
e 184
Synthesis of 2—(((2R, 3S, 4R, 5R)(6-amino-2—ch1oro-9H-puriny1)—3 -ethyny1-3 ,4-
dihydroxytetrahydrofuranyl)methoxy)—2-(thiazolyl)pent—4-ynoic acid
1531*:N()3002 O /— N(BOC)2
sx 1 TFA CHZCIZ
gN «N m
A01 o N <1*H5
0 NékC|2.aq.LiOH THF 1: <N
o Nc’k
|| Qj IIM
—AcO OAc AGO: bAc HO OH
Example 184
Proceeding as described in Example 179 above but substituting BnBr with propargyl
bromide provided the title compound as a mixture of diastereomers (ca. 1:1) and isolated as a
white solid.
1H NMR (CD3OD, 300 MHz) 5 8.95 (s, 1H), 8.79-8.83 (d, J: 1395 Hz, 1H), 7.73 (s, 1H),
6.04-6.06 (d, J: 705 Hz, 1H), .05 (dd, J: 7.29, 17.91 Hz, 1H), 4.24—4.30 (m, 1H),
3.69-3.94 (m, 2H), 3.34-3.38 (m, 2H), 3.04 (s, 0.5H), 2.93 (s, 0.5H), 2.22—2.30 (dt, J: 174,
19.62 Hz, 1H); LC/MS [M + H] = 505.0.
Examples 185 and 186
Synthesis of (S)(((2R, 35, 4R, 5R)(6-aminochloro-9H-purinyl)ethyny1-3,4-
dihydroxytetrahydrofurany1)methoxy)-N-hydroxy(thiazolyl)acetamide
(S)(((2R, 3S, 4R,5R)—5-(6-aminochloro-9H-purinyl)-3 -ethynyl-3,4-
oxytetrahydrofuranyl)methoxy)—N—hydroxy(thiazol—4—yl)acetan1ide
O—é—J—o<l1NfN£ZCI NH2OHm H20 \N/>—(:>>—NHH33$:a 17>""?;NH:3315:“
_S 0-7 +
MeOH 40°C
ACO OAc —HO OH —HO OH
Example 185 Example 186
To a solution of (2R, 3R, 4R,5R)—5-(6—amino—2-chloro-9H—purinyl)((2-ethoxy
oxo—1-(thiazolyl)ethoxy)methyl)—3—ethynyltetrahydrofuran-3,4-diyl diacetate (2 g, 3.45
mmole) in MeOH (20 mL) was added 50% NHzOH in H20 (30 mL). The reaction mixture
was stirred at 40 °C for 1 h before it was concentrated under reduced pressure. The crude
residue was purified by preparative reversed-phase HPLC to provide a pair of diastereomeric
title products which the stereo configuration was assigned arbitrarily. Both ts were
isolated as white solids.
(S)—2-(((2R, SS, 4R, 5R)—5 inochloro—9H-purinyl)—3 -ethynyl-3 ,4-dihydroxytetra-
hydrofuranyl)rnethoxy)-N-hydroxy(thiazolyl)acetarnide: 1H NMR (CD3OD, 300
MHz) 6 9.02-9.03(d,J=1.77 Hz, 1H), 8.45 (s, 1H), 7.68-7.69 (d, J: 1.8 Hz, 1H), .01
(d, J: 6.96 Hz, 1H), 4.92-4.95 (d, J: 6.93 Hz, 1H), 4.29-4.32 (q, .1: 2.82, 2.28 Hz, 1H),
3.91-4.10 (m, 2H), 3.18 (s, 1H); LC/MS [M + H] = 482.0.
(R)-2—(((2R, SS, 4R, 5R)—5 ino-2—chloro—9H—purinyl)—3 -ethynyl-3 ,4—dihydroxytetra—
hydrofuranyl)methoxy)-N—hydroxy(thiazolyl)acetamide: 1H NMR (CD3OD, 300
MHz) 6 8.97 (s, 1H), 8.46 (s, 1H), 7.68 (s, 1H), 5.97-6.00 (d, J= 6.96 Hz, 1H), 4.88-4.90 (d,
J: 6.93 Hz, 1H), 4.33-4.35 (m, 1H), .08 (m, 2H), 3.12 (s, 1H); LC/MS [M + H] =
4820.
Examples 187 and 188
Synthesis of (S)—2—(((2R,3S, 4R,5R)(2-chloro-6—(methylamino)—9H—purinyl)—3-ethynyl-
3,4-dihydroxytetrahydrofuran-2—yl)methoxy)-3—phenyl—2—(thiazolyl)propanoic acid
(R)(((2R, SS, 4R, 5R)-5 -(2—chloro—6-(n1ethylamino)—9H—purinyl)-3 -ethynyl-3 ,4-
dihydroxytetrahydrofuranyl)methoxy)—3-phenyl(thiazolyl)propanoic acid
o HN o HN
</ 11 OH (”l/k“ i7”
N /
N N/J\Cl aq.LIOH.
\ </” 1‘“
CI 0 N N O N
O O N//,\Cl +
TMSOTf. BSA _ THF _
MeCN Acd aOAc Hd ’IOH
Example 187 Example 188
Proceeding as described in Examples 170 and 171 above but substituting 2—chloro—N-
isopropyl-9H—purinamine with 2-chloro-N-methyl-9H-purinamine provided the title
compounds as a pair of diastereomers (ca. 1:1) and isolated as White solids.
(S)-2—(((2R,3S,4R,5R)—5-(2—ch1oro-6—(methylamino)—9H—purinyl)—3-ethynyl-3,4—dihydroxy-
tetrahydrofuranyl)methoxy)-3 -pheny1(thiazoly1)propanoic acid: 1H NW (CD3OD,
300 MHz) 5 8.99 (s, 1H), 7.97 (s, 1H), 7.69 (s, 1H), 7.08-7.22 (m, 5H), 5.93-5.95 (d, J= 6.9
Hz, 1H), 4.96-4.98 (d, J: 6.0 Hz, 1H), 3.59-4.22 (m, 5H), 3.01-3.06 (m, 4H), LC/MS [M +
H] = 571.0.
(R)—2-(((2R, 3S, 4R, 5R)-5 -(2-chloro—6-(methy1amino)-9H—purin-9—yl)-3 -ethynyl-3 ,4-
dihydroxytetrahydrofuran-2—yl)methoxy)-3—phenyl—2-(thiazolyl)propanoic acid: 1H NMR
(CD3OD, 300 MHz) 5 8.97-8.98 (d, J: 1.83 Hz, 1H), 8.15 (s, 1H), 7.58-7.59 (d, .1: 1.77 Hz,
1H), .09 (m, 5H), 598—600 (d, J: 7.17 Hz, 1H), 4.98-5.01 (d, J: 7.26 Hz, 1H), 4.27-
4.29 (t, J: 3.48 Hz, 1H), 3.93 (m, 2H), 3.58-3.80 (q, J= 14.46, 38.7 Hz, 2H), 3.07 (s, 3H),
2.94 (s, 1H); LC/MS [M + H] = 571.0.
es 189 and 190
Synthesis of (((2R, 3S, 4R,5R)(6-aminochloro—9H—purinyl)ethynyl-3,4-
dihydroxytetrahydrofuranyl)methoxy)—2-cyanopheny1propanoic acid
(R)(((2R, SS, (6-aminochloro-9H—puriny1)-3 -ethyny1-3,4-
dihydroxytetrahydrofuran-Z-y1)methoxy)—2-cyano-3 -pheny1propanoic acid
N N(BOC)2
N N
\ \ //
< o
/ i N W N
EtO N2 H </ l AIN OfBr \N
HO N / —>HO 0 N </ l
o N on : :0: , N C EtO o N A
E 7 toluene. 95 °C K2003 DMF :10}, N Cl
N NH2 0
O /
/N \ N §—OH N \
50% TFA < j AN LIOH, MeOH. - </ l i + </ l A
—>EtO O N / —> O N / O N /
O N 0‘
90"" 0 N CI ::0: , N
THF,H20 CI
Acd bAc HO: 90H HC§ ”0H
Example 189 Example 190
Step 1:
To a solution of R, 3R, 4R, 5R)(6-N,N’ -(bis-(Zert—butoxycarbonyl)amino)—2-chloro-
9H-purinyl)ethynyl(hydroxymethyl)tetrahydrofuran-3,4-diyl diacetate (510 mg,
0.836 mmol) in toluene (5 mL) was added ethyl 2-cyano-2—diazoacetate (134 mg, 0.961
mmol). The mixture was trated in vacuo. The mixture was taken up in dry toluene (2
mL) and followed by addition of c)4 (8 mg, 17 umol) under argon atmosphere. The
al was stirred and heated at 80 0C for 30 minutes before additional ethyl 2-cyano-2—
cetate (254 mg, 1.82 mmol) was added over 60 min at 80 °C. The reaction was further
heated at 80 °C for 80 minutes before it was cooled to room temperature and concentrated.
The crude product was purified by CombiFlash silica gel chromatography (5 — 65% of EtOAc
in hexanes) to provide a diastereomeric mixture of (2R, 3R, 4R, 5R)-5—(6-N,N ’-(bis-(tert—
butoxycarbonyl)amino)—2-chloro-9H-purinyl)((1-cyanoethoxyoxoethoxy)methyl)-
3-ethynyltetrahydrofuran-3,4-diyl ate (230 mg, 38% yield) as an off-white foam.
Step 2:
An oven dried flask was charged with ((2R, 3R, 4R,5R)—5-(6—N,N ’-(bis-(lert—
butoxycarbonyl)amino)—2-chloro-9H-puriny1)((1-cyanoethoxyoxoethoxy)methyl)-
nyltetrahydrofuran-3,4-diyl diacetate (230 mg, 0.319 mmol) and taken up in dry DMF
(4 mL). To this mixture was added CszCO3 (208 mg, 0.639 mmol) and followed by the
addition of benzyl bromide (109 mg, 0.639 mmol). The mixture was stirred at 25°C for 30
minutes before it was diluted with cold saturated aqueous NH4C1 (40 mL) and extracted with
EtOAc (40 mL). The aqueous phases were extracted with EtOAc (2 x 40 mL)‘ The
ed organic layer was dried over NazSO4, filtered and concentrated. The crude product
was purified by CombiFlash silica gel column chromatography (10 — 70% EtOAc in hexanes)
to provide (2R, 3R, 4R, 5R)—5—(6-N,N’ -(bis-(terl-butoxycarbonyl)amino)—2-chloro-9H-purin—9-
(((2-cyanoethoxy-1—oxo-3—phenylpropan-2—yl)oxy)methyl)—3 -ethynyltetrahydro-
furan-3,4-diyl diacetate as a pair of diastereomers (215 mg, 83% yield) as an off-white solid.
Step 3:
A solution (2R, 3R, 4R, 5R)-5—(6-N,N’ —(bis-(tert—butoxycarbonyl)amino)chloro-9H—
purinyl)(((2-cyano- l -ethoxy- l -oxo-3 -phenylpropanyl)oxy)methyl)-3 -ethynyltetra-
hydrofuran-3,4-diyl diacetate (215 mg, 0.265 mmol) in a solution of TFA (1 mL) in DCM (1
mL) was stirred for 2 h before it was concentrated under reduced pressure. The e was
azetroped with DCM (8 X 8 mL) under reduced pressure. The residue was taken up in a
mixture ofMeOH in H20 (2.2 mL, 5:1 = v:v) and followed by addition ofLiOH'HzO (77 mg,
1.86 mmol, 7 eq) and THF (0.5 mL). The mixture was stirred at ambient temperature for 40
minutes before it was concentrated to dryness. The residue was dissolved in H20 (15 mL).
The aqueous phase was extracted with EtOAc (2 x 10 mL). The aqueous phase was acidified
to pH 25 with 1N aq. HCl solution. The aqueous phase was extracted with EtOAc (3 x 50
mL). The combined organic layer was washed with brine (50 mL), dried over ,
filtered and concentrated. The crude residue was ed by preparative reversed-phase
HPLC to provide the title compounds as a pair of diastereomers: (S)(((2R,3S,4R,5R)(6-
aminochloro-9H-purinyl)ethynyl-3,4-dihydroxytetrahydrofuran—2-yl)methoxy)
cyanophenylpropanoic acid (337 mg, 26% yield) and (R)(((2R,3S,4R,5R)-5—(6-amino-
2-chloro-9H-purinyl)—3-ethynyl—3,4-dihydroxytetrahydrofuran—2-yl)methoxy)cyano
phenylpropanoic acid (30 mg, 23% yield) which the stereo configuration was assigned
rily. Both were isolated as off-white solids.
(S)(((2R, 3S, 4R, 5R)—5 ino—2-chloro—9H—purinyl)-3 -ethynyl-3 ,4—dihydroxytetrahydrofuranyl
)methoxy)cyano—3-phenylpropanoic acid: 1H NMR , 300 MHz) 5
8.32 (bs, 1H), 7.20-7.36 (m, 5H), 6.02 (d, J=7.00 Hz, 1H), 4.68 (d, J=7.02 Hz, 1H), 4.33-4.37
(m, 1H), 4.18 (dd, J=9.91, 3.96 Hz, 1H), 3.99 (dd, J=9.94, 2.19 Hz, 1H), 3.41 (bs, 2H), 3.03
(s, 1H), LC/MS [M + H] = 499.1.
(R)(((2R, 3S, 4R, 5R)-5 -(6—amino—2-chloro—9H—purinyl)-3 -ethynyl-3 ,4-dihydroxytetra—
hydrofuran-2—yl)methoxy)-2—cyano—3—phenylpropanoic acid: 1H NMR (CD3OD, 300 MHz)
8.04 (bs, 1H), 7.21-7.39 (m, 5H), 5.99 (d, J=6.90 Hz, 1H), 4.79 (d, J=6.93 Hz, 1H), 4.31-
4.36 (m, 1H), 4.19 (dd, J=10.07, 4.34 Hz, 1H), 4.12 (dd, J=10.10, 3.30 Hz, 1H), 3.38-3.44
(m, 2H), 3.09 (s, 1H), LC/MS [M + H] = 499.1.
Examples 191 and 192
Synthesis of (S)(((2R, 3S, 4R, 5R)—5-(6-aminochloro—9H-purinyl)ethynyl-3,4-
dihydroxytetrahydrofurany1)methoxy)—3 -pheny1(1H-tetrazol-5—yl)propanoic acid
(R)(((2R, SS, 4R, 5R)-5—(6-aminochloro-9H—purin-9—yl)-3 -ethynyl-3,4-
dihydroxytetrahydrofuranyl)methoxy)—3 -phenyl(1H-tetrazolyl)propanoic acid
l A ,SEM
“O (N ,/N\
o N CI N 5“ N(Boc)2
NI; \\N 0 O ’N
MN;O N=N N
1 SEM Cl K co) DMF . .
- \N
, 2 3, \N—SEM Aco‘ ’OAc
\ </ l X Benzyl bromide
—>EtO
EtO H N’ EC 0 N
0 N/
2)4—(AcNH)C6H5SOZN3 Rh2(OAc)4,toluene 0' DMF,052003
DBU,CHSCN _
Acd l’OAc
N/N‘N Naaoc)2 H o NH2 N/,"“NH o NH2
11’ N \ ‘N’ AX—OH N \ \Ng’h. OH N
1)aqLIOH,MeOH. -‘ .
o </ l i </ l l + </ l A
O N / /
O N / o N
O N Cl o N C. O
2)TFA,DCM N CI
Aw“ ’oAc H6 ’OH Ho‘ ’OH
Example 191 Example 192
Step 1:
To a solution of ethyl lH—tetrazole-S-acetate (3 g, 19.21 mmol) in DNEF (40 mL)
under argon atmosphere at 25 0C was added 2-(trimethylsilyl)ethoxymethyl chloride (4.1 mL,
23.05 mmol) and powdered potassium carbonate (5.31 g, 38.42 mmol). The on mixture
was stirred overnight before it was diluted with brine (70 mL) and EtOAc (70 mL). The
aqueous phase was extracted with EtOAc (2 X 70 mL). The ed organic layer was
washed with brine (70 mL) and water (70 mL), dried over NazSO4 and concentrated. The
residue was purified by silica gel column chromatography (15—48% EtOAc in s) to
provide ethyl 2-(2-((2-(trimethy1silyl)ethoxy)methyl)-2H—tetrazol—5-yl)acetate (2.379 g) as a
light yellow oil.
Step 2:
To a solution of ethyl 2-(2-((2-(trimethylsi1yl)ethoxy)methyl)—2H-tetrazol-5—yl)acetate
(2.379 g, 8.31 mmol) in dry acetonitrile (25 mL) under argon atmosphere was added DBU
(1.87 mL, 12.47 mmol). To this e was added 4-acetamidobenzenesulfonyl azide
(2.395 g, 9.96 mmol) in 3 equal portions over 5 minutes. The reaction mixture was stirred for
3.5 h the organic le was removed under reduced pressure. The residue was purified by
silica gel column chromatography (20% EtOAc in hexanes) to provide ethyl 2-diazo(2-((2-
(trimethylsilyl)ethoxy)methyl)-2H—tetrazoly1)acetate (2.316 g) as an oil.
Step 3:
To a solution of (2R, 3R, 4R,5R)(6-(bis-(terl—butoxycarbony1)amino)chloro-9H-
purinyl)—3-ethynyl(hydroxymethyl)tetrahydrofuran-3,4-diy1 diacetate (2 g, 3.28 mmol)
in toluene (8 mL) at 20 0C under N2 atmosphere was added Rh2(OAc)4 (29 mg, 0.066 mmol,
0.066 eq) and ethyl 2-diazo—2-(2-((2-(trimethylsily1)ethoxy)-methyl)-2H—tetrazoly1)acetate
(1.08 g, 3.44 mmol, 1.05 eq). The mixture was stirred at 75 °C for 1 h before additional ethyl
o(2-((2-(trimethylsi1y1)ethoxy)methyl)—2H—tetrazoly1)acetate (720 mg) was added
over 80 min. The on e was cooled to ambient temperature and concentrated. The
crude al was purified by Combi-Flash silica gel column (5 — 80% EtOAc in hexanes) to
provide a diastereomeric mixture of (2R, 3R, 4R, 5R)(6-(bis-(tert—butoxycarbonyl)amino)
chloro-9H—puriny1)((2—ethoxy—2-oxo(2-((2—(trimethy1silyl)ethoxy)methyl)—2H—
tetrazolyl)ethoxy)methyl)—3-ethyny1tetrahydrofuran-3,4-diyl diacetate (1.608 g) as a gum.
Step 4:
To a solution of (2R, 3R, 4R,5R)(6-(bis-(terl—butoxycarbonyl)amino)chloro-9H-
purinyl)((2-ethoxyoxo(2-((2-(trimethyl si1y1)ethoxy)methy1)-2H-tetrazol-5 -
yl)ethoxy)methyl)—3-ethynyltetrahydrofuran-3,4-diy1 diacetate (1.555 g, 1.739 mmol) in dry
toluene (10 mL). The mixture was concentrated under d pressure. The residue was
taken up in dry DMF (10 mL) and followed by addition of benzyl bromide (1.189 g, 6.96
mmol) amd dried CszCO3 (1.133 g, 3.478 mmol). The mixture was stirred at 25°C for 5.5 h
before it was diluted with saturated aq. NH4C1 on (60 mL), The aqueous phase was
extracted with EtOAc (3 x 60 mL). The combined organic layer was washed with brine (60
mL), dried over Na2SO4, filtered and concentrated. The crude t was purified by flash
silica gel column chromatography (5 — 65% EtOAc in s) to provide a diastereomeric
mixture of (2R, 3R, 4R, 5R)(6-(bis—(tert—butoxycarbonyl)amino)—2-chloro—9H-purinyl)
(((1-ethoxyoxo-3 —phenyl—2-(2-((2-(trimethy1sily1)ethoxy)methyl)-2H-tetrazoly1)propan-
2-y1)oxy)methyl)—3-ethyny1tetrahydrofuran-3,4-diy1 diacetate (1.041 g) as a foam.
Step 5:
To a solution of (2R, 3R, 4R, 5R)—5-(6-(bis-(terZ-butoxycarbony1)amino)chloro-9H-
puriny1)—2-(((1-ethoxyoxo-3 -pheny1(2-((2—(trimethy1silyl)ethoxy)methyl)—2H—
tetrazol-5 -yl)propan—2-yl)oxy)methy1)-3 -ethynyltetrahydrofuran-3,4-diy1 diacetate (1 .041 g,
1.057 mmol) in a mixture ofMeOH and H20 (12 mL, 6:1 = vzv) was added powdered
LiOH‘HzO (349 mg, 8.5 mmol). The mixture was stirred at 23°C for 16 h before it was
concentrated to dryness. The e was dissolved in H20 (40 mL) and it was extracted with
EtOAc (40 mL). The aqueous phase was acidified to pH 2.5 with 1N aq. HCl on and
extracted with EtOAc (3 x 40 mL). The combined organic layer was washed with brine (40
mL), dried over NazSO4, filtered and concentrated to provide a diastereomeric e of 2-
(((2R, 3S, 4R, 5R)-5 -(6-((Zert—butoxycarbonyl)amino)chloro-9H—purin-9—yl)-3 -ethynyl-3 ,4-
dihydroxytetrahydrofuran-2—yl)methoxy)-3—phenyl—2-(2-((2—(t1imethylsilyl)ethoxy)methyl)—
2H-tetrazolyl)propanoic acid (784 mg) as an oil.
Step 6:
To a solution of 2-(((2R, 3S, 4R, 5R)-5—(6-((terI-butoxycarbonyl)amino)chloro-9H—
puriny1)—3-ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)—3-phenyl(2-((2-
(trimethylsilyl)ethoxy)methyl)-2H-tetrazol—5—yl)propanoic acid (138 mg, 0.179 mmol) in
DCM (0.9 mL) under argon atmosphere at 0 0C was added TFA (0.9 mL). The mixture was
stirred at 0°C for 5 h and then d to ambient for 15 min before the organic volatile was
removed under the reduced pressure. The residue was azetroped with DCM (3 x 15 mL)
under reduced pressure. The crude e was purified by preparative reversed-phase HPLC
to provide the two title products as a pair of diastereomers: (S)—2-(((2R,3S,4R,5R)—5-(6-
aminochloro-9H-purinyl)ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)
phenyl(lH—tetrazol—S-yl)propanoic from the first fraction and (R)—2-(((2R,3S,4R,5R)-5—(6-
aminochloro-9H-purinyl)ethynyl-3,4-dihydroxytetrahydrofuranyl)methoxy)
pheny1(lH-tetrazol-S-yl)propanoic acid from the later fraction. Both isolated as ite
solids.
(((2R, 3S, 4R, 5R)—5 -(6—amino—2-chloro-9H—purinyl)-3 -ethynyl-3 ,4—dihydroxytetra-
hydrofuran-2—y1)methoxy)-3—phenyl—2-(lH—tetrazol—S-yl)propanoic acid: 1H NMR (CD3OD,
300 MHz); 6 8.37 (s, 1H), 7.11-7.23 (m, 5H), 5.96 (d, J:6.57 Hz, 1H), 4.81 (d, J:6.57 Hz,
1H), 4.25-4.30 (m, 1H), 4.01 (dd, J=10.19, 2.29 Hz, 1H), 3.78 (d, J=13.90 Hz, 1H), 3.67 (d,
J:13.90 Hz 1H), 3.72-3.79 (m, 1H), 3.06 (s, 1H); LC/MS [M + H] = 542.2.
(R)(((2R, 3S, 4R, 5R)-5 -(6-aminochloro-9H—purinyl)-3 -ethynyl-3 ,4-dihydroxytetra-
hydrofuran—2-yl)methoxy)—3-phenyl(1H—tetrazolyl)propanoic acid: 1H NMR (CD3OD,
300 MHz); 6 8.37 (s, 1H), 6.92-7.11 (m, 5H), 6.01 .11Hz, 1H),5,06(d,J:7.11Hz,
1H), 4.35—4.39 (m, 1H), 4.11 (dd, J=10.06, 2.52 Hz, 1H), 4.01 (dd, J=10.06, 5.49 Hz, 1H),
3.80 (d, J:14.75 Hz 1H), 3,67 (d, J:14.75 Hz 1H), 2.96 (s, 1H), LC/MS [M + H] = 542.2.
Examples 193 and 194
Synthesis of (S)—2-(((2R, SS, 4R,5R)(6—amino—2-ch1oro—9H—purinyl)ethynyl-3,4—
dihydroxytetrahydrofuranyl)methoxy)—2-(2-phenylthiazolyl)acetic acid
(R)(((2R, 3S, 4R,5R)—5-(6-aminochloro-9H—purinyl)-3 -ethynyl-3,4-
dihydroxytetrahydrofuran-Z-yl)methoxy)(2-phenylthiazol-4—yl)acetic acid
N \ I N(Boc)2
</ 1 N
NACI c)z 0 N
N \
HO N /
O o N’S
toluene, 95°C </ i *N TFA
\ —> E10 0 N
o N’ _’
EtO C' DOM
_ ’
Aw“ ’OAc N2 — X 7/
_ .
Sj/Q 8’; s/;\
I ””2 K/N NH2 N
\ NH2
H (,N [\N LiOH,MeOH o g H </N 0
\N + “NH </N \N
E10 0: N /
o N Cl THF,H20 H0 0: N
o NAG, HO 0: o ,N NAG
A06 OAc H6 bH H6 90H
Example 193 Example 194
Proceeding as described in Example 179 but substituting ethyl 2-diazo(thiazol
yl)acetate with ethyl (2-phenylthiazoly1)diazoacetate which was prepared Via the
procedure bed by re, Quentin, et al., cal Communications 2014, 50,
6617—6619) provided the title compounds as a pair of diastereomers (ca. 1:1). The stereo
configuration was assigned arbitrarily. Both were isolated as off-white solids.
(S)—2-(((2R, SS, 4R, 5R)—5 inochloro-9H—purinyl)—3 -ethynyl-3 ,4-dihydroxytetra-
uran-Z-yl)methoxy)(2-pheny1thiazolyl)acetic acid: 1H NMR (CD3OD, 300
MHz), 5 9.03 (bs, 1H), 7.91—7.97 (m, 2H), 7.60 (s, 1H), 7.39—7.45 (m, 3H), 6.06 (d, J:7.45
Hz, 1H), 5.28 (s, 1H), 4.92 (d, J:7.45 Hz, 1H), 4.29—4.33 (m, 1H), 4.12 (dd, J:10.45, 2.51
Hz, 1H), 4.01 (dd, J:10.46, 2.56 Hz, 1H), 2.92 (s, 1H), LC/MS [M + H] = 543.1.
(R)—2-(((2R, 3S, 4R, 5R)-5 -(6—amino—2-chloro—9H—purinyl)-3 -ethynyl-3 ,4—dihydroxytetra—
hydrofurany1)methoxy)—2-(2-phenylthiazolyl)acetic acid: 1H N1VIR (CD3OD, 300
MHz); 5 9.15 (s, 1H), 7.90-7.96 (m, 2H), 7.61 (s, 1H), 7.38-7.44 (m, 3H), 6.09 (d, J=7.48 Hz,
1H), 5.23 (d, J:7.48 Hz, 1H), 5.30 (s, 1H), 4.26-4.29 (m, 1H), 3.93 (dd, J:10.67, 2.18 Hz,
1H), 3.76 (dd, J=10.64, 2.48 Hz, 1H), 3.17 (s, 1H); LC/MS [M + H] = 5432.
Example 195
Synthesis of 4-((((2R, 3S, 4R, 5R)(6-aminochloro—9H-purinyl)—3-ethynyl-3,4-
dihydroxytetrahydrofuranyl)methoxy)(carboxy)methyl)thiazole-2—carboxylic acid
0 O COzEl \
002El
S <’ l N
0 N‘< 4-(AcNH)C5H5SOZN3 O N/ HO N
051 EtOJk/lk/Br 0 NAG,
H2N —> S —> s
\ \ +
Toluene, u-wave EtOM/ DBU,MeCN E10
N2 Acd bAc
Rh2(OAc)4
CO2H toluene. 95 °C
N 00 El
NH 2
\ 2
N(Boc)2
O H N 1. TFA, DCM o gN (N/ \N
[NAG N
. 2.aq.LIOH,THF \N
HO O > { </ l
:10); EtO o; N
o NAG
H(5 ’0H \: a/
AcO 0A0
Example 195
Step 1:
To a microwave vial was d with ethyl thiooxamate (1.91 g, 14.36 mmol) and
ethyl 4-bromoacetoacetate (3 g, 14.36 mmol) in dry toluene (27 mL). The e was
irradiated in a microwave r at 90 0C for 1 hour. The on mixture was cooled to
ambient and the solvent decanted and then was concentrated. The crude residue was purified
by CombiFlash silica gel chromatography (2—56% EtOAc in hexanes) to provide ethyl 4-(2-
ethoxyoxoethyl)thiazolecarboxylate (890 mg, 26% yield) as a thick oil.
Step 2:
To a solution of ethyl 4-(2-ethoxyoxoethyl)thiazolecarboxylate (890 mg, 3 .66
mmol) in dry acetonitrile (12 mL) under argon atmosphere was added DBU (0.82 mL, 5.49
mmol) and 4-acetamidobenzenesulfonyl azide (1.055 g, 4.39 mmol). The reaction e
was stirred for 1.5 hours before it was concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (20% EtOAc in hexanes) to provide ethyl 4—(1-
2-ethoxyoxoethyl)thiazole—2-carboxylate (894 mg, 90% yield) as a yellowish solid.
Step 3:
—274—
Proceeding as described in Example 179 but substituting ethyl 2-diazo(thiazol
yl)acetate with ethyl 4-(1-diazoethoxyoxoethyl)thiazolecarboxylate provided the title
compound as a mixture of diastereomers (ca. 1:1) and isolated as off-white solids.
Isomer 1: 1H NMR , 300 MHz): 5 8.93 (s, 1H), 7.91 (s, 1H), 6.06 (d, .1442 Hz,
1H), 5.39 (s, 1H), 5.13 (d, J:7.42 Hz, 1H),4.24-4.31 (m, 1H), 4.03—4.09 (m, 1H), 3.75-3.83
(m, 1H), 2.95 (s, 1H), LC/MS [M + H] = 511.1.
Isomer 2: 1H NMR (CD3OD, 300 MHz): 5 8.87 (s, 1H), 7.93 (s, 1H), 6.04 (d, J:7.42 Hz,
1H), 5.33 (s, 1H), 4.91 (d, J=7.45 Hz, 1H),4.24-4.31 (m, 1H), 3.92—4.01 (m, 2H), 3.19 (s,
1H); LC/MS [M+H] = 511.1.
Example 196
Synthesis of ((2R, 3S, 4R, 5R)(6-aminochloro—9H—puriny1)ethynyl-3,4-
dihydroxytetrahydrofuran-Z-yl)methoxy)—1-carboxyphenylethyl)thiazolecarboxylic acid
0 0
s CE OH
\ I N(Boc)2
N(Boc)2 NHz
O N/ N/
</N \N S
BnBr \8 1)aq LiOH,MeOH N
l —> </N \N —> </ \N
/ l 0 I
EC 0 N
o N/km DMF,C52003 O 2)TFA,DCM
o N NKCI o N
o NAG
OEt 0H
_ X 7’ X 7o
ACO OAC Acd "OAc HO: ”OH
Example196
ding as described in Example 179 above but substituting (2R, 3R, 4R, 5R)(6-
N,N’ (tert—butoxycarbony1)amino)—2—chloro-9H—purin—9-yl)—3-ethynyl(hydroxyl-
methyl)tetrahydrofuran-3,4—diyl diacetate with (2R, 3R, 4R, 5R)(6-N,N’ -(bis-(lert—butoxycarbonyl
))chloro—9H—puriny1)((2-ethoxy(2-(ethoxycarbonyl)thiazol-4—yl)-
2-oxoethoxy)methyl)—3-ethynyltetrahydrofuran-3,4—diyl diacetate provided the title
compound as a mixture of diastereomers (ca. 1:1) and isolated as an off-white solid.
Isomer 1: 1H (CD3OD, 300 MHz): 5 8.17 (bs, 1H), 7.81 (s, 1H), 6.92-7.25 (m, 5H),
.95 (d, J:7.02 Hz, 1H), 4.89 (d, J:7.02 Hz, 1H), 4.29—4.34 (m, 1H), 3.59—4.05 (m, 4H),
3.01 (s, 1H); LC/MS [M + H] = 601.1.
Isomer 2: 1H NMR (CD3OD, 300 MHz): 8 8.05 (bs, 1H), 7.90 (s, 1H), 6.92-7.25 (m, 5H),
6.00 (d, J=7.41 Hz, 1H), 5.04 (d, J=7.42 Hz, 1H), 4.21-4.26 (m, 1H), 3.59—4.05 (m, 4H),
3.06 (s, 1H); LC/MS [M + H] = 601.1.
Examples 197
Synthesis of 2-(((2R, 3S, 4R, (6-aminochloro-9H—purinyl)-3 -ethynyl-3 ,4-
dihydroxytetrahydrofuran-Z-yl)methoxy)—2-(4—(2-aminopyridin-3 -yl)benzyl)malonic acid
NH2 9 2 o NH2
2 0
| 1. TFA DCM
0 CE N / 2. aq. LiOH THF
</ \N —>l EtO</r:‘:’\/kNNC/kl—> <N
Pd(dppf)C|2, ch03
BO 0 N A
O N CI dioxane, H20
_ Acd bAC
. . /
A60“ ’OAc N \ N \
Example 197
\ \
Proceeding as described in Example 22 above but substituting (2-oxo-1,2-
dihydropyridinyl)boronic acid with 3-(4,4,5,5-tetramethyl—1,3,2—dioxaborolan-2—
yl)pyridinamine provided the title compound as a white solid.
1H NMR (CD3OD, 300 MHz) 5 8.43 (s, 1H), 7.85-7.87 (dd, .1: 1.5, 6.42 Hz, 1H), 7.65-7.68
(dd, J: 1.53, 7.38 Hz, 1H), 7.37—7.40 (d, J: 8.13 Hz, 2H), 7.09-7.12 (d, J: 8.07 Hz, 2H),
6.88-6.93 (t, J: 6.9 Hz, 1H), 5.99-6.01 (d, J: 6.72 Hz, 1H), 4.77—4.79 (d, J: 7.0, 1H), 4.37—
4.40 (m, 1H), 398-4. 12 (m, 2H), 3.34—3.42 (m, 2H), 3.09 (s, 1H), LC/MS [M + H] = 6101.
Examples 198 & 199
Synthesis of (5)6 -([1,1'-biphenyl]—4-yl)—2—(((2R,3S,4R,5R)(6-amino-2—chloro-9H—purin
yl)-3,4-dihydroxymethy1tetrahydrofuran-Z-yl)methoxy)(thiazolyl)propanoic acid
(R)-3 '-biphenyl]yl)(((2R,3S,4R,5R)(6-aminoch1oro-9H—purinyl)—3 ,4-
dihydroxymethyltetrahydrofuran-Z-yl)methoxy)(thiazolyl)propanoic acid
o N(BOC)2
S O 0/
N(Boc)2 <\ \ o N(Boc)2
N 0/
</N \N </N' ”S o é‘fi/L
l A N2 K
HO N N O N
O N CI O
Rh2(OAc)4 052003 DMF Obi/“NAGO
. , , ‘
AC6 bAc Acd bAc O owl
TFA, DCM
O\_ NH2 NH2
0 NH2
OH <N OH
8 3 \ N (N \ N
-‘ 0/
L / l .... /
NAG l
0 N 0 N
o o NAG aq. LiOH, THF
HO OH HO OH
AcO ’0
Example 198 Example 199 O
Proceeding as described in Example 1 above but substituting (2R,3R,4R,5R)—5-(6-(bis-
(lert—butoxycarbonyl)amino)chloro-9H—purinyl)(((z‘erZ-butyldiphenylsilyl)oxy)-
methyl)ethynyltetrahydrofuran-3,4-diyl diacetate and diethyl 2-diazomalonate with
(2R, 3R, 4R, 5R)(6—(N,N ’-bis-(lert—butoxycarbonyl)amino)chloro-9H—purinyl)
(hydroxylmethyl)methyltetrahydrofuran-3,4-diy1 diacetate and methyl 2-diazo—2-(thiazol-
4-yl)acetate ed a pair of reomeric title products (ca. 1:1) which the stereo
configuration was assigned arbitrarily. Both products were purified by preparative HPLC
and isolated as white solids.
(S)-3—([1,1'-biphenyl]yl)—2-(((2R,SS,4R,5R)—5-(6—amino—2-chloro—9H—purinyl)—3 ,4-
dihydroxymethyltetrahydrofuranyl)methoxy)—2-(thiazolyl)propanoic acid: 1H NMR
(CD3OD, 300 MHz) 6 9.04 (s, 1H) 8.42 (s, 1H), 7.74 (s, 1H), 7.21-7.45 (m, 9H), 6.00-6.03
(d, J: 8 Hz, 1H), 4.67-4.70 (d, J: 7 Hz, 1H), 4.13 (s, 1H), 3.88-3.85 (m, 2H), 3.62-3.66 (d, J
= 14 Hz, 1H), 344-3447 (d, J=11Hz, 1H), 1.37 (s, 3H); LC/MS [M + H] = 623.2.
(R)—3 -([1,1’-biphenyl]yl)—2-(((2R, SS, 4R, 5R)-5—(6-amino—2-chloro-9H—purin-9—yl)—3 ,4-
oxymethyltetrahydrofuranyl)methoxy)—2-(thiazolyl)propanoic acid: 1H NMR
(CD3OD, 300 MHz) 6 9.04 (s, 1H) 8.21
, (s, 1H), 7.27-7.69 (m, 10H), 5.93-5.95 (d, J: 7 Hz,
1H), 4.52-4.55 (d, J: 8 Hz, 1H), 4.04 (s, 1H), 3.79—3.85 (m, 3H), 1.36 (s, 3H); LC/MS [M +
H] = 623.2.
Example 200
Synthesis of 4'—(2—(((2R, 3S, 4R, 5R)(6-amino-2—chloro—9H—purinyl)—3 ,4-dihydroxy-3 -
methyltetrahydrofuranyl)methoxy)-2—carboxy(thiazolyl)ethyl)-[ 1 , 1'-biphenyl]—2-
carboxylic acid
O N(BOC)2
/ </ l A
o o N /
s \ < [A/ \N o N Cl
g 1.052003,DMF
N o N /
o N Cl : ,7
2.TFA,DCM H5 OH
3. aq. LiOH, THF
. ,
Acd bAc
Proceeding as described in Example 179 above but substituting (2R, 3R, 4R, 5R)((6-
N,N’-bis-(tert—butoxycarbonyl)amino)—2-ch1oro-9H—purinyl)—3-ethyny1(hydroxylmethyl
hydrofuran-3,4-diyl diacetate and BnBr with (2R, 3R, 4R, 5R)-5—(6-(N,N ’-bis-(tert—
butoxycarbonyl)amino)—2-chloro-9H—purin-9—yl)—2-((2-methoxyoxo-l-(thiazol-4—
yl)ethoxy)methyl)—3-methyltetrahydrofuran-3,4-diyl diacetate and momethyl)-l, 1'-
yl provided the title compound as a mixture of diastereomers (ca. 1:1) and ed as
an off-white solid.
LC/MS [M + H] = 667.2.
Example 201
Synthesis of 4'—(2-(((2R, SS, 4R, 5R)(6-aminochloro-9H—purinyl)—3 ,4-dihydroxy—3 -
methyltetrahydrofuranyl)methoxy)—2-carboxy-2—( lH-tetrazolyl)ethyl)-[ 1, l '-biphenyl]—2-
ylic acid
milN \
/ N
9 H0
0 N CI
ACHN fi—N3 SEM\ O N(Boc)2
SEM-CI, K2003 SEM
\ o ,N‘N o 5 -, SEM\ OEt N
[FI\NH \
o DMF (N‘N O DBU,MeCN N9 \ 8000 0300 N,N
l \ N
N Mk N¢NJ\/"\OEI N </ j
\ / N§N O N
N OEt Rh2(OAc)4 0 N/J\C|
N2 toluene
BocO: I’OBoc
002Me
Br 052003, DMF
</ \N
l 0E” NACI ilmlignicilfiF
H5 V’OH
ExampleZO1
Step 1:
To a solution of ethyl 2-(lH—tetrazol—S-yl)acetate (500 mg, 3.24 mmol) and
trimethylsilyl)ethoxymethyl chloride (0.69 mL, 3.89 mmol) in dry DMF (7 mL) under argon
atmosphere at 25 0C was added powdered potassium carbonate (896 mg, 6.48 mmol). The
reaction mixture was stirred overnight before it was diluted with H20 (30 mL) and extracted
with EtOAc (3 x 30 mL). The combined organic layer was washed with brine (30 mL) and
water (30 mL) and then dried over Na2S04 and concentrated. The residue was purified by
CombiFlash silica gel column chromatography (8—58% EtOAc in hexanes) to provide ethyl
2-(2-((2-(trimethylsilyl)ethoxy)methyl)-2H—tetrazol—5-yl)acetate (200 mg) as an oil.
Steps 2 — 6:
ding as described in Example 1 above but substituting methyl 2-(thiazol
yl)acetate with ethyl 2-(2-((2-(trimethylsilyl)ethoxy)methyl)-2H—tetrazolyl)acetate
provided a pair of diastereomeric title products (ca. 1:1) which the stereo configuration was
assigned arbitrarily. Both products were purified by preparative HPLC and isolated as off-
white solids.
1H NMR (CD3OD, 300 MHz): Isomer 1: 5 8.50 (s, 1H), 7.73-7.79 (m, 2H), 7.31-7.56 (m,
3H), .24 (m, 4H), 6.04 (d, J:7.87 Hz, 1H), 4.64 (d, J:7.88 Hz, 1H), 4.10-4.14 (m,
1H), 3.46—4.00 (m, 4H), 1.35 (s, 3H), Isomer 2: 5 8.31 (s, 1H), 7.73-7.79 (m, 2H), 7.31-7.56
(m, 3H), 7.01-7.24 (m, 4H), 5.99 (d, J:7.75 Hz, 1H), 4.48 (d, J:7.72 Hz, 1H), 4.19-4.23 (m,
1H), .00 (m, 4H), 1.42 (s, 3H), LC/MS [M + H] = 652.2.
Example 202
Synthesis of (((((2R, 3S, 4R, 5R)—5-(6-amino-2—chloro-9H—purin—9-yl)—3—ethynyl-3,4-
dihydroxytetrahydrofuranyl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid
N(Boc)2 NHBoc NH2
mfifikm N \
LiOH H o / f”
MeOHz <N lN/J\c|_>TFA DOM ()(ilfiN
—>HO: o HO HA
—Ac5 OAc H6 6H —HO OH
A-B 3.1 3.2
(3.4:: 'FLC. P<0><0Me>s
Cl/ \/ \ TEAB
‘3 9 \
</ l N
HOjPVfiKO N
o NA
HO OH X7! Cl
H5 6H
Example 202
Step 1:
To a solution of (2R,3R,4R,5R)—5-(6-(bis-(tert-butoxycarbonyl)amino)chloro-9H—
purinyl)—3-ethynyl(hydroxymethyl)tetrahydrofuran-3,4-diyl diacetate (329 mg, 0.539
mmol) in i-PrOH (1.6 mL), MeOH (1.1 mL) and H20 (0.8 mL) was added ed LiOH
(111 mg, 2.69 mmol). The mixture was stirred for 30 minutes before the organic valotile was
removed under reduced pressure and the residue was dilueted with H20 (12 mL). The pH of
the aq. layer was adjusted to ~ 3 with 1N aq. HCl and ted with EtOAc (3 X 12 mL).
The combined organic layer was dried over MgSO4, filtered and concentrated to provide tert-
butyl oro((2R, SR, 45, 5R)ethynyl-3 ,4-dihydroxy-5 -(hydroxymethyl)tetrahydro-
WO 46403
furan—2-yl)—9H—pu1in—6-yl)carbamate which was used in the next step directly without further
purification.
Step 2:
Tert—butyl oro—9-((2R, 3R, 4S, 5R)ethynyl-3 ,4-dihydroxy(hydroxymethyl)-
tetrahydrofuranyl)-9H-purinyl)carbamate (0.539 mmol) was taken up in a mixture of
DCM (1 mL) and TFA (05 mL). The reaction mixture was stirred for 3 h before it was
concentrated. The residue was taken up in DCM (10 mL) and concentrated again ted 5
cycles). The residue was dried further in the vacuum oven for 18 h to e crude
(2R, SS, 4R, 5R)—5 -(6-aminochloro—9H—purinyl)-3 -ethynyl(hydroxymethyl)tetrahydro-
furan-3,4-diol as an off-white solid.
Step 3:
To an oven dried flask was charged with crude (2R,3S,4R,5R)(6-amino—2-chloro-
9H-purinyl)ethynyl-2—(hydroxymethyl)tetrahydrofuran-3,4-diol and dry trimethyl
phosphate (2.5 mL) under argon atmosphere. The mixture was cooled at 0 0C and followed
by dropwise addition of a solution of methylenebis(phosphonic dichloride) (673 mg, 2.7
mmol) in dry trimethyl phosphate (1.1 mL) over 10 minutes. The reaction mixture was
stirred at O 0C for 3 h before a on of triethylammonium carbonate (1 M, 1.9 mL) was
added dropwise. The e was stirred for 15 minutes at O 0C and then stirred for 2 h at
t temperature. The crude mixture was purified by preparative reversed-phase HPLC
to provide a impure product. This impure product was further purified by reserved-phase
HLPC twice to provide the desired (((((2R,3S, 4R,5R)(6-aminochloro-9H-purinyl)—3-
ethynyl-3,4—dihydroxytetrahydrofuranyl)methoxy)(hydroxy)phosphoryl)methyl)-
phosphonic acid (34 mg) as a light brown solid.
1H NMR (CD3OD, 300 MHz): 5 8.75 (bs, 1H), 6.07 (br, 1H), 4.86 (bs, 1H), 4.31-4.61 (m,
3H), 3.20 (s, 1H), 2.54 (br, 1H); LC/MS [M + H] = 484.0.
Example 203
Synthesis of (((((2R, 3S, 4R,5R)—5-(6-(benzylamino)chloro-9H—purinyl)—3-ethynyl-3,4-
dihydroxytetrahydrofuranyl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid
WO 46403
TBDPSO
N \
TBDPSO
“:0y-o AC2O
AcOH H so2
</ l i
4 /
0* —-\-103:0Ac</”Nl Ni 0| TBDPSO N
O N Cl
Aco‘ Ac BSA TMSOTf _
MeCN 5 L,
AcO OAc
CI CI
</ \N .9? \
I col N
NACI“ H </ l CI—P P-CI
C|/V\C| Ho_PVRO
TBAF,THF HO N
0 NACI BnNH2
—> ,N
. HO, CI)H : :0: —>
_ P(O)(OMe)3
_. ._ — : '— diEdlxihe
A05 bAc 2) aq. NH4003H Acd bAc
NHBn HN
N \ N \
</ l
HO_|OFL (IF? HO_IOFI’ (IF?
\/ ‘0 (nN / \/ ‘0 N /,Nk
HO’ (IJH O N -
0' fl, HO’ (IDH O N C'
THF, MeOH
_ ~ _ _ ~ .
Acd bAc H6 6H
e 203
Step 1:
While under nitrogen, a solution of (3aR,5R, 6R, 6aR)(((tert—butyldiphenylsilyl)—
oxy)methyl)—6-ethynyl-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxolol (14.48 g, 32
mmoL) (prepared using the methods described in Hulpia, F. et a1. . Med. Chem. Lett.
2016, 26, 1970-1972) in acetic acid (130 mL) was cooled to 14-17 °C and treated with acetic
anhydride (3201 mL, 341 mmoL, 10.7 eq) and concentrated sulfuric acid (576 uL, 10.8
mmoL, 0.34 eq). After stirring at for 2.5 h. The mixture was diluted with ethyl acetate (200
mL each) and washed with water. The aqueous phase was extracted with ethyl acetate (25
mL), and the combined organic solution washed with sodium bicarbonate (aqueous,
ted, 200 mL), dried over NazSO4, d, and concentrated. The residual oil was
purified by flash column chromatography on silica gel column (0—3% ethyl acetate in
dichloromethane) to provide (3R, 4R, 5R)—5-(((Zert-butyldiphenylsilyl)oxy)methyl)—4-
ethynyltetrahydrofuran-2,3,4-triyl triacetate as a e of anomers and isolated as a white
solid in good yield (9.5 g, 55%).
Step 2:
While under nitrogen, 2,6-dichloroadenine (291 g, 15.4 mmoL, 1.01 eq) and MO-
bis(trimethylsilyl)acetamide (4.87 mL, 19.6 mmoL, 1.29 eq) in anhydrous acetonitrile (90
mL) was stirred at room temperature. Next, a solution of (2R, 3R, 4R, 5R)-2,4-bis(acetyloxy)—
-{[(Zerl—butyldiphenylsilyl)oxy]methyl}-4—ethynyloxolan—3-yl acetate (82 g, 15.22 mmoL)
in ous acetonitrile (10 mL) was added, followed by dropwise addition of trimethylsilyl
trifluoromethanesulfonate (3.67 mL, 20.3 mmoL, 1.33 eq). The reaction was warmed to 50
°C for 18h, then cooled to room temperature. Saturated aqueous sodium bicarbonate (10
mL), was added and the mixture was stirred for ten minutes. The resulting mixture was
extracted with ethyl acetate (3 x 100 mL) and the ed organic layer was dried
(NazSO4), filtered, and concentrated. The residue was purified by flash column
chromatography on silica gel column (0—30% ethyl e in hexanes) to provide
(2R, 3R, 4R, 5R)(((terl—butyldiphenylsilyl)oxy)methyl)-5—(2,6-dichloro-9H—purin—9-yl)-3—
ethynyltetrahydrofuran-3,4-diyl diacetate as a white solid (8.2 g, 81%).
Step 3:
A on of (2R, 3R, 4R, 5R)—2-(((ZerZ-butyldiphenylsilyl)oxy)methyl)(2,6-dichloro-
9H-purinyl)—3-ethynyltetrahydrofuran-3,4-diyl diacetate (1.6 g, 2.4 mmoL) in anhydrous
THF (25 mL) was cooled to 0 oC and treated with acetic acid (0.192 mL, 3.36 mmoL) and
tetrabutylammonium fluoride in THF (1N, 3.36 mL, 3.36 mmoL). After the addition was
complete, the reaction was warmed to room temperature with continued stirring for 3h. The
reaction mixture was concentrated. The crude residue was purified via flash column
chromatography on silica gel (0—50% ethyl acetate in hexanes) to afford (2R, 3R, 4R, 5R)—5-
(2,6-dichloro-9H-puriny1)—3 -ethynyl(hydroxymethyl)tetrahydrofuran-3 ,4-diyl diacetate
(0.88 g, 86%) as a white foam.
Step 4:
A solution of (2R, 3R, 4R, 5R)(2,6-dichloro-9H—purin-9—y1)ethynyl(hydroxyl-
methyl)tetrahydrofuran-3,4—diyl diacetate (100 mg, 0.233 mmoL) in trimethylphosphate (4
mL) was cooled to 0 oC and d with a second solution of methylenebis(phosphonic
dichloride) (116 mg, 0.467 mmoL, 2 eq) in hylphosphate (4 mL). After the addition
was complete, stirring was continued for 2 h then the cooling bath was removed and stirring
was continued for 18h. Ammonium bicarbonate (0.7 M aqueous TEAB, pH 8.5) was added
slowly with vigorous stirring until no more gas evolution was observed. Once quenched,
NaHCO3 (satd., aqueous; 5 mL) was added and mixture stirred for 1h at room temperature.
The reaction mixture was washes with romethane, acidified with 2N HCl to pH~1 and
extracted with ethyl acetate (10 x 50 mL). The combined organic layer was dried over
sodium e, filtered and concentrated in vacuo. The residual oil was azeotroped with
e (3 x 10 mL) to give (((((2R, 3R, 4R, 5R)-3,4-diacetoxy(2,6-dichloro-9H—purinyl)-
nyltetrahydrofuranyl)methoxy)(hydroxy)phosphoryl)-methyl)phosphonic acid as an
off-white solid that was used in the next step without further purification.
Step 5:
A solution of (((((2R, 3R, 4R, 5R)-3,4—diacetoxy(2,6-dichloro-9H—purin-9—yl)
ethynyltetrahydrofuranyl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid from
Step 4 (~90 mg) was dissolved in anhydrous dioxane (8 mL), cooled to 0 °C, then treated
with diisopropylethylamine mL, 0.513 mmoL, 2.2 eq) and benzylamine (0.036 mL,
0.33 mmoL, 1.4 eq). After the addition was te, the reaction was stirred at room
temperature for 18 h and concentrated to provide (((((2R, 3R, 4R, 5R)-3,4-diacetoxy(6-
(benzylamino)chloro-9H-purinyl)ethynyltetrahydrofuranyl)methoxy)(hydroxy)-
phosphoryl)methyl)phosphonic acid. The crude product was used directly in the subsequent
hydrolysis without further purification.
The crude product from Step 5 was dissolved in 1:1 MeOH/THF (2 mL) and treated
with LiOH (84 mg, 3.5 mmoL, 15 eq) in water (1 mL). After the on was complete, the
reaction was stirred at room temperature for 18 h before it was acidified to pH~1 with 2N
HCl and concentrated. The resulting reaction mixture was diluted in 1:1 acetonitrile in water
with 0.1% TFA (4 mL) and purified via reverse phase HPLC to give R, SS, 4R, 5R)(6-
(benzylamino)chloro-9H-purinyl)ethynyl-3,4-dihydroxytetrahydrofuran
yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid as a white solid (9.2 mg, 7%) after
lyophilization.
1HWR (D20) 5 8.63 (s, 1 H), 7.41 (m, 5 H), 6.07 (d, J = 6.9Hz, 1 H), 4.96 (d, J = 7.0Hz, 1
H), 4.46 (s, 1 H), 4.37 (d, J: 12.0Hz, 1 H), 4.25 (d, J: 11.5Hz, 1 H), 3.21 (s, 1 H), 2.38 (t, J
= 20.0Hz, 2 H) HPLC: Rt = 17.2 min, 97.9%. ESI—MS for C21H24CleO9P2 calcd. 587.07,
found 586.8 (M-), ESI-MS for C12H9C1N5 calcd. 258.05, found 258.4 (M-ribose fragment).
Example 204
sis of ((((2R, 3S, 4R, (6-(benzylamino)chloro-9H-purinyl)ethynyl-3,4-
dihydroxytetrahydrofuran—2-yl)methoxy)methy1)phosphonic acid
Cl CI
0 o <rN \ N \
|| || / N N
. /
EtO-PVOH szo, TEA EtO—PVOTf LIH'V'DS'THF (I? < l
' —*Eto’
+ HO N
0 NAG EtO-Il3/\O N
o NAG
_ _
AGO: EDAC AGO: :OAC
NHBn NHBn
N \ N N
1. TMSBr MeCN \
o <f * < l N
BnNH 2. KOEt, EtOH 0
-lTlAO N
o NACI —. Ho—lD'AO N
o NAG
DIEA,dioxane OEt
_ (IDH S ;
A06 :OAC —HC3: 6H
Example 204
Step 1:
A flamed dried round bottom flask was charged with diethyl hydroxymethylphos—
e (780 mg, 4.64 mmol) and triethylamine (0838 mL, 6.031 mmoL, 1.3 eq) in
anhydrous dichloromethane (20 mL) was cooled to -78°C and treated trifluoromethane-
sulfonic ide (0.847 mL, 5.10 mmoL, 1.3 eq) dropwise. The reaction was stirred for 10
min as the reaction was warmed to 0°C. After 30 min, the on mixture was poured into
ether (precooled to 0°C) and the crystalline itate filtered. The e was then washed
sequentially with water (1x100 mL), 1 M HCl (1x100 mL), and saturated aqueous sodium
chloride (1 x 125 mL). Organic layer was dried (MgSO4), filtered, and concentrated to
provide crude (diethoxyphosphoryl)methyl trifluoromethanesulfonate obtained as a yellow
oil, was dissolved in anhydrous THF and this solution used directly in the next step without
further pun'fication.
Step 2:
A solution of (2R, 3R, 4R, 5R)(2,6-dichloro-9H-purin-9—yl)ethynyl-2—(hydroxyl-
methyl)tetrahydrofuran-3,4—diyl diacetate (350 mg, 0.815 mmoL) and (diethoxyphosphoryl)-
methyl trifluoromethanesulfonate (294 mg, 0.978 mmoL, 1.2 eq) in THF (20 mL) was cooled
to -78°C and treated with LiHMDS (1M in THF; 0980 mL, 0.978 mmoL, 1.2 eq) in a
dropwise. After stirring for 1.5 h, reaction was quenched with solid NH4Cl, diluted with
water and extracted with ethyl acetate. The organic layer was dIied (MgSO4), filtered, and
concentrated. Purification by flash column chromatography on silica gel (0—100% ethyl
acetate in hexanes) afforded (2R, 3R, 4R, 5R)(2,6-dichloro-9H-purinyl)(((diethoxy-
oryl)methoxy)methyl)ethynyltetrahydrofuran-3,4-diyl diacetate (140 mg, 30%) as a
pale yellow oil.
Step 3:
A solution of (2R, 3R, 4R, 5R)(2,6-dichloro-9H-purinyl)(((diethoxyphos-
phoryl)methoxy)methyl)—3—ethynyltetrahydrofuran-3,4-diyl diacetate (85mg, 0.147 mmoL)
and diisopropylethylamine (40 11L, 0.235 mmoL, 1.6 eq) in anhydrous dioxane (8 mL) was
cooled to 0°C was treated with benzylamine (19 11L, 0.176 mmoL, 1.2 eq). After the on
was complete, the on was warmed to room temperature and stirred for 18 h. The
mixture was diluted with water and extracted with ethyl acetate. The c layer was dried
(NazSO4), filtered, and concentrated to e crude (2R, 3R, 4R, (6-(benzylamino)—2-
chloro-9H-purinyl)(((diethoxyphosphoryl)methoxy)methyl)—3 -ethynyltetrahydrofuran-
3,4-diyl diacetate (93mg, 96%) as a white solid which was used directly in the subsequent
step without further purification.
Step 4:
The crude product from the previous step was dissolved in anhydrous acetonitrile (10
mL) and treated with bromotrimethylsilane (0.24 mL, 1.8 mmoL, 12 eq) se. After the
addition was complete, the solution was stirred at room temperature for 22 h and quenched
with water (5 mL). After stirring an additional 2-3 min, the solution was extracted with ethyl
acetate (4x100 mL). The organic layer was, dried (NazSO4), filtered, and concentrated to afford
((((2R, 3S, 4R, 5R)—5 -(6-(benzylamino)chloro-9H—purinyl)-3 -ethynyl-3 ,4-dihydroxytetra-
hydrofuranyl)methoxy)methyl)phosphonic acid as an off-white solid. This crude solid was
dissolved in absolute EtOH at 0 oC and treated with KOEt (51 mg, 0.61 mmoL, 4 eq) in one
portion. The reaction was stirred at room temperature for 20 min before it was acidified with
AcOH (0.52 mL, 091 mmoL, 6 eq) and d an additional 10 min. The crude product was
purified via reverse-phase HPLC and dried by lyophilization to give ((((2R,3S,4R,5R)—5-(6-
(benzylamino)—2-chloro-9H—purin-9—yl)ethynyl-3,4-dihydroxytetrahydrofuran-2—
yl)methoxy)methyl)phosphonic acid (6 mg, 7%) as a white solid.
1H NMR (D20) 5 8.41 (s, 1H), 7.19 (m, 5 H), 5.84 (d, J: 7.2Hz, 1H), 4.82 (d, J: 7.1Hz, 1
H), 4.21 (m, 1 H), 4.19 (m, 2 H), 3.79 (d, J= 3.8Hz, 2H), 3.57 (m, 2 H), 2.98 (s, 1 H).
HPLC: Rt = 7.19 min, 97.5%. ESI-MS for C20H21C1N507P calcd, 509.09, found 509 (M+),
ESI-MS for C11H8ClN6 calcd. 258.05, found 259 (M-ribose fragment).
Example 205
Synthesis of (((((2R, 3S, 4R, 5R)(6-(benzylamino)—2-chloro-9H—purinyl)-3,4-dihydroxy
methyltetrahydrofuranyl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid
TBDPSO / \
TBDPSO N
0’43le A020 <: </ l OAc
AcOH sto4 TBDPSO N A
A0 BSA TMSOTf
MeCN 5 -:
AcO OAc
CI 0 o HN
iNiC1.P(O)(OMe)3CI—ClP\/P'\Clcl (I? (I? (N \N
TBAF,THF HO H0‘f’v'f‘o N
o NAG
—> HO
, OH
2. CO3H b
‘ _ .
A05 5A0 3.BnNH2,D|EA,dioxane H5 '5...
4. aq .LiOH THF MeOH
’ ’ Example 205
Step 1:
While under nitrogen an ice-cooled on of R,6aS)(((terl—butyldiphenyl-
silyl)oxy)methyl)—2,2-dimethyldihydrofuro[2,3-d][1,3]dioxol-6(5]-D-one (6 g, 14.1 mmoL) in
anhydrous THF (100 mL) was treated with 3M methyl magnesium chloride in THF (5.9 mL,
1.4 eq) dropwise. After the addition was complete, the cooling bath was removed, and
stirring was continuing for 1 h. The mixture was cooled back to 0 OC and quenched with a
saturated s ammonium chloride (10 mL), diluted with ethyl acetate (100 mL) and
washed with water (80 mL). The aqueous was re-extracted with ethyl acetate (1 x 50 mL)
and the ed organic layer was dried over sodium sulfate, filtered, and concentrated.
The residual oil was purified by flash column chromatography on silica (0—30% ethyl acetate
in hexanes) to provide R, 6R, 6aR)—5-(((Zerl—butyldiphenylsilyl)oxy)methyl)-2,2,6-
trimethyltetrahydrofuro[2,3-d][1,3]dioxol—6-ol as a pale Viscous oil (4.2 g, 67%).
Step 2:
While under nitrogen, a solution of (3aR, 5R, 6615)(((Zert—butyldiphenylsilyl)oxy)-
methyl)-2,2—dimethyldihydrofuro[2,3-d][1,3]dioxol—6(5H)—one (2.25 g, 5.08 mmoL) in
dichloromethane (35 mL) and water (3.5 mL) cooled to O 0C and treated with trifluoroacetic
acid (15 mL). After 2.5 h, saturated aqueous NaHCOs was added until the solution was pH~8
and mixture was extracted with dichloromethane (2 x 150 mL). The combined organic layer
was dried over sodium sulfate, filtered, and concentrated. The crude oil was azeotroped with
toluene (3 x 5 mL), diluted with dichloromethane (45 mL) was treated with pyridine (12 mL),
acetic anhydride (4.77 mL, 5083 mmoL) and catalytic 4-DMAP (142 mg, 1.17 mmoL).
After stirring 18 h, the reaction was diluted with ethyl acetate (200 mL each) and washed
sequentially with saturated aqueous NH4C1 (3 x 100 mL), 0.5 N HCl (2 X 100 mL), and
saturated aqueous sodium chloride (1 X 120 mL). The combined organic layer was dried over
sodium sulfate, d, and concentrated. The residual oil was purified by flash column
chromatography on silica gel (0—30% ethyl acetate in hexanes) to provide (3R, 4R, 5R)
(((tert—butyldiphenylsilyl)oxy)methyl)methyltetrahydrofuran-2,3,4-triyl triacetate (2.1 g,
78%) as ess solid.
Steps 3 — 6:
Proceeding as described in Example 203 above but substituting R, 6R, 6aR)
(((terl—butyldiphenyl silyl)-oxy)methyl)—6-ethynyl-2,2-dimethyltetrahydrofuro[2, 3 —d][1,3]—
dioxolol with (30R, 5R, 6aS)—5-(((tert—butyldiphenyl-silyl)oxy)methy1)-2,2-dimethyldi-
hydrofuro[2,3-d][1,3]dioxol—6(5]10-one provided the title compound (8 mg, 3%) as as a white
solid.
1H NMR MSO-d6, 6: 1) 8.46 (bs, 1 H), 7.23 (m, 5 H), 5.84 (d, J: 6.9Hz, 1 H),
4.45 (d, J: 7.0Hz, 1 H), 4.12 (s, 1 H), 3.95 (m, 3 H), 3.54 (m, 1 H), 2.18 (bs, 2 H), 1.31 (s, 3
H). ESI-MS for C19H24C1N509P2 calcd. 563.1, found 562.1 (M-).
Example 206
Assay 1: Inhibition of the CD73 Enzyme in vitro
For measurements of soluble CD73 enzyme activity, recombinant CD73 was obtained
from R&D Systems, Cat. No. 5795—EN—010. Serial dilutions of test compounds were
incubated with recombinant CD73 and AMP in reaction buffer (25 mM Tris HCl pH7 .5, 5
mM MgC12, 50 mM NaCl, 0.25 mM DTT, 0.005% Triton . The final reaction volume
was 25 11L and the final concentrations of recombinant CD73 and AMP were 0.5 nM and 50
11M, respectively. Reactions were allowed to proceed for 30 s at room temperature
before the addition of 100 uL Malachite Green (Cell Signaling Technology, Cat. No. .
After 5 minutes at room temperature, absorbance at 630 nm was determined on a microplate
spectrophotometer. The concentration of inorganic phosphate was determined using a
phosphate standard curve.
Assay 2: tion of the CD73 Enzyme in vitro
For measurements of e CD73 enzyme activity, recombinant CD73 was obtained
from R&D Systems, Cat. No. 5795-EN—010. Serial dilutions of test compounds were
incubated with recombinant CD73 and AMP in reaction buffer (25 mM Tris HCl pH7 .5, 5
mM MgCl2, 50 mM NaCl, 0.25 mM DTT, 0.005% Triton X-lOO). The final on volume
was 25 uL and the final concentrations of recombinant CD73 and AMP were 0.05 nM and 50
uM, respectively. Reactions were allowed to proceed for 1 hour at 37°C before the addition
of 100 uL Malachite Green (Cell Signaling Technology, Cat. No. 12776). After 5 minutes at
room temperature, absorbance at 630 nm was determined on a microplate spectrophotometer.
The concentration of inorganic phosphate was determined using a phosphate standard curve.
The ICso data for both assays is given below in Table 2. ND indicates not ined.
Table 2
Assay 1 Assay 2
Example # Compound
WO 46403
Assay 1 Assay 2
Example # Compound
WO 46403
Assay 1 Assay 2
Example # Compound
Assay 1 Assay 2
Example # Compound
Assay 1 Assay 2
e # Compound
Assay 1 Assay 2
e # Compound
WO 46403
Assay 1 Assay 2
Example # Compound
—294—
Assay 1 Assay 2
Example # Compound
Assay 1 Assay 2
Example # Compound
WO 46403
Assay 1 Assay 2
Example # Compound
Assay 1 Assay 2
e # Compound
W0 246403
Assay 1 Assay 2
Example # Compound
W0 20192’246403 2019/038245
Assay 1 Assay 2
Example # Compound
Assay 1 Assay 2
e # Compound
WO 46403
Assay 1 Assay 2
Example # Compound
WO 46403
Assay 1 Assay 2
Example # Compound
W0 20192’246403
Assay 1 Assay 2
e # Compound
—304—
WO 46403
Assay 1 Assay 2
Example # Compound
WO 46403
Assay 1 Assay 2
Example # Compound
Assay 1 Assay 2
e # Compound
Assay 1 Assay 2
e # Compound
WO 46403
Assay 1 Assay 2
Example # Compound
Assay 1 Assay 2
Example # Compound
Assay 1 Assay 2
Example # Compound
W0 20192’246403 2019/038245
Assay 1 Assay 2
Example # Compound
Assay 1 Assay 2
e # Compound
Assay 1 Assay 2
e # Compound
—314—
W0 246403
Assay 1 Assay 2
Example # Compound
Assay 1 Assay 2
e # Compound
Assay 1 Assay 2
Example # Compound
Assay 1 Assay 2
Example # Compound
W0 20192’246403
Assay 1 Assay 2
e # Compound
Assay 1 Assay 2
Example # Compound
Assay 1 Assay 2
e # Compound
WO 46403
Assay 1 Assay 2
Example # Compound
WO 46403
Assay 1 Assay 2
Example # Compound
Assay 1 Assay 2
Example # Compound
—324—
W0 20192’246403 2019/038245
Assay 1 Assay 2
Example # Compound
198 ND
Assay 1 Assay 2
e # Compound
199 ND
200 ND
Assay 1 Assay 2
e # Compound
Example 207
Activation of Tumor-Directed Immune Res onse with CD73 Inhibitors
EG7 cells were implanted subcutaneously into C57BL/6 mice Compound 9 (50
mg/kg) or vehicle was orally administered BID starting day one post implant (N=10 per
. Tumors were excised on day 14 and analyzed by flow cytometry. Compound 9
increased the %CD8+ cells of CD45+ cells as shown in (* indicates p<0.05). EG7
cells were implanted subcutaneously into C57BL/6 mice. D8 antibody was dosed i.p.
on days -1, 0, 5, and 10. Compound 9 (50 mg/kg) or vehicle was orally dosed BID starting on
day 1. shows that depletion of CD8+ T cells reverses efficacy (**** indicates
p<0.0001 vs Compound 9 + anti-CD8). Compound 9 alone showed more of a tumor volume
ion that the combination of Compound 9 than the anti-CD8 antibody.
Example 208
Reversal of AMP-Mediated Suppression of CD8+ T Cells using CD73 Inhibitors
Human CD8+ T cells were d with CellTrace CFSE and then pre-incubated with
an adenosine deaminase inhibitor and nd 9 or vehicle for 20 minutes. 20 uM AMP
was added for assessing T cell proliferation and CD25 expression. 10 uM AMP was added
for assessing cytokine production. T cells were activated with d-CD3, d-CD28, and hILZ.
After 4 days, eration and CD25 expression were assessed by flow cytometry and
cytokine levels in the atant were measured by ELISA. ECsos were determined using a
four-parameter dose-response curve equation. s the EC50=11.6nM for CD8+ T
cell proliferation. depicts the EC50=9.6 nM for CD8+ T cell activation.
depicts the EC50=4,5 nM for IFNy production. depicts theEC50=5.6nM for
Granzyme B production.
Example 209
Selectivity of CD73 Inhibitors
Compounds of the invention are ive for CD73 and do not exhibit proliferative
effects. Using Compound 9, the activity of cell e CD39 was ed using K562 cells
expressing human CD39 and Kinase-G10. Activity of recombinant human ENTPD2 and
ENTPD3 was assessed using a malachite green assay. Each of the enzymes CD39, ENTPD2
AND ENTPD3 all showed an ICso of 0 nM. Compound 9 was screened in the
Eurofins Safety Screen Panel and the Eurofins s Diversity Kinase Profile Panel. In the
Safety Panel, 1/87 targets were inhibited at >50% at 10 pM of Compound 9. The PDE3
enzyme was inhibited at 59%. In the Kinase Panel, none of the 45 targets were inhibited at
>50%.
Further, Compound 9 did not show anti-proliferative effects against three cell lines.
Viability of EG7 and A375 cells treated with 100 uM Compound 9 was measured using
CellTiter-Glo after 3 days. Proliferation of human CD8+ T cells was measured by flow
cytometry after 4 days of treatment with 100 uM Compound 9 using CellTrace CFSE Cell
Proliferation Kit. shows the comparable %cell survival of EG7 cells, a mouse T cell
lymphoma cell line. shows the comparable %cell survival of A3 75 cells, a human
melanoma cell line. shows the comparable % divided cells of human CD8+ T cells.
Example 210
CD73 tion
The potency of nd 9 was evaluated against recombinant CD73 and CD73-
expressing SK-MEL-28 cells using a malachite green assay. Inhibition of CD73 in plasma
was measured using LC/MS to assess conversion of MP into 15Ns—ADO.
tes the nanomolar inhibition of CD73 cells from both human and mouse sources. depicts the IC50=0.17 nM for human recombinant CD73 cells. depicts the
ICso=0.38 nM for human plasma CD73 cells. tion of CD73 in plasma was measured
using LC/MS to assess conversion of 15Ns-AMP into 15Ns-ADO. depicts the
IC50=O.21 nM for human CD73 cell surface.
Example 211
CD73 Inhibitor Oral Dosing Phamacodynamics
Single dose nd 9 (50 mg/kg) was administered orally to mice and plasma was
collected at indicated time points. Compound 9 levels were measured by LC/MS. The ICso in
mouse plasma was 1 nM as shown in . Plasma was harvested from mice 2 hours
post dose and spiked with 15Ns-AMP and a TNAP inhibitor. 15Ns-ADO levels were measured
by LC/MS. depicts the 92% inhibition of mouse plasma CD73 cells.
Example 212
Single-Agent Efficacy of Orally Dosed CD73 Inhibitors
Compounds of the invention show potent anti-tumor effects, evidenced in reducing
tumor volume in a mouse model. In one model, EG7 cells were ted subcutaneously
into C57BL/6 mice. Compound 9 or vehicle was orally administered BID starting day one
post implant (N=10 per group). depicts the further decrease in tumor volume with
increasing doses of Compound 9. In another model, EG7 cells were implanted
subcutaneously into 6 mice. Compound 9 was orally administered BID (100 mg/kg)
starting day one post implant (N=10 per group). Vehicle was orally administered BID starting
day one post implant (N=20) until day five post implant, at which time, mice were
randomized by tumor volume into two groups. Compound 9 (100 mg/kg) or vehicle was
orally administered BID to N=10 per group starting day six post implant. A depicts
the decrease in tumor volume with stration of Compound 9 to mice harboring
established tumors. FIGs. 13B—D show individual replications of this measurement for each
dosing. B is e. C is dosing of Compound 9 started on day 1. D is Compound 9 started on day 6. In another model, CT26 cells were implanted
subcutaneously into Balb/c mice. 100 mg/kg Compound 9 or vehicle was orally administered
BID starting day one post implant (N=10 per group). depicts the decrease in tumor
volume ed to vehicle. **** indicates p<0.0001 vs e; NS indicates not cant
(two—way ANOVA).
Example 213
CD73 Inhibitor Efficacy in Combination with Immunooncology and Chemotherapeutic
Agents
EG7 cells were implanted subcutaneously into C57BL/6 mice for each experiment.
Anti-PD-Ll antibody (5 mg/kg) was dosed i.p. on Study Days 3, 5
, 7, 9, 11, 13. Compound 9
(100 mg/kg) or e was orally administered BID starting one day post implant. FIG 7A
depicts the reduction in tumor volume with single agent and combination therapy. **
indicates p<0.01; **** indicates p<0.0001 (two-way ANOVA). FIGs. 7B-7E show the
individual replications of this measurement for each dosing. is e, is
anti—PD-Ll antibody, is nd 9, and is Compound 9 + Anti-PD—Ll.
Oxaliplatin was dosed i.p. 6 mg/kg on Study Days 7 and 14. Compound 9 (100
mg/kg) or vehicle was orally stered BID starting one day post implant. FIG 8A depicts
the reduction in tumor volume with single agent and combination therapy. **** indicates
p<0.0001 (two-way ANOVA). FIGs. 8B—8E show the individual replications of this
measurement for each dosing. is e, is oxaliplatin, is
Compound 9, and FIG. SE is Compound 9 + oxaliplatin.
Doxorubicin was dosed i.v. 2.5 mg/kg on Study Days 7 and 14. Compound 9 (50
mg/kg) or e was orally stered BID starting one day post implant. FIG 9A depicts
the reduction in tumor volume with single agent and combination therapy. * indicates p<0.05,
*** indicates p<0.001 (two—way ANOVA). FIGs. 9B-9E show the individual replications of
this measurement for each dosing. is e, is doxorubicin, is
Compound 9, and is Compound 9 + doxorubicin.
Docetaxel was dosed i.p. 5 mg/kg on Study Days 5, 12, and 19. Compound 9 (100
mg/kg) or vehicle was orally administered BID starting one day post implant. FIG 12A
depicts the reduction in tumor volume with single agent and combination therapy. * indicates
p<0.05, **** indicates p<0.0001 (two-way ANOVA). FIGs. 12B-10E show the individual
replications of this measurement for each dosing. B is vehicle, C is
docetaxel, D is Compound 9, and E is Compound 9 + docetaxel.
Example 214
CD73 Inhibitor Efficacy in le Tumors
Serum was procured from Discovery Life es. Serum from head and neck
squamous cell carcinoma (HNSCC), n cancer, triple-negative breast cancer and
esophageal cancer ts were incubated with a serial dilution of Compound 9 in the
presence of a TNAP inhibitor. Conversion of 15Ns-AMP to 15Ns-ADO was measured by
LC/MS. A depicts the sub-nanomolar inhibition ofHNSCC serum. B depicts
the sub-nanomolar inhibition of ovarian cancer serum. C s the sub-nanomolar
inhibition of TNBC serum. D depicts the sub-nanomolar inhibition of esophageal
cancer serum.
Example 215
Expression of CD73 in Multiple Human Tumors
depicts normalized mRNA expression levels of CD73 in tumor and normal
tissues. Expression levels of CD73 (NTSE) were obtained from the TCGA (tumor) or GTEX
(normal) databases using the UCSC Xena rm and analyzed using an ed t-test.
The expression of CD73 as measured by a Logz (Normalized Count +1) was greater than
vehicle for atic, esophageal, stomach, head and neck, colon, lung and kidney clear cell
tumors.
Incorporation by nce
All publications and patents mentioned herein are hereby orated by reference in
their entirety as if each individual publication or patent was specifically and individually
indicated to be incorporated by reference. In case of conflict, the present application,
including any definitions herein, will control.
Eguivalents
While specific embodiments of the subject invention have been discussed, the above
specification is illustrative and not restrictive. Many variations of the invention will become
apparent to those skilled in the art upon review of this specification and the claims below.
The full scope of the invention should be determined by nce to the claims, along With
their full scope of equivalents, and the specification, along with such variations.
WO 46403
1. A compound of formula (1):
Y 0 Het
R2b R1 b
R23 R1a
or a pharmaceutically acceptable salt and/or g thereof, wherein
R4 O O
555\ R15/ V]
Y is R6 or R15
Het is heterocyclyl or heteroaryl,
Rlais selected from H, halo, hydroxy, cyano, azido, amino, C1-6alkyl, hydroxyCr.
6alkyl, amino-C1-6alkyl, -O-C(O)-O-C1-6alkyl, yloxy, C1-6alkoxy, C2.6alkenyl, and
C2-6alkynyl;
R11) is selected from H, halo, C1-6alkyl, hydroxy-C1-6alkyl, amino-Cr-salkyl,
C2-6alkenyl, and Cz-salkynyl,
Rzais selected from halo, hydroxy, cyano, azido, amino, C1.6alkyl, hydroxy—Ci-salkyl,
amino-C1-6alkyl, C1-6acyloxy, -O-C(O)-O-C1-6alkyl, Cmalkoxy, C2-6alkenyl, and C2-6alkynyl,
R21) is selected from halo, C1-6alky1, C2-6alkenyl, and C2.6alkynyl, preferably
substituted or unsubstituted Czalkynyl, most preferably unsubstituted Czalkynyl,
R3 is selected from H and alkyl;
R4 is selected from H, alkyl, CN, aryl, heteroaryl, -C(O)OR9, RHR12, -
S(O)2R10, -P(O)(OR”)(OR12), and -P(O)(OR”)(NR13R14);
R5 is ed from H, cyano, alkyl, cycloalkylalkyl, heterocyclylalkyl, aralkyl,
heteroaralkyl, and -C(O)OR9;
R6 is selected from —C(O)OR9, -C(O)NR16R17, and —P(O)(OR“)(OR12),
R9 is independently ed from H, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl,
heterocyclylalkyl, aryl, aralkyl, heteroaryl, and heteroaralkyl,
R10 is independently selected from alkyl, alkenyl, alkynyl, amino, cycloalkyl,
cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, and heteroaralkyl,
each R11 and R12 is independently selected from H, alkyl, cycloalkyl, lkylalkyl,
heterocyclyl, cyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or
11 and R12, together with the nitrogen
atom to which they are attached, form a 5- to
7-membered heterocyclyl,
R13 is, independently for each occurrence, H or alkyl;
R14 is, independently for each occurrence, alkyl or aralkyl,
each R15 is independently selected from hydroxy, alkoxy acyloxy and NR13R14;
each R16 and R17 is independently selected from H, hydroxy, alkyl, cycloalkyl,
lkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, aryl, heteroaralkyl, or
16 and R17, together with the en
atom to which they are attached, form a 5- to
7-membered heterocyclyl.
2. The compound of claim 1, wherein a) and b), or a) and c):
6:)?TILT/1C0HoNH2 NH2
iifb’fiC
a) the compound is not HO OH
Ho WINK/“C ”if?
H F
N HNN
—334—
Cari/iNH2 NH2
Ho 060p
0 OWI:
O NH2
0 OH N
HO 0 01*“N
O NACI 0
BF Wad
N“ O NH2
NO? O OEt N
O N/=N WNH <’ '1
Etc 0 N
O N
HO CI
“0 6H “Y”
CI Ho‘ ’OH
, ,Or
0 NH2
0 OH N
</ P”
b) if R4 and R6 are each -C(O)OH and R5 is benzyl substituted on the phenyl ring with
a cyclyl or heteroaryl sub stituent, then the heterocyclyl or heteroaryl sub stituent is
selected from unsubstituted or substituted pyrrolidinyl, piperazinonyl, piperidonyl,
tetrahydropyrimidonyl, pyridonyl, and pyridyl; and
c) if R4 is -C(O)OH or tetrazolyl, R6 is -C(O)OH, and R5 is benzyl tuted on the
phenyl ring with a second phenyl ring, then either the benzyl phenyl ring or the second
phenyl ring is substituted with -C(O)OR9 where R9 is H or alkyl.
3. The compound of claim 1 or 2, having the following structure:
Y X Het
R2b R1b
R23 R121
4 flwcmmmwmofdmm3gwwmmflwcmmmmfloffixmdaflflmsmeumame
(IA):
Y Het
R2!) 5” Rlb
R23 2R1a
. The nd of any one of claims 1-4, wherein R121 is in the B-configuration.
6 Umcmmmmflofdmm5AMwmmflwcmmmmfloffixmdaflflmsmeMmame
Y X Het
R2b "’lll/R1b
R23 R161
(113)
7. The compound of any preceding claim, wherein R231 is in the d-configuration.
8 Umcmmmmflofdmm7AMEmmflwcmmmmflofflnmflaaflmsmeMmame
(1C):
R2b ‘5 R110
R25 R13
9. The compound of any one of claims 1-6, wherein R2a is in the B-configuration.
. The compound of claim 9, wherein the compound of Formula (I) has the structure
(1D):
Y X Het
R2b\\“ R")
R23 R161
(113)
11. The nd of claim 3, wherein the compound of Formula (I) has the structure
(IE):
”III/[Rm
12. The compound of any one of claims 1-1 1, wherein
R5 is aralkyl or heteroaralkyl with a para substituent on the aryl or heteroaryl ring
selected from heterocyclyl, aryl, and aryl, and
R21) is methyl, ethyl, or C2-6alkynyl.
R5%\551
13. The compound of any one of claims 1-12, n Y is R6
14. The compound of any preceding claim, wherein R5 is selected from H, alkyl, aralkyl
and heteroaralkyl.
. The compound of claim 14, wherein each alkyl, aralkyl and heteroaralkyl at R5 is
unsubstituted or substituted with one or more tuents selected from halo, alkyl, alkoxy,
carbonyl, amino, amido, cycloalkyl, cyclyl, and heteroaryl.
16. The compound of claim 15, wherein the substituents on the alkyl, l and
heteroaralkyl at R5 are selected from halo, haloalkyl, alkoxy, amino, carbonyl, aryl,
heterocyclyl, and heteroaryl.
17. The compound of any one of claims 1-11, wherein R5 is benzyl substituted on the
phenyl ring (e. g., at a para position) with a heterocyclyl or heteroaryl substituent, e.g.,
wherein:
the phenyl ring substituent is selected from substituted piperidonyl, piperazinonyl,
tetrahydropyrimidonyl, nyl, and pyridyl, and, optionally,
the piperidonyl, tetrahydropyrimidonyl, pyridonyl, or pyridyl is tuted with one
or more of alkyl, hydroxyalkyl or alkoxyalkyl.
18. The compound of any one of claims 1-14, wherein R5 is benzyl substituted on the
O O
N2 HNJKNX
phenyl ring (e.g., at the 4-position) with K)
9 ,
W0 246403
\Nifi; \/\NJ\N}{
K) K)
\ yi“ /\~/ V\
| |
\ \ \
O O
HO\/\N \O/\N
l l
\ \
O OMe NH2
/o\/\N a; \ \ a;
I NI NI
\ / /
19. The compound of any one of claims 1-18, wherein
W0 20192’246403 2019/038245
0 OH O NH2
R5 \[Zo){ HO ){
z W9:o 0/
R6 represents o o
, ,
0 NH2 0 NH O N
H2N HO
0}{ 0jg HO 03°:
0 O O
7 7 7
/OH /OH 0
o 0 Me
\P—OH \P—OH O§s/
MeO jg EC 3; HO
o o ojg
O O O
7 7 7
0 OH
II» 0 0“
0 0H
O jg EtO
O Ojg
—340—
W0 246403
o OEt 0 OH 0 0H
EtO ){ HO HO
O Ojg Ojg
OH \ /0 OH
0% HO 0):
7 7
O OH
O O
7 7
F3C F3C
O OH O OEt
HO }{ HO
0 Ofig
O O
—341—
W0 246403
MeO CI
0 OH \ / O OH
HO jg HO
O 0);:
—342—
W0 246403
—343—
WO 46403
—344—
R15 H
P P— —g
R15/ V
. The compound of any one of claims 1-19, n Y is R
21. The compound of claim 20, wherein each R15 is hydroxy.
22. The compound of any one of claims 1-21, wherein Het is selected from
/ NH / \N
N w
"7’“~< mg, 0
O ,and /
23. The compound of any one of claims 1-21, wherein Het is
—345—
Qfi3 “33.;\ZZ/
wherein
Z is CH or N;
Ra is selected from H, halo, hydroxy, alkyl, thiophenyl, -NR7R8, aralkyl, aryl, and
heteroaryl, preferably from H, Cl, -NR7R8, and ,
Rb is selected from halo, alkyl, haloalkyl, hydroxyalkyl, alkylthio, amido, yl,
amido, and heteroaryl,
R7 is selected from H, hydroxy, alkyl, aralkyl, heteroaralkyl, cycloalkyl, and
heterocyclyl, and
R8 is H or alkyl, or
R7 and R8, together with the nitrogen atom to which they are attached, form a 4- to 7-
membered heterocyclyl ring.
24. The nd of claim 23, wherein Het is
</ \
/ Z
7c NA
. The compound of claim 23 or 24, wherein R21 is selected from H, halo, alkyl, thienyl,
NR7R8, aryl, and heteroaryl, preferably from H, Cl, -NR7R8, and phenyl.
26. The compound of claim 23-25, wherein Rb is selected from halo, alkyl, yalkyl,
haloalkyl, amido, carbonyl, amido, and heteroaryl.
27. The compound of claim 23-26, wherein R7 is selected from H, alkyl, aralkyl,
heteroaralkyl, cycloalkyl, and heterocyclyl.
28. A compound of formula (II):
R4 R3
0 Het
R2b R1 b
R23 R1a
or a pharmaceutically acceptable salt and/or prodrug thereof, wherein
Het is heterocyclyl or aryl,
Rlais selected from H, halo, hydroxy, cyano, azido, amino, C1-6alkyl, hydroxyCi-
6alkyl, C1-6alkyl, -O-C(O)-O-C1-6alkyl, Cmacyloxy, C1-6alkoxy, C2.6alkenyl, and
kynyl;
R1b is selected from H, halo, C1-6alkyl, hydroxy-Crsalkyl, amino-C1-6alkyl,
C2-6alkeny1, and kynyl;
Rzais selected from halo, hydroxy, cyano, azido, amino, C1.6alkyl, hydroxy-C1-6alkyl,
amino-Ci-salkyl, Cmacyloxy, -O-C(O)-O-C1-6alkyl, koxy, C2-6alkenyl, and C2-6alkynyl,
R21) is selected from H, halo, C1-6alkyl, C2-6alkenyl, and C2—6alkynyl,
R3 is selected from H and alkyl,
R4 is ed from alkyl, aryl, heteroaryl, -C(O)OR9, -C(O)NR”R12, -S(O)2R10,
-P(O)(OR”)(OR12), and -P(O)(OR”)(NR13R14),
R5 is selected from H, cyano, alkyl, cycloalkylalkyl, heterocyclylalkyl, aralkyl,
heteroaralkyl, and -C(O)OR9,
R6 is selected from -C(O)OR9, -C(O)NR“R12 and -P(O)(OR”)(OR12),
R9 is independently selected from H, alkyl, alkenyl, alkynyl, cycloalkyl,
cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, l, heteroaryl, and heteroaralkyl,
R10 is ndently selected from alkyl, alkenyl, alkynyl, amino, cycloalkyl,
cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, and heteroaralkyl,
each R11 and R12 is independently selected from H, alkyl, cycloalkyl, cycloalkylalkyl,
heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or
— 3417 —
11 and R12, together with the nitrogen
atom to which they are attached, form a 5- to
7-membered heterocyclyl;
R13 is H or alkyl; and
14 is alkyl
or aralkyl;
provided that a), b) and c); or a), b) and d);
O NH2 NH2
3: wig/AGOHO VIE/NAG
x‘ 'z s r
\ I
a) the compound is not HO OH HO OH
0 NH2
O OH <N’ \N
l NAG]
HO fir“!*0
HO F (3L HO
HZ:1”Log/Eli”:NH2 O
AC <15;
g :WNN*0]
O Ho O
O NH2
0 OH </N ' \i O NH2
HO OWN N/ 0 OH
Cl </N \N
0 l
F HO o N
~_ o NACI
OH O
b) sz is selected from halo, C2-6alkyl, C2-6alkenyl, and kynyl, preferably
substituted or unsubstituted nyl, most preferably unsubstituted Czalkynyl,
c) if R4 and R6 are each -C(O)OH and R5 is benzyl tuted on the phenyl ring with
a heterocyclyl or heteroaryl substituent, then the phenyl ring substituent is selected from
unsubstituted or substituted piperidonyl, tetrahydropyrimidonyl, pyridonyl, and pyridyl; and
d) if R4 is -C(O)OH or tetrazolyl, R6 is -C(O)OH, and R5 is benzyl substituted on the
phenyl ring with a second phenyl ring, then either the benzyl phenyl ring or the second
phenyl ring is substituted with -C(O)OR9 where R9 is H or alkyl.
29. The compound of any one of claims 1—28, wherein R1a is H or hydroxy.
. The compound of any one of claims 1-29, wherein R1b is H or hydroxy.
3 l, The compound of any one of claims 1-29, wherein R1a and R2a are each y,
32. The compound of any one of claims 1-29, wherein R1a is hydroxy and R11) is H.
33. The compound of any one of claims 1-32, wherein R2a is hydroxy or C1-6alkyl.
—349—
34. The compound of any one of claims 1—33, wherein R21) is C2-6alkyl, C2.6alkenyl or C2-
6alkynyl.
. The compound of any one of claims 1-32, wherein R2a is Me and sz is ethynyl.
36. The nd of any one of claims 1-32, wherein R2a is hydroxy and R2b is ethyl or
Vinyl.
37, The compound of any one of claims 1-32, wherein R2a is hydroxy and sz is ethynyl.
38. The nd of claim 34, wherein R21) is propynyl, butynyl, E :1 or
_ / \NH
tituted or substituted /
39. The compound of any one of claims 1-38, wherein the compound of Formula II has
the structure:
R4 R3
R57i\ X Het
RZb R1b
R23 R13
40. The compound of any one of claims 1-39, wherein R1a is in the d-configuration.
41. The compound of claim 40, wherein the compound of a (II) has the structure
(IIAa):
R4 R3
Mi Het
R2b 3’ R1b
R23 [/1213
(IIAa)
42. The compound of any one of claims 1-41, wherein R1a is in the B-configuration.
43. The compound of claim 42, wherein the compound of Formula (II) has the ure
(IIIS):
R4 R3
R5%\ X Het
sz "'IIIIR1b
R23 R15:
(IIBa)
44. The compound of any one of claims 1-43, wherein R2a is in the d-configuration.
45. The compound of claim 44, wherein the compound of a (II) has the structure
(IICa):
46. The compound of any one of claims 1-43, wherein R2a is in the B-configuration.
47. The compound of claim 46, wherein the compound of Formula (II) has the structure
R4 R3
R5>i\ X Het
R2b\\“ R1b
R223 R121
(11D)
48. The compound of claim 39, wherein the compound of Formula (II) has the structure
(IIEa):
49. The compound of any preceding claim, wherein R3 is H.
50. The compound of any one of claims 1-49, wherein R4 is selected from -C(O)OR9, -
C(O)NR“R12, -S(O)2R10, and -P(O)(OR“)(OR12).
51. The nd of claim 50, wherein R4 is -C(O)OR9 and R9 is H or alkyl.
52. The compound of claim 50, wherein R4 is -C(O)NRHR12.
53. The compound of claim 52, wherein each R11 and R12 is ndently selected from
H and alkyl; or R11 and R12, together with the nitrogen atom to which they are attached, form
a 5- to 7-membered heterocyclyl.
54. The compound of claim 50, wherein R4 is -S(O)2R10 and R10 is alkyl or aryl.
55. The nd of any one of claims 28-54, wherein R5 is selected from H, alkyl,
aralkyl and heteroaralkyl.
56. The compound of claim 55, wherein each alkyl, aralkyl and heteroaralkyl at R5 is
unsubstituted or substituted with one or more substituents selected from halo, alkyl, alkoxy,
carbonyl, amino, amido, cycloalkyl, heterocyclyl, and heteroaryl.
57. The compound of claim 56, wherein the tuents on the alkyl, aralkyl and
heteroaralkyl at R5 are selected from halo, kyl, alkoxy, carbonyl, aryl, heterocyclyl, and
heteroaryl.
58. The compound of claim 56, wherein R5 is aralkyl substituted on the aryl ring (e.g., at
a para position) with a 5- to 7-membered heterocyclyl or a 5- to ered heteroaryl.
WO 46403
59. The compound of any one of claims 28-58, wherein R5 is selected from H, methyl,
ethyl, -CH2-ethynyl, and -CH2-Vinyl.
60. The compound of claim 55, wherein R5 is selected from benzyl, -CH2-pyridyl, -CH2-
pyridazinyl, —CH2-oxazolyl, —CH2-thiophenyl, -CH2—furanyl, —CH2—thiazolyl, and -CH2-
benzothiazolyl, preferably from benzyl and -CH2-thiophenyl.
61. The compound of claim 55, wherein R5 is benzyl substituted on the phenyl ring with a
heterocyclyl or heteroaryl substituent, e.g., wherein:
the phenyl ring substituent is ed from substituted piperidonyl,
tetrahydropyrimidonyl, pyridonyl, and pyridyl, and, optionally,
the piperidonyl, ydropyrimidonyl, pyridonyl, or pyridyl is substituted with one
or more of alkyl, hydroxyalkyl or alkoxyalkyl.
62. The nd of claim 61, wherein R5 is benzyl substituted on the phenyl ring (e.g.,
$2mix EEX
o o
“656 W656
o o
HO\/\N \O/\N
\ \
, 7
63. The compound of any preceding claim, n R6 is -C(O)OR9 and R9 is H or alkyl.
64. The compound of any one of claims 1-62, wherein R6 is -C(O)NR16R17.
65. The compound of any one of claims 1-63, wherein R4 and R6 are each -C(O)OH,
preferably wherein R5 is benzyl.
66. The compound of any one of claims 28-49, wherein
0 OH O NH2
HO HO
0J; Ojg
R6 La:
represents 0 0
, ,
o NH2 0 NH 0 no
H2N fig HO O Ojg HO 0%
o o O
—354—
WO 46403
OH OH
HO EtO
OEt OH OH
EtO HO HO
OH \ /0 OH
W0
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/688,225 | 2018-06-21 | ||
US62/827,505 | 2019-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ790347A true NZ790347A (en) | 2022-07-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11858957B2 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
KR102638592B1 (en) | Ectonucleotidase inhibitors and uses thereof | |
AU2017333933B2 (en) | Cyclic dinucleotide compounds | |
TWI767937B (en) | Ectonucleotidase inhibitors and methods of use thereof | |
JP7317014B2 (en) | Cyclic dinucleotides as STING agonists | |
WO2019125974A1 (en) | Cyclic di-nucleotide compounds as sting agonists | |
NZ790347A (en) | Ectonucleotidase inhibitors and methods of use thereof | |
EA046381B1 (en) | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF THEIR APPLICATION | |
EA039042B1 (en) | Ectonucleotidase inhibitors and methods of use thereof |